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ABSTRACT	  Özgün	  Erdoğan:	  PHF8	  regulates	  the	  gene-­‐specific,	  transcriptionally	  active	  chromatin	  state	  to	  promote	  TLR4-­‐induced	  acute	  inflammation	  and	  adaptive	  immunity	  (Under	  the	  direction	  of	  Xian	  Chen)	  
This	  dissertation	  examines	  the	  role	  of	  PHF8	  in	  the	  regulation	  of	  LPS-­‐induced	  inflammatory	  response	  in	  macrophages	  and	  activation	  of	  adaptive	  immunity.	  I	  extend	  prior	  work	  on	  PP2Ac-­‐dependent	  activation	  of	  endotoxin	  tolerance	  to	  reveal	  that	  PHF8	  is	  negatively	  regulated	  by	  chronic-­‐active	  PP2Ac	  in	  endotoxin	  tolerance,	  leading	  to	  our	  observation	  that	  PHF8	  broadly	  regulates	  LPS-­‐induced	  acute	  inflammation	  response	  in	  macrophages.	  This	  research	  offers	  four	  conclusions:	  (1)	  PHF8	  enzymatic	  activity	  is	  important	  for	  LPS-­‐induced	  cytokine	  expression	  in	  macrophages,	  (2)	  PHF8	  targets	  H3K9me1/2	  for	  demethylation	  to	  promote	  LPS-­‐induced	  gene-­‐specific	  transcription,	  (3)	  PHF8	  binds	  to,	  and	  regulates	  NFκB	  transcription	  factor	  activity,	  and	  (4)	  PHF8	  broadly	  regulates	  the	  secretion	  of	  molecules	  involved	  in	  activation	  of	  adaptive	  immunity.	  In	  addition	  to	  the	  biological	  and	  biochemical	  experiments	  that	  provide	  evidence	  for	  PHF8-­‐dependent	  H3K9me1/2	  demethylation,	  cytokine	  expression,	  and	  NFκB	  activation,	  we	  conducted	  proteomic	  dissection	  of	  LPS-­‐induced	  macrophage	  secretome	  revealing	  important	  roles	  of	  PHF8	  in	  activation	  of	  adaptive	  immunity.	  Moreover,	  the	  secretome	  analysis	  illustrates	  that	  PHF8	  is	  a	  major	  regulator	  of	  LPS-­‐induced	  secretion	  of	  molecules	  involved	  in	  activation	  of	  adaptive	  immunity.	  Further,	  through	  T	  cell	  proliferation	  and	  activation	  assays,	  I	  provide	  evidence	  that	  the	  activation	  of	  T	  cells	  by	  macrophages	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depends	  on	  the	  LPS-­‐induced	  PHF8	  activity.	  Our	  findings	  advance	  our	  understanding	  of	  regulation	  of	  LPS	  response	  by	  PHF8,	  and	  reveal	  that	  PHF8	  bridges	  the	  innate	  immunity,	  and	  adaptive	  immunity	  responses.	  These	  results	  also	  offer	  insights	  to	  differential	  regulation	  of	  acute-­‐	  vs	  chronic-­‐inflammation	  by	  the	  antagonistic	  activities	  of	  chromatin	  writers	  and	  erasers,	  namely	  H3K9me1/2	  methyltransferase	  G9a	  and	  H3K9me1/2	  demethylase	  PHF8,	  respectively.
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CHAPTER	  1:	  INTRODUCTION	  
OVERVIEW	  	   The	  mammalian	  immune	  system	  is	  a	  complicated	  and	  tightly	  regulated	  system	  that	  can	  recognize	  self	  and	  non-­‐self	  cells	  or	  molecules,	  providing	  protection	  from	  a	  wide	  variety	  of	  pathogens.	  Recognition	  of	  non-­‐self	  molecules	  leads	  cells	  of	  immunity	  to	  activate	  various	  signaling	  pathways,	  which	  lead	  to	  activation	  or	  repression	  of	  specific	  genes	  to	  induce	  inflammation	  response.	  At	  the	  core	  of	  this	  gene-­‐specific	  regulation	  of	  inflammation	  is	  the	  chromatin	  remodeling.	  As	  the	  need	  to	  understand	  the	  tight	  regulation	  of	  epigenetics	  in	  inflammation	  response	  increases,	  various	  chromatin	  modifiers	  functioning	  as	  pro-­‐	  or	  anti-­‐inflammatory	  factors	  have	  been	  studied	  extensively.	  Here	  I	  provide	  an	  overview	  of	  innate	  immunity,	  Toll-­‐like	  receptors	  (TLR),	  and	  epigenetic	  regulation	  of	  both	  transcription	  and	  inflammation	  response	  through	  methylation.	  
INNATE	  IMMUNITY	  AND	  TOLL-­‐LIKE	  RECEPTORS	  Mammalian	  immunity	  is	  composed	  of	  two	  systematic	  layers:	  innate	  and	  adaptive	  immunity.	  They	  are	  responsible	  for	  recognition	  of	  pathogens	  and	  elimination	  of	  them,	  respectively.	  As	  the	  first	  line	  of	  host	  defense,	  pathogen	  recognition	  in	  innate	  immunity	  is	  achieved	  through	  activation	  of	  pattern	  recognition	  receptors	  (PRRs).	  PRRs	  are	  activated	  through	  recognition	  of	  the	  specific	  pathogen-­‐associated	  molecular	  patterns	  (PAMPs)	  (Janeway	  &	  Medzhitov,	  2002).	  Currently	  the	  main	  PRRs	  known	  in	  the	  innate	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immune	  system	  are	  the	  TLR,	  the	  NOD-­‐like	  receptors	  (NLR),	  the	  RIG-­‐like	  receptors	  (RLR),	  cytosolic	  DNA	  sensors	  (CDS),	  and	  the	  C-­‐type	  lectin	  receptors	  (CLR)	  (Kawai	  &	  Akira,	  2011).	  The	  first	  PRR	  family	  to	  be	  identified	  and	  most	  widely	  studied	  was	  TLR	  that	  recognizes	  a	  wide	  range	  of	  PAMPs	  and	  activates	  downstream	  pathways.	  	  As	  type	  I	  transmembrane	  proteins,	  TLRs	  are	  composed	  of	  an	  extracellular	  ectodomain	  containing	  Leucine-­‐rich-­‐repeat	  (LRR)	  motif	  and	  a	  cytoplasmic	  Toll-­‐interleukin-­‐1	  Receptor	  (Toll-­‐IL-­‐1R	  or	  TIR)	  domain	  responsible	  for	  relaying	  the	  signal	  to	  the	  downstream	  adapters	  (Akira	  et	  al,	  2006)	  (Figure1A).	  LRR	  domain	  consists	  of	  19-­‐25	  tandem	  copies	  of	  the	  leucine-­‐rich	  motif	  of	  24-­‐29	  amino	  acids	  such	  as	  XLXXLXLXX	  and	  
XΦXXΦXXXXFXXLX	  where	  X	  represents	  any	  amino	  acid	  and	  Φ	  represents	  a	  hydrophobic	  amino	  acid	  (Figure	  1B)	  (Akira	  &	  Takeda,	  2004).	  These	  repeats	  are	  composed	  of	  a	  β-­‐strand	  and	  an	  α-­‐helix	  connected	  with	  loops	  creating	  a	  concave	  surface	  responsible	  for	  ligand	  recognition	  (Figure	  1C-­‐D).	  On	  the	  other	  hand,	  TIR	  domains	  have	  only	  20-­‐30%	  sequence	  homology	  with	  three	  conserved	  regions	  required	  for	  signaling.	  	  TLRs	  are	  divided	  into	  subfamilies	  based	  on	  the	  ligand	  they	  recognize:	  TLR1,	  TLR2,	  and	  TLR6	  recognize	  lipids,	  TLR7,	  TLR8,	  and	  TLR9	  recognize	  nucleic	  acids,	  TLR3	  recognizes	  double	  stranded	  DNA	  (dsDNA)	  from	  viruses,	  TLR4	  recognizes	  lipopolysaccharide	  (LPS)	  from	  Gram-­‐negative	  bacteria,	  and	  TLR5	  recognizes	  flagellin	  from	  Flagellated	  bacteria	  (Figure	  2,	  Table	  1)	  (Akira	  et	  al,	  2006).	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Table	  1	  TLR	  ligands	  and	  cellular	  localization	  (Kumar	  et	  al,	  2011)
	  	  	   Upon	  ligand	  recognition,	  TLRs	  induce	  host	  defense	  genes	  through	  activation	  of	  two	  major	  downstream	  pathways	  based	  on	  the	  adapter	  protein	  involved:	  Myeloid	  differentiation	  primary	  response	  gene	  88	  (MyD88)-­‐dependent	  and	  MyD88-­‐independent,	  also	  known	  as	  TIR-­‐domain	  containing	  adapter-­‐inducing	  interferon-­‐β	  (TRIF)-­‐dependent,	  pathways	  (Janeway	  &	  Medzhitov,	  2002).	  All	  TLRs	  except	  TLR3	  are	  MyD88-­‐dependent	  pathways	  while	  TLR4	  stimulation	  activates	  both	  MyD88-­‐dependent	  and	  –independent	  pathways	  (Figure	  2).	  Throughout	  this	  dissertation,	  I	  focused	  mainly	  on	  studying	  the	  events	  downstream	  MyD88-­‐dependent	  TLR4	  signaling.	  
MyD88-­‐Dependent	  Signaling	  	  Since	  MyD88	  is	  involved	  in	  all	  TLR	  signaling	  pathways	  except	  TLR3,	  it	  is	  critical	  for	  innate	  immunity	  signaling	  responses	  (Akira	  &	  Takeda,	  2004).	  The	  structure	  of	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MyD88	  is	  composed	  of	  a	  C-­‐terminal	  TIR	  domain,	  an	  N-­‐terminal	  Death	  Domain	  (DD),	  and	  a	  short	  intermediate	  domain	  (ID)	  (Lin	  et	  al,	  2010).	  TIR	  domain	  is	  responsible	  for	  the	  recruitment	  of	  MyD88	  as	  a	  scaffold	  to	  the	  activated	  TLR	  to	  relay	  the	  signal	  to	  downstream	  elements	  (Ohnishi	  et	  al,	  2009).	  On	  the	  other	  hand,	  DD	  is	  responsible	  for	  homophilic	  interaction	  with	  the	  downstream	  elements	  such	  as	  IL-­‐1R-­‐associated	  kinases	  (IRAKs)	  IRAK-­‐1	  and	  IRAK-­‐4	  (Akira	  et	  al,	  2006).	  Activated	  IRAKs	  associate	  with	  Tumor	  necrosis	  factor	  (TNF)	  receptor	  (TNFR)-­‐associated	  factor	  6	  (TRAF6),	  inducing	  ubiquitination	  of	  the	  Inhibitor	  of	  kappaB	  (IκB)	  kinase	  (IKK)/Nuclear	  factor	  kappaB	  (NFκB)	  essential	  modulator	  	  (NEMO)	  complex	  and	  itself.	  In	  addition,	  another	  complex	  composed	  of	  Transforming	  growth	  factor-­‐β	  (TGF-­‐β)-­‐activated	  kinase	  1	  (TAK1)	  and	  TAK1	  binding	  proteins	  is	  recruited	  to	  TRAF6.	  TAK1	  recruitment	  is	  crucial	  for	  phosphorylation	  and	  subsequent	  activation	  of	  IKK-­‐β	  for	  the	  degradation	  of	  IκB,	  which	  in	  return	  exposes	  the	  nuclear-­‐localization	  signal,	  thus	  enables	  the	  early-­‐phase	  activation	  of	  NFκB	  transcription	  factor	  for	  the	  pro-­‐inflammatory	  cytokine	  expression	  (Figure	  2).	  	  
NFκB	  IN	  INFLAMMATION	  RESPONSE	  Downstream	  TLR	  pathways,	  transcription	  factor	  NFκB	  regulates	  the	  transcription	  of	  many	  immune	  response-­‐related	  genes	  such	  as	  cytokines,	  growth	  factors,	  effector	  enzymes	  in	  response	  to	  activation	  of	  immunity-­‐related	  receptors	  (Hayden	  &	  Ghosh,	  2004).	  Proteins	  in	  the	  NFκB	  family	  are	  divided	  into	  two	  subfamilies	  called	  the	  ‘NFκB’	  and	  the	  ‘Rel’	  proteins,	  all	  of	  which	  include	  an	  amino-­‐terminal	  conserved	  DNA-­‐binding/dimerization	  domain	  called	  the	  Rel-­‐homology	  domain	  (RHD)	  (Figure	  3)	  (Gilmore,	  2006).	  The	  NFκB	  subfamily	  proteins	  p100	  and	  p105	  are	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comprised	  of	  an	  inhibitory	  C-­‐terminus	  with	  multiple	  ankyrin	  repeat	  domains;	  they	  get	  activated	  through	  removal	  of	  these	  inhibitory	  domains	  by	  proteolysis	  leading	  to	  the	  exposure	  of	  the	  active	  forms	  p52	  and	  p50,	  respectively	  (Hoffmann	  &	  Baltimore,	  2006).	  These	  activated	  forms,	  as	  they	  don’t	  have	  trans-­‐activation	  domains	  (TADs),	  require	  heterodimerization	  with	  the	  Rel	  proteins	  to	  initiate	  transcription	  (Hayden	  &	  Ghosh,	  2012).	  The	  Rel	  proteins	  p65/RelA,	  RelB,	  and	  RelC	  have	  a	  C-­‐terminal	  TADs,	  which	  can	  activate	  transcription	  across	  many	  species	  although	  their	  sequences	  are	  not	  conserved	  the	  same	  way	  (Gilmore,	  2006).	  All	  five	  members	  of	  NFκB	  family	  can	  form	  homodimers	  or	  heterodimers	  in	  vivo,	  except	  RelB,	  which	  exists	  only	  in	  heterodimers	  in	  vivo	  (Figure	  
4).	  The	  variety	  of	  different	  homodimers	  and	  heterodimers	  create	  a	  multi-­‐layered	  regulation	  system	  as	  different	  dimers	  have	  different	  DNA-­‐binding	  site	  specificities	  and	  protein-­‐protein	  interactions	  at	  the	  promoters.	  In	  this	  thesis,	  I	  mainly	  focus	  on	  the	  transcriptional	  activity	  of	  the	  p65	  subunit	  downstream	  MyD88-­‐dependent	  TLR4	  pathways,	  because	  its	  nuclear	  translocation	  and	  DNA-­‐binding	  are	  indicators	  of	  transcriptional	  activation	  of	  NFκB	  target	  genes.	  	  
IκB	  Family	  Proteins	  Regulate	  p65	  Activity	  NFκB	  activity	  is	  regulated	  by	  interaction	  with	  seven	  IκB	  family	  proteins	  IκBα,	  IκBβ,	  IκBγ,	  IκBε,	  B-­‐cell	  lymphoma-­‐3	  (BCL-­‐3),	  IκBζ,	  and	  IκBζ	  as	  well	  as	  the	  precursor	  proteins	  p100	  and	  p105	  (Hayden	  &	  Ghosh,	  2012).	  IκB	  family	  proteins	  contain	  five	  to	  seven	  ankyrin	  repeats	  that	  modulate	  the	  interaction	  NFκB	  proteins	  (Hayden	  &	  Ghosh,	  2004).	  This	  interaction	  covers	  the	  Nuclear	  localization	  signal	  (NLS)	  of	  p65	  to	  successfully	  keep	  it	  in	  the	  inhibited	  state	  in	  the	  cytosol	  (Figure	  5)	  (Gilmore,	  2006).	  Through	  this	  inhibitory	  mechanism,	  the	  degradation	  of	  IκBs	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of	  IκBs	  by	  NFκB	  transcriptional	  activity	  leads	  to	  the	  dynamic	  balance	  between	  nuclear	  and	  cytoplasmic	  localization	  of	  NFκB,	  respectively	  (Sun	  &	  Andersson,	  2002).	  
Regulation	  of	  Transcriptional	  Activity	  of	  p65	  via	  Phosphorylation	  NFκB	  activity	  is	  also	  regulated	  by	  post-­‐translational	  modifications	  (PTMs),	  such	  as	  phosphorylation,	  acetylation,	  and	  methylation.	  Currently,	  phosphorylation	  of	  p65	  is	  the	  most	  common	  and	  most	  widely	  studied	  NFκB	  PTM	  because	  it	  is	  associated	  with	  rapid	  transactivation	  and	  transcriptional	  activity	  of	  p65	  (Figure	  6,	  Figure	  7)	  (Vermeulen	  et	  al,	  2006);	  thus,	  in	  this	  overview	  I	  will	  focus	  on	  the	  p65	  regulation	  through	  phosphorylation.	  Currently,	  five	  phosphorylation	  sites	  have	  been	  discovered	  to	  regulate	  p65	  activity:	  S276,	  S311,	  S468,	  S529,	  and	  S536	  (Figure	  6).	  S276	  resides	  in	  the	  RHD	  and	  gets	  phosphorylated	  by	  cyclic	  AMP-­‐dependent	  kinase	  (PKAc)	  (Zhong	  et	  al,	  1997)	  and	  by	  Mitogen-­‐	  and	  stress-­‐activated	  protein	  kinase	  1	  (MSK1)	  upon	  TNF	  treatment	  (Vermeulen	  et	  al,	  2003).	  Phosphorylation	  of	  this	  site	  is	  essential	  for	  gene	  activation	  (Zhong	  et	  al,	  1998).	  	  Another	  important	  phosphorylation	  is	  the	  phosphorylation	  of	  S311	  by	  Protein	  kinase	  C-­‐ζ	  (PKCζ)	  that	  is	  responsible	  for	  recruitment	  of	  cAMP	  response	  element	  binding	  protein	  (CREB)-­‐binding	  Protein	  (CBP)	  and	  RNA	  polymerase	  II	  (RNA-­‐PII)	  to	  the	  IL-­‐6	  promoter	  (Duran	  et	  al,	  2003).	  Moreover,	  S529	  is	  phosphorylated	  by	  casein	  kinase	  II	  (CKII)	  (Wang	  &	  Baldwin,	  1998)	  and	  IKK2	  enhancing	  transactivity	  of	  p65	  (Sakurai	  et	  al,	  1999).	  In	  addition	  to	  S529,	  IKK2	  also	  phosphorylates	  S536	  for	  transactivation	  upon	  IκB	  phosphorylation	  leading	  to	  enhanced	  binding	  to	  promoters	  with	  LPS	  stimulation.	  Ribosomal	  S6-­‐kinase	  1	  (RSK1)	  also	  phosphorylates	  S536	  through	  DNA	  damage	  response	  via	  p53	  signaling	  (Bohuslav	  et	  al,	  2004).	  In	  contrary	  to	  the	  other	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p65	  phosphorylation	  sites,	  S468	  phosphorylation	  is	  known	  as	  a	  negative	  regulator	  of	  transcription	  factor	  activity	  of	  p65	  upon	  TNF	  or	  IL-­‐1	  (Buss	  et	  al,	  2004;	  Mattioli	  et	  al,	  2004).	  	  It	  is	  important	  to	  note	  that	  the	  dynamic	  regulation	  of	  p65	  phosphorylation	  status	  is	  sustained	  by	  the	  interplay	  between	  kinases	  and	  phosphatases.	  	  Protein	  phosphatase-­‐2A	  (PP2A),	  protein	  phosphatase	  4	  (PP4),	  protein	  phosphatase	  1γ	  (PP1γ),	  wild-­‐type	  p53-­‐induced	  phosphatase	  1	  (WIP1),	  and	  phosphoserine	  phosphatase	  (SerB)	  are	  some	  of	  the	  known	  negative	  regulators	  of	  p65	  keeping	  it	  in	  the	  inactive	  state	  (Peng	  et	  al,	  2015;	  Takeuchi	  et	  al,	  2013;	  Yang	  et	  al,	  2001;	  Yeh	  et	  al,	  2004).	  	  	  
ENDOTOXIN	  TOLERANCE	  Inflammatory	  response,	  if	  persistent,	  may	  lead	  to	  severe	  reaction	  in	  the	  form	  of	  chronic	  inflammation	  since	  excessive	  cytokine	  production	  is	  harmful	  to	  the	  host	  (Beutler	  et	  al,	  1985;	  Kanterman	  et	  al,	  2012).	  Thus,	  the	  immune	  system	  is	  programmed	  to	  turn	  of	  inflammation	  to	  prevent	  tissue	  damage	  by	  immunosuppression.	  This	  phenomenon	  is	  called	  endotoxin	  tolerance	  (ET)	  (Dobrovolskaia	  &	  Vogel,	  2002).	  There	  are	  multiple	  inhibitory	  mechanisms	  that	  regulate	  endotoxin	  tolerance.	  
First,	  the	  expression	  and	  availability	  of	  the	  surface	  receptors	  are	  affected	  by	  the	  second	  exposure	  to	  the	  endotoxin	  (Fujihara	  et	  al,	  2003).	  In	  ET,	  RAW	  264.7	  cells	  show	  decreased	  mRNA	  expression	  of	  TLR4	  (Poltorak	  et	  al,	  1998)	  as	  well	  as	  decreased	  association	  of	  TLR4/Lymphocyte	  antigen	  96	  complexes	  (TLR4/MD2)	  (Akashi	  et	  al,	  2000;	  Nomura	  et	  al,	  2000).	  Second,	  the	  signaling	  pathway	  downstream	  the	  receptor	  gets	  interrupted.	  For	  example,	  ET	  leads	  to	  decreased	  IKK	  activation	  (Kohler	  &	  Joly,	  1997),	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IκB	  degradation	  (Medvedev	  et	  al,	  2000),	  NFκB	  translocation	  (Fujihara	  et	  al,	  2000;	  Kohler	  &	  Joly,	  1997;	  Medvedev	  et	  al,	  2000),	  IRAK-­‐1	  activation	  (Jacinto	  et	  al,	  2002;	  Li	  et	  al,	  2000),	  and	  ratio	  of	  p50/p65	  heterodimers	  to	  p50/p50	  homodimers	  (Adib-­‐Conquy	  et	  al,	  2000).	  In	  addition,	  increased	  negative	  regulators	  of	  TLR	  signaling,	  such	  as	  kinase	  IRAK-­‐M	  (Kobayashi	  et	  al,	  2002),	  suppressor	  of	  cytokine	  signaling	  1	  (SOCS1)	  (Kinjyo	  et	  al,	  2002),	  and	  MyD88short	  (MyD88s)	  (Burns	  et	  al,	  2003),	  a	  short	  alternative	  spliced	  form	  of	  MyD88	  lacking	  the	  ID,	  contributes	  to	  the	  ET.	  The	  last	  inhibitory	  mechanism	  is	  the	  regulation	  of	  secreted	  proteins/mediators	  via	  prolonged	  LPS	  stimulation,	  downregulating	  of	  cytokine	  expression	  in	  ET	  (Fujihara	  et	  al,	  2003).	  For	  example,	  prolonged	  LPS-­‐induced	  Interleukin	  10	  (IL10)	  secretion	  in	  macrophages	  disrupts	  expression	  of	  other	  inflammatory	  molecules	  such	  as	  cytokine	  Interfeuron-­‐γ	  (IFNγ)	  (Varma	  et	  al,	  2001),	  Tumor	  necrosis	  factor	  α	  (TNFα),	  Interleukin	  6	  (IL6),	  and	  macrophage	  colony	  stimulating	  factor	  (CSF)	  in	  ET	  (Berlato	  et	  al,	  2002).	  Similarly,	  increased	  Interfeuron-­‐β	  (IFNβ)	  leads	  to	  decreased	  TNFα	  and	  Interleukin	  8	  (IL8)	  expression	  in	  ET	  (Zaric	  et	  al,	  2011).	  	  ET,	  or	  also	  known	  as	  acquired	  immune	  tolerance,	  including	  that	  to	  endotoxin	  or	  LPS,	  if	  deregulated,	  is	  a	  major	  molecular	  feature	  of	  the	  pathogenesis	  of	  many	  chronic	  diseases	  including	  asthma,	  sepsis,	  and	  cancer	  (Biswas	  &	  Tergaonkar,	  2007).	  Deciphering	  the	  mechanisms	  that	  regulate	  LPS-­‐induced	  diverse	  inflammatory	  responses	  will	  be	  beneficial	  for	  diagnosis	  of,	  prevention	  of,	  and	  therapies	  for	  various	  inflammation-­‐associated	  diseases.	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EPIGENETIC	  REGULATION	  OF	  INFLAMMATION	  RESPONSE	  	  Inflammation	  response	  is	  also	  regulated	  at	  the	  epigenetic	  level	  by	  the	  LPS-­‐induced	  gene-­‐specific	  chromatin	  modifications,	  whereby	  the	  promoters	  of	  a	  select	  class	  of	  pro-­‐inflammatory	  or	  “tolerizeable”	  (T-­‐class)	  genes	  have	  differentially	  programmed	  chromatin	  based	  on	  the	  “inflammatory-­‐phenotype”,	  acutely	  versus	  chronically	  inflamed	  nature,	  of	  the	  stimulated	  cells	  (Foster	  et	  al,	  2007).	  As	  the	  core	  components	  of	  the	  chromatin,	  the	  properties	  of	  histones	  can	  be	  altered	  by	  different	  PTMs	  to	  their	  N-­‐	  terminal	  “tails”	  that	  leads	  to	  a	  predetermined	  combination	  of	  histone	  marks	  known	  as	  the	  “histone	  code”	  (Strahl	  &	  Allis,	  2000).	  These	  differentially	  modified	  histone	  marks	  determined	  whether	  the	  promoter	  they	  are	  in	  is	  in	  an	  open/active	  or	  closed/repressed	  chromatin	  state	  called	  euchromatin	  or	  heterochromatin,	  respectively	  (Figure	  8);	  thus,	  gene-­‐specific	  transcription	  is	  regulated	  through	  histone	  PTMs	  to	  achieve	  specific	  biological	  outcomes,	  such	  as	  inflammation	  response	  (Adcock	  et	  al,	  2007).	  The	  histone	  PTMs	  are	  added	  or	  removed	  by	  different	  enzymes	  termed	  “writers”	  and	  “erasers”,	  respectively	  (Figure	  8,	  Figure	  9)	  (Falkenberg	  &	  Johnstone,	  2014).	  Moreover,	  to	  signal	  for	  recruitment	  and	  activity	  of	  downstream	  effectors,	  histone	  “readers”	  are	  recruited	  to	  histone	  PTM	  sites	  (Yun	  et	  al,	  2011).	  	  Currently	  there	  are	  various	  PTMs	  known	  to	  modify	  histone	  N-­‐tails:	  methylation,	  acetylation,	  phosphorylation,	  citrullination,	  ubiquitination,	  SUMOylation,	  ADP-­‐ribosylation,	  and	  proline	  isomerization	  (Figure	  10)	  (Bayarsaihan,	  2011;	  Rothbart	  &	  Strahl,	  2014).	  DNA	  is	  also	  modified	  by	  methylation	  of	  the	  5	  position	  of	  the	  pyrimidine	  ring	  of	  cytosine	  (5mC)	  in	  somatic	  cells	  accompanying	  the	  histone	  PTMs	  for	  certain	  biological	  outcomes	  (Klose	  &	  Bird,	  2006).	  Histone	  PTMs	  are	  known	  as	  highly	  dynamic	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and	  reversible	  modifications	  and	  are	  regulated	  by	  the	  enzymatic	  activity	  of	  histone	  modifying	  enzymes	  such	  as	  acetyltransferases,	  deacetylases,	  methyltransferases,	  demethylases,	  kinases,	  phosphatases,	  ubiquitilases,	  and	  proline	  isomerases	  (Kouzarides,	  2007).	  Here,	  I	  will	  focus	  on	  histone	  methylation	  since	  the	  scope	  of	  this	  research	  is	  more	  relevant	  to	  this	  PTM	  and	  provide	  information	  on	  how	  this	  PTM	  is	  regulated.	  
Epigenetic	  Regulation	  of	  Transcription	  Through	  Methylation	  PTM	  Histone	  lysine	  methylation	  (Kme)	  is	  the	  most	  widely	  studied	  chromatin	  PTM	  with	  six	  well	  characterized	  lysines	  including	  H3K4,	  -­‐9,	  -­‐27,	  -­‐36,	  -­‐79,	  and	  H4K20	  (Shi	  &	  Whetstine,	  2007).	  In	  eukaryotes,	  Kme	  patterns	  regulate	  the	  chromatin	  architecture	  by	  dictating	  activated	  or	  repressed	  conformation	  (Barski	  et	  al,	  2007).	  Particularly	  on	  histone	  H3,	  the	  transcription-­‐associated	  Kme	  occurs	  at	  multiple	  lysine	  residues:	  methylated	  H3K4,	  H3K36,	  and	  H3K79	  are	  associated	  with	  transcriptional	  activation	  of	  specific	  genes	  while	  methylated	  H3K9	  and	  H3K27	  are	  associated	  mostly	  with	  gene	  repression	  (Martin	  &	  Zhang,	  2005).	  Site-­‐scpecific	  Kme	  levels	  are	  tightly	  regulated	  by	  the	  antagonistic	  activities	  of	  lysine	  methyltransferases	  (KMTs)	  and	  lysine	  demethylases	  (KDMs)	  to	  maintain	  cell	  homeostasis.	  Specific	  biological	  processes	  that	  promote	  gene	  activation,	  such	  as	  induced	  inflammatory	  response,	  require	  coordinated	  changes	  in	  the	  activity	  of	  LPS-­‐induced	  KMTs	  and	  KDMs	  increasing	  the	  activating	  methylation	  marks	  while	  decreasing	  the	  repressive	  methylation	  marks,	  respectively,	  at	  the	  promoters	  of	  those	  specific	  genes.	  
Histone	  lysine	  methyltransferases	  catalyze	  the	  transfer	  of	  a	  methyl-­‐group	  from	  S-­‐adenosylmethionine	  (SAM)	  to	  a	  lysine’s	  ε-­‐amino	  group	  (Bannister	  &	  Kouzarides,	  2011).	  All	  KMTs,	  except	  Disruptor	  of	  telomeric	  silencing	  (Dot1),	  are	  comprised	  of	  a	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conserved	  globular	  catalytic	  domain,	  which	  is	  called	  Su(var)3-­‐9,	  Enhancer-­‐of-­‐zeste	  and	  Trithorax	  (SET)	  domain.	  KMTs	  are	  relatively	  specific;	  they	  modify	  the	  target	  lysine	  to	  a	  specific	  degree	  (mono-­‐,	  di-­‐,	  or	  tri-­‐methyl	  state);	  for	  instance	  SET	  domain	  proteins	  7	  and	  9	  (Set7/9)	  can	  only	  mono-­‐methylate	  H3K4.	  Various	  targets	  of	  known	  KMTs	  are	  listed	  in	  
Table	  2.	  
Table	  2	  Histone	  lysine	  methyltransferases	  	  
Methyltransferases,	  their	  target	  site,	  and	  function	  (Bannister	  &	  Kouzarides,	  2011)	  
	  	  KMTs	  that	  belong	  to	  mixed	  lineage	  leukemia	  (MLL)	  protein	  family	  including	  MLL1,	  MLL2,	  MLL3,	  MLL4,	  SET1A,	  SET1B,	  and	  Absent,	  small,	  or	  homeotic	  1	  (ASH1)	  methylate	  H3K4	  (Wang	  &	  Zhu,	  2008).	  This	  family	  of	  KMTs	  are	  involved	  in	  development,	  and	  genetics,	  while	  MLL1	  gene	  mutations	  were	  found	  associated	  with	  leukemia.	  In	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addition,	  H3K4	  is	  methylated	  by	  SET,	  and	  Myeloid,	  Nervy,	  and	  Deformed	  epidermal	  Autoregulatory	  Factor	  1	  (MYND)	  domain-­‐containing	  3	  (SMYD3)	  during	  gene	  activation	  (Gibbons,	  2005).	  H3K9	  methylation	  is	  involved	  in	  many	  biological	  processes	  such	  as	  transcriptional	  regulation,	  X	  chromosome	  silencing,	  heterochromatin	  formation,	  and	  DNA	  methylation	  (Wang	  &	  Zhu,	  2008).	  One	  of	  the	  most	  widely	  studied	  H3K9	  KMT	  is	  G9a,	  which	  dimethylates	  H3K9	  in	  euchromatic	  regions;	  this	  G9a-­‐mediated	  H3K9	  methylation	  is	  responsible	  for	  the	  silencing	  of	  individual	  genes	  (Martin	  &	  Zhang,	  2005).	  In	  addition	  to	  G9a,	  KMT	  Suppressor	  Of	  Variegation	  3-­‐9	  Homolog	  1	  (Suv39h1)	  methylates	  H3K9	  (Wang	  &	  Zhu,	  2008).	  Suv39h1	  targets	  both	  euchromatin	  and	  heterochromatin	  and	  regulates	  heterochromatin	  formation	  as	  well	  as	  transcriptional	  inhibition	  by	  tri-­‐methylating	  H3K9.	  Moreover,	  Suv39h1-­‐dependent	  H3K9	  methylation	  recruits	  the	  chromodomain	  of	  Heterochromatin	  protein	  1	  (HP1)	  during	  meiosis	  and	  cell	  cycle	  leading	  to	  DNA	  methylation	  for	  transcriptional	  repression	  (Biel	  et	  al,	  2005;	  Martin	  &	  Zhang,	  2005;	  Peters	  et	  al,	  2001).	  	  H3K27	  methylation	  is	  catalyzed	  by	  Enhancer	  of	  zeste	  2	  polycomb	  repressive	  complex	  2	  subunit	  (EZH2),	  which	  forms	  the	  Polycomb	  repressive	  complex	  (PRC)	  with	  other	  Polycomb-­‐group	  (PcG)	  proteins	  (Wang	  &	  Zhu,	  2008).	  As	  an	  H3K27	  methyltransferase,	  EZH2	  has	  an	  inhibitory	  effect	  on	  transcription	  and	  is	  known	  to	  regulate	  cell	  differentiation,	  fetal	  development,	  cell	  proliferation,	  and	  X	  chromosome	  inactivation	  (Biel	  et	  al,	  2005;	  Wang	  &	  Zhu,	  2008).	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Histone	  demethylation	  was	  considered	  irreversible	  for	  decades	  due	  to	  the	  stability	  of	  the	  C-­‐N	  bond	  (Mosammaparast	  &	  Shi,	  2010).	  The	  first	  experimental	  evidence	  for	  an	  enzyme	  that	  catalyzes	  demethylation	  was	  the	  functional	  characterization	  of	  lysine-­‐specific	  demethylase	  1	  (LSD1,	  also	  known	  as	  KDM1A)	  as	  a	  member	  of	  the	  amine	  oxidase	  superfamily	  (Shi	  et	  al,	  2004).	  Demethylation	  by	  the	  amine	  oxidases	  occurs	  through	  cleavage	  of	  the	  α-­‐carbon	  bond	  of	  the	  substrate	  leading	  to	  an	  imine	  intermediate	  that	  further	  gets	  hydrolyzed	  to	  produce	  an	  aldehayde	  and	  amine	  (Shi	  &	  Whetstine,	  2007).	  This	  is	  a	  flavin	  adenine	  dinucleotide	  (FAD)-­‐dependent	  reaction	  that	  requires	  a	  protonated	  nitrogen	  making	  it	  recognize	  only	  mono-­‐	  or	  di-­‐methylated	  lysine	  substrates	  (Figure	  11)	  (Bannister	  &	  Kouzarides,	  2011;	  Shi	  &	  Whetstine,	  2007).	  Thus,	  LSD1	  is	  specific	  for	  demethylation	  of	  H3K4me1/me2	  (Varier	  &	  Timmers,	  2011).	  However,	  LSD1	  specificity	  and	  activity	  is	  regulated	  by	  protein-­‐protein	  interactions	  (Shi	  &	  Whetstine,	  2007).	  Although	  in	  vitro	  purified	  LSD1	  can	  demethylate	  H3K4me1/2,	  nucleosomal	  H3K4me1/2	  demethylation	  by	  LSD1	  requires	  an	  interaction	  with	  the	  corepressor	  complex	  Corepressor	  for	  element-­‐1-­‐silencing	  transcription	  factor	  (CoREST)	  through	  the	  tower	  domain	  leading	  to	  increased	  stability	  of	  LSD1	  (Figure	  12)	  (Shi	  &	  Whetstine,	  2007).	  	  Another	  protein-­‐protein	  interaction	  regulating	  the	  LSD1	  substrate	  specificity	  is	  the	  androgen	  receptor	  (AR)	  complex	  formation,	  which	  switches	  LSD1	  from	  transcriptional	  repressor	  to	  transcriptional	  activator	  by	  changing	  the	  substrate	  specificity	  from	  H3K4me1/2	  to	  H3K9me1/2	  (Figure	  12).	  The	  second	  super	  family	  of	  KDMs	  is	  the	  dioxygenase	  family	  that	  demethylates	  histones	  in	  a	  α-­‐keto-­‐glutarate	  (αKG,	  also	  known	  as	  2-­‐oxoglutarate)	  and	  Fe(II)-­‐ion	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dependent	  manner	  through	  their	  catalytic	  Jumonji	  C-­‐terminal	  (JmjC)	  domain	  (Varier	  &	  Timmers,	  2011).	  The	  oxidative	  decarboxylation	  of	  αKG	  is	  coupled	  to	  hydroxylation	  of	  the	  methyl	  group	  that	  creates	  an	  unstable	  hydroxymethyl	  ammonium	  intermediate	  releasing	  formaldehyde	  (Figure	  13)	  (Mosammaparast	  &	  Shi,	  2010).	  The	  first	  JmjC	  proteins	  that	  were	  identified	  as	  KDMs	  are	  the	  Jumonji	  domain-­‐containing	  2	  (JMJD2)	  family	  proteins	  and	  the	  very	  first	  characterized	  high-­‐resolution	  structure	  belonged	  to	  JMJD2A,	  an	  H3K9	  and	  H3K36	  KDM,	  in	  this	  family.	  JMJD2A	  structure	  revealed	  that	  it	  consists	  of	  a	  Jumonji	  N-­‐terminal	  domain	  (JmjN),	  a	  JmjC	  domain,	  a	  C-­‐terminal	  zinc-­‐finger	  motif,	  and	  a	  β-­‐hairpin	  (Figure	  14A).	  The	  catalytic	  core	  consists	  of	  the	  JmjC	  domain	  in	  which	  two	  histidine	  and	  one	  glutamate	  residue	  are	  essential	  for	  catalytic	  activity	  as	  they	  chelate	  the	  catalytic	  iron	  atom	  as	  shown	  in	  Figure	  14B.	  
Role	  of	  Lysine	  Methylation	  in	  Regulation	  of	  Inflammation	  Response	  The	  first	  histone	  Kme	  discovered	  regulating	  the	  inflammatory	  response	  is	  the	  dynamically	  regulated	  H3K9	  methylation	  (Saccani	  &	  Natoli,	  2002).	  Gene-­‐specific	  activation	  and	  post-­‐induction	  repression	  of	  some	  of	  the	  inducible	  inflammatory	  genes	  happens	  through	  demethylation	  and	  remethylation	  of	  H3K9,	  respectively.	  Moreover,	  demethylation	  and	  remethylation	  of	  H3K9	  is	  correlated	  with	  RNA-­‐PII	  recruitment	  and	  release,	  respectively,	  to	  the	  promoters.	  	  In	  line	  with	  this	  observation,	  later	  on,	  H3K9me2	  was	  found	  as	  a	  major	  regulator	  of	  ET	  through	  the	  activity	  of	  HAT	  G9a	  in	  the	  promoters	  of	  “T-­‐class”	  genes	  (El	  Gazzar	  et	  al,	  2008).	  Moreover,	  by	  doing	  so,	  G9a	  recruits	  HP1	  forming	  a	  repressive	  complex	  at	  promoters	  of	  RelB-­‐dependent	  genes	  in	  ET,	  diminishing	  the	  NFκB	  binding	  (Chan	  et	  al,	  2005;	  Chen	  et	  al,	  2009;	  El	  Gazzar	  et	  al,	  2007).	  Subsequently,	  DNA	  Methyl-­‐transferase	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(DNMT)	  3A/B	  (DNMT3A/B)	  gets	  recruited	  to	  the	  repressive	  complex	  for	  CpG	  meythylation	  (Figure	  15)	  (El	  Gazzar	  et	  al,	  2008).	  G9a	  also	  recruits	  members	  of	  other	  repressive	  complexes	  such	  as	  CoREST,	  C-­‐terminal	  binding	  protein	  (CtBP),	  and	  Switch/Sucrose	  Non-­‐Fermentable	  (SWI/SNF),	  creating	  a	  strong	  transcriptionally	  repressive	  environment	  for	  immunosuppression	  at	  ET	  and	  leading	  to	  global	  changes	  in	  the	  histone	  PTM	  landscape,	  chromatin	  remodeling,	  and	  activities	  of	  select	  transcription	  factors	  (Figure	  16)	  (Liu	  et	  al,	  2014).	  	  H3K27me3,	  another	  repressive	  histone	  PTM,	  regulates	  expression	  of	  specific	  inflammatory	  genes	  (De	  Santa	  et	  al,	  2007).	  Regulation	  of	  H3K27me3	  is	  achieved	  by	  the	  opposite	  activities	  of	  KDM	  Jumonji	  domain-­‐containing	  3	  (JMJD3,	  also	  known	  as	  KDM6B)	  and	  KMT	  complex	  PcG	  in	  macrophage	  response	  (De	  Santa	  et	  al,	  2007;	  Ishii	  et	  al,	  2009;	  Köhler	  &	  Villar,	  2008).	  JMJD3	  is	  induced	  with	  inflammatory	  stimulation	  and	  gets	  recruited	  to	  PcG	  target	  genes,	  decreasing	  H3K27me3	  levels	  at	  Signal	  Transducers	  and	  Activators	  of	  Transcription	  6	  (STAT6)	  promoter	  and	  enhancing	  transcriptional	  activity.	  The	  subsequent	  activation	  of	  STAT6	  enhances	  binding	  to	  JMJD3	  promoter	  and	  positively	  regulates	  the	  expression	  of	  specific	  inflammatory	  genes.	  Interestingly,	  JMJD3	  controls	  the	  transcription	  of	  the	  70%	  of	  the	  LPS-­‐inducible	  genes	  (De	  Santa	  et	  al,	  2009),	  indicating	  the	  essential	  role	  of	  histone	  PTM	  changes	  in	  macrophage	  activation.	  Lysine	  demethylase	  5B	  (KDM5B,	  also	  known	  as	  Jumonji/	  AT-­‐rich	  interactive	  domain	  -­‐	  or	  ARID-­‐	  domain-­‐containing	  protein	  1B	  or	  JARID1B)	  is	  another	  histone	  demethylase	  that	  regulates	  inflammation	  response	  (Ptaschinski	  et	  al,	  2015).	  KDM5B	  is	  a	  histone	  H3K4	  demethylase	  that	  negatively	  regulates	  innate	  cytokine	  expression	  to	  alter	  the	  immune	  response,	  as	  in	  ET,	  contributing	  to	  the	  development	  of	  chronic	  lung	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disease.	  Similarly,	  LSD	  represses	  inflammatory	  genes	  in	  preadipocytes	  through	  increased	  recruitment	  of	  CCAAT-­‐enhancer	  binding	  protein	  (CEBP)	  and	  p65	  to	  the	  IL6	  promoter	  (Hanzu	  et	  al,	  2013).	  With	  obesity,	  LSD1	  gets	  decreased	  leading	  to	  expression	  of	  pro-­‐inflammatory	  cytokines	  and	  obesity-­‐associated	  inflammation.	  There	  have	  been	  other	  reports	  demonstrating	  evidence	  for	  the	  role	  LSD1	  in	  cytokine	  repression	  of	  IL1α,	  IL1β,	  IL6,	  and	  IL8	  (Janzer	  et	  al,	  2012).	  Histone	  KMTs,	  which	  target	  activating	  methyl-­‐marks	  on	  H3,	  may	  act	  as	  co-­‐activators	  of	  inducible	  inflammatory	  genes;	  one	  such	  example	  is	  the	  H3K4	  KMT	  Set7/9	  that	  regulates	  select	  inflammatory	  gene	  transcription	  through	  regulation	  of	  NFκB	  recruitment	  to	  the	  cytokine-­‐induced	  inflammatory	  promoters	  (Figure	  17)	  (Fujimaki	  et	  al,	  2015;	  Li	  et	  al,	  2008).	  Similarly,	  a	  H3K4	  KMT	  MLL1	  regulates	  the	  TNF-­‐induced	  activation	  of	  NFκB	  target	  genes	  (Wang	  et	  al,	  2014b).	  Activated	  NFκB	  recruits	  MLL1,	  through	  binding,	  to	  the	  target	  genes.	  	  On	  the	  other	  hand,	  there	  are	  repressive	  KMTs	  that	  suppress	  pro-­‐inflammatory	  gene	  expression	  in	  immunosuppression	  or	  ET.	  For	  example,	  	  H3K4/H3K36	  KMT	  ASH1	  Like	  (ASH1L)	  suppresses	  NFκB	  signaling	  and	  proinflammatory	  gene	  expression	  for	  successful	  immunosuppression	  (Xia	  et	  al,	  2013).	  Similarly,	  SET	  and	  MYND	  domain	  containing	  2	  (Smyd2)	  is	  a	  negative	  regulator	  of	  macrophage	  activation	  (Xu	  et	  al,	  2015).	  With	  macrophage	  activation	  Smyd2	  expression	  gets	  dramatically	  decreased	  and	  in	  ET	  Smyd2	  dimethylates	  H3K36	  at	  TNF	  and	  IL6	  promoters	  and	  inhibits	  NFκB	  signaling	  in	  macrophages.	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FIGURES	  
	  
Figure	  1	  TLR	  structure	  	  
(A)	  Structural	  model	  of	  TLR3-­‐dsRNA	  complex	  based	  on	  the	  mTLR3-­‐dsRNA	  structure	  (3CIY)	  and	  	  
TLR3	  TIR	  domain	  homology	  model	  on	  the	  TLR10	  TIR	  structure	  structure	  (2J67)	  (Botos	  et	  al,	  
2011).	  (B)	  LRR	  consensus	  sequence	  for	  TLR3	  where	  orange	  highlighted	  residues	  represent	  the	  β-­‐
sheets	  (Botos	  et	  al,	  2011).	  (C)	  A	  LRR	  loop	  from	  hTLR3	  with	  the	  conserved	  residues	  forming	  the	  
hydrophobic	  core	  where	  the	  box	  highlights	  the	  ligand	  binding	  residues.	  	  (D)	  Ribbon	  diagram	  of	  
TLR3	  ectodomain	  structure	  (2A0Z)	  (Bell	  et	  al,	  2005).	  
	  
Figure	  2	  Mammalian	  TLR	  signaling	  pathways	  
TLR5,	  TLR11,	  and	  the	  heterodimers	  of	  TLR2-­‐TLR1,	  or	  TLR2-­‐TLR6	  reside	  on	  the	  cell	  surface	  to	  bind	  
to	  their	  respective	  ligands.	  TLR7-­‐TLR8,	  TLR9,	  and	  TLR13	  reside	  in	  the	  endosomes	  to	  recognize	  the	  
microbial	  nucleic	  acids.	  TLR4	  localizes	  to	  both	  cell	  surface	  and	  endosomes.	  Surface	  TLRs	  lead	  to	  
activation	  of	  pro-­‐inflammatory	  cytokines	  while	  the	  endosomal	  TLRs	  induce	  type	  I	  IFN	  (O'Neill	  et	  
al,	  2013).	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Figure	  3	  Domain	  structure	  of	  the	  NFκB	  signaling	  proteins	  
The	  general	  domain	  structure	  of	  Rel	  and	  NFκB	  subfamily	  transcription	  factors	  (left)	  consists	  of	  a	  
conserved	  DNA-­‐binding/dimerization	  domain	  called	  the	  Rel	  homology	  domain	  (RHD)	  with	  
nuclear	  localization	  and	  IkB	  binding	  sequences.	  The	  C-­‐terminal	  halves	  of	  the	  Rel	  proteins	  have	  
transcriptional	  activation	  domains	  (TAD).	  The	  C-­‐terminal	  halves	  of	  the	  NFκB	  subfamily	  proteins	  
have	  ankyrin	  repeat-­‐containing	  inhibitory	  domains	  (red	  bars),	  which	  can	  be	  removed	  by	  
proteasome-­‐mediated	  proteolysis.	  As	  with	  the	  C-­‐terminal	  domains	  of	  the	  NF-­‐kB	  proteins,	  the	  
independent	  IκB	  proteins	  consist	  mainly	  of	  ankyrin	  repeats,	  and	  several	  (IκBα,	  IκBβ,	  IκBε,	  IBγ)	  
have	  two	  N-­‐terminal	  serine	  residues	  (S)	  that	  serve	  as	  IKK	  phosphorylation	  sites,	  which	  signal	  the	  
protein	  for	  ubiquitination	  and	  degradation.	  The	  generalized	  structures	  of	  IKKα	  and	  β	  (kinase	  
domain;	  HLH,	  helix-­‐loop-­‐helix;	  LZ,	  leucine	  zipper;	  NBD,	  NEMO	  binding	  domain)	  and	  of	  NEMO	  (CC,	  
coiled	  coil;	  LZ,	  leucine	  zipper;	  ZF,	  zinc	  finger)	  are	  also	  shown	  (right)	  (Gilmore,	  2006).	  	  
	  
Figure	  4	  NFκB	  dimers	  
Five	  NFκB	  polypeptides	  can	  form	  15	  transcription	  factor	  homo-­‐	  and	  hetero-­‐dimers.	  The	  top	  four	  
rows	  show	  nine	  dimers	  that	  can	  function	  as	  transcriptional	  activators,	  the	  fifth	  row	  indicates	  
dimers	  lacking	  transcriptional	  activation	  domains,	  and	  the	  bottom	  row	  shows	  dimers	  that	  are	  not	  
able	  to	  bind	  DNA	  (Hoffmann	  &	  Baltimore,	  2006).	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Figure	  5	  NFκB	  bound	  to	  IκB	  proteins	  
(A)	  The	  structure	  of	  IBα	  to	  the	  p50:RelA	  heterodimer	  where	  the	  NLS	  of	  RelA,	  which	  is	  
unstructured	  in	  the	  absence	  of	  	  IκB	  proteins,	  folds	  into	  a	  helical	  structure	  when	  bound	  to	  IκBα	  
while	  the	  NLS	  of	  p50	  doesn’t	  interact	  with	  IκBα.	  (B)	  The	  structure	  of	  IBβ	  bound	  to	  RelA	  
homodimer.	  One	  NLS	  interacts	  with	  IκBβ	  as	  that	  in	  A	  while	  the	  other	  has	  weak	  contacts	  (Hoffmann	  
&	  Baltimore,	  2006).	  	  
	  
	  
Figure	  6	  Phosphorylated	  residues	  of	  p65	  (RelA)	  	  
The	  known	  phosphorylated	  residues	  are	  S276,	  S311,	  S468,	  S529,	  and	  S536	  (Vermeulen	  et	  al,	  
2006).	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Figure	  7	  Model	  of	  regulation	  of	  NFκB	  transactivation	  through	  phosphorylation	  
Following	  stimulation,	  activated	  IKK	  complexes	  phosphorylate	  IκB,	  leading	  to	  its	  degradation.	  
NFκB	  dimers	  enter	  the	  nucleus	  as	  p65	  is	  phosphorylated	  and	  binds	  to	  CBP.	  The	  inactive	  p50–p50–
HDAC1	  complex	  gets	  replaced	  by	  the	  active	  p50-­‐p65-­‐CBP	  complexes	  activating	  the	  transcription	  
of	  target	  genes.	  Furthermore,	  HDAC3	  might	  help	  to	  switch	  off	  NFκB	  activity	  by	  deacetylating	  p65	  
and	  enhancing	  the	  binding	  affinity	  between	  p65–p50	  and	  IκBα	  (Li	  &	  Verma,	  2002).	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Figure	  8	  Chromatin	  modifications	  and	  regulators	  
Chromatin	  modifications	  open	  or	  close	  the	  chromatin	  structure,	  thereby	  activating	  or	  repressing	  
gene	  expression.	  These	  modifications	  are	  catalyzed	  or	  reversed	  by	  different	  enzymes	  known	  as	  
“writers”	  or	  “erasers,”	  respectively.	  An	  example	  of	  writer	  and	  eraser	  for	  each	  modification	  is	  
shown	  in	  the	  color	  of	  the	  modification.	  Modified	  residues	  are	  recognized	  and	  interpreted	  by	  
different	  protein	  modules,	  known	  as	  “readers.”	  Overall,	  the	  chromatin	  compaction,	  loss	  of	  histone	  
activation	  marks,	  and	  removal	  of	  transcription	  factors	  accompany	  gene	  (Bierne	  et	  al,	  2012).	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Figure	  9	  Dynamic	  epigenetic	  regulation	  
Epigenetic	  writers	  such	  as	  histone	  acetyltransferases	  (HATs),	  histone	  methyltransferases	  (HMTs),	  
protein	  arginine	  methyltransferases	  (PRMTs)	  and	  kinases	  lay	  down	  epigenetic	  marks	  on	  amino	  
acid	  residues	  on	  histone	  tails.	  Epigenetic	  readers	  such	  as	  proteins	  containing	  bromodomains,	  
chromodomains	  and	  Tudor	  domains	  bind	  to	  these	  epigenetic	  marks.	  Epigenetic	  erasers	  such	  as	  
histone	  deacetylases	  (HDACs),	  lysine	  demethylases	  (KDMs)	  and	  phosphatases	  catalyse	  the	  
removal	  of	  epigenetic	  marks.	  Addition	  and	  removal	  of	  these	  post-­‐translational	  modifications	  of	  
histone	  tails	  leads	  to	  the	  addition	  and/or	  removal	  of	  other	  marks	  in	  a	  highly	  complicated	  histone	  
code.	  Together,	  histone	  modifications	  regulate	  various	  DNA-­‐dependent	  processes,	  including	  
transcription,	  DNA	  replication	  and	  DNA	  repair	  (Falkenberg	  &	  Johnstone,	  2014).	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Figure	  10	  Modifications	  of	  the	  histone	  histone	  tails	  	  
The	  sites	  of	  the	  PTMs	  are	  indicated	  with	  corresponding	  cellular	  functions	  on	  the	  left	  (Arnaudo	  &	  
Garcia,	  2013).	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Figure	  11	  Chemical	  mechanism	  for	  FAD-­‐dependent	  demethylation	  	  
The	  reaction	  schematic	  shows	  LSD1	  removing	  a	  methyl	  group	  from	  a	  dimethylated	  lysine	  residue	  
and	  the	  reaction	  can	  be	  repeated	  until	  lysine	  is	  unmethylated	  (Shi	  &	  Whetstine,	  2007).	  
	  
	  
Figure	  12	  Schematic	  diagrams	  of	  LSD1	  Domains	  
3D	  structures,	  and	  mechanism	  of	  action	  are	  shown.	  LSD1	  domains	  are	  indicated	  by	  different	  
colors	  (AOD:	  Amine	  oxidase	  domain).	  LSD1	  alone	  demethylates	  H3K4me1/2.	  CoREST	  interacts	  
with	  the	  tower	  region	  of	  LSD1	  (upper	  interaction)	  leading	  to	  nucleosomal	  demethylation.	  The	  
human	  androgen	  receptor	  has	  also	  been	  shown	  to	  interact	  with	  LSD1	  to	  demethylate	  H3K9me1/2	  
(Shi	  &	  Whetstine,	  2007).	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Figure	  13	  Chemical	  mechanism	  for	  demethylation	  by	  JmjC	  
The	  reaction	  schematic	  shows	  Fe(II)	  and	  the	  α-­‐keto-­‐glutarate-­‐dependent	  dioxygenase-­‐mediated	  
demethylation.	  Red	  indicates	  carbons	  that	  are	  demethylated	  in	  each	  reaction	  (Mosammaparast	  &	  
Shi,	  2010).	  
	  
Figure	  14	  Structure	  of	  JMJD2A	  bound	  to	  substrate	  
(A)	  Overall	  structure	  showing	  the	  domains	  of	  JMJD2A	  bound	  to	  H3K36me3	  and	  inhibitor	  N-­‐
oxalglycine	  (NOG)	  (Mosammaparast	  &	  Shi,	  2010).	  (B)	  The	  catalytic	  core	  of	  JMJD2A	  consists	  of	  His	  
and	  Glu	  aminoacids	  responsible	  for	  coordinating	  the	  Fe(II)	  (red	  circle)	  and	  α-­‐ketoglutarate	  (Shi	  &	  
Whetstine,	  2007).	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Figure	  15	  	  Proinflammatory	  gene	  silencing	  by	  G9a	  during	  endotoxin	  tolerance	  
G9a	  is	  responsible	  for	  the	  recruitment	  of	  DNA	  methyltransferases	  in	  addition	  to	  increased	  
repressive	  histone	  H3K9	  methylation	  (El	  Gazzar	  et	  al,	  2008).	  
	  
Figure	  16	  G9a	  stabilizes	  c-­‐Myc	  and	  promotes	  cell	  survival	  in	  ET	  
(A)	  In	  LPS-­‐responsive	  macrophages	  the	  chromatin	  remodeling	  complex	  favors	  the	  acetylated	  
H3K9	  for	  active	  transcription	  of	  pro-­‐inflammatory	  genes.	  (B)	  In	  ET,	  G9a	  recruites	  the	  repressive	  
chromatin	  remodeling	  complexes	  for	  silencing	  of	  proinflammatory	  genes	  while	  selectively	  
promotes	  c-­‐Myc	  transcription	  factor	  activity	  to	  repress	  select	  genes	  (Liu	  et	  al,	  2014).	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Figure	  17	  Regulatory	  function	  of	  SET7/9	  on	  NFκB	  and	  inflammatory	  gene	  expression	  	  
SET7/9	  transforms	  the	  promoter	  from	  a	  “dormant”	  state	  to	  “active”	  state	  as	  it	  stabilizes	  and	  
enhances	  p65	  recruitment	  to	  select	  gene	  promoters	  where	  H3K4	  methylation	  is	  increased	  
simultaneously	  for	  augmented	  expression	  (Li	  et	  al,	  2008).	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CHAPTER	  2:	  CHRONICALLY	  ACTIVE	  PP2Ac	  DEPHOSPHORYLATES	  VARIOUS	  
CHROMATIN	  MODIFIERS	  TO	  REGULATE	  ENDOTOXIN	  TOLERANCE	  
OVERVIEW	  Protein	  phosphatase	  PP2A	  is	  a	  major	  regulator	  of	  ET	  in	  macrophages	  (Xie	  et	  al,	  2013).	  PP2Ac	  not	  only	  dephosphorylates	  NFκB	  for	  successful	  suppression	  of	  target	  genes,	  but	  also	  affects	  the	  chromatin	  modeling	  in	  ET;	  however,	  it	  is	  still	  not	  clear	  how	  PP2Ac	  broadly	  affects	  the	  changes	  on	  the	  chromatin	  state.	  Here,	  we	  proposed	  to	  screen	  
ET-­‐specific	  PP2Ac	  targets	  that	  get	  dephosphorylated	  in	  ET	  using	  Amino-­‐acid-­‐coded	  mass	  
tagging	  (AACT)-­‐based	  quantitative	  phosphoproteomics	  to	  clarify	  the	  exact	  pathways	  and	  
biological	  processes	  modulated	  by	  chronically	  active	  PP2Ac	  activity.	  Our	  phosphoproteomic	  analysis	  revealed	  that	  the	  over-­‐represented	  biological	  processes	  extensively	  affected	  by	  chronically	  active	  PP2Ac	  were	  chromatin-­‐associated.	  Identifying	  ET-­‐specific	  PP2Ac-­‐targeted	  chromatin	  regulators	  helped	  us	  identify	  both	  functionally	  characterized	  and	  novel	  phosphosites	  involved	  in	  phenotypic	  control	  of	  acute	  versus	  chronic	  inflammation,	  leading	  to	  discovery	  of	  additional	  roles	  of	  PP2Ac	  in	  ET-­‐specific	  immunosuppression.	  Moreover,	  analysis	  of	  the	  PP2Ac-­‐dependent	  changes	  in	  the	  histone	  PTMs	  revealed	  H3K9me2	  and	  H3K27me2	  as	  the	  mostly	  affected	  histone	  PTM	  sites;	  thus,	  we	  conclude	  that	  the	  chromatin	  regulators,	  including	  PHF8,	  targeting	  these	  sites	  are	  crucial	  in	  the	  regulation	  of	  inflammatory	  phenotype.
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INTRODUCTION	  
Protein	  Phosphatases	  and	  PP2A	  	   Protein	  phosphorylation	  regulates	  many	  cellular	  processes,	  including	  regulation	  of	  proteolysis,	  transcription,	  metabolism,	  cell-­‐cycle	  progression,	  cell	  differentiation,	  cytoskeleton	  organization,	  cell	  movement,	  apoptosis,	  cell-­‐cell	  communication,	  neuronal	  functions,	  and	  immune	  responses	  (Johnson,	  2009).	  With	  such	  diverse	  functional	  roles	  in	  the	  cell,	  phosphorylation	  mainly	  targets	  hydroxyl-­‐group	  containing	  amino	  acids	  serine,	  threonine,	  and	  tyrosine	  with	  86.4%,	  11.8%	  and	  1.8%	  degree	  of	  phosphorylation,	  respectively	  (Seshacharyulu	  et	  al,	  2013).	  The	  high	  diversity	  of	  proteins	  regulated	  by	  phosphorylation	  demands	  high	  diversity	  of	  these	  enzymes	  enabling	  the	  proper	  regulation	  of	  the	  phosphorylation-­‐dependent	  events	  in	  the	  cell	  (Virshup,	  2000).	  	  Phosphoprotein	  phosphatases	  (PPPs),	  grouped	  into	  protein	  serine/threonine	  phosphatases	  (PSPs)	  and	  phosphotyrosine	  phosphatases	  (PYPs),	  are	  the	  enzymes	  that	  are	  responsible	  for	  the	  removal	  of	  the	  phosphate	  group	  in	  the	  presence	  of	  a	  water	  molecule.	  There	  are	  many	  subfamilies	  of	  PPPs:	  PP1,	  PP2A,	  PP2B,	  PP4,	  PP5,	  PP6,	  and	  PP7	  (Seshacharyulu	  et	  al,	  2013).	  	  PP2A	  is	  one	  of	  the	  most	  highly	  expressed	  phosphatase	  subunit	  constituting	  up	  to	  1%	  of	  the	  cellular	  protein	  (Virshup,	  2000).	  	  It	  controls	  many	  cellular	  events,	  including	  metabolism,	  cell	  cycle,	  DNA	  replication,	  transcription,	  translation,	  signal	  transduction,	  cell	  proliferation,cytoskeleton	  dynamics,	  cell	  mobility,	  and	  apoptosis	  (Figure	  18).	  PP2A	  holoenzymes	  exist	  in	  either	  dimeric	  or	  trimeric	  form;	  dimeric	  form	  is	  composed	  of	  a	  catalytic	  subunit	  (PP2Ac)	  and	  a	  scaffold	  subunit	  (PP2AA)	  while	  the	  trimeric	  form	  also	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includes	  the	  regulatory	  subunit	  (PP2AB)	  (Figure	  19)	  (Seshacharyulu	  et	  al,	  2013).	  The	  C-­‐terminal	  tail	  of	  PP2Ac	  is	  responsible	  for	  interaction	  with	  regulatory	  and	  scaffold	  subunits	  (Seshacharyulu	  et	  al,	  2013).	  The	  scaffold	  subunit,	  PP2AA,	  has	  multiple	  regulatory	  roles.	  In	  the	  heterotrimeric	  holoenzyme,	  PP2AA	  creates	  a	  structural	  bridge	  to	  accommodate	  the	  interaction	  between	  the	  catalytic	  subunit,	  regulatory	  subunit,	  and	  the	  substrates.	  On	  the	  other	  hand,	  in	  the	  dimeric	  form,	  it	  regulates	  the	  catalytic	  specificity.	  However,	  the	  main	  regulator	  of	  the	  holoenzyme	  is	  the	  regulatory	  subunit,	  PP2AB;	  it	  modulates	  the	  temporal	  and	  spatial	  specificity.	  	  
PP2A:	  A	  Major	  Regulator	  of	  NFκB	  Signaling	  One	  of	  the	  most	  important	  regulators	  of	  inflammatory	  response	  is	  the	  phosphatase	  PP2A;	  inhibition	  of	  PP2A	  catalytic	  activity	  was	  previously	  reported	  to	  affect	  macrophage	  regulation,	  cytokine	  expression,	  superanion	  generations,	  and	  phagocytosis	  (Barber	  et	  al,	  1995;	  Mayer	  et	  al,	  1995;	  Sung	  &	  Walters,	  1993;	  Zhang	  et	  al,	  2000).	  Moreover,	  various	  effects	  of	  the	  PP2A	  activity	  on	  the	  regulation	  of	  NFκB,	  such	  as	  inhibition	  of	  host	  response,	  have	  been	  characterized	  (Maslash-­‐Hubbard,	  2011).	  First,	  PP2A	  dephosphorylates	  and	  inhibits	  IKKα	  and	  IKKβ	  to	  regulate	  NFκB	  activity	  (Barisic	  et	  al,	  2008;	  DiDonato	  et	  al,	  1997);	  this	  effect	  is	  reversed	  with	  the	  PP2A	  inhibitor	  Okadaic	  acid	  (OA)	  treatment	  (Sun	  et	  al,	  1995).	  PP2Ac	  also	  downregulates	  MAPK	  pathways	  broadly,	  affecting	  cytokine	  expression	  through	  Activating	  Protein	  1	  (AP1)	  transcription	  factor	  inhibition	  (Shanley	  et	  al,	  2001).	  More	  importantly,	  PP2Ac	  directly	  dephosphorylates	  p65	  to	  downregulate	  its	  transcriptional	  activity	  (Hsieh	  et	  al,	  2011;	  Yang	  et	  al,	  2001);	  thus,	  its	  activity	  is	  an	  important	  regulator	  of	  immune	  tolerance	  (Sun	  et	  al,	  2015b).	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PP2A	  activity	  is	  associated	  with	  chronic	  inflammation	  while	  its	  inhibition	  excarbates	  the	  acute	  cigarette	  smoke-­‐induced	  acute	  inflammation	  in	  lungs	  (Wallace	  et	  al,	  2012).	  Recently,	  PP2Ac	  was	  functionally	  characterized	  as	  a	  major	  transcriptional	  regulator	  of	  ET	  in	  macrophages	  for	  successful	  immunosuppression	  of	  pro-­‐inflammatory	  genes	  (Sun	  et	  al,	  2015b;	  Xie	  et	  al,	  2013).	  Constitutively	  active	  PP2Ac	  inhibits	  TLR4-­‐
MyD88	  complex,	  gets	  translocated	  into	  the	  nucleus	  with	  MyD88,	  and	  selectively	  silences	  
pro-­‐inflammatory	  genes	  by	  establishing	  an	  immunosuppressive	  pattern	  on	  the	  chromatin	  (Figure	  20)	  (Xie	  et	  al,	  2013).	  	  Although	  PP2A	  activity	  leads	  to	  ET-­‐specific	  repressive	  chromatin	  state,	  the	  functional	  determinants	  of	  downstream	  modulators	  that	  are	  involved	  in	  the	  maintenance	  of	  the	  repressive	  chromatin	  are	  still	  missing.	  PP2Ac	  might	  directly	  target	  and	  remove	  the	  transcriptionally	  active	  mark	  phospho-­‐H3S10	  from	  nucleosomes	  in	  ET	  as	  it	  does	  in	  regulation	  of	  cell	  cycle	  and	  heat-­‐shock	  response	  (Nowak	  et	  al,	  2003;	  Simboeck	  et	  al,	  2010).	  On	  the	  other	  hand,	  PP2Ac	  might	  regulate	  the	  activity	  of	  chromatin	  modifying	  enzymes	  through	  dephosphorylation	  to	  maintain	  ET-­‐specific	  chromatin	  state.	  Although	  some	  Histone	  deacetrylases	  (HDACs),	  including	  HDAC4,	  HDAC5,	  and	  HDAC7,	  and	  Histone	  acetyl-­‐transferases	  (HATs),	  including	  p300	  and	  PCAF,	  show	  PP2Ac-­‐mediated	  dephosphorylation-­‐dependent	  change	  in	  enzymatic	  activity,	  there	  is	  no	  evidence	  for	  a	  similar	  mechanism	  in	  PP2Ac-­‐dependent	  ET	  control.	  	  To	  provide	  evidence	  for	  PP2Ac-­‐dependent	  activity	  in	  the	  regulation	  of	  chromatin	  modifying	  enzymes,	  various	  strategies,	  such	  as	  phosphoprotemic	  analysis,	  can	  be	  used.	  	  In	  this	  chapter,	  I	  aim	  to	  screen	  ET-­‐specific	  PP2A	  targets	  to	  identify	  the	  phosphorylation	  sites	  on	  chromatin	  modifying	  enzymes	  that	  may	  be	  involved	  in	  the	  ET-­‐specific	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chromatin	  states.	  Here,	  we	  use	  a	  phosphoproteomic	  screening	  method	  first,	  to	  identify	  possible	  PP2Ac-­‐targeted	  phosphorylation	  sites	  within	  the	  cell,	  followed	  by	  an	  immunoblotting-­‐based	  screening	  methods,	  to	  identify	  which	  histone	  PTMs	  are	  affected	  as	  a	  result	  of	  ET-­‐induced	  PP2Ac	  activity.	  	  
Phosphoprotein	  Sequencing	  Using	  Quantitative	  Proteomics	  	   Protein	  phosphorylation	  is	  one	  of	  the	  most	  widely	  studied	  PTM	  controlling	  the	  protein	  function	  (Delom	  &	  Chevet,	  2006).	  As	  a	  reversible	  and	  highly	  dynamic	  PTM,	  phosphorylation	  cannot	  be	  predicted	  by	  the	  genome	  and	  analytical	  measurements	  (Goshe,	  2006).	  Various	  traditional	  biochemical	  methods	  have	  been	  developed	  to	  characterize	  phosphorylation	  site	  of	  a	  protein	  of	  interest,	  many	  of	  which	  involve	  32P-­‐labeling	  of	  the	  proteins	  to	  analyze	  potential	  phospho-­‐sites	  (Delom	  &	  Chevet,	  2006;	  Goshe,	  2006).	  These	  methods	  depend	  on	  immunoblot	  analysis	  with	  phospho-­‐imaging	  to	  determine	  the	  level	  of	  32P-­‐label	  incorporation	  and	  phospho-­‐site	  specific	  antibodies	  for	  detection	  (Goshe,	  2006).	  The	  technical	  limitations	  of	  these	  traditional	  methods	  include	  inconvenience	  of	  radioactivity,	  post-­‐lysis	  labeling,	  time-­‐consuming	  sample	  preparation,	  lack	  of	  adaptation	  to	  high	  throughput	  pipelines,	  difficulty	  in	  antibody	  generation/validation,	  and	  low	  antibody	  specificity	  (Delom	  &	  Chevet,	  2006).	  Recently	  the	  development	  of	  mass	  spectrometric	  methods	  has	  overcome	  many	  of	  these	  technical	  limitations	  although	  there	  are	  still	  technical	  challenges	  for	  analysis	  of	  phosphoproteins	  due	  to	  five	  main	  reasons.	  First,	  phosphorylation	  stoichiometry	  is	  relatively	  low	  since	  a	  small	  fraction	  of	  cellular	  protein	  is	  phosphorylated	  at	  a	  given	  time.	  Second,	  any	  given	  phosphoprotein	  is	  heterogenous	  since	  there	  may	  be	  multiple	  phosphorylated	  sites	  and	  states	  and	  phosphorylation	  occurs	  at	  the	  solvent	  accessible	  space;	  thus,	  bottom-­‐up	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approach	  enables	  higher	  protein	  sequence	  coverage.	  Third,	  phosphorylated	  targets	  may	  have	  low	  abundance	  in	  cells,	  and	  thus	  need	  enrichment	  before	  analysis.	  Fourth,	  most	  analytical	  techniques	  may	  locate	  major	  phosphorylation	  sites	  but	  minor	  sites	  may	  be	  difficult	  to	  identify.	  Finally,	  during	  sample	  preparation	  cellular	  phosphatases	  may	  target	  those	  phosphorylation	  sites	  unless	  phosphatase	  inhibitors	  are	  used.	  	  	   One	  of	  the	  most	  widely	  used	  techniques	  for	  separation	  of	  proteins	  is	  sodium	  dodecyl	  sulfate	  polyacrylamide	  gel	  electrophoresis	  (SDS-­‐PAGE)	  which	  can	  be	  used	  with	  Liquid	  chromatography-­‐tandem	  mass	  spectrometry	  (LC-­‐MS/MS)	  in	  combination	  with	  immunoprecipitation	  to	  identify	  and	  characterize	  phosphoproteins	  (Figure	  21)	  (Goshe,	  2006).	  The	  major	  drawback	  of	  the	  gel-­‐based	  LC-­‐MS/MS	  analysis	  of	  phosphoproteins	  is	  that	  at	  least	  two	  unique	  peptides	  are	  required	  for	  confirmation	  of	  protein	  abundance	  in	  a	  gel	  slice.	  Moreover,	  even	  when	  sample	  amount	  is	  increased,	  sequence	  coverage	  can	  be	  low	  if	  the	  protein	  has	  low	  efficiency	  of	  peptide	  extraction	  from	  the	  gel.	  The	  peptide	  coverage	  can	  be	  increased	  with	  two-­‐dimensional	  (2D)	  gel	  analysis	  in	  which	  proteins	  are	  separated	  by	  isoelectrophoresis	  in	  addition	  to	  the	  molecular	  weight	  (Figure	  22).	  Although	  it	  enhances	  the	  peptide	  coverage,	  the	  efficiency	  of	  separation	  of	  highly	  acidic,	  highly	  basic,	  very	  small,	  or	  very	  large	  proteins	  with	  2D-­‐PAGE	  is	  low.	  Using	  protein	  mixture	  isolated	  from	  cells	  overcomes	  the	  issues	  related	  to	  gel	  analysis.	  This	  ‘bottom-­‐up’	  method	  involves	  proteolytic	  digestion	  of	  the	  cellular	  proteins	  to	  produce	  peptides	  that	  are	  resolved	  by	  liquid	  chromatography	  and	  analyzed	  by	  the	  mass	  spectrometer.	  	  Here,	  we	  employed	  the	  ‘bottom-­‐up’	  method	  to	  quantitatively	  analyze	  the	  phosphoproteome	  to	  overcome	  potential	  issues	  that	  may	  arise	  from	  gel-­‐based	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proteomic	  approaches	  such	  as	  low	  protein	  abundance,	  low	  efficiency	  of	  peptide	  extraction	  or	  enrichment,	  and	  protein	  degradation.	  
Phosphoproteome	  Enrichment	  Methods	  Since	  phosphorylated	  proteins	  constitute	  a	  small	  portion	  of	  the	  isolated	  proteins	  from	  cell	  lysates,	  their	  detection	  requires	  preferential	  enrichment	  of	  phospho-­‐peptides	  by	  noncovalent	  binding	  and	  recognition	  of	  phosphate	  groups	  via	  specific	  chemical	  derivatization,	  immunoprecipitation,	  or	  Immobilized	  Metal	  Affinity	  Chromatography	  (IMAC)	  (Goshe,	  2006).	  
Specific	  Chemical	  Derivatization:	  This	  approach	  takes	  advantage	  of	  the	  chemistry	  of	  phosphorylated	  amino	  acids	  by	  β-­‐elimination	  or	  the	  addition	  of	  cystamine	  (Delom	  &	  Chevet,	  2006).	  One	  of	  the	  main	  disadvantages	  of	  chemical	  derivatization	  is	  the	  requirement	  for	  high	  amount	  of	  protein	  for	  successful	  Mass	  spectrometry	  (MS)	  identification.	  Moreover,	  the	  selectivity	  of	  these	  methods	  still	  needs	  to	  be	  validated.	  
Immunoprecipitation:	  Phosphorylated	  proteins	  can	  be	  immunoprecipitated	  using	  phospho-­‐specific	  antibodies	  with	  an	  efficiency	  correlated	  with	  the	  specificity	  of	  the	  antibody	  (Delom	  &	  Chevet,	  2006).	  Currently	  antibodies	  specific	  to	  phospho-­‐tyrosine	  residues	  are	  widely	  used	  to	  enrich	  even	  low-­‐abundance	  tyrosine	  phosphorylated	  proteins	  although	  their	  selectivity	  is	  low.	  On	  the	  other	  hand	  there	  are	  no	  phospho-­‐serine-­‐specific	  and/or	  phospho-­‐threonine-­‐specific	  antibodies	  for	  enrichment	  of	  proteins	  that	  are	  phosphorylated	  on	  either	  serine	  or	  threonine	  residues;	  thus,	  it	  still	  is	  a	  challenge	  to	  enrich	  these	  proteins	  using	  immunoprecipitation.	  
IMAC:	  IMAC	  relies	  on	  the	  high	  affinity	  of	  phosphate	  groups	  to	  cations	  such	  as	  Zn2+,	  Fe3+,	  and	  Ga3+	  bound	  to	  tethered	  chelating	  reagents	  present	  on	  solid	  phase	  columns	  (Goshe,	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2006).	  In	  this	  method	  first	  proteins	  are	  digested	  into	  peptides;	  phosphopeptides	  are	  isolated	  by	  IMAC	  and	  analyzed	  off-­‐line	  or	  on-­‐line	  using	  LC-­‐MS/MS	  (Delom	  &	  Chevet,	  2006).	  It	  should	  be	  noted	  that	  aspartyl-­‐	  and	  glutamyl-­‐peptides	  have	  high	  affinity	  for	  the	  strong	  cations	  used	  in	  IMAC,	  causing	  non-­‐specific	  binding.	  Moreover	  multiply	  phosphorylated	  residues	  have	  higher	  affinity	  to	  the	  metal	  and	  get	  more	  enriched.	  Non-­‐specific	  binding	  can	  be	  decreased	  by	  using	  esterification	  of	  acidic	  residues,	  i.e.	  converting	  the	  carboxylic	  acid	  groups	  of	  peptides	  to	  their	  corresponding	  methyl	  esters,	  prior	  to	  IMAC	  procedure.	  In	  the	  recent	  years	  higher	  selectivity	  and	  sensitivity	  is	  achieved	  by	  using	  Titanium	  dioxide	  (TiO2)	  as	  a	  potent	  chelator	  for	  phosphopeptides.	  Thus,	  in	  our	  approach,	  we	  employed	  TiO2-­‐based	  phosphoenrichment	  of	  peptides	  for	  its	  advantages	  in	  terms	  of	  sensitivity,	  selectivity,	  and	  coverage.	  
MS	  Analysis	  	   After	  the	  enrichment	  step,	  the	  phosphopeptides	  are	  sequenced	  in	  the	  mass	  spectrometer	  with	  precise	  identification	  (Delom	  &	  Chevet,	  2006).	  The	  methods	  used	  for	  phospho-­‐peptide	  sequencing	  are	  precursor	  ion	  and	  neutral	  loss	  scanning.	  Precursor	  scanning	  relies	  on	  collision-­‐induced	  dissociation	  (CID)	  since	  phosphopeptides	  produce	  sequence-­‐specific	  fragments	  as	  well	  as	  phosphate-­‐specific	  fragments.	  Negative	  ion	  mode	  produces	  ions	  at	  mass-­‐to-­‐charge	  ratio	  (m/z)	  79	  and	  63	  corresponding	  to	  PO3-­‐	  and	  PO2-­‐	  groups,	  respectively.	  Moreover,	  in	  the	  positive	  ion	  mode,	  CID	  of	  phospho-­‐serine-­‐	  and	  phospho-­‐threonine-­‐containing	  peptides	  causes	  neutral	  loss	  of	  Phosphoric	  acid	  (H3PO4)	  via	  β-­‐elimination	  corresponding	  to	  a	  loss	  of	  98	  Da	  and	  49	  Da	  from	  single	  charged	  and	  double	  charged	  precursors,	  respectively.	  While	  β-­‐elimination	  does	  not	  happen	  for	  phospho-­‐tyrosine	  residues,	  they	  produce	  a	  characteristic	  immonium	  ion	  at	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m/z	  216.	  Precursor	  ion	  scanning	  method	  screens	  only	  the	  peptides	  with	  a	  chosen	  marker	  ion	  (m/z	  is	  79	  for	  phosphorylation)	  eliminating	  all	  other	  species,	  but	  this	  method	  is	  not	  amenable	  for	  inline	  LC-­‐coupling.	  However	  precursor	  ion	  scanning	  has	  high	  selectivity	  and	  specificity	  to	  phospho-­‐residues	  while	  it	  enables	  detection	  of	  serine,	  threonine,	  and	  tyrosine	  phosphorylations.	  On	  the	  other	  hand	  neutral	  loss	  scanning	  uses	  the	  mass	  shift	  of	  gas-­‐phase	  β-­‐elimination	  reaction	  that	  causes	  a	  neutral	  loss	  of	  H3PO4	  (H3PO4	  -­‐98	  Da)	  or	  dephosphorylation	  (HPO3	  -­‐80	  Da).	  Due	  to	  the	  chemistry	  of	  the	  serine	  and	  threonine	  residues	  a	  shift	  of	  69	  Da	  and	  83	  Da	  indicates	  the	  location	  of	  phosphorylated	  serine	  and	  threonine	  residues,	  respectively.	  Phosphotyrosines	  are	  tolerant	  to	  this	  loss.	  One	  weakness	  of	  this	  method	  is	  the	  requirement	  of	  prior	  knowledge	  of	  the	  charged	  state	  of	  the	  phosphopeptide.	  In	  addition,	  false	  positive	  identification	  is	  a	  big	  disadvantage	  of	  this	  scanning	  method.	  	  
Data	  Analysis	  After	  the	  identification	  of	  individual	  phosphopeptides,	  careful	  analysis	  of	  quantitative	  changes	  is	  required.	  Based	  on	  the	  quantitative	  changes	  observed,	  the	  biological	  interpretation	  and	  relevance	  of	  the	  results	  should	  be	  analyzed	  carefully	  based	  on	  the	  current	  knowledge	  of	  direct/indirect	  interaction	  between	  proteins,	  interaction	  of	  the	  biological	  pathways,	  phosphorylation-­‐dependent	  changes	  in	  signaling	  pathways,	  experimentally	  observed	  biological	  functions	  of	  those	  proteins,	  known	  functional	  significance	  of	  the	  identified	  phosphorylation	  sites,	  and	  other	  known	  PTMs	  interacting	  with	  identified	  phosphorylation	  sites.	  Various	  data	  analysis	  databases	  and	  programs	  that	  can	  achieve	  such	  thorough	  analysis	  are	  widely	  used	  in	  interpretation	  of	  the	  results	  and	  identification	  of	  the	  novel	  PTM	  sites.	  Here,	  we	  used	  Ingenuity	  Pathway	  Analysis	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(IPA)	  to	  do	  the	  network	  analysis,	  identification	  of	  targeted	  biological	  processes,	  and	  interconnected	  pathways.	  	  
MATERIALS	  AND	  METHODS	  
Reagents	  LPS	  was	  purchased	  from	  Invitrogen.	  All	  protease	  inhibitor	  cocktails	  were	  purchased	  from	  Sigma-­‐Aldrich	  (St.	  Louis,	  MO).	  All	  culture	  media	  and	  fetal	  bovine	  serum	  (FBS)	  were	  obtained	  from	  GIBCO	  and	  dialyzed	  FBS	  was	  purchased	  from	  Invitrogen.	  All	  stable	  isotope-­‐enriched	  amino	  acids,	  including	  12C6-­‐arginine,	  13C6-­‐arginine,	  and	  
13C615N4-­‐arginine,	  12C6-­‐lysine,	  13C6-­‐lysine	  and	  13C615N2-­‐	  lysine,	  were	  obtained	  from	  Cambridge	  Isotope	  and	  Sigma-­‐Aldrich.	  Trypsin	  was	  purchased	  from	  Promega.	  All	  chemicals	  were	  sequence-­‐	  or	  HPLC-­‐grade	  unless	  specifically	  indicated.	  Antibodies	  for	  p-­‐IκBa	  (S32),	  IκBa,	  p-­‐p65	  NFκB	  (S536),	  and	  p65	  were	  purchased	  from	  Cell	  Signaling.	  Antibody	  for	  PP2Ac	  (clone	  1D6)	  was	  from	  Millipore.	  Antibodies	  for	  Lmnb1	  and	  p65	  were	  from	  Santa	  Cruz	  Biotechnology	  while	  antibodies	  to	  γ-­‐tubulin,	  histone	  H3,	  H3K9me2,	  H3K9me1,	  H3K27me2	  were	  from	  Abcam.	  Bacterial	  clones	  for	  shRNA	  against	  PP2Ac	  or	  against	  PLKO.1	  were	  purchased	  from	  Sigma-­‐Aldrich.	  
Cell	  Culture	  RAW	  264.7	  cells	  were	  maintained	  in	  4.5	  g/L	  glucose	  Dulbecco’s	  minimal	  essential	  media	  (DMEM)	  with	  10%	  FBS.	  For	  all	  LPS	  pre-­‐treatment	  0.1	  μg/mL	  LPS	  is	  used	  while	  high	  dose	  LPS	  treatment	  and	  second	  challenges	  were	  done	  with	  1	  μg/mL	  LPS.	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Transfection	  and	  Stable	  PP2Ac	  Knock-­‐down	  (PP2Ac-­‐KD)	  RAW	  Cell	  Line	  The	  lentiviral	  plasmids	  pLKO.1	  expressing	  shRNA-­‐PP2Ac	  (targeting	  sequences	  CCAGATACAAATTACCTGTT	  and	  CGACGAGTGTTTAAGGAAATA)	  were	  purchased	  from	  Sigma.	  A	  pLKO.1	  empty	  vector	  (EV)	  without	  a	  specific	  shRNA	  sequence	  was	  used	  as	  the	  wild-­‐type	  (WT)	  control.	  To	  produce	  virus,	  pLKO.1-­‐shRNA	  plasmids	  were	  co-­‐transfected	  into	  293T	  cells	  with	  ViraPowerMix	  (Invitrogen)	  by	  jetPRIMETM	  in	  vitro	  DNA	  and	  siRNA	  transfection	  reagent	  (Polyplus).	  Pseudo-­‐virus	  in	  supernatants	  was	  collected	  48	  h	  after	  transfection	  and	  used	  to	  transduce	  RAW	  264.7	  cells	  by	  spinoculation.	  48	  h	  after	  transfection,	  8	  μg/ml	  puromycin	  was	  added	  to	  select	  puromycin-­‐resistant	  clones.	  Stable	  clones	  were	  maintained	  in	  medium	  containing	  4	  μg/mL	  puromycin.	  The	  PP2Ac	  expression	  in	  PP2Ac-­‐KD	  cell	  line	  was	  monitored	  with	  immunoblotting	  and	  Real-­‐time	  Polymerase	  chain	  reaction	  (qPCR).	  
AACT-­‐labeling	  Mass	  tagging	  with	  both	  Arg	  and	  Lys	  was	  performed	  to	  increase	  the	  phosphoproteomic	  coverage.	  Stable	  isotope	  labeled	  media	  was	  prepared	  by	  using	  4.5	  g/L	  glucose	  DMEM	  without	  Lysine	  and	  Arginine	  and	  10%	  dialyzed	  FBS.	  Cells	  were	  grown	  in	  the	  media	  supplemented	  with	  either	  12C6-­‐	  Arg/12C6-­‐Lys	  (K0R0,	  “L”),	  or	  13C6-­‐Arg/13C6-­‐Lys	  (K6R6,	  “M”),	  or	  13C6	  15N4-­‐Arg/13C6	  15N2-­‐Lys	  (K8R10,	  “H”)	  until	  >95%	  incorporation	  of	  isotope	  labeling	  is	  achieved	  and	  the	  labeling	  efficiency	  was	  checked	  using	  MS.	  	  The	  RAW	  264.7	  cells	  stably	  expressing	  shRNA	  for	  pLKO.1	  empty	  vector	  were	  cultured	  in	  ‘‘L’’	  medium	  and	  remained	  unstimulated	  (WT-­‐N).	  	  This	  control	  cell	  line	  was	  also	  cultured	  in	  ‘‘M’’	  medium,	  was	  stimulated	  with	  0.1	  μg/mL	  LPS	  for	  24	  h,	  and	  then	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challenged	  with	  1.0	  μg/mL	  LPS	  for	  15	  min	  (WT-­‐TL).	  RAW	  cells	  expressing	  shRNA	  for	  PP2Ac	  in	  double-­‐tagged	  ‘‘H’’	  medium	  were	  also	  stimulated	  with	  0.1	  mg/mL	  LPS	  for	  24	  h	  followed	  by	  a	  second	  challenge	  with	  1.0	  mg/mL	  LPS	  for	  15	  min	  (PP2AKD-­‐TL)	  before	  samples	  were	  prepared	  for	  phosphoproteomic	  analysis	  (Figure	  23).	  
Quantitative	  Phosphoproteomic	  Analysis	  using	  AACT	  
Sample	  Preparation	  All	  cells	  were	  harvested	  and	  lysed	  in	  lysis	  buffer	  containing	  8	  M	  urea,	  50	  mM	  Tris	  pH	  8.0,	  75	  mM	  NaCl,	  1	  mM	  MgCl2,	  500	  units	  Benzonase,	  and	  protease-­‐phosphatase	  inhibitor	  cocktail	  set	  I	  and	  II	  (Calbiochem).	  5	  mg	  of	  each	  lysate	  was	  mixed	  equally	  and	  reduced	  with	  Dithiothreitol	  (DTT)	  followed	  by	  alkylation	  with	  iodoacetamide	  (IAA).	  Proteins	  were	  digested	  first	  with	  endoproteinase	  Lys-­‐C	  (Wako	  USA).	  The	  solution	  was	  then	  diluted	  4-­‐fold	  with	  25	  mM	  Tris	  pH	  8.0,	  1	  mM	  CaCl2	  and	  further	  digested	  with	  trypsin	  (Promega).	  The	  digestion	  was	  stopped	  by	  0.4	  %	  Trifluoroacetic	  acid	  (TFA)	  (final	  concentration).	  Desalting	  was	  achieved	  on	  a	  Sep-­‐Pak	  Light	  C18	  cartridge	  (Waters)	  and	  peptides	  were	  freeze-­‐dried.	  Dried	  peptides	  were	  resuspended	  in	  30	  %	  Acetonitrile	  (ACN),	  0.1%	  TFA	  and	  loaded	  on	  a	  1	  mL	  Resource	  15S	  (GE	  Healthcare)	  column	  for	  strong	  cation	  exchange	  chromatography	  (SCX).	  A	  linear	  gradient	  was	  performed	  from	  5	  mM	  to	  100	  mM	  KCl	  in	  30%	  ACN,	  5	  mM	  KH2PO4,	  0.1%	  TFA.	  Negatively	  charged	  peptides	  were	  eluted	  with	  high	  salt	  buffer	  (350	  mM	  KCl	  in	  30%	  ACN,	  5	  mM	  KH2PO4,	  0.1%	  TFA).	  The	  phospho-­‐peptides	  were	  enriched	  directly	  in	  SCX	  fractions	  (Xie	  et	  al,	  2013).	  Briefly,	  1-­‐5	  mg	  of	  5	  mm	  Titansphere	  beads	  (GL	  Sciences)	  suspended	  in	  80%	  ACN/1%	  TFA	  was	  added	  to	  each	  fraction	  and	  incubated	  for	  30	  min	  at	  room	  temperature	  (RT).	  The	  beads	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were	  collected	  by	  centrifugation	  and	  washed	  three	  times	  with	  150	  μL	  60%	  ACN/1%	  TFA,	  then	  transferred	  on	  to	  the	  top	  of	  a	  C8	  disc	  (Empore)	  placed	  in	  a	  200	  μL	  pipette-­‐tip.	  Bound	  phosphopeptides	  were	  eluted	  with	  15%	  NH4OH/40%	  ACN.	  Elutes	  were	  dried	  and	  desalted	  on	  a	  StageTip	  containing	  a	  4	  x	  1	  mm	  C18	  extraction	  disk	  (3M).	  
Mass	  Spectrometry	  Samples	  were	  analyzed	  via	  reverse	  phase	  (RP)	  LC-­‐MS/MS	  using	  a	  nano-­‐LC	  ultra2D	  system	  coupled	  to	  a	  Velos	  Orbitrap	  mass	  spectrometer	  (Thermo	  Scientific,	  San	  Jose,	  CA).	  LC-­‐MS	  experiments	  were	  performed	  in	  a	  data-­‐dependent	  mode	  with	  Full-­‐MS	  (externally	  calibrated	  to	  a	  mass	  accuracy	  of	  <	  5	  ppm,	  and	  a	  resolution	  of	  60	  000	  at	  m/z	  400)	  followed	  by	  CID-­‐MS/MS	  of	  the	  top	  10	  most	  intense	  ions.	  Mass	  spectra	  were	  processed,	  and	  peptide	  identification	  was	  performed	  using	  the	  Andromeda	  search	  engine	  in	  MaxQuant	  (Max	  Planck	  Institute)	  against	  a	  mouse	  uniprot	  database.	  All	  searches	  were	  carried	  out	  using	  cysteine	  carbamidomethylation	  as	  a	  fixed	  modification	  while	  methionine	  oxidation	  and	  protein	  N-­‐terminal	  acetylation,	  and	  phosphorylation	  at	  STY	  residues	  were	  selected	  as	  dynamic	  modifications.	  AACT/SILAC	  quantitation	  was	  performed	  in	  MaxQuant	  [ver.	  1.2.2.5]	  with	  the	  Andromeda	  search	  engine.(Cox	  et	  al.,	  2011)	  The	  searches	  were	  carried	  out	  initially	  at	  200	  ppm.	  Precursor	  ion	  mass	  tolerance	  followed	  by	  a	  main	  search	  of	  the	  m/z,	  and	  retention	  time	  corrected	  features	  using	  a	  precursor	  ion	  mass	  tolerance	  of	  5	  ppm.	  Peptides	  were	  confidently	  identified	  using	  a	  target-­‐decoy	  approach	  with	  a	  peptide	  false-­‐discovery-­‐rate	  (FDR)	  of	  1%	  and	  a	  protein	  FDR	  of	  5%.	  Phosphorylation	  sites	  were	  localized	  using	  PTM	  score	  with	  phosphorylation	  site	  localization	  FDR	  of	  1%.	  Data	  processing	  and	  statistics	  were	  performed	  using	  Perseus	  [ver.	  1.2.0.17]	  (Cox	  and	  Mann,	  2011).	  Protein	  quantitation	  was	  performed	  on	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biological	  replicate	  runs	  and	  a	  two	  sample	  t-­‐test	  statistics	  was	  used	  with	  a	  p-­‐value	  of	  5%	  to	  report	  statistically	  significant	  fold	  changes.	  In	  this	  experiment,	  mass	  tagging	  with	  both	  Arg	  and	  Lys	  was	  performed	  to	  increase	  the	  phosphoproteomic	  coverage.	  The	  AACT	  ratios	  of	  the	  proteins	  were	  derived	  from	  the	  comparison	  of	  the	  extracted	  ion	  chromatogram	  peak	  areas	  of	  all	  matched	  light	  (L)	  peptides	  with	  those	  of	  the	  medium	  (M)	  or	  heavy	  (H)	  peptides.	  The	  ratios	  of	  M/L	  or	  H/L	  were	  also	  verified	  by	  visual	  inspection	  of	  the	  raw	  mass	  spectra.	  In	  MS	  spectra,	  for	  each	  arginine-­‐containing	  peptide,	  a	  set	  of	  three	  isotope	  signals	  with	  the	  mass	  spacing	  of	  6	  Da	  and	  10	  Da	  was	  observed	  as	  L	  isotope	  peak	  was	  originally	  from	  the	  non-­‐stimulated	  WT	  cells,	  and	  the	  6	  Da	  (M)	  or	  10	  Da	  heavier	  (H)	  isotope	  peaks	  came	  from	  either	  WT-­‐TL	  or	  PP2Ac-­‐KD-­‐TL	  cells,	  respectively.	  In	  reference	  to	  the	  criteria	  previously	  established	  by	  our	  group	  (Xie	  et	  al.,	  2009)	  as	  well	  as	  others	  (Zhang	  et	  al.,	  2006),	  	  an	  approximate	  30%	  increases	  in	  isotope	  intensity	  or	  a	  M/L	  or	  H/L	  value	  over	  1.3	  was	  determined	  as	  the	  quantitative	  threshold	  to	  distinguish	  the	  PP2Ac	  targeted	  phosphopeptides.	  M/L	  and	  H/L	  ratios	  for	  each	  protein	  were	  determined	  by	  averaging	  the	  ratio	  found	  for	  at	  least	  two	  unique	  AACT-­‐containing	  peptides.	  Most	  proteins	  were	  identified	  in	  high	  confidence	  with	  more	  than	  one	  peptide.	  For	  those	  proteins	  that	  were	  identified	  by	  a	  single	  peptide,	  the	  MS/MS	  spectra	  were	  manually	  inspected	  to	  ensure	  correct	  identification.	  For	  most	  proteins,	  the	  relative	  standard	  deviation	  for	  quantification	  between	  peptides	  of	  the	  same	  protein	  was	  less	  than	  20%.	  
Canonical	  Pathway	  Analysis	  Biological	  processes	  and	  molecular	  functions	  of	  the	  proteins	  identified	  as	  potential	  PP2Ac	  targets	  were	  categorized	  by	  Ingenuit
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Redwood	  City,	  http://www.qiagen.com/ingenuity).	  Normalized	  M/L	  ratios	  were	  used	  to	  identify	  the	  change	  in	  phosphorylation	  of	  the	  peptides	  with	  ET	  in	  WT	  cells	  compared	  to	  unstimulated	  WT	  cells	  while	  H/L	  ratios	  revealed	  the	  phosphorylation	  change	  in	  PP2Ac-­‐KD-­‐TL	  peptides	  compared	  to	  unstimulated	  WT	  cells.	  To	  focus	  on	  the	  phospho-­‐peptides	  that	  are	  regulated	  downstream	  PP2Ac,	  the	  dataset	  was	  trimmed	  to	  include	  only	  the	  peptides	  that	  showed	  an	  increase	  in	  phosphorylation	  in	  PP2Ac-­‐KD-­‐TL	  compared	  to	  WT-­‐TL.	  The	  canonical	  pathways	  were	  similarly	  ordered	  according	  to	  the	  ratio	  of	  phospho-­‐peptides	  that	  showed	  an	  increase	  in	  PP2Ac-­‐KD-­‐TL	  compared	  with	  WT-­‐TL.	  	  
Detection	  of	  the	  changes	  in	  Histone	  PTMs	  via	  Western	  Blotting	  Paired	  WT	  and	  PP2Ac-­‐KD	  RAW	  cells	  were	  stimulated	  with	  1.0	  μg/mL	  LPS	  for	  0,	  5,	  15,	  and	  30	  mins	  with	  (TL)	  or	  without	  (NL)	  a	  low	  dose	  (0.1	  μg/mL)	  LPS	  pre-­‐treatment.	  Cells	  were	  harvested	  and	  lysed	  with	  buffer	  containing	  0.5%	  NP-­‐40,	  10	  mM	  Tris	  pH	  7.5,	  150	  mM	  NaCl,	  0.4	  mM	  EDTA,	  2	  mM	  Na3PO4,	  1x	  phosphatase	  inhibitor	  cocktail	  (Pierce),	  1x	  protease	  inhibitor	  cocktail	  (Sigma-­‐Aldrich).	  	  The	  lysates	  were	  sonicated	  twice	  at	  level	  3	  for	  5	  sec	  for	  successful	  release	  of	  the	  chromatin,	  then	  were	  separated	  on	  an	  SDS-­‐	  PAGE	  gel	  under	  reducing	  conditions	  and	  then	  transferred	  to	  a	  Polyvinylidene	  fluoride	  (PVDF)	  membrane.	  The	  membranes	  were	  blocked	  with	  milk	  for	  1	  h	  at	  RT	  on	  an	  orbital	  shaker.	  Following	  primary	  antibody	  incubation	  for	  1	  h	  at	  RT,	  we	  probed	  the	  membranes	  with	  a	  horseradish	  peroxidase	  conjugated	  secondary	  antibody	  and	  bands	  were	  detected	  using	  an	  enhanced	  chemiluminescence	  (ECL)	  Western	  Blotting	  Detection	  Kit	  (GE	  Life	  Sciences).	  Densitometry	  analysis	  was	  performed	  using	  ImageJ	  software	  and	  comparing	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the	  amount	  of	  H3K9me2	  and	  H3K27me2	  to	  total	  H3.	  The	  densities	  were	  then	  normalized	  to	  the	  unstimulated	  sample.	  
RESULTS	  
Phosphoproteomic	  analysis	  reveals	  broad	  range	  of	  signaling	  pathways	  regulated	  
by	  PP2Ac	  in	  ET-­‐macrophages	  The	  quantitative	  phosphoproteomics	  of	  PP2Ac-­‐targeted	  proteins	  in	  ET	  macrophages	  revealed	  1319	  proteins	  in	  total,	  18	  of	  which	  (1%)	  were	  not	  phosphorylated	  while	  1301	  proteins	  included	  phospho-­‐peptides	  (Figure	  24,	  left).	  This	  indicates	  that	  our	  phospho-­‐enrichment	  technique	  was	  highly	  efficient	  (99%).	  Moreover,	  out	  of	  the	  18,492	  peptides	  that	  were	  identified	  (Figure	  24,	  right),	  18,298	  were	  phospho-­‐peptides	  that	  had	  only	  one	  (61%)	  phosphorylation	  (Figure	  25,	  left)	  while	  phosphopeptide	  enrichment	  successfully	  discovered	  peptides	  with	  up	  to	  6	  phosphorylations	  (Figure	  25,	  right).	  In	  addition,	  we	  analyzed	  the	  distribution	  of	  various	  phospho-­‐STY	  residues,	  and	  observed	  that	  86%	  phosphosites	  were	  identified	  as	  phospho-­‐S,	  13%	  were	  identified	  as	  phospho-­‐T,	  and	  1%	  were	  identified	  as	  phospho-­‐Y	  (Figure	  26).	  	  For	  accurate	  quantification	  we	  used	  the	  Mass	  Error	  data	  from	  MaxQuant	  database	  search	  to	  normalize	  the	  quantification	  of	  the	  peak	  intensities	  (Figure	  27).	  Moreover,	  we	  used	  the	  ratios	  of	  intensities	  H/L,	  M/L,	  and	  H/M	  that	  refer	  to	  the	  relative	  ratio	  of	  abundance	  of	  each	  peptide	  in	  PP2Ac-­‐KD-­‐TL	  compared	  to	  WT-­‐N,	  WT-­‐TL	  compared	  to	  WT-­‐N,	  and	  PP2Ac-­‐KD-­‐TL	  compared	  to	  WT-­‐TL,	  respectively.	  Further,	  we	  trimmed	  the	  dataset	  to	  the	  peptides	  that	  show	  increased	  phosphorylation	  in	  PP2Ac-­‐KD-­‐
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TL	  compared	  to	  WT-­‐TL	  since	  we	  aim	  to	  identify	  the	  phosphopeptides	  that	  are	  directly	  or	  indirectly	  targeted	  by	  PP2Ac	  in	  ET.	  	   Using	  IPA	  analysis,	  the	  top	  10	  signaling	  pathways	  to	  include	  the	  highest	  number	  of	  proteins	  targeted	  by	  PP2Ac	  specifically	  in	  ET	  macrophages	  (i.e.	  the	  phosphorylation	  of	  these	  proteins	  showed	  an	  increase	  in	  PP2Ac-­‐KD	  cell	  line	  compared	  to	  WT	  in	  ET-­‐macrophages)	  were	  identified	  as	  DNA	  Methylation	  and	  Transcriptional	  Repression,	  PI3/AKT	  Signaling,	  Prostate	  Cancer	  Signaling,	  Insulin	  Receptor	  Signaling,	  Superpathway	  of	  Inositol	  Phosphate	  Compounds,	  Rac	  Signaling,	  HGF	  Signaling,	  ERK/MAPK	  Signaling,	  Telomerase	  Signaling,	  and	  ATM	  Signaling	  (Figure	  28).	  Moreover	  8	  of	  these	  pathways	  showed	  PP2Ac-­‐dependent	  dephosphorylation	  of	  chromatin	  regulators	  in	  ET	  macrophages	  as	  shown	  in	  Figure	  29A-­‐I.	  In	  addition	  to	  these,	  many	  other	  various	  PP2Ac-­‐targeted	  signaling	  pathways	  crosstalk,	  indicating	  PP2Ac-­‐targeted	  proteins	  broadly	  affect	  the	  signaling	  pathways	  (Figure	  30).	  	  	   In	  our	  previous	  PP2Ac	  study,	  we	  demonstrated	  that	  chronic-­‐active	  PP2Ac	  dephosphorylates	  caspases	  to	  inhibit	  apoptosis	  (Xie	  et	  al,	  2013).	  PP2Ac	  is	  also	  known	  as	  a	  major	  regulator	  of	  cell	  survival	  through	  dephosphorylation	  of	  ATM,	  leading	  to	  decreased	  apoptosis	  (Figure	  31)	  (Goodarzi	  et	  al,	  2004).	  Here,	  identification	  of	  ATM	  signaling	  pathway	  as	  an	  ET-­‐specific	  PP2Ac	  target	  demonstrates	  an	  alternative	  pathway	  for	  PP2Ac-­‐induced	  cell	  survival	  in	  LPS-­‐stimulated	  macrophages	  supporting	  our	  conclusion	  that	  chronic-­‐active	  PP2Ac	  is	  important	  for	  regulation	  of	  cell	  survival.	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PP2Ac	  dephosphorylates	  various	  chromatin	  modifiers	  to	  regulate	  gene	  
transcription	  in	  ET	  macrophages	  Since	  the	  over-­‐represented	  pathways	  showed	  PP2Ac-­‐dependent	  dephosphorylation	  of	  chromatin	  regulators	  in	  ET	  macrophages	  as	  shown	  in	  Figure	  30,	  we	  manually	  trimmed	  the	  dataset	  to	  chromatin	  regulators	  to	  understand	  how	  PP2Ac	  may	  regulate	  ET-­‐specific	  gene	  regulation	  in	  macrophages	  and	  observed	  various	  chromatin	  regulators	  with	  various	  phosphosites	  in	  the	  dataset	  (Table	  3).	  Among	  these	  chromatin	  regulators,	  demethylases	  (DM)	  KDM1A	  (also	  known	  as	  LSD1),	  Lysine-­‐specific	  Demethylase	  5A	  (KDM5A,	  also	  known	  as	  Jumonji/ARID	  domain-­‐containing	  protein	  1A	  or	  JARID1A,	  and	  Retinoblastoma-­‐binding	  protein	  2	  or	  RBP2),	  and	  Plant	  Homeodomain	  (PHD)	  Finger	  8	  (PHF8)	  (Figure	  32),	  and	  methyltransferases	  (MT)	  methyl	  CpG	  binding	  protein	  2	  (MeCP2),	  mRNA	  cap	  guanine-­‐N7	  methyltransferase	  (MCES),	  tRNA	  (adenine-­‐N(1)-­‐)-­‐methyltransferase	  non-­‐catalytic	  subunit	  (TRM6),	  Nuclear	  SET	  domain-­‐containing	  protein	  2	  (NSD2),	  EZH2,	  MLL1,	  Nuclear	  SET	  domain-­‐containing	  protein	  3	  (NSD3),	  DNMT3A,	  DNMT1,	  and	  MLL4	  (Figure	  31)	  showed	  ET-­‐specific	  PP2Ac-­‐dependent	  dephosphorylation.	  In	  addition,	  we	  found	  deacetylases	  
HDAC1,	  HDAC2,	  and	  Suppressor	  of	  defective	  silencing	  3	  protein	  homolog	  (SDS3),	  and	  acetyltransferase	  MYST1	  with	  ET-­‐specific	  PP2Ac-­‐dependent	  dephosphorylation	  patterns	  (Figure	  33).	  	  
Table	  3	  Epigenetic	  regulators	  with	  phosphosites	  in	  the	  phosphoproteome	  dataset	  
Demethylases	  JHD2C,	  KDM1A,	  KDM2B,	  KDM5A,	  KDM5C,	  PHF8	  
Methyltransferases	  ASH1L,	  COMT,	  DNM3A,	  DNMT1,	  EZH2,	  MCES,	  MECP2,	  MLL1,	  MLL4,	  NSD2,	  NSD3,	  RG9D2,	  TRM6	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Deacetylases	  HDAC1,	  HDAC2,	  SDS3,	  SAP30	  	  
Acetyltransferases	  MYST1,	  MYST2,	  NAA15,	  NAA30	  	  	   Among	  the	  potential	  ET-­‐specific	  PP2Ac-­‐targeted	  phosphosites	  of	  chromatin	  modifiers,	  only	  a	  few	  were	  previously	  characterized	  functionally:	  KDM1A	  phosphorylations	  at	  P-­‐S132	  and	  P-­‐S138	  (Figure	  32,	  top-­‐left),	  PHF8	  phosphorylation	  at	  S843	  (Figure	  30,	  bottom-­‐right),	  MeCP2	  phosphorylation	  at	  S80	  (Figure	  33,	  top-­‐left),	  
HDAC1	  phosphorylations	  at	  S421	  and	  S423	  (Figure	  34A,	  top-­‐left),	  and	  HDAC2	  phosphorylations	  at	  S422	  and	  S424	  (Figure	  34A,	  top-­‐middle).	  S132	  and	  S138	  of	  
KDM1A	  are	  phosphorylated	  by	  Casein	  Kinase	  2	  (CK2)	  to	  positively	  regulate	  DNA	  damage	  response	  by	  recruiting	  p53-­‐binding	  protein	  1	  (53BP1)	  to	  DNA	  damage	  sites	  (Mosammaparast	  &	  Shi,	  2010;	  Peng	  et	  al,	  2015),	  and	  are	  dephosphorylated	  by	  Protein	  Phosphatase,	  Mg2+/Mn2+	  Dependent,	  1D	  (PPM1D).	  Since	  these	  phosphorylations	  are	  involved	  in	  cell	  growth	  regulation	  (Fradet-­‐Turcotte	  et	  al,	  2013;	  Ward	  et	  al,	  2003)	  and	  DNA	  damage	  response	  is	  activated	  in	  the	  LPS-­‐induced	  TLR4	  signaling	  (Harberts	  &	  Gaspari,	  2013;	  Kutikhin	  et	  al,	  2014),	  their	  dephosphorylation	  by	  PP2Ac	  in	  ET	  may	  be	  involved	  in	  the	  negative	  regulation	  of	  the	  TLR4-­‐induced	  DNA	  damage	  response	  pathways	  in	  ET.	  On	  the	  other	  hand,	  S843	  phosphorylation	  of	  PHF8	  by	  Cyclin	  E-­‐CDK	  (Sun	  et	  al,	  2015a)	  positively	  regulates	  its	  activity	  in	  the	  control	  of	  cell	  cycle	  progression.	  Therefore	  PP2Ac-­‐dependent	  dephosphorylation	  in	  ET	  might	  contribute	  to	  the	  immunosuppression	  of	  inflammation-­‐related	  genes	  through	  deactivation	  of	  PHF8.	  
MeCP2	  S80	  (Figure	  35A)	  is	  a	  Homeodomain	  Interacting	  Protein	  Kinase	  2	  (HIPK2)	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target	  in	  fibroblasts	  in	  regulation	  of	  apoptosis	  (Bracaglia	  et	  al,	  2009)	  and	  is	  important	  for	  MeCP2-­‐chromatin	  association	  (Tao	  et	  al,	  2009).	  Since	  S80	  phosphorylation	  of	  MeCP2	  is	  correlated	  to	  the	  induction	  of	  apoptosis,	  its	  dephosphorylation	  by	  PP2Ac	  in	  ET	  might	  be	  one	  of	  the	  anti-­‐apoptotic	  mechanisms	  that	  underlies	  PP2Ac-­‐mediated	  immunosuppression.	  In	  addition,	  both	  phosphorylations	  of	  HDAC1	  and	  HDAC2	  (Figure	  
35B-­‐C)	  are	  important	  for	  their	  catalytic	  activity	  and	  their	  ability	  to	  form	  active	  complexes	  (Adenuga	  &	  Rahman,	  2010;	  Pflum	  et	  al,	  2001).	  Since	  these	  deacetylases	  are	  responsible	  for	  gene-­‐scpecific	  activation	  of	  transcription,	  PP2A-­‐dependent	  dephosphorylation	  might	  be	  one	  of	  the	  mechanisms	  for	  PP2Ac	  to	  suppress	  inflammatory	  response	  in	  ET.	  
PP2Ac	  regulates	  the	  cross-­‐talk	  between	  TLR4	  and	  AKT	  pathways	  through	  
modulating	  the	  phosphoproteome	  in	  ET	  macrophages	  The	  phosphosite	  database	  analysis	  (Hornbeck	  et	  al,	  2004)	  of	  the	  potential	  	  novel	  PP2Ac-­‐targets	  revealed	  that	  these	  phosphorylations	  were	  identified	  in	  previous	  phospho-­‐enrichment	  studies	  (Table	  4)	  in	  LPS-­‐induced	  TLR4	  activation	  (Weintz	  et	  al,	  2010;	  Wu	  et	  al,	  2012),	  growth	  hormone-­‐induced	  AKT	  signaling	  (Hsu	  et	  al,	  2011),	  and	  insulin	  receptor-­‐induced	  AKT	  signaling	  (Humphrey	  et	  al,	  2013;	  Yu	  et	  al,	  2011).	  Growth	  hormone-­‐	  or	  insulin	  receptor-­‐induced	  AKT	  signaling	  is	  a	  major	  regulator	  of	  survival,	  transcription,	  proliferation,	  and	  cell	  growth	  (Figure	  36)	  (Tchevkina	  &	  Komelkov,	  2012).	  Especially	  since	  PP2Ac	  is	  chronically	  active	  with	  prolonged	  LPS	  stimulation,	  the	  phosphosites	  shared	  by	  the	  phosphoproteome	  of	  LPS-­‐induced	  TLR4	  activation	  reveals	  the	  enzymes	  whose	  phosphorylation	  is	  involved	  in	  the	  phenotype-­‐specific	  chromatin	  changes.	  Moreover	  the	  phosphosite	  database	  analysis	  of	  the	  potential	  novel	  PP2Ac	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targets	  revealed	  that	  these	  phosphorylations	  were	  shared	  in	  phosphoproteomic	  studies	  of	  both	  growth	  hormone-­‐induced	  and	  insulin-­‐induced	  AKT	  signaling	  (Figure	  36).	  As	  AKT	  signaling	  is	  identified	  in	  the	  IPA	  analysis	  among	  the	  most	  overrepresented	  pathways	  that	  get	  dephosphorylated	  by	  PP2Ac	  in	  ET	  (Figure	  26,	  Figure	  27B),	  we	  conclude	  that	  AKT	  signaling	  and	  downstream	  transcriptional	  machinery	  that	  of	  gets	  regulated	  by	  PP2Ac	  in	  LPS-­‐tolerant	  macrophages.	  	  	  
Table	  4	  ET-­‐specific	  PP2Ac-­‐targeted	  phosphosites	  of	  chromatin	  regulators	  
These	  phosphosites	  are	  shared	  by	  other	  phosphoproteomic	  studies	  
	  AKT	  is	  a	  known	  substrate	  of	  PP2Ac	  in	  regulation	  of	  pro-­‐	  or	  anti-­‐survival	  signaling	  (Kuo	  et	  al,	  2008).	  More	  importantly,	  AKT	  activity	  induces	  survival,	  and	  is	  regulated	  by	  LPS-­‐induced	  TLR4	  activation	  (Bauerfeld	  et	  al,	  2012)	  through	  MyD88	  and	  IRAK1	  (Li	  et	  al,	  2003).	  Thus,	  the	  PP2Ac-­‐targeted	  phosphosites	  we	  identified	  that	  also	  occur	  in	  the	  AKT-­‐signaling	  datasets	  provide	  novel	  targets	  for	  AKT-­‐targeted	  regulators	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of	  survival	  in	  LPS	  response.	  Moreover	  these	  common	  phosphosites	  indicate	  the	  strength	  of	  our	  phosphoproteomic	  strategy	  in	  covering	  known	  interactions	  between	  TLR4	  and	  other	  signaling	  pathways	  and	  discovering	  novel	  targets	  of	  major	  kinases/phosphatases	  in	  an	  unbiased	  screening.	  In	  addition,	  they	  indicate	  that	  these	  results	  are	  replicable	  and	  not	  artifacts.	  
PP2Ac-­‐mediated	  ET	  is	  regulated	  by	  altered	  H3K9me2,	  H3K27me2,	  and	  H3S10P	  in	  
macrophages	  To	  understand	  the	  phenotypic	  outcome	  of	  the	  PP2Ac	  activity	  on	  the	  chromatin	  PTM	  and	  thereby	  to	  screen	  functionally	  responsible	  chromatin	  modifiers,	  we	  performed	  immunoblotting	  of	  the	  various	  histone	  PTMs	  in	  paired	  WT	  and	  PP2Ac-­‐KD	  RAW	  macrophages	  that	  were	  either	  non-­‐stimulated,	  or	  stimulated	  with	  a	  high	  dose	  LPS	  (1	  μg/mL)	  for	  5,	  15,	  and	  30	  mins	  with	  (TL)	  or	  without	  (NL)	  a	  prior-­‐stimulation	  of	  low	  dose	  LPS	  (0.1	  μg/mL)	  for	  24	  h	  (Figure	  37,	  left).	  We	  immunoblotted	  for	  PP2Ac	  and	  P-­‐p65	  (S536)	  to	  screen	  the	  knockdown	  efficiency	  and	  inflammation	  phenotype,	  respectively,	  and	  we	  used	  γTubulin	  immunoblot	  as	  a	  total	  protein	  control.	  Moreover,	  Since	  PP2Ac	  is	  known	  as	  a	  major	  regulator	  of	  chronic	  inflammation	  in	  macrophages	  (Xie	  et	  al,	  2013),	  we	  confirmed	  that	  the	  PP2Ac-­‐KD	  cells	  were	  hypersensitive	  to	  LPS	  stimulation,	  as	  determined	  by	  the	  increase	  in	  P-­‐p65	  (S536),	  in	  both	  acute	  (NL)	  and	  chronic	  (TL)	  LPS	  stimulation.	  	  We	  compared	  histone	  PTM	  immunoblots	  in	  WT	  and	  PP2Ac-­‐KD	  cell	  line	  and	  observed	  that	  
• Repressive	  ET-­‐specific	  H3	  PTMs	  H3K9me2	  and	  H3K27me2	  show	  a	  TL-­‐specific	  decrease	  in	  PP2Ac-­‐KD	  compared	  to	  WT	  RAW	  cells	  (Figure	  37,	  right	  panel).	  This	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indicates	  that	  PP2Ac	  activity	  in	  ET	  is	  significant	  for	  abundance	  of	  these	  repressive	  PTMs	  and	  lack	  thereof	  leads	  to	  increased	  demethylation.	  
• H3S10P	  is	  diminished	  in	  WT-­‐TL	  cells	  while	  it	  is	  increased	  in	  PP2Ac-­‐KD	  –TL	  cells	  compared	  to	  their	  non-­‐stimulated	  pairs.	  H3S10	  phosphorylation	  is	  one	  of	  the	  earliest	  PTMs	  characterized	  as	  active-­‐promoter	  mark	  in	  LPS-­‐induced	  response	  (Saccani	  et	  al,	  2002).	  Previously,	  PP2Ac	  was	  reported	  as	  the	  major	  phosphatase	  removing	  this	  phosphorylation	  in	  ET-­‐macrophages	  (Xie	  et	  al,	  2013).	  Thus,	  we	  observed	  diminished	  H3S10	  phosphorylation	  in	  ET	  in	  WT	  cells	  and	  a	  significant	  increase	  in	  phosphorylated	  H3S10	  mark	  in	  all	  conditions	  of	  PP2Ac-­‐KD	  cells.	  Since	  PP2Ac	  activity	  is	  significantly	  enhanced	  in	  ET,	  the	  increase	  in	  H3S10	  phosphorylation	  in	  PP2Ac-­‐KD	  cells	  compared	  to	  that	  of	  WT	  cells	  is	  augmented	  in	  TL	  condition.	  This	  indicates	  that	  the	  activation	  marker	  H3S10P	  is	  dephosphorylated	  by	  PP2Ac	  in	  ET	  macrophages.	  
• Not	  only	  H3K9me2	  but	  also	  the	  combination	  of	  H3K4me2	  and	  H3K9me2	  (referred	  to	  as	  H3K4me2K9me2)	  shows	  significant	  TL	  condition-­‐specific	  decrease	  in	  PP2Ac-­‐KD	  cells	  compared	  to	  WT	  cells.	  This	  indicates	  that,	  not	  only	  the	  repressive	  PTMs,	  but	  also	  the	  activating	  PTMs,	  such	  as	  H3K4me2,	  get	  regulated	  by	  the	  chronic-­‐active	  PP2Ac	  for	  activation	  of	  ET-­‐specific	  genes.	  
PP2Ac	  inhibits	  the	  activity	  of	  PHF8	  in	  ET	  to	  repress	  transcription	  The	  repressive	  H3K9me2	  and	  H3K27me2	  methylations	  are	  associated	  with	  decreased	  response	  to	  LPS	  and	  decreased	  pro-­‐inflammatory	  gene	  expression	  (El	  Gazzar	  et	  al,	  2008;	  Wen	  et	  al,	  2008).	  On	  the	  other	  hand,	  increased	  H3K9me2	  and	  H3K27me2	  abundance	  at	  the	  LPS-­‐induced	  promoters	  is	  identified	  as	  an	  ET-­‐specific	  gene	  regulation	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mechanism	  in	  macrophages	  (El	  Gazzar	  et	  al,	  2008;	  Liu	  et	  al,	  2014;	  Turgeon	  et	  al,	  2013).	  In	  TL	  condition,	  these	  repressive	  methylations	  are	  highly	  abundant	  and	  they	  show	  a	  significant	  decrease	  in	  specifically	  TL	  condition	  with	  PP2Ac-­‐KD.	  This	  indicates	  the	  significance	  of	  PP2Ac	  in	  possibly	  increasing	  the	  corresponding	  KMT	  activity,	  decreasing	  
the	  corresponding	  KDM	  activity,	  or	  both	  through	  dephosphorylation	  in	  prolonged	  LPS	  stimulation.	  Given	  the	  H3K27me3	  blot	  shows	  the	  opposite	  trend,	  we	  conclude	  that	  PP2Ac	  targets	  H3K9me2-­‐	  and	  H3K27me2/me3-­‐specific	  KDMs	  to	  inhibit	  their	  
demethylase	  activity	  for	  transcriptional	  repression	  in	  ET	  macrophages.	  As	  mentioned	  above,	  the	  only	  ET-­‐specific	  PP2Ac-­‐targeted	  KDMs	  in	  our	  dataset	  were	  KDM1A	  and	  KDM5A,	  which	  demethylate	  H3K4	  (Christensen	  et	  al,	  2007;	  Klose	  et	  al,	  2007;	  Metzger	  et	  al,	  2005),	  and	  PHF8,	  which	  demethylates	  H3K9me1/2	  and	  H3K27me2	  (Zhu	  et	  al,	  2010).	  Thus,	  we	  derived	  the	  data-­‐dependent	  hypothesis	  that	  PHF8	  activates	  activates	  gene-­‐specific	  transcription	  through	  demethylation	  of	  repressive	  histone	  PTMs	  H3K9me1/2	  and	  H3K27me2	  in	  LPS-­‐induced	  inflammation	  and	  its	  enzymatic	  activity	  is	  negatively	  regulated	  by	  PP2Ac-­‐dependent	  dephosphorylation	  in	  ET.	  In	  line	  with	  our	  hypothesis,	  we	  found	  that	  PHF8	  is	  the	  only	  chromatin	  regulator	  that	  showed	  more	  than	  2	  phosphopeptides	  that	  are	  dephosphorylated	  by	  chronic	  active	  PP2Ac	  in	  ET	  (Figure	  38).	  	  
DISCUSSION	  Phosphorylation	  is	  one	  of	  the	  most	  abundant	  reversible	  PTM	  in	  the	  cell.	  It	  is	  involved	  in	  regulation	  of	  signaling	  pathways,	  degradation	  of	  proteins,	  cross-­‐linking	  pathways,	  formation	  of	  protein	  complexes,	  and	  enzymatic	  activity	  of	  various	  significant	  enzymes.	  PP2Ac	  is	  a	  broad	  regulator	  of	  various	  signaling	  pathways	  as	  it	  targets	  a	  broad	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range	  of	  proteins	  for	  dephosphorylation.	  Specifically	  in	  ET,	  PP2Ac	  negatively	  regulates	  the	  LPS-­‐induced	  gene	  expression	  (Xie	  et	  al,	  2013).	  The	  impact	  of	  PP2Ac	  on	  the	  transcriptional	  chromatin	  elements	  is	  not	  known.	  Here	  we	  employed	  a	  powerful	  phosphoproteomic	  strategy	  to	  screen	  chronic	  active	  PP2Ac	  targets	  that	  play	  a	  role	  in	  the	  regulation	  of	  ET.	  Our	  quantitative	  analysis	  revealed	  transcriptional	  repression	  as	  the	  most	  extensively	  regulated	  signaling	  pathway	  by	  PP2Ac	  in	  ET.	  More	  importantly,	  validating	  the	  phenotypic	  response,	  we	  identified	  well-­‐known	  phosphorylation	  sites	  of	  PP2Ac-­‐targeted	  chromatin	  modifiers	  such	  as	  HDAC1	  and	  MeCP2.	  Moreover,	  we	  discovered	  various	  novel	  phosphosites	  on	  chromatin	  regulators	  that	  may	  contribute	  to	  the	  transcriptional	  repression	  in	  ET	  via	  regulation	  by	  PP2Ac-­‐dependent	  dephosphorylation;	  thus,	  these	  novel	  phosphosites	  may	  be	  major	  candidates	  for	  further	  studies	  investigating	  transcriptional	  regulation	  of	  LPS-­‐induced	  TLR4	  signaling	  and/or	  ET.	  In	  addition,	  we	  found	  that	  H3K9me2	  and	  H3K27me2	  are	  the	  most	  extensively	  affected	  histone	  H3	  PTMs	  by	  the	  PP2Ac-­‐KD	  in	  specifically	  ET	  phenotype,	  which	  suggests	  that	  PP2Ac	  mediates	  the	  inactivation	  of	  the	  
histone	  demethylases,	  the	  activation	  of	  histone	  methyltransferases,	  or	  both	  targeting	  these	  repressive	  sites.	  Through	  detailed	  analysis	  of	  PP2Ac-­‐targeted	  phosphorylations	  we	  observed	  that,	  among	  the	  identified	  KDMs,	  PHF8	  includes	  the	  highest	  number	  of	  phosphosites	  that	  are	  targeted	  by	  ET-­‐specific	  PP2Ac	  activity.	  Interestingly,	  Ser843	  (Ser880	  in	  human)	  of	  PHF8	  that	  we	  found	  targeted	  by	  chronically	  active	  PP2Ac	  was	  reported	  to	  be	  phosphorylated	  by	  CDK2/cyclin	  E	  kinase,	  enhancing	  the	  KDM	  activity	  of	  PHF8	  toward	  H3K9me2	  and	  promoting	  rDNA	  transcription	  and	  S-­‐phase	  progression	  of	  293T,	  Hela,	  or	  U2OS	  cells	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(Sun	  et	  al,	  2015a).	  	  Because	  of	  the	  transcriptionally	  repressive	  nature	  of	  chronically	  active	  PP2Ac	  and	  PP2Ac-­‐mediated	  dephosphorylation	  of	  catalytically	  important	  S843	  of	  PHF8,	  we	  postulate	  that	  the	  KDM	  activity	  of	  PHF8	  could	  be	  modulated	  in	  a	  phosphorylation-­‐dependent	  way,	  independently	  from	  cyclin	  E/Cyclin-­‐dependen	  kinase	  2(CDK2).	  	  Further	  biochemical	  and	  biophysical	  studies	  on	  the	  effect	  of	  PP2Ac-­‐mediated	  dephosphorylation	  on	  the	  activity	  of	  various	  chromatin	  regulators	  will	  help	  us	  understand	  the	  mechanism	  on	  gene-­‐specific	  transcriptional	  regulation	  downstream	  PP2Ac	  in	  ET	  and,	  similarly,	  discover	  how	  acute	  inflammation	  may	  be	  regulated	  in	  the	  transcriptional	  level	  through	  chromatin	  remodeling.	  Understanding	  the	  major	  regulators	  of	  LPS-­‐induced	  gene-­‐specific	  transcription	  would	  help	  us	  treat	  innate	  inflammation-­‐related	  or	  –induced	  diseases,	  understand	  the	  mechanisms	  of	  dysregulated	  immunity,	  develop	  alternative	  methods	  and	  developments	  in	  immunotherapy,	  and	  prevent	  chronic	  inflammation-­‐induced	  cancer	  progression.	  	  
FUTURE	  WORK	  	   To	  understand	  the	  mechanism	  underlying	  the	  PP2Ac-­‐mediated	  regulation	  of	  chromatin	  remodeling,	  more	  biochemical	  experiments	  exploring	  the	  changes	  in	  activity	  of	  the	  potential	  PP2Ac-­‐targeted	  chromatin	  regulators	  that	  were	  found	  in	  the	  phosphoprotemic	  analysis	  mentioned	  above.	  For	  this	  particular	  experiment	  set,	  we	  will	  need	  to	  compare	  the	  specific	  histone	  demethylase	  and	  methyltransferase	  activities	  in	  paired	  WT	  and	  PP2Ac-­‐KD	  cells.	  Currently,	  the	  commercially	  available	  histone	  demethylase	  or	  methyltransferace	  activity	  assay	  kits	  enable	  quantification	  of	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modification-­‐specific	  overall	  activity	  of	  various	  enzymes,	  rather	  than	  the	  enzyme-­‐specific	  activity;	  thus,	  we	  will	  need	  to	  immunoprecipitate	  those	  chromatin	  modifiers	  to	  measure,	  and	  compare,	  their	  specific	  enzymatic	  activity.	  Understanding	  whether,	  and	  how	  enzymatic	  activity	  of	  each	  KDM	  or	  KMT	  gets	  altered	  by	  PP2Ac-­‐KD	  in	  ET	  phenotype	  will	  help	  us	  pinpoint	  how	  PP2Ac	  might	  regulate	  ET-­‐specific	  transcriptional	  repression.	  Once	  specific	  enzymes	  are	  discovered,	  we	  will	  perform	  mutation	  studies	  (Ser	  to	  Ala	  and	  Ser	  to	  Asp)	  to	  demonstrate	  whether	  these	  PP2Ac-­‐targeted	  phosphosites	  are	  (1)	  significant	  for	  the	  KDM	  or	  KMT	  activity,	  (2)	  involved	  in	  the	  for	  phenotypic-­‐transcriptional	  regulation	  of	  inflammatory	  genes,	  (3)	  actually	  dephosphorylated	  by	  PP2Ac,	  and	  (4)	  playing	  a	  role	  in	  the	  stability	  of	  these	  enzymes.	  The	  initial	  candidate	  for	  such	  extensive	  analysis	  is	  PHF8	  as	  it	  is	  regulated	  by	  PP2Ac	  in	  ET	  according	  to	  our	  phosphoproteomic	  data.	  	  	   Moreover,	  bottom-­‐up	  and	  top-­‐down	  quantitative	  proteomic	  screening	  of	  histone	  PTMs	  of	  paired	  WT	  and	  PP2Ac-­‐KD	  cells	  in	  different	  inflammation	  phenotypes	  (N,	  NL,	  and	  TL)	  will	  also	  help	  us	  discover	  histone	  PTMs	  that	  are	  significant	  for	  phenotypic	  and	  transcriptional	  regulation	  of	  LPS-­‐induced	  inflammation.	  Overexpression	  and	  knockdown	  studies	  of	  PHF8	  would	  also	  be	  helpful	  to	  screen	  histone	  PTMs	  to	  demonstrate	  PHF8-­‐dependent	  histone	  combinatorial	  code	  regulation	  with	  LPS	  stimulation	  in	  macrophages.	  In	  addition,	  mutational	  studies	  of	  PHF8	  to	  screen	  demethylation	  of	  various	  PTMs	  would	  decipher	  specific	  PTMs	  of	  PHF8	  that	  regulate	  its	  enzymatic	  activity.	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FIGURES	  
	  
Figure	  18	  Role	  of	  PP2A	  in	  various	  signaling	  pathways	  
Methylation	  and	  phosphorylation	  PTMs	  regulate	  PP2A	  activity	  occurring	  in	  the	  conserved	  C-­‐
terminal	  sequence	  TPDYFL.	  PP2A	  activity	  PP2A	  activity	  is	  important	  part	  in	  the	  majority	  of	  the	  
cellular	  pathways,	  including	  AKT,	  Wnt,	  apoptosis,	  and	  cell	  growth	  survival	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Figure	  19	  Schematic	  representation	  of	  diversity	  of	  the	  PP2A	  holoenzymes	  
PP2A	  holoenzymes	  are	  heterotrimers	  consisting	  of	  a	  scaffold	  (A)	  and	  a	  catalytic	  (C)	  subunit	  that	  is	  
associated	  with	  one	  of	  the	  regulatory	  subunits	  (B).	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Figure	  20	  Chronic-­‐active	  PP2Ac	  regulates	  chromatin	  modifications	  
The	  chronic-­‐active	  PP2Ac-­‐mediated	  control	  of	  the	  inflammation	  occurs	  via	  regulation	  of	  TLR-­‐
induced,	  MyD88-­‐dependent,	  gene-­‐specific	  chromatin	  modifications	  (Xie	  et	  al,	  2013).	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Figure	  21	  Schematic	  representation	  of	  phosphoprotein	  analysis	  workflow	  
The	  most	  commonly	  used	  methods	  to	  resolve,	  to	  purify	  or	  to	  enrich	  phosphoproteins	  are	  shown	  in	  
the	  Protein	  separation	  section.	  Peptides	  resulting	  from	  trypsin	  digestion	  of	  phosphoproteins	  may	  
be	  analyzed	  directly	  by	  MS	  or	  by	  Edman	  degradation.	  Other	  approaches	  may	  be	  used	  for	  the	  
enrichment	  of	  phosphopeptides	  as	  shown	  in	  the	  Peptide	  separation	  section.	  MALDI	  and	  ESI	  are	  
usually	  used	  for	  identification	  of	  phosphoproteins.	  The	  two	  predominant	  techniques	  for	  
identification	  of	  the	  precise	  sites	  of	  phosphorylation	  are	  i)	  Edman	  degradation	  and	  ii)	  MS	  analysis	  
(Neutral	  loss	  and	  Precursor	  ion)	  as	  shown	  in	  the	  Identification	  section.	  1D/2D	  GE:	  On-­‐
dimensional/Two-­‐dimensional	  gel	  electrophoresis.	  Chem.	  Modif.:	  Chemical	  Modification.	  ESI:	  
Electrospray	  Ionisation.	  Ib:	  Immunoblot.	  IMAC:	  Immobilized	  Metal	  Affinity	  Chromatography.	  Ip-­‐α	  
PY:	  Immunopurification	  using	  a	  phospho-­‐tyrosine	  antibody.	  LC:	  Liquid	  Chromatography.	  MALDI:	  
Matrix-­‐Assisted	  Laser	  Desorption	  Ionization.	  ProQ:	  Pro-­‐Q	  DiamondTM.	  AR:	  Autoradiography.	  β-­‐
Elemin:	  β-­‐elimination	  reaction	  (Delom	  &	  Chevet,	  2006).	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Figure	  22	  Proteomic	  analysis	  using	  two-­‐dimensional	  gel	  electrophoresis	  
Proteins	  obtained	  from	  both	  control	  and	  treated	  samples	  are	  separated	  based	  on	  their	  isoelectric	  
point	  in	  the	  first	  dimension	  (isoelectric	  focusing)	  and	  their	  molecular	  mass	  in	  the	  second	  
dimension	  (SDS-­‐PAGE).	  Spot	  intensity	  detected	  by	  differential	  phosphoprotein	  staining	  is	  used	  to	  
quantify	  changes	  in	  phosphorylation.	  Spots	  of	  varying	  intensity,	  reflecting	  a	  measurable	  change	  in	  
protein	  phosphorylation	  (a	  few	  are	  indicated	  with	  circles),	  are	  excised,	  and	  the	  proteins	  
contained	  in	  each	  gel	  slice	  are	  subjected	  to	  in-­‐gel	  proteolysis.	  The	  resulting	  peptides	  are	  extracted	  
and	  analyzed	  by	  MS.	  Based	  on	  the	  mass	  spectral	  data	  acquired,	  a	  variety	  of	  database	  searching	  
algorithms	  are	  used	  to	  identify	  the	  peptides	  and	  map	  sites	  of	  phosphorylation,	  which	  in	  turn,	  
identify	  the	  phosphoproteins	  present	  in	  the	  sample	  (Goshe,	  2006).	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Figure	  23	  Quantitative	  phosphoproteomics	  workflow.	  
Workflow	  of	  LPS	  stimulation	  and	  sample	  preparation	  involves	  amino	  acid-­‐coded	  labeling,	  lysis,	  
digestion,	  desalting	  SCX	  fractionation,	  followed	  by	  TiO2	  Phosphoenrichment	  (Erdoğan	  et	  al,	  2016).	  
	  	  
	  
Figure	  24	  Phosphoproteomic	  analysis	  shows	  99%	  phospho-­‐enrichment	  efficiency.	  
Proteins	  (left,	  blue)	  and	  peptides	  (right,	  orange)	  that	  were	  identified	  in	  the	  phosphoproteomic	  
analysis	  revealed	  99%	  phospho-­‐enrichment	  efficiency.	  1319	  total	  proteins	  and	  18,492	  total	  
peptides	  were	  identified.	  1301	  of	  the	  proteins	  were	  phosphorylated	  while	  18,298	  peptides	  were	  
phosphopeptdies.	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Figure	  25	  Identified	  phosphopeptides	  mostly	  cover	  single	  phosphorylation	  
The	  percentage	  of	  the	  number	  of	  phosphorylation	  per	  peptide	  is	  given	  on	  the	  left	  while	  the	  right	  




Figure	  26	  Distribution	  of	  Phospho	  STY	  identifications	  
86%	  of	  the	  phosphopeptides	  were	  Phospho-­‐S,	  while	  13%	  and	  1%	  were	  Phospho-­‐T	  and	  Phospho-­‐Y,	  
respectively.	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Figure	  27	  Identified	  mass	  error	  	  
The	  mass	  error	  was	  identified	  by	  MaxQuant	  for	  normalization	  of	  the	  quantitative	  proteomics	  
	  
Figure	  28	  The	  top	  signaling	  pathways	  targeted	  by	  PP2Ac	  in	  ET	  macrophages	  
Only	  the	  top	  10	  over-­‐represented	  signaling	  pathways	  are	  shown.	  
	  These	  signaling	  pathways	  include	  the	  highest	  number	  of	  proteins	  that	  show	  increased	  
phosphorylation	  in	  PP2Ac-­‐KD	  RAW	  cells	  compared	  to	  WT	  RAW	  cells	  in	  ET	  (Erdoğan	  et	  al,	  2016).	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Figure	  29	  Top	  signaling	  pathways	  that	  are	  targeted	  by	  PP2Ac	  	  
PP2Ac	  broadly	  targets	  the	  signaling	  pathways	  through	  dephosphorylating	  chromatin	  regulators	  
in	  ET.	  	  The	  top	  signaling	  pathways	  including	  proteins	  with	  increased	  phosphorylation	  in	  
PP2AcKD-­‐TL	  compared	  to	  WT-­‐TL	  include	  many	  chromatin	  regulators	  (Erdoğan	  et	  al,	  2016).	  The	  
most	  extensive	  change	  in	  PP2Ac-­‐dependent	  dephosphorylation	  occurs	  in	  the	  DNA	  Methylation	  
and	  Transcriptional	  Pathway	  in	  line	  with	  transcriptionally-­‐repressive	  role	  of	  PP2Ac.	  A.	  DNA	  
Methylation	  and	  Transcriptional	  Pathway,	  B.	  PI3/AKT	  Signaling,	  C.	  Insulin	  Receptor	  Signaling,	  D.	  
Rac	  Signaling,	  E.	  HGF	  Signaling,	  F.	  ERK/MAPK	  Signaling,	  G.	  Telomerase	  Signaling,	  H.	  ATM	  Signaling,	  
and	  I.	  Legend	  for	  shape	  and	  shade	  colors.	  
	  
Figure	  30	  PP2Ac	  affects	  a	  borad	  range	  of	  signaling	  pathways	  in	  ET.	  	  
IPA	  Canonical	  Pathway	  Analysis	  reveals	  the	  signaling	  pathways	  whose	  proteins	  show	  increased	  	  
phosphorylation	  with	  PP2Ac-­‐KD	  compared	  to	  WT	  RAW	  cells	  in	  ET-­‐tolerant	  macrophages.	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Figure	  31	  PP2Ac	  negatively	  regulates	  ATM	  signaling.	  
ATM	  activity	  is	  regulated	  by	  authophosphorylation	  which	  is	  negatively	  regulated	  by	  PP2Ac	  
activity	  (Goodarzi	  et	  al,	  2004).	  	  	  	   	  
	   100	  
	  
	  
Figure	  32	  The	  MS	  spectra	  of	  KDMs	  that	  are	  dephosphorylated	  by	  PP2Ac	  in	  ET.	  
Top	  Row:	  KDM1A	  (P-­‐S132	  and	  P-­‐S138)	  and	  KDM5A	  (P-­‐S1598	  and	  P-­‐S1603),	  Middle	  and	  Bottom	  
Rows:	  PHF8	  (P-­‐S766,	  P-­‐S817,	  P-­‐S820,	  and	  P-­‐S843).	  Green	  circle:	  m/z	  of	  WT-­‐N	  (Light),	  Yellow	  
circle:	  m/z	  of	  WT-­‐TL	  (Medium),	  and	  Red	  circle:	  m/z	  of	  PP2Ac-­‐KD-­‐TL	  (Heavy).	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Figure	  33	  The	  MS	  spectra	  of	  KMTs	  that	  are	  targeted	  by	  PP2Ac	  in	  ET.	  
Top	  Row:	  MeCP2	  P-­‐S78/P-­‐S80,	  MCES	  P-­‐S11/P-­‐S15,	  MCES	  P-­‐S152,	  and	  TRM6	  P-­‐T284.	  2nd	  Row:	  NSD2	  
P-­‐T110/P-­‐T115,	  EZH2	  P-­‐S362/P-­‐S366,	  MLL1	  P-­‐S3032,	  and	  NSD3	  P-­‐S561,	  and	  Bottom	  Row:	  
DNMT3A	  P-­‐S102,	  DNMT1	  P-­‐S138,	  and	  MLL4	  P-­‐S1927/P-­‐S1932.	  Green	  circle:	  m/z	  of	  WT-­‐N	  (Light),	  
Yellow	  circle:	  m/z	  of	  WT-­‐TL	  (Medium),	  and	  Red	  circle:	  m/z	  of	  PP2Ac-­‐KD-­‐TL	  (Heavy).	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Figure	  34	  The	  MS	  spectra	  of	  PP2Ac-­‐targeted	  deacetylases	  and	  acetyltransferases	  
(A)	  deacetylases	  and	  (B)	  acetyltransferases	  (B)	  that	  are	  targeted	  by	  PP2Ac	  in	  ET.	  Green	  circle:	  m/z	  
of	  WT-­‐N	  (Light),	  Yellow	  circle:	  m/z	  of	  WT-­‐TL	  (Medium),	  and	  Red	  circle:	  m/z	  of	  PP2Ac-­‐KD-­‐TL	  
(Heavy).	  	  
	   103	  
	  
	  
Figure	  35	  MS-­‐MS	  Spectra	  of	  known	  PP2Ac	  targets.	  
MeCP2	  pS80	  (A),	  HDAC1	  pS421	  and	  pS423	  (B),	  and	  HDAC2	  pS422	  and	  pS424	  (C)	  (Erdoğan	  et	  al,	  
2016).	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Figure	  36	  Growth	  factors	  and	  insulin	  regulation	  of	  mTORC	  signaling	  via	  AKT.	  	  
mTORC1	  activity	  is	  modulated	  by	  a	  number	  of	  positive	  (shown	  in	  red)	  and	  negative	  (shown	  in	  
blue)	  regulators.	  Growth	  factors	  activate	  mTORC1	  indirectly	  by	  suppressing	  the	  function	  of	  its	  
negative	  regulator	  TSC1/TSC2	  complex.	  PI3K-­‐AKT	  dependent	  phosphorylation	  inhibits	  the	  
TSC1/2	  complex	  allowing	  activation	  of	  TORC1.	  AKT	  also	  activates	  mTORC1	  through	  negative	  
phosphorylation	  of	  mTORC1	  suppressor,	  PRAS40.	  (REF:	  DOI:	  10.5772/48274)	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Figure	  37	  Histone	  PTM	  changes	  regulated	  by	  PP2Ac	  activity	  in	  ET	  
Left	  panel	  shows	  the	  immunoblotting	  of	  histone	  PTMs	  H3K9me2,	  H3K27me2,	  H3K27me3,	  
H3K4meK9me2,	  and	  H3S10P	  	  using	  H3	  immunoblot	  as	  a	  loading	  control	  for	  these.	  Inflammation	  
phenotype	  was	  confirmed	  with	  the	  P-­‐p65	  (S536)	  immunoblot,	  PP2Ac	  immunoblot	  shows	  the	  
PP2Ac	  knockdown	  efficiency,	  and	  γtubulin	  is	  used	  as	  the	  cellular	  loading	  control.	  Right	  panel	  
shows	  the	  	  quantification	  of	  the	  densitometer	  scanning	  of	  H3K9me2	  (blue	  line)	  and	  H3K27me2	  
(red	  line)	  bands	  from	  the	  immunoblots	  (Erdoğan	  et	  al,	  2016).	  	  
	  
Figure	  38	  The	  MS/MS	  (Left)	  and	  MS	  (Right)	  spectra	  of	  PHF8	  phosphopeptides.	  	  
These	  phosphopeptides	  are	  targeted	  by	  PP2Ac	  in	  ET	  (Erdoğan	  et	  al,	  2016).	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CHAPTER	  3:	  PHF8	  IS	  ACTIVATED	  IN	  LPS-­‐INDUCED	  MACROPHAGES	  TO	  POSITIVELY	  
REGULATE	  CYTOKINE	  EXPRESSION	  AND	  NFκB	  ACTIVITY
OVERVIEW	  Epigenetic	  regulation	  of	  gene-­‐specific	  transcription	  determines	  the	  phenotype-­‐specific	  LPS-­‐induced	  inflammation	  response	  in	  macrophages.	  Through	  the	  phosphoproteomic	  screening	  of	  PP2Ac-­‐targeted	  chromatin	  modifiers	  in	  ET-­‐macrophages,	  we	  identified	  PHF8	  as	  a	  positive	  regulator	  of	  LPS-­‐induced	  acute	  inflammation.	  To	  understand	  how	  PHF8	  regulates	  the	  LPS-­‐induced	  acute	  inflammation	  response,	  we	  performed	  immunoblotting	  to	  understand	  the	  histone	  PTMs	  that	  are	  altered	  by	  PHF8	  in	  LPS	  response.	  Our	  analysis	  identified	  H3K9me1	  and	  H3K9me2	  as	  the	  major	  targets	  of	  PHF8	  during	  LPS-­‐induced	  inflammation	  response	  in	  macrophages.	  Then,	  by	  performing	  co-­‐immunoprecipitation	  (CoIP),	  we	  demonstrated	  that	  PHF8	  binds	  to	  p65	  subunit	  of	  NFκB	  in	  acute	  inflammation,	  regulates	  the	  nuclear	  translocation	  of	  phosphorylated	  p65,	  and	  the	  complex	  formation	  is	  weakened	  with	  prolonged	  LPS	  stimulation.	  These	  results	  indicate	  that	  the	  PHF8-­‐dependent	  NFκB	  regulation	  in	  LPS-­‐stimulated	  macrophages	  is	  transient.	  Moreover,	  via	  dual	  luciferase-­‐reporter	  assay,	  we	  demonstrated	  that,	  by	  binding	  to	  p65,	  PHF8	  positively	  regulates	  NFκB	  transcriptional	  activity	  upon	  LPS	  stimulation.	  To	  further	  prove	  the	  gene-­‐specific	  transcriptional	  regulation	  of	  inflammatory	  genes	  by	  PHF8	  in	  LPS	  response,	  we	  performed	  qPCR	  experiments	  and	  demonstrated	  that	  PHF8	  is	  involved	  in	  the	  gene-­‐specific	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transcriptional	  regulation	  of	  pro-­‐inflammatory	  cytokines.	  Overall	  the	  transient	  activation	  of	  PHF8	  supports	  our	  conclusions	  that	  PHF8	  is	  activated	  in	  LPS-­‐induced	  acute	  
inflammation,	  positively	  regulates	  NFκB	  transcriptional	  activity,	  modulates	  the	  gene-­‐
specific	  pro-­‐inflammatory	  cytokine	  expression,	  and	  is	  negatively	  regulated	  by	  PP2Ac-­‐
dependent	  dephosphorylation	  in	  ET.	  
INTRODUCTION
Histone	  Demethylase	  PHF8	  PHF8	  is	  a	  JmjC	  domain	  containing	  histone	  KDM	  that	  removes	  the	  repressive	  methyl	  marks	  from	  H3K9me1/2,	  H3K27me2,	  or	  H4K20me1,	  promoting	  the	  transcription	  of	  target	  genes	  (Fortschegger	  et	  al,	  2010;	  Klose	  et	  al,	  2006).	  The	  domain	  structure	  of	  PHF8	  is	  composed	  of	  an	  amino-­‐terminal	  PHD	  Finger	  domain	  responsible	  detection	  of	  Kme	  and	  a	  catalytic	  JmjC	  domain	  (Figure	  39)	  (Klose	  et	  al,	  2006).	  The	  Serine-­‐rich	  region	  is	  towards	  the	  carboxy-­‐terminus.	  The	  PP2Ac-­‐targeted	  phospho-­‐Serine	  residues	  identified	  in	  the	  phosphoproteomic	  study	  occur	  at	  or	  near	  the	  Ser-­‐rich	  domain	  and	  they	  are	  conserved	  among	  human	  and	  mouse	  (Figure	  39,	  Figure	  40).	  Based	  on	  the	  crystal	  structure,	  JmjC	  domain	  has	  eight	  β-­‐sheets	  that	  create	  an	  enzymatic	  core	  that	  binds	  to	  Fe(II)	  and	  and	  αKG,	  hydroxylating	  the	  substrate	  and	  leading	  to	  removal	  of	  the	  methyl	  group	  in	  the	  form	  of	  formaldehyde	  (Figure	  41)	  (Clifton	  et	  al,	  2006;	  Yu	  et	  al,	  2010;	  Yue	  et	  al,	  2010).	  PHF8	  activity	  regulates	  brain	  and	  craniofacial	  development	  in	  zebrafish	  and	  its	  truncated	  or	  missense	  mutations	  lead	  to	  X-­‐linked	  mental	  retardation	  (XLMR)	  associated	  with	  cleft	  lip/palate	  (CL/P)	  (Kleine-­‐Kohlbrecher	  et	  al,	  2010;	  Laumonnier	  et	  al,	  2005;	  Qi	  et	  al,	  2010).	  More	  recent	  studies	  shed	  light	  on	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the	  functional	  mechanism	  of	  neuronal	  development	  by	  PHF8	  activity	  through	  regulation	  of	  cytoskeletal	  dynamics	  (Asensio-­‐Juan	  et	  al,	  2012).	  PHF8	  regulates	  organization	  of	  actin	  cytoskeleton,	  cell	  adhesion,	  and	  neuronal	  growth	  through	  H4K20me1	  demethylation	  at	  the	  promoters	  of	  Ras	  homolog	  gene	  family,	  member	  A	  (RhoA),	  Ras-­‐related	  C3	  botulinum	  toxin	  substrate	  1	  (Rac1),	  and	  Glycogen	  synthase	  kinase-­‐3	  Beta	  (GSK3β).	  PHF8	  is	  a	  transcriptional	  coactivator	  that	  recognizes	  H3K4me3	  mark	  at	  the	  promoters	  of	  the	  active	  or	  poised	  genes	  and	  gets	  recruited	  to	  those	  promoters	  for	  interaction	  with	  RNA-­‐PII	  (Figure	  42)	  (Fortschegger	  et	  al,	  2010).	  PHF8	  was	  also	  identified	  as	  a	  transcriptional	  regulator	  of	  ribosomal	  RNA	  (rRNA)	  through	  its	  H3K9me2	  demethylase	  activity	  (Zhu	  et	  al,	  2010).	  To	  positively	  regulate	  ribosomal	  DNA	  (rDNA)	  transcription,	  PHF8	  interacts	  with	  RNA-­‐PI	  and	  Tryptophan-­‐Aspartic	  acid	  (WD)-­‐repeat	  domain	  5	  (WDR5)-­‐containing	  H3K4	  KMT	  complexes	  (Feng	  et	  al,	  2010).	  On	  the	  other	  hand,	  PHF8	  is	  an	  essential	  regulator	  of	  cell	  cycle	  progression	  through	  its	  H4K20me1	  demethylase	  activity	  (Liu	  et	  al,	  2010).	  Following	  recruitment	  to	  the	  promoters	  of	  cell-­‐cycle	  related	  genes,	  PHF8	  demethylates	  repressive	  H4K20me1	  marks	  to	  enable	  G1/S	  transition.	  Moreover,	  in	  prophase,	  phosphorylation	  dependent	  dissociation	  of	  PHF8	  from	  
the	  promoters	  lead	  to	  increased	  H4K20me1.	  H4K20me1	  demethylation	  by	  PHF8	  is	  also	  crucial	  for	  G2/M	  transition	  (Lim	  et	  al,	  2013);	  it	  activates	  the	  G2/M	  gene	  expression	  for	  progression	  of	  mitosis	  and	  its	  loss	  leads	  to	  prolonged	  G2	  phase	  or	  defective	  mitosis.	  More	  importantly,	  this	  regulation	  of	  cell-­‐cycle	  by	  PHF8	  is	  a	  phosphorylation-­‐dependent	  process	  (Sun	  et	  al,	  2015a).	  Cyclin	  E/CDK	  phosphorylates	  PHF8	  at	  S844	  activating	  H3K9me2	  demethylation	  to	  induce	  PHF8-­‐dependent	  rRNA	  transcription	  and	  cell	  cycle	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progression.	  Phosphorylation-­‐dependent	  regulation	  of	  PHF8	  activity	  was	  also	  reported	  in	  the	  all-­‐trans	  retinoic	  acid	  (ATRA)	  response	  in	  acute	  promyelocytic	  leukemia	  (APL)(Arteaga	  et	  al,	  2013).	  Overall,	  these	  suggest	  that	  phosphorylation	  may	  be	  a	  broad	  mechanism	  for	  regulation	  of	  PHF8	  activity.	  	  In	  line	  with	  its	  role	  in	  cell-­‐cycle	  progression,	  PHF8	  regulates	  the	  migration	  and	  invasion	  of	  Prostate	  cancer	  (PrCa)	  (Björkman	  et	  al,	  2012),	  (ESCC)	  (Sun	  et	  al,	  2013),	  non-­‐small	  cell	  lung	  cancer	  (NSCLC)	  (Shen	  et	  al,	  2014),	  and	  laryngeal	  and	  hypopharyngeal	  squamous	  cell	  carcinoma	  (LHSCC)	  (Zhu	  et	  al,	  2015);	  more	  importantly,	  in	  all	  of	  these	  cancers,	  high	  PHF8	  expression	  leads	  to	  poor	  survival,	  indicating	  that	  PHF8	  may	  be	  a	  potential	  diagnostic	  marker.	  The	  knockdown	  studies	  revealed	  that	  PHF8	  knockdown	  leads	  to	  DNA	  damage	  and	  apoptosis	  (Shen	  et	  al,	  2014),	  decreased	  cell	  motility	  (Björkman	  et	  al,	  2012),	  reduction	  in	  the	  migratory	  and	  invasive	  cells	  (Sun	  et	  al,	  2013),	  and	  increased	  expression	  of	  pro-­‐apoptotic	  genes	  Tumor	  protein	  p53	  (TP53),	  B-­‐cell	  Lymphoma	  2(Bcl2)-­‐like	  protein	  4	  (BAX),	  and	  Caspase	  3	  (CASP3)	  (Muranko,	  2014).	  These	  indicate	  that	  PHF8	  is	  an	  important	  target	  in	  cancer	  progression	  as	  it	  positively	  regulates	  the	  cell	  migration	  and	  invasion.	  Recent	  studies	  revealed	  that	  PHF8	  has	  a	  role	  of	  inhibiting	  the	  Akt-­‐Mechanistic	  target	  of	  rapamycin	  (mTOR)	  pathway	  both	  in	  vivo	  and	  in	  vitro	  (Liu	  et	  al,	  2015).	  Moreover,	  PHF8	  is	  a	  major	  regulator	  of	  bone	  repair	  and	  wound	  healing	  through	  regulation	  of	  special	  At-­‐rich	  sequence-­‐binding	  protein	  2	  (SATB2)	  expression	  (Han	  et	  al,	  2015).	  These	  functional	  roles	  of	  PHF8	  might	  be	  involved	  in	  LPS-­‐induced	  cell	  response,	  as	  cytoskeleton	  changes,	  cell	  cycle,	  cell	  migration,	  and	  transcription	  are	  important	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events	  in	  inflammation	  response.	  However,	  the	  role	  of	  PHF8	  in	  the	  control	  of	  inflammation	  response	  hasn’t	  been	  investigated.	  	  Here,	  we	  are	  first	  to	  identify	  PHF8	  as	  a	  major	  regulator	  of	  inflammatory	  gene	  expression.	  Our	  results	  show	  that	  it	  demethylates	  H3K9me1/me2,	  binds	  to	  p65,	  positively	  regulates	  the	  transcriptional	  activity	  of	  p65,	  and	  regulates	  the	  gene-­‐specific	  transcription	  of	  pro-­‐inflammatory	  cytokines	  upon	  LPS	  stimulation	  in	  macrophages.	  	  
MATERIALS	  AND	  METHODS	  
Reagents	  LPS	  was	  purchased	  from	  Invitrogen.	  All	  protease	  inhibitor	  cocktails	  were	  purchased	  from	  Sigma-­‐Aldrich	  (St.	  Louis,	  MO).	  All	  culture	  media	  and	  FBS	  were	  obtained	  from	  GIBCO.	  Trypsin	  was	  purchased	  from	  Promega.	  All	  chemicals	  were	  sequence-­‐	  or	  HPLC-­‐grade	  unless	  specifically	  indicated.	  Antibodies	  for	  p-­‐IκBa	  (S32),	  IκBa,	  p-­‐p65	  NFκB	  (S536),	  and	  p65	  were	  purchased	  from	  Cell	  Signaling.	  Antibodies	  for	  Lmnb1	  and	  p65	  were	  from	  Santa	  Cruz	  Biotechnology	  while	  antibodies	  to	  γ-­‐tubulin,	  histone	  H3,	  H3K9me2,	  H3K9me1,	  and	  H3K27me2	  were	  from	  Abcam.	  Antibody	  for	  PHF8	  was	  from	  Bethyl	  Labs.	  Bacterial	  clones	  for	  shRNA	  against	  PHF8	  or	  against	  PLKO.1	  were	  purchased	  from	  Sigma-­‐Aldrich.	  293-­‐TLR4-­‐MD2-­‐CD14	  cells	  were	  purchased	  from	  Invivogen.	  PureProteome	  Magnetic	  beads	  for	  CoIP	  experiments	  were	  purchased	  from	  Millipore.	  	  
Plasmids	  pMSCV-­‐hPHF8-­‐FLAG-­‐Neo	  	  and	  EcoPak	  viral	  packaging	  plasmids	  were	  kindly	  provided	  by	  Dr.	  Greg	  Wang.	  pBabe-­‐puro	  (EV)	  was	  purchased	  from	  Sigma.	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Cell	  Culture	  RAW	  264.7	  cells	  were	  maintained	  in	  4.5	  g/L	  glucose	  DMEM	  with	  10%	  FBS.	  For	  all	  LPS	  pre-­‐treatment	  0.1	  μg/mL	  LPS	  is	  used	  while	  high	  dose	  LPS	  treatment	  and	  second	  challenges	  were	  done	  with	  1	  μg/mL	  LPS.	  
Transfection	  and	  Stable	  PHF8	  Knock-­‐down	  (PHF8-­‐KD)	  RAW	  Cell	  Line	  The	  lentiviral	  plasmids	  pLKO.1	  expressing	  shRNA-­‐PHF8	  (targeting	  sequences	  CGACCCTGATAATAAGACCAA	  and	  GCAAGATGAAACTCGGTGATT	  in	  human	  and	  mouse,	  respectively)	  were	  purchased	  from	  Sigma.	  A	  pLKO.1	  empty	  vector	  without	  a	  specific	  shRNA	  sequence	  was	  used	  as	  the	  wild-­‐type	  control.	  To	  produce	  virus,	  pLKO.1-­‐shRNA	  plasmids	  were	  co-­‐transfected	  into	  293T	  cells	  with	  ViraPowerMix	  (Invitrogen)	  by	  jetPRIMETM	  in	  vitro	  DNA	  and	  siRNA	  transfection	  reagent	  (Polyplus).	  Pseudo-­‐virus	  in	  supernatants	  was	  collected	  48	  h	  after	  transfection	  and	  used	  to	  transduce	  RAW	  264.7	  cells	  by	  spinoculation.	  48	  h	  after	  transfection,	  8	  μg/ml	  puromycin	  was	  added	  to	  select	  puromycin-­‐resistant	  clones.	  Stable	  clones	  were	  maintained	  in	  medium	  containing	  4	  μg/mL	  puromycin.	  The	  expression	  level	  of	  PHF8	  in	  PHF8-­‐KD	  cell	  line	  was	  monitored	  with	  immunoblotting	  and	  qPCR.	  
Immunoblotting	  of	  Histone	  PTMs	  Paired	  WT	  and	  PHF8-­‐KD	  RAW	  cells	  were	  stimulated	  with	  1.0	  μg/mL	  LPS	  for	  0,	  ¼,	  2,	  8,	  and	  24	  h.	  Cells	  were	  harvested	  and	  lysed	  with	  buffer	  containing	  0.5%	  NP-­‐40,	  10	  mM	  Tris	  pH	  7.5,	  150	  mM	  NaCl,	  0.4	  mM	  EDTA,	  2	  mM	  Na3PO4,	  1x	  phosphatase	  inhibitor	  cocktail	  (Pierce),	  and	  1x	  protease	  inhibitor	  cocktail	  (Sigma-­‐Aldrich).	  	  The	  lysates	  were	  sonicated	  twice	  at	  level	  3	  for	  5	  sec	  for	  successful	  release	  of	  the	  chromatin,	  then	  were	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separated	  on	  an	  SDS-­‐	  PAGE	  gel	  under	  reducing	  conditions,	  and	  transferred	  to	  a	  PVDF	  membrane.	  The	  membranes	  were	  blocked	  with	  milk	  for	  1	  h	  at	  RT	  on	  an	  orbital	  shaker.	  Following	  primary	  antibody	  incubation	  for	  1	  h	  at	  RT,	  we	  probed	  the	  membranes	  with	  a	  horseradish	  peroxidase	  conjugated	  secondary	  antibody	  and	  bands	  were	  detected	  using	  an	  ECL	  Western	  Blotting	  Detection	  Kit	  (GE	  Life	  Sciences).	  	  
RNA	  Isolation	  and	  qPCR	  for	  PHF8	  mRNA	  expression	  analysis	  Stable	  cell	  lines	  were	  seeded	  into	  12	  well	  cell	  culture	  dishes	  and	  treated	  with	  LPS	  for	  indicated	  times.	  Total	  RNA	  was	  isolated	  using	  illustra	  RNAspin	  Mini	  Kit	  (GE	  Healthcare	  Life	  Sciences).	  First-­‐strand	  cDNA	  was	  synthesized	  by	  M-­‐MLV	  reverse	  transcriptase	  (Promega)	  and	  diluted	  5-­‐fold	  for	  qPCR.	  qPCR	  was	  performed	  using	  Maxima	  SYBRGreen/ROX	  (Thermo	  Scientific),	  and	  primer	  sequences	  “5-­‐aacacaacaaatgctaatct-­‐3”,	  and	  “5-­‐agaagttccctccgaatgct-­‐3”.	  All	  measurements	  were	  normalized	  against	  Glyceraldehyde	  3-­‐phosphate	  dehydrogenase	  (GAPDH)	  as	  the	  internal	  control	  using	  2-­‐ΔΔCt	  method	  with	  primer	  sequences	  “5-­‐aactttggcattgtggaagg-­‐3”,	  and	  “5-­‐acacattgggggtaggaaca-­‐3”.	  	  
Nuclear-­‐Cytoplasmic	  Fractionation	  for	  Immunoblotting	  RAW	  264.7	  cells	  under	  different	  inflammatory	  conditions	  were	  washed	  once	  with	  cold	  PBS,	  scraped,	  and	  collected	  by	  centrifugation.	  The	  nuclear	  and	  cytoplasmic	  proteins	  were	  fractionated	  with	  a	  CelLytic	  NuCLEAR	  Extraction	  Kit	  (Sigma)	  according	  to	  the	  manufacturer’s	  instructions.	  Briefly,	  the	  cell	  pellets	  were	  resuspended	  in	  hypotonic	  lysis	  buffer	  (10	  mM	  Hepes	  pH	  7.9,	  1.5	  mM	  MgCl2,	  and	  10	  mM	  KCl,	  10	  mM	  DTT,	  protease	  inhibitors,	  and	  phosphatase	  inhibitors).	  Resuspended	  cells	  were	  incubated	  on	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ice	  for	  15	  min	  for	  to	  swell	  the	  cells,	  which	  were	  then	  lysed	  gently	  using	  10%	  IGEPAL	  CA-­‐630	  (NP40)	  solution	  at	  a	  final	  concentration	  of	  0.6	  %;	  the	  lysates	  were	  vortexed	  and	  centrifuged	  immediately	  for	  30	  sec	  at	  10,000	  x	  g.	  The	  supernatants	  containing	  the	  cytoplasmic	  fraction	  were	  removed	  to	  new	  tubes.	  After	  removal	  of	  cytoplasmic	  fraction,	  the	  nuclear	  fraction	  was	  lysed	  with	  buffer	  containing	  50	  mM	  TrisHCl,	  pH	  7.5;	  150	  mM	  NaCl,	  0.5%	  Triton-­‐X	  100,	  1X	  phosphatase	  inhibitor	  cocktail	  (Pierce),	  1	  X	  protease	  inhibitor	  cocktail	  (Sigma-­‐Aldrich)	  followed	  by	  a	  sonication	  for	  10	  sec	  at	  level	  3	  (5	  sec	  on,	  5	  sec	  off;	  twice)	  for	  the	  removal	  of	  DNA	  from	  chromatin.	  The	  cytosol	  and	  nucleus	  protein	  mixtures	  were	  run	  on	  SDS-­‐PAGE	  gels	  in	  reducing	  conditions	  and	  the	  proteins	  were	  transferred	  onto	  PVDF	  membranes.	  The	  membranes	  were	  blocked	  in	  milk	  at	  RT	  for	  1	  h.	  Primary	  antibody	  incubation	  was	  performed	  at	  RT	  on	  a	  rotator	  for	  1	  h	  while	  secondary	  antibody	  incubation	  was	  performed	  at	  4	  °C	  overnight.	  	  
Co-­‐immunoprecipitation	  of	  PHF8-­‐p65	  Complexes	  PureProteome	  magnetic	  beads	  (20	  μL	  per	  CoIP	  sample)	  were	  washed	  with	  PBS	  three	  times,	  re-­‐equilibrated	  with	  PBS-­‐Tween	  20	  (0.1	  %	  final).	  The	  antibody	  (IgG,	  p65	  or	  PHF8)	  was	  added	  into	  the	  mixture	  (1	  μg	  per	  CoIP	  sample)	  and	  incubated	  rotating	  at	  4	  °C.	  The	  next	  day	  the	  antibody-­‐bound	  beads	  were	  washed	  with	  PBS	  and	  then	  crosslinked	  to	  reduce	  the	  antibody	  contamination	  in	  eluted	  protein	  solution	  by	  incubating	  in	  5.2	  mg/mL	  Dimethyl	  Pimelimidate	  (DMP)	  for	  30	  min	  at	  RT.	  The	  crosslinking	  was	  quenched	  with	  100	  mM	  ethanolamine	  in	  PBS	  rotating	  for	  2	  h	  at	  RT.	  The	  cross-­‐linked	  antibodies	  were	  stored	  in	  PBS-­‐Tween	  20	  (0.1	  %	  final)	  with	  0.1	  %	  sodium	  azide	  at	  4	  °C	  for	  a	  day	  until	  the	  lysates	  were	  prepared.	  For	  whole	  cell	  lysate	  coIP,	  we	  lysed	  the	  non-­‐stimulated	  and	  LPS-­‐stimulated	  cells	  in	  nuclear	  lysis	  buffer	  and	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sonicated	  for	  10	  sec	  (5	  sec	  on,	  5	  sec	  off)	  at	  level	  3.	  For	  the	  nuclear-­‐lysate	  specific	  CoIP,	  after	  the	  LPS	  stimulation	  for	  0,	  15,	  30,	  and	  60	  min,	  or	  24	  h,	  cytoplasmic	  and	  nuclear	  proteins	  were	  fractionated	  as	  mentioned	  above.	  10%	  of	  the	  equal	  amounts	  of	  sonicated	  nuclear	  lysates	  for	  each	  condition	  were	  separated	  as	  the	  input	  control	  in	  immunobloting.	  The	  remaining	  nuclear	  lysates	  were	  used	  for	  CoIP.	  The	  cross-­‐linked	  antibody	  mixtures	  were	  washed	  and	  equilibrated	  with	  the	  nuclear	  lysis	  buffer.	  The	  samples	  were	  added	  to	  the	  antibody	  mixture	  and	  incubated	  on	  a	  rotator	  overnight	  at	  4	  °C.	  The	  unbound-­‐proteins	  were	  washed	  with	  lysis	  buffer	  for	  three	  times	  and	  eluted	  in	  60	  μL	  1	  X	  SDS-­‐loading	  buffer	  by	  boiling	  for	  10	  min.	  The	  protein	  fractions	  including	  cytosol,	  nuclear,	  and	  CoIP	  were	  separately	  ran	  on	  SDS-­‐PAGE	  gels	  under	  reducing	  conditions	  and	  then	  transferred	  to	  PVDF	  membranes.	  The	  membranes	  were	  blocked	  with	  milk	  for	  1	  h	  at	  RT	  on	  an	  orbital	  shaker.	  Following	  primary	  antibody	  incubation	  for	  1	  h	  at	  RT,	  we	  probed	  the	  membranes	  with	  a	  horseradish	  peroxidase	  conjugated	  secondary	  antibody	  and	  bands	  were	  detected	  using	  an	  ECL	  Western	  Blotting	  Detection	  Kit	  (GE	  Life	  Sciences).	  
NF-­‐κB	  reporter	  assay	  293/TLR4-­‐MD2-­‐CD14	  Cells	  were	  seeded	  on	  24-­‐well	  plates	  one	  day	  before	  transfection	  so	  that	  they	  will	  be	  90	  %	  confluent	  at	  the	  time	  of	  transfection.	  The	  next	  day,	  cells	  were	  transfected	  with	  225	  ng	  pGL2-­‐ELAM	  promoter	  Firefly	  luciferase	  transgene	  plasmid	  and	  450	  ng	  plasmids	  indicated.	  The	  pRL-­‐	  TK	  plasmid,	  which	  expresses	  Renilla	  luciferase,	  was	  transfected	  into	  cells	  at	  75	  ng	  as	  an	  internal	  control	  to	  normalize	  transfection	  efficiency	  and	  sample	  handling.	  The	  cells	  were	  stimulated	  with	  1	  μg/mL	  LPS	  for	  6	  hours	  before	  harvesting.	  The	  activities	  of	  the	  two	  kinds	  of	  luciferase	  were	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measured	  with	  their	  respective	  substrates	  with	  a	  dual	  luciferase	  assay	  kit	  (Promega).	  The	  luminescence	  reading	  reflecting	  NF-­‐κB	  activity	  was	  obtained	  from	  the	  division	  of	  Firefly	  luciferase	  reading	  by	  Renilla	  luciferase	  reading.	  The	  data	  represented	  in	  the	  corresponding	  figures	  were	  the	  luminescence	  normalized	  to	  the	  control	  sample	  transfected	  with	  empty	  vector	  instead	  of	  functional	  plasmids.	  Y-­‐axis	  indicates	  relative	  NF-­‐κB	  activity.	  The	  error	  bar	  represents	  standard	  deviation	  of	  triplicates.	  Similar	  results	  were	  obtained	  in	  three	  independent	  biological	  experiments.	  
RNA	  Isolation	  and	  qPCR	  for	  Pro-­‐inflammatory	  mRNA	  expression	  The	  same	  methods	  for	  PHF8	  RNA	  isolation	  and	  qPCR	  for	  PHF8	  mRNA	  expression	  was	  used.	  We	  prepared	  2	  sets	  of	  the	  same	  cells	  with	  the	  same	  stimulation	  conditions	  to	  simultaneously	  prepare	  samples	  for	  immunoblots	  in	  addition	  to	  RNA	  extraction.	  Stable	  cell	  lines	  were	  seeded	  into	  12	  well	  cell	  culture	  dishes	  and	  treated	  with	  LPS	  for	  indicated	  times.	  Total	  RNA	  was	  isolated	  using	  illustra	  RNAspin	  Mini	  Kit	  (GE	  Healthcare	  Life	  Sciences).	  First-­‐strand	  cDNA	  was	  synthesized	  by	  M-­‐MLV	  reverse	  transcriptase	  (Promega)	  and	  diluted	  5-­‐fold	  for	  qPCR.	  qPCR	  was	  performed	  using	  Maxima	  SYBR	  Green/ROX	  (Thermo	  Scientific).	  All	  measurements	  were	  normalized	  against	  GAPDH	  as	  the	  internal	  control	  using	  2-­‐ΔΔCt	  method.	  The	  sequences	  of	  primers	  are	  included	  in	  
Table	  5.	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   Gene	   Primer	  Sequence	  
	   	   Left	  (5'	  to	  3')	   Right	  (5'	  to	  3')	  
Mouse	   IL1a	   gcaacgggaagattctgaag	   tgacaaacttctgcctgacg	  
	   IL1b	   gcccatcctctgtgactcat	   aggccacaggtattttgtcg	  
	   IFNb	   ccatccaagagatgctccag	  	   gtggagagcagttgaggaca	  
	   IL6	   ccggagaggagacttcacag	   cagaattgccattgcacaac	  
	   IL10	   ggttgccaagccttatcgga	   acctgctccactgccttgct	  
	   GAPDH	   aactttggcattgtggaagg	   acacattgggggtaggaaca	  
	   TNFa	   ccccaaagggatgagaagtt	   gtgggtgaggagcacgtagt	  
	   PHF8	   aacacaacaaatgctaatct	   agaagttccctccgaatgct	  
Table	  5	  Primer	  Sequences	  for	  qPCR	  	  	  
RESULTS	  
PHF8	  Knockdown	  leads	  to	  increased	  H3K9me1	  and	  H3K9me2	  in	  LPS-­‐induced	  
macrophages	  As	  a	  KDM	  negatively	  regulated	  by	  PP2Ac-­‐dependent	  dephosphorylation	  in	  ET,	  we	  wanted	  to	  explore	  the	  role	  of	  PHF8	  in	  acute	  LPS	  response	  in	  macrophages.	  First	  we	  used	  a	  lentiviral	  shRNA-­‐based	  strategy	  to	  knockdown	  PHF8	  mRNA	  expression.	  Our	  immunoblotting	  and	  qPCR	  results	  show	  that	  we	  successfully	  knocked	  down	  PHF8	  with	  70%	  efficiency	  as	  shown	  in	  Figure	  43.	  	  After	  a	  few	  passages	  we	  validated	  the	  stable	  cell	  line	  and	  performed	  a	  time-­‐course	  LPS-­‐stimulation	  (0,	  ¼,	  2,	  8,	  and	  24	  h)	  on	  paired	  WT	  and	  PHF8-­‐KD	  cells	  to	  immunoblot	  for	  various	  histone	  PTMs.	  In	  this	  screening	  method,	  we	  wanted	  to	  identify	  the	  histone	  PTMs	  showing	  an	  increase	  in	  the	  PHF8-­‐KD	  cell	  line	  as	  they	  are	  potentially	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or	  directly,	  targeted	  by	  PHF8.	  Initially,	  we	  confirmed	  the	  LPS-­‐response	  phenotype	  by	  blotting	  NFκB	  transactivation	  marker	  phospho-­‐p65	  (S536),	  which	  significantly	  increased	  within	  the	  first	  15	  min	  LPS	  stimulation	  and	  gradually	  decreased	  over	  time	  until	  8	  h,	  diminishing	  by	  24	  h	  (Figure	  44,	  top).	  We	  used	  γTubulin	  as	  cellular	  loading	  control.	  On	  the	  other	  hand,	  we	  performed	  the	  histone	  PTM	  immunoblots	  using	  total	  H3	  immunoblot	  as	  the	  loading	  control	  (Figure	  44,	  bottom).	  	  In	  WT	  RAW	  cells,	  H3K9me1	  and	  H3K9me2	  marks	  showed	  a	  decrease	  with	  LPS	  stimulation	  while	  H3K9me2	  was	  specifically	  increased	  with	  prolonged	  LPS	  stimulation.	  On	  the	  other	  hand,	  the	  initial	  decrease	  in	  these	  marks	  wasn’t	  observed	  in	  the	  PHF8-­‐KD	  cells	  indicating	  that	  PHF8	  is	  involved	  in	  the	  H3K9me1/me2	  demethylation	  in	  early	  LPS	  response.	  Moreover,	  as	  oppose	  to	  WT,	  in	  PHF8-­‐KD	  cells	  H3K9me1	  abundance	  increased	  significantly	  with	  prolonged	  LPS	  stimulation	  indicating	  that	  PHF8	  doesn’t	  demethylate	  H3K9me2	  with	  prolonged	  LPS	  stimulation	  but	  it	  may	  still	  demethylate	  H3K9me1	  in	  this	  phenotype.	  PHF8	  is	  known	  to	  demethylate	  H3K27me2	  in	  vitro;	  thus,	  we	  checked	  the	  H3K27me2	  levels	  and	  observed	  that	  PHF8-­‐KD	  caused	  an	  increase	  in	  H3K27me2	  both	  with	  and	  without	  LPS	  stimulation.	  More	  importantly,	  the	  LPS-­‐induced	  gene-­‐specific	  activation	  mark	  H3S10	  phosphorylation	  (Xie	  et	  al,	  2013)	  abundance	  dramatically	  decreased	  in	  early	  activation	  and	  diminished	  with	  several	  hours	  earlier	  with	  LPS	  stimulation	  in	  PHF8-­‐KD	  cells	  compared	  to	  that	  in	  WT	  cells.	  PHF8-­‐dependency	  of	  the	  abundance	  of	  the	  activation	  marker	  H3S10P	  indicates	  that	  the	  gene-­‐specific	  activation	  of	  LPS-­‐induced	  transcription	  is	  dependent	  on	  the	  LPS-­‐induced	  activity	  of	  PHF8.	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PHF8	  is	  involved	  in	  regulation	  of	  p65-­‐dependent	  gene-­‐specific	  transcription	  of	  pro-­‐
inflammatory	  cytokines	  in	  macrophages	  upon	  LPS	  stimulation	  In	  our	  initial	  immunoblots	  (Figure	  43	  and	  Figure	  44),	  we	  observed	  that	  p65	  phosphorylation	  showed	  a	  slight	  decrease	  in	  PHF8-­‐KD	  compared	  to	  that	  one	  in	  WT	  cells	  in	  acute	  LPS	  response,	  indicating	  that	  PHF8	  may	  be	  positively	  regulating	  the	  transactivation	  of	  p65.	  To	  understand	  how	  PHF8	  may	  regulate	  p65	  activity,	  we	  performed	  a	  series	  of	  experiments	  that	  compare	  WT	  and	  PHF8-­‐KD	  cells	  such	  as	  immunoblots	  of	  nuclear-­‐cytoplasmic	  fractionation	  to	  screen	  P-­‐p65	  abundance,	  CoIP	  of	  p65	  and	  PHF8	  to	  detect	  complex	  formation,	  and	  p65	  Luciferase	  activity	  assay	  to	  detect	  changes	  in	  p65	  activity.	  	  
PHF8	  regulates	  LPS-­‐induced	  nuclear	  translocation	  of	  p65	  Our	  immunoblot	  screening	  of	  nuclear	  and	  cytoplasmic	  fractions	  of	  WT	  and	  PHF8-­‐KD	  cells	  that	  were	  stimulated	  with	  LPS	  for	  0,	  ¼,	  1,	  and	  24	  h	  revealed	  that	  total	  abundance	  of	  p65	  and	  P-­‐p65	  in	  cytoplasmic	  fraction	  is	  similar	  in	  both	  cell	  lines.	  However,	  we	  observed	  a	  dramatic	  decrease	  in	  the	  fraction	  of	  both	  p65	  and	  P-­‐p65	  (S536)	  that	  are	  translocated	  to	  nucleus	  with	  PHF8-­‐KD	  (Figure	  45).	  Moreover,	  the	  abundance	  of	  PHF8	  is	  decreased	  in	  both	  cytosol	  and	  nucleus	  with	  24	  h	  LPS	  stimulation.	  The	  abundance	  of	  IκBα	  and	  P-­‐IκBα	  were	  used	  for	  inflammation	  phenotype	  confirmation	  while	  Lmnb1	  and	  γTubulin	  immunoblots	  were	  used	  as	  loading	  control	  for	  nuclear	  fraction	  and	  total	  protein,	  respectively.	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PHF8	  and	  p65	  form	  a	  complex	  in	  an	  LPS-­‐induced	  manner	  	   To	  understand	  whether	  PHF8	  binds	  to	  p65	  to	  regulate	  its	  LPS-­‐induced	  nuclear	  translocation,	  we	  performed	  a	  series	  of	  CoIP	  experiments.	  First,	  as	  an	  initial	  screen,	  we	  co-­‐immunoprecipitated	  the	  p65-­‐bound	  complexes	  from	  the	  whole	  cell	  lysates	  of	  paired	  WT	  and	  PHF8-­‐KD	  cells	  that	  were	  either	  non-­‐stimulated	  or	  stimulated	  with	  LPS	  for	  15	  mins	  (Figure	  46).	  Within	  those	  complexes,	  we	  identified	  PHF8	  co-­‐immunoprecipitated	  with	  p65	  pull-­‐down	  in	  WT	  RAW	  cells	  while	  no	  such	  interaction	  was	  observed	  in	  the	  PHF8-­‐KD	  cells.	  However,	  we	  observed	  that	  the	  percentage	  of	  the	  PHF8	  that	  was	  pulled	  down	  with	  p65	  was	  very	  low	  in	  comparison	  to	  the	  input	  (whole	  cell	  lysate).	  This	  may	  be	  explained	  by	  high	  abundance	  of	  PHF8	  mostly	  in	  nuclear	  fraction	  while	  most	  of	  the	  p65	  still	  exists	  in	  the	  cytoplasmic	  fraction,	  even	  with	  the	  LPS	  stimulation,	  as	  we	  showed	  in	  
Figure	  45.	  Thus,	  we	  decided	  to	  perform	  the	  following	  CoIP	  experiments	  only	  using	  the	  nuclear	  fractions.	  For	  the	  nuclear	  CoIP,	  we	  also	  decided	  to	  use	  an	  additional	  24	  h	  LPS	  stimulation	  as	  a	  negative	  control	  for	  p65	  translocation.	  Our	  subcellular	  fractionation	  results,	  consistent	  with	  our	  previous	  nuclear-­‐cytoplasmic	  fractionations,	  showed	  that	  both	  total	  and	  phosphorylated	  p65	  abundance	  in	  nuclear	  fraction	  decreased	  with	  PHF8-­‐KD	  (Figure	  47,	  Right).	  In	  line	  with	  our	  previous	  observation	  of	  lower	  PHF8	  expression	  with	  prolonged	  LPS	  stimulation	  in	  Figure	  45,	  we	  detected	  less	  PHF8	  in	  both	  cytoplasmic	  and	  nuclear	  fractions	  of	  WT	  cells	  with	  24	  h	  LPS	  stimulation	  while	  non-­‐stimulated	  or	  acutely	  stimulated	  cells	  had	  similar	  PHF8	  protein	  expression.	  This	  observation	  supports	  our	  initial	  hypothesis	  that	  PHF8	  activity	  is	  negatively	  regulated	  by	  PP2Ac	  in	  ET	  and	  can	  be	  explained	  by	  decreased	  stability	  or	  solubility	  of	  PHF8	  with	  dephosphorylation.	  Moreover,	  the	  nuclear	  CoIP	  revealed	  that	  PHF8	  formed	  a	  nucleus-­‐
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specific	  complex	  with	  p65,	  the	  complex	  formation	  diminished	  with	  prolonged	  LPS	  stimulation	  as	  p65	  abundance	  in	  nucleus	  decreased,	  and	  PHF8	  binding	  was	  independent	  of	  phosphorylation	  of	  p65	  (Figure	  47,	  Left).	  Further,	  to	  understand	  whether	  there	  is	  a	  transient	  binding	  between	  p65	  and	  PHF8,	  we	  performed	  another	  nuclear	  CoIP	  including	  more	  time	  points	  (1/2	  and	  1	  h)	  of	  LPS	  stimulation	  as	  p65	  abundance	  in	  nucleus	  gradually	  decreases	  between	  ¼	  h	  and	  1	  h.	  In	  addition,	  we	  simultaneously	  performed	  CoIP	  of	  PHF8-­‐bound	  complexes	  in	  WT	  cells	  to	  validate	  the	  transient	  p65-­‐PHF8	  complex	  formation	  (Figure	  48).	  This	  experiment	  revealed	  that	  	  -­‐ PHF8	  is	  bound	  to	  nuclear	  p65	  in	  WT	  RAW	  cells	  only	  in	  the	  LPS-­‐induced	  fraction	  since	  p65	  abundance	  in	  nucleus	  is	  negligible	  without	  LPS	  stimulation.	  -­‐ The	  complex	  formation	  didn’t	  occur	  in	  PHF8-­‐KD	  cells,	  indicating	  that	  the	  PHF8-­‐
p65	  binding	  is	  not	  due	  to	  non-­‐specific	  binding.	  -­‐ More	  importantly,	  the	  amount	  of	  p65	  and	  P-­‐p65	  detected	  in	  the	  nuclear	  p65	  immunocomplexes	  dramatically	  increased	  in	  PHF8-­‐KD	  cells	  compared	  to	  that	  in	  WT	  cells	  indicating	  that	  PHF8	  regulates	  the	  nuclear	  p65	  translocation.	  -­‐ Nuclear	  p65	  and	  P-­‐p65	  (S536)	  were	  in	  the	  immunocomplexes	  of	  PHF8	  in	  WT	  RAW	  cells.	  -­‐ PHF8-­‐bound	  p65	  and	  P-­‐p65	  amount	  increased	  with	  acute	  LPS	  stimulation	  while	  showing	  a	  decrease	  with	  prolonged	  LPS	  stimulation,	  indicating	  that	  the	  PHF8-­‐
dependent	  nuclear	  translocation	  of	  p65	  is	  LPS-­‐dependent	  and	  phenotype-­‐specific.	  In	  summary,	  our	  CoIP	  experiments	  demonstrated	  that	  PHF8	  regulates	  p65	  nuclear	  
translocation	  in	  an	  LPS-­‐dependent	  manner	  in	  mouse	  macrophages.	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PHF8	  binds	  to	  p65	  regulating	  its	  transcriptional	  activity	  in	  macrophages	  upon	  LPS	  stimulation	  In	  addition	  to	  subcellular	  localization,	  we	  assayed	  the	  transcriptional	  activity	  of	  p65	  using	  a	  dual-­‐reporter	  luciferase	  assay	  to	  determine	  whether	  p65	  transcriptional	  activity	  is	  controlled	  by	  PHF8	  in	  LPS-­‐induced	  TLR4	  response.	  Our	  luciferase	  activity	  assay,	  as	  shown	  in	  Figure	  49,	  demonstrated	  that	  the	  transcriptional	  activity	  of	  p65	  was	  significantly	  reduced	  in	  PHF8-­‐KD	  cells	  compared	  to	  WT	  cells.	  This	  observation	  indicates	  that	  PHF8	  positively	  regulates	  the	  transcriptional	  activity	  of	  p65.	  
PHF8	  regulates	  gene-­‐specific	  pro-­‐inflammatory	  mRNA	  expression	  via	  regulating	  
NFκB	  in	  LPS-­‐stimulated	  macrophages	  Since	  we	  found	  PHF8	  as	  a	  regulator	  of	  the	  p65	  transcriptional	  activity,	  we	  wanted	  to	  validate	  the	  conclusion	  by	  performing	  qPCR	  for	  selected	  pro-­‐inflammatory	  cytokines	  IL1α,	  IL10,	  IL6,	  TNFα,	  and	  IFNβ	  (Figure	  50).	  To	  confirm	  the	  inflammatory	  phenotype	  of	  the	  cells	  we	  performed	  immunoblots	  (Figure	  50A)	  showing	  the	  diminished	  PHF8	  in	  PHF8-­‐KD	  cells,	  and	  increased	  P-­‐p65	  (S536)	  coupled	  with	  decreased	  IκBα	  in	  acute	  LPS	  stimulation	  in	  both	  cell	  lines.	  The	  qPCR	  also	  confirmed	  the	  PHF8-­‐KD	  (Figure	  50B).	  We	  observed	  that	  cytokines	  IL1α,	  IL10,	  and	  IL6	  mRNA	  expression	  significantly	  reduced	  in	  PHF8-­‐KD	  beyond	  2h	  of	  LPS	  stimulation	  (Figure	  50B).	  This	  indicates	  that	  PHF8	  promotes	  the	  mRNA	  transcription	  of	  IL1α,	  IL10,	  and	  IL6	  through	  
positively	  regulating	  NFκB	  transactivation.	  On	  the	  other	  hand	  TNFα	  expression	  didn’t	  show	  significant	  difference	  with	  PHF8-­‐KD	  possibly	  due	  to	  other	  signaling	  events	  that	  aren’t	  regulated	  by	  PHF8.	  Importantly,	  IFNβ,	  shows	  significantly	  higher	  LPS-­‐induced	  mRNA	  expression	  in	  the	  PHF8-­‐KD	  cells,	  can	  act	  as	  an	  inhibitor	  of	  inflammation	  (Billiau,	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1995).	  Thus,	  in	  PHF8-­‐KD	  cells,	  the	  increased	  mRNA	  expression	  of	  IFNβ	  in	  combination	  with	  decreased	  mRNA	  expression	  of	  pro-­‐inflammatory	  cytokines	  implies	  that	  PHF8-­‐
dependent	  activation	  of	  cytokines	  is	  both	  gene-­‐specific	  and	  pro-­‐inflammatory	  phenotype-­‐
specific.	  Because	  these	  cytokines	  are	  regulated	  by	  NFκB,	  our	  data	  demonstrates	  that	  PHF8	  positively	  regulates	  LPS-­‐induced,	  NFκB-­‐dependent	  transcription	  of	  select	  pro-­‐inflammatory	  genes.	  
DISCUSSION	  	   LPS-­‐induced	  inflammation	  response	  is	  tightly	  regulated	  in	  multiple	  layers	  of	  signaling	  events.	  As	  it	  is	  the	  closest	  layer	  to	  inflammatory	  gene	  expression,	  understanding	  the	  dynamic	  and	  transient	  transcriptional	  regulation	  by	  chromatin	  modifiers	  is	  essential	  to	  provide	  therapies	  or	  prevention	  methods	  against	  inflammatory	  disorders.	  Various	  chromatin	  modifiers	  have	  been	  identified	  in	  the	  regulation	  of	  transcription	  in	  inflammation	  response	  and	  TLR4	  signaling	  and	  are	  not	  limited	  to	  G9a-­‐HP1	  complex	  (Chan	  et	  al,	  2005;	  El	  Gazzar	  et	  al,	  2008),	  DNMT3A/B	  (El	  Gazzar	  et	  al,	  2008),	  JMJD3	  (De	  Santa	  et	  al,	  2007),	  KDM5B	  (Ptaschinski	  et	  al,	  2015),	  KDM1A	  (Hanzu	  et	  al,	  2013),	  and	  MLL1	  (Wang	  et	  al,	  2014b).	  Our	  study	  is	  the	  first	  to	  provide	  the	  proof	  for	  PHF8-­‐dependent	  LPS	  response	  in	  macrophages.	  This	  functional	  characterization	  of	  PHF8	  as	  one	  of	  the	  chromatin	  modifiers	  regulating	  the	  pro-­‐inflammatory	  cytokine	  expression	  not	  only	  deciphers	  the	  H3K9-­‐demethylase-­‐dependent	  activation	  of	  LPS-­‐induced	  inflammation	  response,	  but	  also	  connects	  the	  missing	  link	  between	  PP2Ac-­‐activity	  and	  its	  role	  in	  chromatin	  regulation	  of	  ET.	  	  	   The	  second	  layer	  of	  LPS	  response	  regulation	  is	  through	  the	  modulation	  of	  transcriptional	  activity	  of	  NFκB	  via	  regulating	  complexes	  and	  PTMs	  on	  its	  subunits.	  The	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most	  extensively	  studied	  and	  well	  known	  PTM	  on	  p65	  subunit	  is	  the	  phosphorylation	  of	  p65	  on	  S536	  (Sakurai	  et	  al,	  1999),	  which	  is	  essential	  for	  p65	  translocation	  to	  the	  nucleus.	  Transcriptional	  activity	  of	  p65	  is	  also	  regulated	  by	  other	  PTMs	  such	  as	  methylation	  and	  acetylation	  (Vermeulen	  et	  al,	  2006);	  however,	  the	  involvement	  of	  a	  chromatin	  modifier	  in	  p65	  nuclear	  translocation	  hasn’t	  been	  identified,	  yet.	  Here	  we	  provide	  the	  first	  evidence	  for	  the	  regulation	  of	  p65	  transactivation	  by	  demethylase	  PHF8	  
upon	  LPS	  stimulation	  in	  macrophages.	  Moreover,	  functional	  characterizations	  of	  various	  p65	  PTMs,	  except	  Phospho-­‐S536,	  in	  regulation	  of	  NFκB	  transcriptional	  activity	  still	  need	  validation.	  By	  providing	  evidence	  for	  PHF8-­‐dependent	  nuclear	  translocation	  of	  p65	  with	  LPS	  stimulation,	  our	  study	  is	  the	  first	  to	  demonstrate	  the	  control	  mechanism	  for	  
NFκB	  activity	  change	  downstream	  S536	  phosphorylation	  by	  IKK2.	  	  	   The	  pro-­‐inflammatory	  cytokine	  production	  is	  an	  essential	  step	  of	  macrophage	  biology	  in	  innate	  immunity	  of	  mammals.	  Even	  though	  post-­‐transcriptional	  and	  post-­‐translational	  regulation	  of	  cytokines	  affect	  the	  overall	  cytokine	  production	  or	  secretion,	  the	  initial	  step	  is	  regulation	  of	  NFκB	  signaling.	  Here,	  this	  study	  is	  the	  first	  to	  functionally	  
identify	  PHF8	  demethylase	  as	  a	  regulator	  of	  gene-­‐specific	  cytokine	  expression	  in	  TLR4-­‐
dependent	  macrophage	  response.	  Our	  analysis	  revealed	  a	  very	  important	  piece	  in	  the	  epigenetic	  regulation	  of	  cytokines	  while	  showing	  evidence	  for	  PHF8	  as	  a	  target	  to	  develop	  therapeutic	  strategies	  in	  inflammation-­‐induced	  diseases.	  	  	  
FUTURE	  WORK	  	   Here	  we	  identified	  PHF8	  as	  a	  major	  regulator	  of	  innate	  immune	  response	  downstream	  TLR4	  signaling	  pathway;	  this	  regulation	  occurs	  through	  LPS-­‐induced	  activation	  of	  PHF8,	  complex	  formation	  between	  p65	  and	  PHF8,	  increased	  nuclear	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translocation	  of	  p65,	  increased	  transcriptional	  activity	  of	  p65,	  and	  decreased	  repressive	  H3K9me1/2	  at	  p65	  target	  genes.	  However	  the	  mechanism	  of	  p65-­‐PHF8	  binding	  in	  LPS-­‐induced	  inflammation	  is	  still	  unclear.	  To	  understand	  the	  role	  of	  this	  complex	  on	  the	  activity	  and	  nuclear-­‐translocation	  of	  p65,	  we	  will	  need	  information	  on	  whether	  PHF8	  activity	  leads	  to	  any	  PTM	  changes	  on	  p65,	  affects	  nuclear	  translocation	  through	  making	  NLS	  exposed	  to	  the	  environment	  through	  conformational	  changes,	  regulates	  other	  activity-­‐inducing	  complexes	  of	  p65,	  or	  modulates	  other	  enzymes	  targeting	  p65	  PTMs	  downstream	  LPS.	  	  To	  understand	  whether	  PHF8	  catalytic	  activity	  alters	  any	  p65	  PTMs,	  we	  will	  perform	  proteomic	  screening	  on	  co-­‐immunoprecipitated	  p65-­‐PHF8	  complexes.	  This	  will	  help	  us	  detect	  any	  PTMs	  that	  occur	  on	  p65	  with	  (LPS-­‐induced)	  and	  without	  (unstimulated)	  PHF8	  activity	  in	  macrophages	  for	  further	  validation	  via	  mutational	  studies.	  In	  addition,	  CoIP	  of	  p65	  NLS,	  using	  an	  antibody	  specifically	  binding	  to	  p65	  NLS,	  in	  paired	  WT	  and	  PHF8-­‐KD	  cells,	  with	  and	  without	  LPS	  stimulation,	  will	  reveal	  whether	  PHF8	  leads	  to	  change	  in	  the	  release	  of	  NLS	  from	  IκB	  complex.	  On	  the	  other	  hand,	  proteomic	  studies	  screening	  to	  compare	  co-­‐immunoprecipitates	  of	  p65	  with	  and	  without	  LPS	  stimulation	  in	  WT	  and	  PHF8-­‐KD	  cells	  will	  help	  us	  understand	  how	  PHF8	  alters	  the	  complexes	  that	  p65	  forms	  with	  LPS	  stimulation.	  Moreover,	  immunoblotting	  	  of	  the	  various	  CoIP	  products	  of	  p65	  from	  the	  same	  set	  of	  cells	  against	  IκB	  and	  PP2Ac	  antibodies	  will	  be	  significant	  as	  these	  are	  the	  most	  widely-­‐known	  p65	  regulators	  inhibiting	  its	  transcriptional	  activity.	  We	  would	  expect	  to	  see	  increased	  IκB	  or	  PP2Ac	  binding	  to	  p65	  with	  LPS	  stimulation	  in	  PHF8-­‐KD	  cells	  compared	  to	  that	  in	  WT	  cells.	  Structural	  and	  biochemical	  binding	  studies	  will	  also	  reveal	  mechanistic	  significance	  of	  PHF8	  activity	  on	  the	  p65	  regulation.	  
	   125	  
FIGURES	  
	  
Figure	  39	  Domain	  structure	  and	  repeats	  of	  PHF8	  
PHF8	  domain	  structure.	  PHD	  domain	  is	  shown	  in	  red,	  JmjC	  domain	  is	  shown	  in	  blue	  and	  Ser-­‐rich	  
repeat	  is	  shown	  in	  orange.	  Black	  bars	  represent	  the	  Ser	  residues	  that	  are	  dephosphorylated	  by	  
PP2Ac	  in	  ET	  (Erdoğan	  et	  al,	  2016).	  	  
	  
Figure	  40	  Mouse	  and	  human	  PHF8	  sequence	  alignment.	  	  
The	  alignment	  shows	  PP2Ac-­‐targeted	  PHF8	  residues.	  PHF8	  sequence	  and	  the	  corresponding	  Ser	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Figure	  41	  The	  JmjC	  domain	  contains	  residues	  required	  for	  Fe(II)	  and	  αKG	  binding	  
(A)	  A	  three-­‐dimensional	  cartoon	  depicting	  the	  polypeptide	  backbone	  structure	  of	  the	  JmjC	  
(Jumonji	  C)	  domain	  of	  JHMD3A/JMJD2A.	  The	  eight	  β-­‐sheets	  of	  the	  cofactor-­‐coordinating	  pocket	  
are	  shown	  in	  grey,	  with	  the	  Fe(II)	  ion	  in	  red	  and	  αKG	  in	  blue.	  The	  α-­‐helical	  region	  that	  associates	  
with	  the	  zinc	  ion	  is	  shown	  in	  green	  and	  the	  zinc	  molecule	  in	  purple.	  (B)	  A	  schematic	  
representation	  of	  the	  JmjC	  domain	  showing	  the	  position	  of	  the	  Fe(II)-­‐binding	  (top)	  and	  αKG-­‐
binding	  (bottom)	  residues.	  The	  amino-­‐acid	  identity	  of	  residues	  within	  active	  hydroxylases	  and	  
demethylases	  and	  amino-­‐acid	  substitutions	  found	  in	  other	  JmjC-­‐domain	  proteins	  are	  shown	  
above	  and	  below	  the	  indicated	  cofactor-­‐binding	  residue	  position.	  (C)	  JHDM	  histone	  demethylases	  
can	  demethylate	  mono-­‐,	  di-­‐	  and	  trimethylated	  lysine	  by	  an	  oxidative	  mechanism	  that	  requires	  
Fe(II)	  and	  αKG	  as	  cofactors.	  Demethylation	  is	  thought	  to	  occur	  by	  direct	  hydroxylation	  of	  the	  
methyl	  group	  (1),	  which	  results	  in	  an	  unstable	  hydroxymethyl	  product	  that	  is	  spontaneously	  
released	  as	  formaldehyde	  (2)	  (Klose	  et	  al,	  2006).	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Figure	  42	  Transcriptional	  transcriptional	  co-­‐activation	  by	  KDM7-­‐family	  proteins	  
Upon	  gene	  induction,	  transcription	  factors	  (TF)	  bind	  to	  specific	  DNA-­‐sequences	  and	  recruit	  co-­‐
activators	  such	  as	  H3K4-­‐methyltransferases	  (KMT2).	  The	  latter	  introduce	  methyl-­‐marks	  on	  
histone	  H3	  tails	  (me-­‐K4)	  which	  protrude	  from	  nucleosomes.	  These	  activation	  chromatin	  marks	  
are	  bound	  by	  proteins	  such	  as	  histone	  demethylases	  of	  the	  KDM7-­‐family.	  This	  class	  of	  chromatin-­‐
modifying	  enzymes	  removes	  repressive	  methyl-­‐marks	  from	  K9	  or	  K27	  on	  H3	  or	  K20	  on	  H4.	  
Furthermore	  KDM7	  can	  interact	  with	  RNA	  polymerases	  I	  or	  II	  (RNAP)	  and	  other	  chromatin-­‐
associated	  factors	  (such	  as	  E2F1	  and	  ZNF711).	  Both	  mechanisms	  lead	  to	  the	  activation	  of	  
transcription	  (Fortschegger	  et	  al,	  2010).	  	  
	  
Figure	  43	  Knockdown	  of	  PHF8	  on	  mouse	  macrophage	  RAW	  cell	  line	  
Using	  shRNA	  against	  GFP	  and	  PHF8	  in	  RAW	  cells,	  we	  made	  stable	  WT	  (shCON)	  and	  PHF8-­‐KD	  
(shPHF8)	  cell	  lines,	  respectively.	  Different	  inflammation	  conditions	  are	  shown	  as	  N	  (non-­‐
stimulated),	  NL	  (acute	  LPS	  stimulation),	  T	  (prolonged	  LPS	  stimulation),	  and	  TL	  (prolonged	  LPS	  
stimulation	  with	  a	  second	  LPS	  challenge).	  We	  measured	  mRNA	  expression	  of	  PHF8	  to	  confirm	  the	  
knock-­‐down	  efficiency	  as	  70%	  using	  qPCR	  (right)	  (Erdoğan	  et	  al,	  2016).	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Figure	  44	  PHF8	  regulates	  LPS-­‐induced	  demethylation	  of	  H3K9me1/me2	  
Site-­‐specific	  lysine	  methylations	  on	  H3	  were	  comparably	  analyzed	  in	  paired	  WT	  (shCON)	  versus	  
PHF8-­‐KD	  (shPHF8)	  RAW	  264.7	  cells	  using	  immunoblotting.	  The	  macrophages	  were	  collected	  at	  
the	  indicated	  time	  points	  of	  LPS	  stimulation	  (1/4,	  2,	  8,	  and	  24	  h)	  (Erdoğan	  et	  al,	  2016).	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Figure	  45	  PHF8	  regulates	  nuclear	  translocation	  of	  p65	  in	  LPS	  response.	  	  
Immunoblot	  analysis	  of	  the	  p65	  and	  P-­‐p65	  abundance	  in	  the	  cytosol	  and	  nucleus	  of	  paired	  WT	  
(shCON)	  and	  PHF8-­‐KD	  (shPHF8)	  cells	  with	  LPS	  stimulation	  for	  indicated	  duration	  (0,	  1/4,	  1,	  and	  
24	  h).	  	  	  
	  
Figure	  46	  PHF8	  is	  co-­‐immunoprecipitated	  with	  p65.	  
Co-­‐immunoprecipitation	  of	  p65-­‐bound	  complexes	  from	  total	  cell	  lysates	  from	  WT	  and	  PHF8-­‐KD	  
cells	  that	  were	  stimulated	  with	  1	  μg/ml	  LPS	  for	  0	  and	  15	  min	  shows	  PHF8	  forming	  a	  complex	  with	  
p65	  only	  in	  WT	  cells	  (Erdoğan	  et	  al,	  2016).	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Figure	  47	  PHF8	  forms	  an	  LPS-­‐inducible	  complex	  with	  p65	  
WT	  and	  PHF8-­‐KD	  stable	  RAW	  cells	  were	  treated	  with	  1	  μg/ml	  LPS	  for	  0,	  ¼,	  and	  24h.	  Following	  
subcellular	  fractionation,	  nuclear	  fractions	  were	  co-­‐immunoprecipitated	  with	  p65	  antibody	  and	  




Figure	  48	  Nucleus-­‐specific	  CoIP	  of	  PHF8	  and	  p65	  	  
WT	  and	  PHF8-­‐KD	  stable	  RAW	  cells	  were	  treated	  with	  1	  μg/ml	  LPS	  for	  0,	  ¼,	  ½,	  1,	  and	  24h.	  
Following	  subcellular	  fractionation,	  nuclear	  fractions	  of	  WT	  cells	  were	  co-­‐immunoprecipitated	  
with	  p65	  or	  PHF8	  antibody	  while	  nuclear	  fractions	  of	  PHF8-­‐KD	  cells	  were	  co-­‐immunoprecipitated	  
with	  p65	  antibody	  only.	  The	  complexes	  were	  immunoblotted	  with	  PHF8,	  P-­‐p65,	  and	  p65	  to	  detect	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complex	  formation	  in	  the	  nucleus.	  1/3	  of	  the	  CoIP	  mixture	  was	  used	  for	  each	  immunoblot	  
(Erdoğan	  et	  al,	  2016).	  	  
	  
Figure	  49	  PHF8	  positively	  regulates	  the	  transcriptional	  activity	  of	  p65.	  
PHF8-­‐KD	  leads	  to	  reduced	  NFκB	  activity.	  293-­‐TLR4-­‐MD2-­‐CD14	  cells	  stably	  expressing	  WT	  
(shCON)	  or	  PHF8-­‐KD	  (shPHF8)	  were	  transfected	  with	  Firefly	  luciferase.	  24	  hours	  after	  the	  
transfection,	  the	  cells	  were	  stimulated	  with	  1μg/ml	  LPS	  and	  were	  collected	  at	  0,	  6,	  8,	  or	  12	  h	  with	  
three	  biological	  replicates.	  The	  activity	  of	  each	  sample	  was	  normalized	  to	  Renilla	  luciferase.	  Each	  
column	  shows	  mean	  ±s.e.	  of	  at	  least	  three	  independent	  experiments.	  *P<0.05	  compared	  with	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Figure	  50	  PHF8	  regulates	  the	  expression	  of	  select	  pro-­‐inflammatory	  cytokines.	  	  
(A)	  Immunoblot	  analysis	  was	  conducted	  to	  monitor	  indicated	  inflammatory	  markers	  (top)	  (B)	  
qPCR	  analysis	  (bottom)	  shows	  the	  mRNA	  expression	  of	  select	  proinflammatory	  cytokines	  in	  
paired	  WT	  (shCON,	  dark	  grey	  bars)	  and	  PHF8-­‐KD	  (shPHF8,	  light	  grey	  bars)	  with	  LPS	  stimulation	  
while	  error	  bars	  show	  the	  mean	  ±s.e.	  of	  three	  independent	  experiments.	  Time	  points	  are	  
indicated	  for	  the	  non-­‐stimulated	  (0	  h)	  and	  stimulated	  RAW	  cells	  (0.25,	  2,	  4,	  8,	  and	  24	  h)	  (Erdoğan	  
et	  al,	  2016).	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CHAPTER	  4:	  PHF8	  REGULATES	  THE	  SECRETION	  OF	  SPECIFIC	  ‘TOLERIZABLE’	  
GENES	  INCLUDING	  CYTOKINES	  AND	  CHEMOKINES	  IN	  LPS-­‐INDUCED	  
MACROPHAGES	  FOR	  SUCCESSFUL	  ACTIVATION	  OF	  ADAPTIVE	  IMMUNITY	  
OVERVIEWAs	  the	  initial	  pathogenic	  detection	  modulators,	  macrophages	  are	  responsible	  for	  identification	  of	  the	  pathogen,	  cytokine/chemokine	  production	  and	  secretion,	  induction	  of	  apoptosis,	  and	  construction	  of	  a	  signaling	  platform	  to	  promote	  migration,	  activation,	  or	  proliferation	  of	  cells	  of	  adaptive	  immunity.	  Here,	  we	  studied	  the	  secreted	  protein	  products	  of	  WT	  and	  PHF8-­‐KD	  macrophages	  to	  understand	  specific	  products	  that	  are	  involved	  in	  PHF8-­‐dependent	  activation	  of	  inflammation	  response	  in	  bacterial	  infection.	  Moreover,	  in	  our	  analysis	  we	  identified	  various	  molecules	  of	  innate	  immunity	  that	  were	  regulated	  by	  PHF8	  upon	  LPS	  stimulation.	  Some	  of	  those	  molecules	  were	  also	  involved	  in	  the	  activation	  of	  adaptive	  immunity.	  Common	  LPS-­‐induced	  PHF8-­‐dependent	  secretion	  products	  and	  activators	  of	  adaptive	  immunity	  indicate	  that	  PHF8	  is	  involved	  in	  the	  missing	  link	  between	  innate	  and	  adaptive	  immunity.	  Further,	  we	  show	  evidence	  on	  the	  regulation	  of	  activation	  and	  proliferation	  of	  CD8+	  T	  cells	  by	  the	  PHF8-­‐dependent	  macrophage	  secretome	  via	  T	  cell	  activation	  and	  proliferation	  assays.	  Overall	  our	  data	  indicates	  that	  PHF8	  is	  a	  major	  regulator	  of	  the	  macrophage	  secretome	  upon	  LPS	  stimulation	  that	  clarifies	  the	  missing	  link	  between	  innate	  and	  adaptive	  immunity.	  Our	  analysis	  also	  shows	  that	  proteomic	  screening	  of	  secreted	  proteins	  is	  a	  powerful	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technique	  in	  identification	  of	  signaling	  molecules/pathways	  at	  the	  crossroad	  of	  signaling	  pathways	  in	  interplay.	  
INTRODUCTION	  
The	  Role	  of	  Macrophage	  Secretome	  in	  Inflammation	  Response	  The	  induction	  of	  proper	  immune	  response	  depends	  on	  the	  successful	  cross-­‐talk	  between	  macrophages	  and	  adaptive	  immunity	  cells	  upon	  bacterial	  infection	  (Chapes	  et	  al,	  1992).	  Macrophages	  are	  highly	  abundant,	  widely	  distributed	  in	  the	  body,	  motile,	  responsive,	  and	  versatile;	  thus,	  they	  widely	  influence	  immune	  and	  inflammatory	  responses	  (Nathan,	  1987).	  Moreover,	  macrophages	  are	  the	  sources	  of	  expression	  and	  secretion	  of	  various	  proteins	  that	  are	  responsible	  for	  activation	  of	  adaptive	  immunity.	  These	  proteins	  include	  polypeptide	  hormones,	  cytokines,	  complement	  components,	  coagulation	  factors,	  various	  enzymes,	  extracellular	  proteins,	  and	  proteins	  of	  cell	  adhesion	  (Table	  6).	  	  The	  macrophage	  secretome	  is	  complex	  and	  various	  products	  affect	  each	  other.	  These	  products	  may	  affect	  each	  other’s	  release	  and	  actions	  as	  well	  as	  protein	  release	  from	  surrounding	  cells.	  These	  proteins	  lead	  to	  various	  biological	  outcomes	  such	  as	  inhibition	  or	  promotion	  of	  cell	  proliferation,	  chemotactic	  attraction,	  induction	  of	  fever,	  etc.	  (Table	  7).	  More	  importantly,	  various	  enzymes	  (Table	  8)	  secreted	  by	  macrophages	  participate	  in	  a	  wide	  range	  of	  inflammatory	  functions	  including	  killing	  tumors	  or	  bacteria,	  accelerating	  inflammation,	  inflammation	  site	  clearing,	  and	  lipoprotein	  metabolism	  (Takemura	  &	  Werb,	  1984).	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Table	  6	  Secretory	  products	  of	  mononuclear	  phagocytes	  (Manes	  et	  al,	  2011).	  	  
	  
Polypeptide	  hormones	  Interleukin	  1-­‐α	  and	  1-­‐β	  	  (colectively,IL-­‐1)	  Tumor	  necrosis	  factor-­‐	  α	  (TNFα)	  	  Interferon-­‐α	  Interferon-­‐γ	  Platelet-­‐derived	  growth	  factor(s)	  Fibroblast	  growth	  factors	  Fibroblast	  activating	  factors	  Transforming	  growth	  factor-­‐β	  (TGFβ)	  Insulin	  like	  activity	  Thymosin	  B4	  Erythropoietin	  Colony-­‐stimulating	  factor	  for	  granulocytes	  and	  macrophages	  (CSF-­‐G/M)	  	  Colony-­‐stimulating	  factor	  for	  granulocytes	  (CSF-­‐G)	  Erythroidcolony-­‐potentiating	  factor	  Factor-­‐inducing	  monocytopoiesis	  β-­‐Endorphin	  Adrenocorticotrophic	  hormone	  Plasmacytoma	  growth	  factor	  Neutrophil-­‐activating	  factor	   	  
Complement	  (C)	  components	  Classicalpath:	  Cl,	  C4,	  C2,	  C3,	  C5	  	  Alternativepath:	  factor	  B,	  factor	  D,	  properdin	  	  Inhibitors:	  C3b	  inactivator,	  β-­‐1H	  	  Active	  fragments	  generated	  by	  macrophage	  proteases:	  C3a,	  C3b,	  C5a,	  Bb	   	  
Coagulation	  factors	  	  Intrinsicpath:	  IX,	  X,	  V,	  prothrombin	  Extrinsicpath:	  VII	  Surface	  activities:	  tisuefactor,	  prothrombinase	  Prothrombolytic	  activity:	  plasminogen	  activator	  Antithrombolytic	  activities:plasminogen	  activator	  inhibitors,	  Plasmin	  inhibitors	   	  
Other	  enzymes	  	  Neutralproteases:	  plasminogen	  activator,	  elastase,	  collagenases,	  angiotensin	  convertase,	  others	  Lipases:	  lipoprotein	  lipase,	  phospholipaseA2	  	  Glucosaminidase:	  lysozyme	  Lysosomal	  acid	  hydrolases:	  proteases,	  lipases,	  (deoxy)ribonucleases,	  phosphatases,	  glycosidases,	  sulfatases	  Deaminase:	  arginase	   	  
Inhibitors	  of	  enzymes	  and	  cytokines	  	  Protease	  inhibitors:	  α-­‐2-­‐macroglobulin,	  α-­‐l-­‐antiprotease,	  plasminogen	  activator	  inhibitors,	  plasmin	  inhibitors,	  collagenase	  inhibitor	  	  Phospholipase	  inhibitor:	  lipomodulin	  (macrocortin)	  	  IL-­‐1	  inhibitors	   	  
Proteins	  of	  extracellular	  matrix	  or	  cell	  adhesion	  	  Fibronectin	  Gelatin-­‐binding	  protein	  of	  95	  kD	  	  Thrombospondin	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Chondroitin	  sulfate	  proteoglycans	   	  
Other	  binding	  proteins	  	  For	  metals:	  transferrin,	  acidic	  isoferitins,	  transcobalamin	  I	  For	  lipids	  apolipoprotein	  E,	  lipid	  transfer	  protein	  	  For	  biotin:	  avidin	  
	  
Purine	  and	  pyrimidine	  products	  	  Thymidine,	  uracil,	  uricacid,	  deoxycytidine	  Neopterin	  (2-­‐amino4-­‐oxo-­‐6-­‐trihydroxypropylpteridine)	   	  
Bioactive	  lipids	  	  Cyclooxygenase	  products:	  prostaglandincE2(PGE2),	  prostaglandin	  F2a,	  prostacyclin,	  thromboxane	  Lipoxygenase	  products:	  monohydroxyeicosatetraenoic	  acids,	  dihydroxyeicosatetraenoic	  acids,	  leukotrienes	  B4,	  C,	  D,	  E	  Platelet-­‐activating	  factors	  (I-­‐O-­‐alkyl-­‐2-­‐acetyl-­‐sn-­‐glyceryl-­‐3-­‐Phosphorylcholine)	   	  
Sterol	  hormones:	  lα,25-­‐Dihydroxyvitamin	  D3	   	  
Bioactive	  oligopeptides:	  Glutathione	   	  
Reactive	  oxygen	  intermediates:	  Superoxide,	  hydrogenperoxide,	  hydroxylradical,	  hypohalousacids	  	  
Reactive	  nitrogen	  intermediates:	  Nitrites,	  nitrates	  
	  	  To	  understand	  the	  factors	  that	  regulate	  the	  secretion	  of	  regulators	  of	  adaptive	  imunity,	  quantitative	  analysis	  of	  secreted	  proteins	  from	  the	  antigen	  presenting	  cells	  through	  various	  screening	  methods	  can	  be	  applied.	  In	  this	  chapter,	  I	  will	  describe	  various	  methods	  that	  are	  used	  for	  screening	  of	  secretomes,	  and	  their	  disadvantages,	  and	  advantages.	  Finally,	  I	  will	  describe	  the	  global	  quantitative	  analysis	  of	  macrophage	  secretome	  via	  proteomics	  and	  demonstrate	  its	  strength	  in	  unbiased	  secretome	  screening	  as	  well	  as	  identification	  of	  novel	  secretome	  components.	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Table	  7	  Macrophage	  products	  with	  similar	  activities	  (Manes	  et	  al,	  2011)
	  
	  
Table	  8	  Enzymes	  secreted	  by	  macrophages	  (Takemura	  &	  Werb,	  1984)	  
	  	   	  
	   138	  
Secretome	  Analysis	  Methods	  To	  understand	  how	  innate	  immunity	  regulates	  the	  adaptive	  immunity	  upon	  LPS	  stimulation,	  various	  methods	  have	  been	  developed	  to	  analyze	  the	  secreted	  cytokines/proteins.	  The	  very	  early	  traditional	  methods	  that	  were	  used	  extensively	  for	  this	  purpose	  are	  (1)	  qPCR,	  which	  measures	  the	  cytokine	  mRNA	  transcript	  abundance	  (Amsen	  et	  al,	  2009),	  and	  (2)	  cDNA	  microarray	  analysis	  (Welsh	  et	  al,	  2003).	  qPCR	  technique	  is	  simple,	  quantitative,	  and	  has	  high	  detection	  efficiency	  with	  small	  amount	  of	  sample;	  but	  its	  major	  drawback	  is	  that	  the	  intracellular	  RNA	  abundance	  doesn’t	  necessarily	  reflect	  the	  level	  of	  expression	  or	  secretion	  of	  a	  protein.	  In	  addition,	  it	  measures	  relative	  abundance	  with	  respect	  to	  a	  selected	  control	  protein,	  leading	  to	  detection	  issues	  such	  as	  inefficiency	  in	  reverse	  transcription,	  RNA	  degradation,	  or	  PCR	  cross-­‐contamination.	  Moreover	  it	  is	  a	  technique	  to	  screen	  for	  proteins	  whose	  sequence	  has	  already	  been	  identified;	  thus,	  it	  lacks	  the	  ability	  to	  identify	  novel	  proteins	  that	  get	  secreted.	  cDNA	  microarray	  analysis,	  similarly,	  screens	  for	  various	  RNAs	  in	  the	  serum	  or	  tissues;	  thus,	  has	  the	  same	  drawback	  of	  need	  for	  prior	  knowledge	  of	  the	  sequence,	  and	  low	  correlation	  between	  RNA	  abundance	  and	  protein	  secretion.	  Although	  this	  technique	  enables	  the	  discovery	  of	  novel	  proteins	  through	  computational	  methods,	  its	  specificity	  and	  sensitivity	  are	  very	  low.	  	  To	  detect	  cytokine	  abundance	  at	  the	  protein	  level	  Enzyme-­‐linked	  immunosorbent	  assay	  (ELISA)	  has	  been	  extensively	  used	  (Sullivan	  et	  al,	  2000).	  ELISA	  detects	  and	  quantifies	  the	  abundance	  of	  cytokines/proteins	  using	  specific	  antibodies	  in	  a	  given	  sample	  (Figure	  51).	  Although	  this	  technique	  is	  simple,	  quantitative,	  and	  sensitive,	  it	  has	  some	  drawbacks.	  First	  of	  all,	  it	  requires	  prior	  knowledge	  on	  the	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proteins	  to	  be	  screened	  because	  it	  is	  an	  antibody-­‐based	  technique;	  thus,	  novel	  target	  discovery	  is	  not	  achievable	  with	  ELISA.	  Moreover,	  the	  antibody-­‐based	  techniques	  rely	  on	  the	  sensitivity	  and	  specificity	  of	  the	  antibody;	  non-­‐specific	  binding	  can	  always	  contaminate	  the	  results	  leading	  to	  false	  positives.	  Another	  major	  flaw	  of	  ELISA	  is	  that	  cytokines	  have	  very	  short	  half-­‐life	  making	  it	  hard	  to	  detect	  in	  complex	  samples	  such	  as	  serum.	  An	  alternative	  to	  this	  technique	  is	  microarray-­‐based	  immunoassay,	  which	  is	  very	  similar	  to	  ELISA	  in	  terms	  of	  sensitivity	  and	  methodology;	  but	  is	  more	  advantageous	  due	  to	  higher	  detection	  capability	  with	  smaller	  sample	  volume	  (Jones	  et	  al,	  2008).	  Antibody	  microarrays	  have	  been	  extensively	  used	  for	  analysis	  of	  secreted	  proteins	  (Figure	  52)	  (Mustafa	  et	  al,	  2011).	  But	  it	  cannot	  overcome	  the	  dependence	  on	  specific	  antibodies	  or	  the	  short	  cytokine	  half-­‐life.	  	  	   Many	  of	  the	  challenges	  that	  arise	  during	  those	  traditional	  methods	  can	  be	  overcome	  with	  the	  use	  of	  proteomics	  for	  secreted	  cytokine/protein	  analysis	  as	  proteomics	  enables	  unbiased	  global	  analysis	  of	  proteins	  in	  biological	  samples	  (Hathout,	  2007).	  Currently,	  with	  the	  development	  of	  technology	  and	  bioinformatics	  approaches,	  hundreds	  to	  thousands	  of	  proteins	  can	  be	  identified	  from	  a	  small	  amount	  of	  sample.	  Various	  studies	  have	  demonstrated	  the	  detection	  sensitivity	  of	  proteomics	  in	  secreted	  protein	  identification.	  Moreover	  the	  proteomic	  analysis	  can	  reveal	  disease	  biomarkers	  (Grønborg	  et	  al,	  2006),	  secretion	  of	  proteins	  involved	  in	  cancer	  aggressiveness	  (Makridakis	  et	  al,	  2010),	  human	  plasma	  proteome	  (Anderson	  &	  Anderson,	  2002),	  or	  inflammation-­‐response	  related	  protein	  secretion	  (Eichelbaum	  et	  al,	  2012).	  Proteomic	  secretome	  analysis	  overcomes	  the	  problems	  associated	  with	  RNA	  based	  approaches	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due	  to	  quantification	  of	  secreted	  protein	  abundance	  and	  with	  antibody-­‐based	  approaches	  such	  as	  specificity,	  quantification,	  and	  false-­‐positives	  (Hathout,	  2007).	  	  Here,	  we	  used	  a	  global	  secretome	  profiling	  method	  to	  identify	  the	  proteins	  that	  are	  secreted	  by	  macrophages	  upon	  LPS	  stimulation	  and	  we	  used	  qPCR	  to	  validate	  the	  identitfied	  novel	  and	  known	  secreted	  proteins	  to	  show	  the	  high	  accuracy	  of	  this	  method.	  	  Moreover,	  bioinformatics	  analysis	  of	  secretome	  data	  demonstrated	  the	  strength	  of	  this	  method	  in	  data-­‐dependent	  discovery.	  
MATERIALS	  AND	  METHODS	  
Reagents	  LPS	  was	  purchased	  from	  Invitrogen.	  All	  protease	  inhibitor	  cocktails	  were	  purchased	  from	  Sigma-­‐Aldrich	  (St.	  Louis,	  MO).	  All	  culture	  media	  and	  FBS	  were	  obtained	  from	  GIBCO.	  Trypsin	  was	  purchased	  from	  Promega.	  All	  chemicals	  were	  sequence-­‐	  or	  HPLC-­‐grade	  unless	  specifically	  indicated.	  Antibodies	  for	  p-­‐IκBa	  (S32),	  IκBa,	  p-­‐p65	  NFκB	  (S536),	  and	  p65	  were	  purchased	  from	  Cell	  Signaling.	  Antibodies	  for	  Lmnb1	  and	  p65	  were	  from	  Santa	  Cruz	  Biotechnology	  while	  antibodies	  to	  γ-­‐tubulin,	  histone	  H3,	  H3K9me2,	  H3K9me1,	  H3K27me2	  were	  from	  Abcam.	  Antibody	  for	  PHF8	  was	  from	  Bethyl	  Labs.	  Bacterial	  clones	  for	  shRNA	  against	  PHF8	  or	  against	  PLKO.1	  were	  purchased	  from	  Sigma-­‐Aldrich.	  
Cell	  Culture	  RAW	  264.7	  cells	  were	  maintained	  in	  4.5	  g/L	  glucose	  DMEM	  with	  10%	  FBS.	  For	  all	  LPS	  treatment	  1	  μg/mL	  LPS	  is	  used.	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Transfection	  and	  Stable	  PHF8-­‐KD	  RAW	  Cell	  Line	  The	  lentiviral	  plasmids	  pLKO.1	  expressing	  shRNA-­‐PHF8	  (targeting	  sequences	  CGACCCTGATAATAAGACCAA	  and	  GCAAGATGAAACTCGGTGATT	  in	  human	  and	  mouse,	  respectively)	  were	  purchased	  from	  Sigma.	  A	  pLKO.1	  empty	  vector	  without	  a	  specific	  shRNA	  sequence	  was	  used	  as	  the	  wild-­‐type	  control.	  To	  produce	  virus,	  pLKO.1-­‐shRNA	  plasmids	  were	  co-­‐transfected	  into	  293T	  cells	  with	  ViraPowerMix	  (Invitrogen)	  by	  jetPRIMETM	  in	  vitro	  DNA	  and	  siRNA	  transfection	  reagent	  (Polyplus).	  Pseudo-­‐virus	  in	  supernatants	  was	  collected	  48	  h	  after	  transfection	  and	  used	  to	  transduce	  RAW	  264.7	  cells	  by	  spinoculation.	  48	  h	  after	  transfection,	  8	  μg/ml	  puromycin	  was	  added	  to	  select	  puromycin-­‐resistant	  clones.	  Stable	  clones	  were	  maintained	  in	  medium	  containing	  4	  μg/mL	  puromycin.	  The	  expression	  level	  of	  PHF8	  in	  PHF8-­‐KD	  cell	  line	  was	  monitored	  with	  immunoblotting	  and	  qPCR.	  
PHF8-­‐dependent	  Secretome	  Profiling	  The	  Secretome	  profiling	  workflow	  is	  shown	  in	  Figure	  53.	  	  
Sample	  Preparation	  Paired	  WT	  and	  PHF8-­‐KD	  RAW	  264.7	  cells	  were	  cultured	  in	  regular	  DMEM	  medium	  with	  10%	  FBS.	  24	  hours	  prior	  to	  the	  LPS	  challenge,	  cells	  were	  washed	  with	  and	  cultured	  in	  serum-­‐free	  DMEM	  containing	  1	  mM	  sodium	  pyruvate	  and	  10	  mM	  L-­‐glutamine	  with	  no	  phenol	  red.	  Cells	  were	  cultured	  in	  the	  same	  medium	  and	  were	  either	  left	  unstimulated	  (0)	  or	  subjected	  to	  a	  single	  LPS	  challenge	  at	  1	  μg/mL	  for	  indicated	  hours	  (2,	  4,	  8,	  24).	  The	  secretome	  containing	  culture	  medium	  was	  centrifuged	  at	  400	  x	  g	  for	  5	  min	  for	  removal	  of	  dead	  cell	  debris.	  The	  supernatant	  was	  collected	  with	  an	  18-­‐
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gauge	  needle,	  syringe-­‐filtered	  with	  0.2	  μm	  13	  mm	  diameter	  PTFE	  filters	  (VWR	  International),	  and	  transferred	  into	  fresh	  tubes	  to	  be	  kept	  at	  -­‐80°C	  until	  further	  processed.	  After	  the	  removal	  of	  extracellular	  media,	  the	  remaining	  attached	  cells	  were	  lysed	  with	  1	  X	  SDS-­‐loading	  buffer	  to	  perform	  Western	  blots	  for	  confirmation	  of	  the	  inflammation	  phenotype.	  	  
Immunoblotting	  	  To	  confirm	  the	  inflammation	  phenotype,	  we	  used	  immunoblotting	  (Figure	  54)	  on	  the	  lysates	  denatured	  in	  SDS-­‐loading	  buffer	  were	  sonicated	  twice	  at	  level	  3	  for	  5	  sec	  for	  successful	  release	  of	  the	  chromatin	  then	  were	  separated	  on	  an	  SDS-­‐PAGE	  gel	  under	  reducing	  conditions	  and	  then	  transferred	  to	  a	  PVDF	  membrane.	  The	  membranes	  were	  blocked	  with	  milk	  for	  1	  h	  at	  RT	  on	  an	  orbital	  shaker.	  Following	  primary	  antibody	  incubation	  for	  1	  h	  at	  RT,	  we	  probed	  the	  membranes	  with	  a	  horseradish	  peroxidase	  conjugated	  secondary	  antibody	  and	  bands	  were	  detected	  using	  an	  ECL	  Western	  Blotting	  Detection	  Kit	  (GE	  Life	  Sciences).	  	  
Protein	  Digestion	  To	  prepare	  the	  medium	  for	  MS	  analysis,	  we	  thawed	  the	  secretome-­‐containing	  medium	  and	  diluted	  in	  4	  X	  lysis	  buffer	  (8	  M	  urea,	  40	  mM	  HEPES	  pH	  7.9)	  to	  bring	  the	  final	  urea	  concentration	  to	  2	  M.	  The	  mixture	  was	  then	  sonicated	  at	  level	  3	  for	  5	  seconds.	  The	  proteins	  were	  reduced	  with	  DTT	  (10	  mM	  final)	  for	  40	  min	  at	  RT	  and	  alkylated	  with	  IAA	  (50	  mM	  final)	  for	  40	  min	  in	  the	  dark	  at	  RT.	  Alkylation	  was	  quenched	  with	  freshly	  prepared	  thiourea	  (100	  mM	  final).	  CaCl2	  was	  added	  to	  1	  mM	  final	  concentration	  for	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optimum	  trypsin	  digestion	  overnight	  at	  RT.	  The	  digestion	  was	  quenched	  with	  TFA	  (0.5%	  final).	  Peptides	  were	  dried	  and	  resuspended	  at	  0.1%	  FA	  for	  MS/MS.	  	  
LC-­‐MS/MS	  We	  used	  reversed	  phase	  LC-­‐MS/MS	  using	  a	  Proxeon	  1000	  nano	  LC	  system	  coupled	  to	  an	  LTQ	  Orbitrap	  Velos	  mass	  spectrometer	  (Thermo	  Scientific,	  San	  Jose,	  CA).	  The	  peptides	  were	  trapped	  using	  a	  3	  cm	  long	  100	  mm	  i.d.	  C18	  column	  at	  5	  μL/min	  liquid	  flow	  that	  was	  diverted	  from	  the	  analytical	  column	  via	  a	  vent	  valve	  while	  elution	  was	  performed	  by	  switching	  the	  valve	  to	  make	  the	  trap	  column	  in-­‐line	  with	  a	  15	  cm	  long,	  75	  μm	  i.d.,	  3.5	  μm,	  300	  Å	  particle	  C18	  analytical	  column.	  The	  digested	  peptides	  were	  separated	  with	  a	  linear	  gradient	  of	  2-­‐35%	  buffer	  B	  over	  240	  min	  at	  a	  300	  nL/min	  flow	  rate	  using	  0.1%	  formic	  acid	  (buffer	  A)	  and	  ACN	  with	  0.1%	  formic	  acid	  (buffer	  B).	  Each	  secretome	  sample	  with	  two	  biological	  replicates	  were	  subjected	  to	  3	  single-­‐shot	  independent	  LC-­‐MS	  runs	  for	  global	  peptide	  analysis.	  Database	  search	  of	  the	  mass	  spectra,	  peptide	  identification,	  and	  Label-­‐free	  Quantification	  (LFQ)	  were	  performed	  as	  previously	  described	  (Liu	  et	  al,	  2014).	  
Bioinformatic	  Analysis	  Mass	  spectra	  were	  analyzed	  using	  MaxQuant	  software	  version	  1.5.0.30	  using	  the	  Andromeda	  search	  engine	  against	  the	  mouse	  Uniprot	  sequence	  database	  including	  248	  common	  contaminants	  and	  reversed	  versions	  of	  all	  sequences	  (Cox	  &	  Mann,	  2008;	  Cox	  et	  al,	  2011).	  Maximum	  allowed	  mass	  error	  was	  set	  to	  4.5	  ppm	  for	  monoisotopic	  precursor	  ions	  and	  0.5	  Da	  for	  MS/MS	  peaks.	  Enzyme	  specificity	  was	  set	  to	  trypsin	  and	  a	  maximum	  of	  two	  missed	  cleavages	  were	  allowed.	  We	  set	  carbamidomethyl-­‐cysteine	  as	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a	  fixed	  modification,	  and	  N-­‐terminal	  acetylation	  and	  methionine	  oxidation	  as	  variable	  modifications.	  For	  identification	  of	  proteins,	  we	  kept	  requirements	  of	  at	  least	  one	  unique	  or	  razor	  peptide	  per	  protein	  group.	  LFQ	  was	  performed	  in	  in	  MaxQuant	  using	  the	  built	  in	  Extracted	  ion	  chromatograms	  (XIC)-­‐based	  fast	  LFQ	  algorithm	  (Luber	  et	  al,	  2010).	  We	  set	  the	  required	  false	  positive	  rate	  as	  1%	  at	  the	  peptide	  and	  5%	  at	  the	  protein	  level,	  and	  the	  minimum	  required	  peptide	  length	  as	  7	  amino	  acids.	  Contaminants,	  reverse	  identification	  and	  proteins	  only	  identified	  by	  site	  were	  excluded	  from	  further	  data	  analysis.	  For	  each	  LPS	  treated	  sample	  of	  a	  given	  phenotype	  and	  time	  point,	  ratios	  were	  calculated	  from	  the	  individual	  protein	  LFQ	  intensities,	  and	  the	  corresponding	  median	  LFQ	  intensities	  of	  the	  untreated	  sample.	  Missing	  values	  were	  imputed	  only	  for	  untreated	  samples	  by	  random	  sampling	  from	  a	  generated	  narrow	  normal	  distribution	  around	  the	  detection	  limit	  for	  proteins.	  The	  calculated	  ratios	  were	  log2	  normalized.	  In	  order	  to	  retrieve	  the	  proteins	  with	  a	  statistically	  different	  quantitative	  ratios	  among	  different	  LPS	  stimulation	  durations,	  we	  used	  multiple	  samples	  statistic	  analysis	  via	  ANOVA	  with	  a	  permutation-­‐based	  FDR	  controlled	  filter.	  The	  p-­‐value	  cut-­‐off	  was	  calculated	  at	  5%	  FDR.	  This	  multiple	  samples	  test	  technique	  does	  not	  capture	  proteins	  with	  no	  dynamic	  (i.e.	  stable	  over	  time)	  since	  they	  are	  of	  no	  interest.	  The	  correlation	  between	  different	  replicates	  was	  confirmed	  with	  a	  Pearson	  correlation	  analysis.	  Finally,	  we	  benchmarked	  our	  LFQ	  secretome	  profiling	  for	  validation	  by	  comparing	  our	  data	  with	  that	  of	  the	  two	  separate	  studies	  of	  LPS-­‐inducible	  secretome	  from	  primary	  bone	  marrow-­‐derived	  macrophages	  (BMDM)	  (Liu	  et	  al,	  2014;	  Meissner	  et	  al,	  2013).	  Further,	  to	  understand	  the	  role	  of	  PHF8	  in	  regulation	  of	  LPS-­‐induced	  inflammation	  and	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interacting	  signaling	  pathways,	  we	  comprehensively	  analyzed	  the	  functional	  categories	  of	  the	  LPS-­‐inducible	  PHF8-­‐dependent	  T-­‐class	  secretome	  using	  David	  bioinformatics	  database	  in	  the	  context	  of	  Gene	  Ontology	  (GO)	  Biological	  Processes	  (GOBP),	  GO	  Cellular	  Components	  (GOCC),	  GO	  Molecular	  Functions	  (GOMF),	  and	  Kyoto	  Encyclopedia	  of	  Genes	  and	  Genomes	  (KEGG)	  pathways	  (Huang	  et	  al,	  2009).	  
RNA	  Isolation	  and	  qPCR	  Stable	  cell	  lines	  were	  seeded	  into	  12	  well	  cell	  culture	  dishes	  and	  treated	  with	  LPS	  for	  indicated	  times.	  Total	  RNA	  was	  isolated	  using	  illustra	  RNAspin	  Mini	  Kit	  (GE	  Healthcare	  Life	  Sciences).	  First-­‐strand	  cDNA	  was	  synthesized	  by	  M-­‐MLV	  reverse	  transcriptase	  (Promega)	  and	  diluted	  5-­‐fold	  for	  qPCR.	  qPCR	  was	  performed	  using	  Maxima	  SYBR	  Green/ROX	  (Thermo	  Scientific).	  All	  measurements	  were	  normalized	  against	  GAPDH	  as	  the	  internal	  control	  using	  2-­‐ΔΔCt	  method.	  The	  sequences	  of	  primers	  are	  included	  in	  Table	  9.	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Table	  9	  Primer	  Sequences	  used	  in	  the	  qPCR	  of	  T-­‐cell	  regulatory	  genes	  
Gene	  (mouse)	   Primer	  Sequence	  
Left	  (5'	  to	  3')	   Right	  (5'	  to	  3')	  
IL1a	   GCAACGGGAAGATTCTGAAG	   TGACAAACTTCTGCCTGACG	  
IL1b	   GCCCATCCTCTGTGACTCAT	   AGGCCACAGGTATTTTGTCG	  
IFNb	   CCATCCAAGAGATGCTCCAG	  	   GTGGAGAGCAGTTGAGGACA	  
IL6	   CCGGAGAGGAGACTTCACAG	   CAGAATTGCCATTGCACAAC	  
IL10	   GGTTGCCAAGCCTTATCGGA	   ACCTGCTCCACTGCCTTGCT	  
GAPDH	   AACTTTGGCATTGTGGAAGG	   ACACATTGGGGGTAGGAACA	  
TNFa	   CCCCAAAGGGATGAGAAGTT	   GTGGGTGAGGAGCACGTAGT	  
PHF8	   AACACAACAAATGCTAATCT	   AGAAGTTCCCTCCGAATGCT	  
ADAM17	   AAGTGCAAGGCTGGGAAATG	   CACACGGGCCAGAAAGGTT	  
B2M	   CCGAACATACTGAACTGC	   AGAAAGACCAGTCCTTGC	  
CCL2	   AGGTCCCTGTCATGCTTCTG	   TCTGGACCCATTCCTTCTTG	  
CCL7	   AATGCATCCACATGCTGCTA	   CTTTGGAGTTGGGGTTTTCA	  
CCL9	   GGTCTGTCTGCCTCTTTTGC	   GGGCTACACAGAGAAACCCT	  
CCL22	   GCTCTCGTCCTTCTTGCTGT	   GCAGGATTTTGAGGTCCAGA	  
CD74	   ACGGCAAATGAAGTCAGAACA	   AAGACTACTAATGGGTCAGAAAT
GG	  
CFB	   CTCGAACCTGCAGATCCAC	   TCAAAGTCCTGCGGTCGT	  
CTSB	   GCCCGACCATTGGACAGAT	   GCCCCAAATGCCCAACA	  
CTSL1	   GACCGGGACAACCACTGTG	   CCCATCAATTCACGACAGGAT	  
CTSS	   AAGCGGTGTCTATGACGACCC	   GAGTCCCATAGCCAACCACAA	  
CTSZ	   CCTGTCCGGGAGGGAGAA	   TGGTTGATAACGGCCTGGTC	  
CXCL16	   TCCTTTTCTTGTTGGCGCTG	   CAGCGACACTGCCCTGGT	  
IFI30	   GTCAGCTGTACCAGGGAACG	   GTCTGGGCTTTGTGGGACAT	  
ITGA4	   TGCACCTCTTGTCTGTCTTGTT	   GTGGCCTTAGCTCCTCCTCT	  
LIF	   AATGCCACCTGTGCCATACG	   CAACTTGGTCTTCTCTGTCCCG	  
TNFSF9	   GCAAGCAAAGCCTCAGGTAG	   TCCAGGAACGGTCCACTAAC	  
TREM2	   AGAGTGTGGTGACGGGTTCC	   TATGACGCCTTGAAGCACTG	  
P14	  CD8+	  T	  cell	  activation	  assay	  For	  T	  cell	  activation	  assay,	  CD8+	  T	  cells	  from	  P14	  transgenic	  mouse	  were	  first	  isolated	  with	  CD8a	  microbeads	  according	  to	  manufacturer’s	  instruction.	  Isolated	  CD8+	  T	  cells	  were	  re-­‐suspended	  in	  1	  mL	  1640	  medium.	  Meanwhile	  WT	  (shCON)	  and	  PHF8-­‐KD	  (shPHF8)	  RAW	  264.7	  cells	  were	  seeded	  in	  6	  well	  plates,	  treated	  with	  1	  μg/mL	  LPS	  for	  0,	  8,	  and	  24	  h;	  then	  were	  treated	  with	  50	  μg/mL	  mitomycin	  C	  for	  30	  min	  at	  37°C.	  Mitomycin	  C-­‐treated	  cells	  were	  washed	  with	  1	  mL	  PBS	  twice.	  0.1x106	  P14	  T	  cells	  are	  co-­‐cultured	  with	  2x105	  WT	  or	  PHF8-­‐KD	  RAW	  cells	  in	  96-­‐well	  plates	  in	  RPMI	  medium	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containing	  50	  U/mL	  mIL-­‐2.	  The	  activation	  of	  CD8+	  T	  cells	  was	  assessed	  by	  flow	  cytometry	  at	  day	  6	  with	  analysis	  of	  T	  cell	  activation	  markers	  of	  CD25,	  CD44,	  and	  CD69.	  	  
P14	  CD8+	  T	  cell	  proliferation	  assay	  For	  T	  cell	  proliferation	  assay,	  CD8+	  T	  cells	  from	  P14	  transgenic	  mouse	  were	  first	  isolated	  with	  CD8a	  microbeads	  according	  to	  manufacturer’s	  instruction.	  Isolated	  CD8+	  T	  cells	  were	  re-­‐suspended	  in	  1	  mL	  1640	  medium	  and	  labeled	  with	  1	  mL	  of	  the	  10	  μM	  Carboxyfluorescein	  diacetate	  succinimidyl	  ester	  (CFSE)	  for	  8	  min	  at	  RT.	  Cells	  were	  washed	  with	  10	  mL	  1640	  medium	  containing	  10%	  FBS.	  	  Meanwhile	  WT	  (shCON)	  and	  PHF8-­‐KD	  (shPHF8)	  RAW	  264.7	  cells	  were	  seeded	  in	  6	  well	  plates,	  treated	  with	  1	  μg/mL	  LPS	  for	  0,	  8,	  and	  24	  h;	  then	  were	  treated	  with	  50	  μg/mL	  mitomycin	  C	  for	  30	  min	  at	  37°C.	  Mitomycin	  C-­‐treated	  cells	  were	  washed	  with	  1	  mL	  PBS	  twice	  and	  then	  labeled	  with	  0.4	  mL	  of	  the	  30	  μg/mL	  GP33-­‐41	  peptide	  in	  PBS	  for	  30	  min	  at	  37°C.	  The	  unattached	  peptides	  were	  washed	  with	  PBS.	  0.1x106	  P14	  T	  cells	  are	  co-­‐cultured	  with	  2x105	  WT	  or	  PHF8-­‐KD	  RAW	  cells	  in	  96-­‐well	  plates	  in	  RPMI	  medium	  containing	  50	  U/mL	  mIL-­‐2.	  The	  proliferation	  of	  CD8+	  T	  cells	  was	  assessed	  by	  flow	  cytometry	  at	  day	  6.	  	  
RESULTS	  
PHF8	  selectively	  promotes	  the	  secretion	  of	  a	  specific	  group	  of	  ‘tolerizable’	  proteins	  
including	  cytokines	  and	  chemokines	  To	  understand	  how	  PHF8	  regulates	  the	  LPS-­‐induced	  inflammation	  and	  overall	  inflammation	  response	  we	  employed	  an	  unbiased	  LFQ	  proteomic	  method	  to	  profile	  the	  LPS-­‐induced,	  time	  resolved	  proteins	  that	  are	  differentially	  secreted	  from	  paired	  WT	  versus	  PHF8-­‐KD	  RAW	  cells	  as	  shown	  in	  Figure	  53.	  The	  non-­‐biased,	  discovery-­‐driven	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secretome	  screening	  is	  a	  powerful	  method	  that	  can	  identify	  not	  only	  PHF8-­‐regulated	  secretory	  proteins	  but	  also	  unknown	  extracellular	  functions	  of	  PHF8	  that	  control	  inflammation.	  To	  this	  end,	  we	  stimulated	  WT	  and	  PHF8-­‐KD	  RAW	  cells	  with	  LPS	  for	  0,	  2,	  4,	  8,	  and	  24	  h;	  representing	  non-­‐stimulated	  (N),	  acutely	  stimulated	  (NL),	  and	  prolonged	  stimulated	  (T)	  inflammatory	  states.	  The	  inflammation	  phenotype	  were	  confirmed	  via	  immunoblotting	  for	  the	  levels	  of	  phospho-­‐p65,	  IκBα,	  and	  phospho-­‐IκBα	  (Figure	  54).	  Our	  imunoblots	  revealed	  that	  PHF8-­‐KD	  was	  stable.	  Moreover,	  the	  immunoblots	  of	  P-­‐p65	  (S536)	  and	  P-­‐IκBα	  showed	  LPS-­‐dependent	  increase	  that	  was	  diminished	  over	  24	  h	  LPS	  stimulation	  confirming	  the	  accurate	  inflammation	  response.	  γTubulin	  was	  used	  as	  a	  cellular	  loading	  control.	  	  We	  performed	  the	  LFQ	  analysis	  on	  two	  biological	  replicates,	  in	  which	  each	  biological	  set	  was	  further	  measured	  with	  three	  technical	  replicates.	  The	  time-­‐resolved	  or	  inflammatory-­‐phenotypic	  changes	  in	  the	  amounts	  of	  secreted	  proteins	  were	  filtered	  to	  proteins	  with	  a	  5%	  permutation-­‐based	  FDR	  that	  show	  statistically	  distinct	  patterns	  in	  each	  time-­‐point	  of	  LPS	  stimulation	  and	  normalized	  for	  all	  inflammatory	  states	  according	  to	  the	  Z-­‐score.	  The	  correlation	  between	  different	  replicates	  was	  confirmed	  with	  a	  Pearson	  correlation	  analysis	  (score	  >0.7)	  (Figure	  55).	  	  From	  this	  analysis	  1002	  proteins	  were	  selected,	  which	  grouped	  by	  unsupervised	  hierarchial	  clustering	  into	  368	  LPS-­‐induced	  in	  WT	  cells	  (Figure	  56),	  318	  of	  which	  (86%	  of	  LPS-­‐induced)	  showed	  PHF8-­‐dependency	  in	  secretion	  as	  their	  LPS-­‐induced	  secretion	  diminished	  in	  PHF8-­‐KD.	  Moreover,	  approximately	  254	  proteins	  (80%	  of	  LPS-­‐inducible	  PHF8-­‐dependent	  secretome)	  showed	  a	  secretion	  pattern	  similar	  to	  the	  inflammatory	  phenotype-­‐specific	  mRNA	  expression	  of	  T-­‐class	  genes	  (Foster	  et	  al,	  2007);	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prolonged	  LPS	  stimulation	  caused	  a	  reduction	  in	  secretion	  of	  proteins	  that	  has	  been	  increased	  by	  an	  acute	  LPS	  stimulation	  (Figure	  56,	  left).	  Therefore,	  we	  defined	  this	  cluster	  of	  LPS-­‐inducible,	  secretory	  proteins	  as	  the	  ‘tolerizable’-­‐	  or	  ‘T-­‐class	  secretome’	  (highlighted	  in	  green	  in	  the	  cluster	  column).	  The	  T-­‐class	  secretome	  is	  given	  in	  
Appendix	  1.	  The	  remaining	  64	  LPS-­‐inducible	  proteins	  (Figure	  56,	  right)	  were	  secreted	  in	  a	  trend	  similar	  to	  the	  mRNA	  expression	  of	  the	  non-­‐tolerizable	  (NT)-­‐class	  
genes	  (highlighted	  in	  yellow	  in	  the	  cluster	  column),	  which	  are	  clustered	  as	  the	  ‘NT-­‐class	  secretome’.	  This	  set	  of	  proteins	  is	  given	  in	  Appendix	  2.	  To	  benchmark	  the	  LFQ	  secretome	  profiling	  for	  validation,	  we	  compared	  our	  data	  of	  the	  RAW	  cell	  secretome	  with	  that	  of	  the	  LPS-­‐inducible	  secretome	  from	  BMDM	  (Meissner	  et	  al,	  2013).	  This	  comparison	  revealed	  175	  secretome	  components	  in	  common	  (Figure	  57,	  Appendix	  3),	  40%	  of	  which	  are	  cytokines	  and	  chemokines	  (Table	  
10).	  Further,	  a	  comparison	  with	  a	  more	  recent	  BMDM	  secretome	  (Liu	  et	  al,	  2014)	  revealed	  632	  common	  components	  (Figure	  57,	  Appendix	  4),	  192	  of	  which	  (30%)	  were	  found	  in	  the	  LPS-­‐inducible	  portion	  including	  most	  of	  the	  cytokines	  and	  chemokines	  (Appendix	  5).	  Some	  defense	  or	  wounding	  response-­‐related	  proteins	  were	  found	  secreted	  upon	  LPS	  stimulation,	  including	  multiple	  cytokines/chemokines,	  complement	  factors,	  Integrin	  beta	  2	  (Itgb2),	  Interleukin	  27	  (IL27),	  and	  lymphocyte	  antigen	  86	  (Ly86),	  in	  line	  with	  a	  recent	  report	  indicating	  the	  regulatory	  role	  of	  PHF8	  in	  wound	  healing	  by	  bone-­‐marrow	  stromal	  cells	  (Han	  et	  al,	  2015).	  	  These	  overlapping	  results	  not	  only	  validated	  the	  accuracy	  of	  our	  LFQ	  secretome	  screening,	  but	  also,	  and	  more	  importantly,	  indicated	  that	  the	  acute	  LPS-­‐induced	  secretion	  of	  select	  cytokines/chemokines,	  and	  many	  other	  immune	  response-­‐related	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proteins,	  is	  PHF8-­‐dependent,	  supporting	  the	  conclusion	  that	  PHF8	  is	  the	  primary	  re-­‐
programmer	  of	  chromatin	  modifications	  associated	  with	  various	  inflammatory	  genes	  specifically	  in	  acutely	  inflamed	  macrophages.	  	  
	  
Table	  10	  List	  of	  cytokines	  and	  chemokines	  identified	  in	  the	  LPS-­‐inducible	  secretome	  	  
The	  table	  also	  shows	  the	  comparison	  with	  previous	  BMDM	  secretome	  studies.	  
Cytokine/Chemokine	   	  PHF8-­‐dependent	  
secretion	  
Identified	  	  in	  
(Meissner	  et	  al,	  2013)	  
Identified	  in	  (Liu	  et	  al,	  
2014)	  
Aimp1	   ✓ 	   ✓ 
Ccl2	   ✓ ✓ ✓ 
Ccl22	   	   ✓ 	  
Ccl3	   	   ✓ ✓ 
Ccl4	   	   ✓ ✓ 
Ccl5	   	   ✓ ✓ 
Ccl7	   ✓ ✓ 	  
Ccl9	   ✓ ✓ ✓ 
Csf3	   	   ✓ 	  
Cxcl10	   ✓ ✓ ✓ 
Cxcl16	   ✓ ✓ 	  
Cxcl2	   ✓ ✓ ✓ 
Ebi3	   ✓ ✓ 	  
Ifnb1	   	   ✓ 	  
Il27	   ✓ ✓ 	  
Il6	   	   ✓ ✓ 
Lif	   ✓ 	   	  
Mif	   	   	   	  
Osm	   	   	   	  
Spp1	   	   ✓ 	  
	  	  
	  
PHF8-­‐dependent	  T-­‐class	  secretome	  is	  involved	  in	  regulation	  of	  diverse	  extracellular	  
processes	  and	  pathways	  upon	  LPS	  stimulation	  	   Since	  our	  previous	  qPCR	  and	  immunoblotting	  results	  revealed	  PHF8	  as	  a	  pro-­‐inflammatory	  active	  demethylase,	  we	  primarily	  focused	  on	  the	  T-­‐class	  PHF8-­‐dependent	  secretome	  for	  further	  analysis.	  To	  explore	  novel	  functions	  of	  PHF8	  in	  regulation	  of	  LPS-­‐
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induced	  inflammation	  and	  interacting	  signaling	  pathways,	  we	  comprehensively	  analyzed	  the	  functional	  categories	  of	  the	  LPS-­‐inducible	  PHF8-­‐dependent	  T-­‐class	  secretome	  using	  David	  bioinformatics	  database	  in	  the	  context	  of	  GOBP,	  GOCC,	  GOMF,	  and	  KEGG	  pathways	  (Huang	  et	  al,	  2009).	  	  
PHF8	  regulates	  the	  antigen	  processing	  and	  presentation	  BP	  upon	  LPS	  stimulation	  GOBP	  analysis	  revealed	  that	  the	  LPS-­‐inducible	  PHF8-­‐dependent	  T-­‐class	  secretome	  is	  involved	  in	  various	  extracellular	  BPs	  such	  as	  defense	  response,	  response	  to	  wounding,	  immune/inflammatory	  response,	  antigen	  processing	  and	  presentation,	  regulation	  of	  complement	  factors,	  cell	  metabolism,	  glycolysis-­‐related	  cell	  adhesion,	  cell	  migration,	  cell-­‐to-­‐cell	  communication,	  and	  T	  cell	  activation	  (Figure	  58).	  More	  importantly,	  the	  PHF8-­‐dependent	  T-­‐class	  proteins	  of	  inflammation	  response	  are	  also	  involved	  in	  other	  related	  BPs,	  including	  defense	  response,	  immune	  response,	  response	  to	  wounding,	  antigen	  presentation,	  DNA	  replication,	  chromosome	  organization,	  and	  mRNA	  processing	  (Table	  11).	  	  	  
Table	  11	  T-­‐class	  GOBP	  enrichment	  
Defense	  Response	  
CD74	  antigen	  (invariant	  polypeptide	  of	  major	  histocompatibility	  complex,	  class	  II	  antigen-­‐associated)	  
aminoacyl	  tRNA	  synthetase	  complex-­‐interacting	  multifunctional	  protein	  1	  
beta-­‐2	  microglobulin	  
chemokine	  (C-­‐C	  motif)	  ligand	  2	  
chemokine	  (C-­‐C	  motif)	  ligand	  7	  
chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  2	  
complement	  component	  factor	  h;	  similar	  to	  complement	  component	  factor	  H	  
complement	  factor	  B	  
histocompatibility	  2,	  D	  region;	  histocompatibility	  2,	  D	  region	  locus	  1	  
histocompatibility	  2,	  K1,	  K	  region;	  similar	  to	  H-­‐2K(d)	  antigen	  
insulin-­‐like	  growth	  factor	  binding	  protein	  4	  
integrin	  beta	  2	  
interleukin	  27	  
lymphocyte	  antigen	  86	  
lysozyme	  2	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phospholipase	  A2,	  activating	  protein	  
protein	  tyrosine	  phosphatase,	  non-­‐receptor	  type	  6	  
	  	  
Immune	  Response	  
CD74	  antigen	  (invariant	  polypeptide	  of	  major	  histocompatibility	  complex,	  class	  II	  antigen-­‐associated)	  
MHC	  class	  I	  like	  protein	  GS10	  
beta-­‐2	  microglobulin	  
chemokine	  (C-­‐C	  motif)	  ligand	  2	  
chemokine	  (C-­‐C	  motif)	  ligand	  7	  
chemokine	  (C-­‐C	  motif)	  ligand	  9	  
chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  2	  
collectin	  sub-­‐family	  member	  12	  
complement	  component	  factor	  h;	  similar	  to	  complement	  component	  factor	  H	  
complement	  factor	  B	  
histocompatibility	  2,	  D	  region;	  histocompatibility	  2,	  D	  region	  locus	  1	  
histocompatibility	  2,	  K1,	  K	  region;	  similar	  to	  H-­‐2K(d)	  antigen	  
interleukin	  27	  
lymphocyte	  antigen	  86	  
protein	  tyrosine	  phosphatase,	  non-­‐receptor	  type	  6	  
tumor	  necrosis	  factor	  (ligand)	  superfamily,	  member	  9	  
	  	  
Response	  to	  wounding	  
aminoacyl	  tRNA	  synthetase	  complex-­‐interacting	  multifunctional	  protein	  1	  
cathepsin	  B	  
chemokine	  (C-­‐C	  motif)	  ligand	  2	  
chemokine	  (C-­‐C	  motif)	  ligand	  7	  
chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  2	  
complement	  component	  factor	  h;	  similar	  to	  complement	  component	  factor	  H	  
complement	  factor	  B	  
insulin-­‐like	  growth	  factor	  binding	  protein	  4	  
integrin	  beta	  2	  
interleukin	  27	  
lymphocyte	  antigen	  86	  
phospholipase	  A2,	  activating	  protein	  
plasminogen	  activator,	  urokinase	  receptor	  
protein	  tyrosine	  phosphatase,	  non-­‐receptor	  type	  6	  
	  	  
Antigen	  presentation	  
CD74	  antigen	  (invariant	  polypeptide	  of	  major	  histocompatibility	  complex,	  class	  II	  antigen-­‐associated)	  
MHC	  class	  I	  like	  protein	  GS10	  
beta-­‐2	  microglobulin	  
histocompatibility	  2,	  D	  region;	  histocompatibility	  2,	  D	  region	  locus	  1	  
histocompatibility	  2,	  K1,	  K	  region;	  similar	  to	  H-­‐2K(d)	  antigen	  
interferon	  gamma	  inducible	  protein	  30	  
	  	  
DNA	  Replication	  
minichromosome	  maintenance	  deficient	  2	  mitotin	  (S.	  cerevisiae)	  
minichromosome	  maintenance	  deficient	  4	  homolog	  (S.	  cerevisiae)	  
minichromosome	  maintenance	  deficient	  6	  (MIS5	  homolog,	  S.	  pombe)	  (S.	  cerevisiae)	  
minichromosome	  maintenance	  deficient	  7	  (S.	  cerevisiae)	  
	  	  
Chromosome	  organization	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H2A	  histone	  family,	  member	  V	  
RuvB-­‐like	  protein	  1	  
RuvB-­‐like	  protein	  2	  
histone	  cluster	  1,	  H1b	  
histone	  cluster	  1,	  H1c	  
histone	  cluster	  1,	  H1d	  
histone	  cluster	  1,	  H1e	  
histone	  cluster	  1,	  H2ad;	  histone	  cluster	  1,	  H2ae;	  histone	  cluster	  1,	  H2ag;	  histone	  cluster	  1,	  H2ah;	  
histone	  cluster	  1,	  H2ai;	  similar	  to	  histone	  2a;	  histone	  cluster	  1,	  H2an;	  histone	  cluster	  1,	  H2ao;	  histone	  
cluster	  1,	  H2ac;	  histone	  cluster	  1,	  H2ab	  
histone	  cluster	  1,	  H2bg;	  histone	  cluster	  1,	  H2be;	  histone	  cluster	  2,	  H2bb;	  histone	  cluster	  1,	  H2bc	  
histone	  cluster	  1,	  H4k;	  histone	  cluster	  1,	  H4m;	  histone	  cluster	  4,	  H4;	  similar	  to	  germinal	  histone	  H4	  
gene;	  histone	  cluster	  1,	  H4h;	  histone	  cluster	  1,	  H4j;	  histone	  cluster	  1,	  H4i;	  histone	  cluster	  1,	  H4d;	  
histone	  cluster	  1,	  H4c;	  histone	  cluster	  1,	  H4f;	  histone	  cluster	  1,	  H4b;	  histone	  cluster	  1,	  H4a;	  histone	  
cluster	  2,	  H4;	  similar	  to	  histone	  H4	  
histone	  cluster	  2,	  H3b;	  histone	  cluster	  1,	  H3f;	  histone	  cluster	  1,	  H3e;	  histone	  cluster	  2,	  H3c1;	  histone	  
cluster	  1,	  H3d;	  histone	  cluster	  1,	  H3c;	  histone	  cluster	  1,	  H3b;	  histone	  cluster	  2,	  H3c2;	  histone	  cluster	  2,	  
H2aa1;	  histone	  cluster	  2,	  H2aa2	  
histone	  deacetylase	  2	  
minichromosome	  maintenance	  deficient	  2	  mitotin	  (S.	  cerevisiae)	  
nucleosome	  assembly	  protein	  1-­‐like	  4	  
poly	  (ADP-­‐ribose)	  polymerase	  family,	  member	  1	  
replication	  protein	  A1	  
	  	  
mRNA	  Processing	  
DEAD	  (Asp-­‐Glu-­‐Ala-­‐Asp)	  box	  polypeptide	  5;	  	  
DEAH	  (Asp-­‐Glu-­‐Ala-­‐His)	  box	  polypeptide	  15	  
HLA-­‐B-­‐associated	  transcript	  1A	  
PRP19/PSO4	  pre-­‐mRNA	  processing	  factor	  19	  homolog	  (S.	  cerevisiae)	  
RNA	  binding	  motif	  protein,	  X	  chromosome	  retrogene	  
U2	  small	  nuclear	  ribonucleoprotein	  auxiliary	  factor	  (U2AF)	  2	  
amyloid	  beta	  (A4)	  precursor	  protein	  
heterogeneous	  nuclear	  ribonucleoprotein	  H1	  
heterogeneous	  nuclear	  ribonucleoprotein	  L	  
non-­‐POU-­‐domain-­‐containing,	  octamer	  binding	  protein;	  predicted	  gene	  8806	  
similar	  to	  heterogeneous	  nuclear	  ribonucleoprotein	  A2/B1;	  heterogeneous	  nuclear	  ribonucleoprotein	  
A2/B1	  
small	  nuclear	  ribonucleoprotein	  polypeptide	  A;	  	  
NHP2	  non-­‐histone	  chromosome	  protein	  2-­‐like	  1	  (S.	  cerevisiae);	  
eukaryotic	  translation	  initiation	  factor	  4A,	  isoform	  3;	  	  
similar	  to	  peptidylprolyl	  isomerase-­‐like	  1;	  peptidylprolyl	  isomerase	  (cyclophilin)-­‐like	  1	  
splicing	  factor	  3a,	  subunit	  1	  
splicing	  factor	  3a,	  subunit	  3	  
splicing	  factor	  3b,	  subunit	  2	  
splicing	  factor	  3b,	  subunit	  3	  
splicing	  factor	  3b,	  subunit	  5	  
splicing	  factor	  proline/glutamine	  rich	  (polypyrimidine	  tract	  binding	  protein	  associated);	  	  
splicing	  factor,	  arginine/serine-­‐rich	  1	  (ASF/SF2);	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Similarly,	  antigen	  processing	  and	  presentation	  was	  found	  in	  the	  KEGG	  pathway	  enrichment	  of	  T-­‐class	  PHF8-­‐dependent	  secretome	  (Figure	  59).	  This	  indicates	  that	  PHF8	  modulates	  the	  inflammation-­‐induced	  secretion	  of	  various	  proteins	  involved	  in	  antigen	  processing	  and	  presentation,	  an	  essential	  and	  significant	  part	  of	  the	  inflammation	  response.	  In	  line	  with	  this	  observation,	  multiple	  members	  of	  a	  major	  antigen	  processing/presentation	  complex	  called	  the	  minichromosome	  maintenance	  (MCM)	  protein	  complex	  were	  found	  as	  a	  highly	  enriched	  GOBP	  in	  the	  T-­‐class	  PHF8-­‐dependent	  secretome	  (Figure	  58).	  	  MCMs	  were	  expressed	  on	  the	  surface	  of	  different	  types	  of	  malignant/proliferative	  cells	  (Das	  et	  al,	  2013)	  but	  there	  is	  little	  knowledge	  of	  how	  they	  are	  regulated	  during	  a	  pro-­‐inflammatory	  response.	  Here,	  the	  MCM	  complex	  constituted	  the	  pathways	  associated	  with	  DNA	  replication	  in	  enriched	  KEGG	  pathways	  (Figure	  59).	  Because	  DNA	  replication	  is	  an	  inflammatory	  process	  (Ishii	  &	  Akira,	  2006),	  PHF8	  may	  regulate	  DNA	  metabolism	  of	  pathogens	  in	  the	  extracellular	  matrix	  via	  regulating	  the	  secretion	  of	  MCM	  complexes.	  	  We	  compared	  our	  PHF8-­‐dependent	  T-­‐class	  secretome	  to	  a	  previous	  PHF8	  Chromatin	  immunoprecipitation	  (ChIP)-­‐sequencing	  (ChIP-­‐seq)	  study	  for	  both	  validation	  and	  analysis.	  PHF8	  ChIP-­‐seq	  study	  revealed	  that	  active	  PHF8	  was	  bound	  to	  the	  promoters	  of	  genes	  involved	  in	  RNA	  processing,	  mRNA	  splicing,	  DNA	  repair,	  and	  cell	  cycle	  (Figure	  60,	  Table	  12).	  In	  agreement	  with	  the	  ChIP-­‐seq	  study,	  our	  T-­‐class	  secretome	  analysis	  involved	  these	  processes	  in	  the	  GOBP	  enrichment	  (Figure	  58);	  given	  these	  processes	  are	  involved	  in	  the	  inflammatory	  response	  regulation,	  we	  concluded	  that	  our	  secretome	  analysis	  revealed	  inflammatory-­‐specific	  regulation	  of	  PHF8-­‐dependent	  secretome	  upon	  LPS	  stimulation.	  	  
	   155	  
Table	  12	  DAVID	  analysis	  of	  functionally	  active	  PHF8	  targets	  (Wang	  et	  al,	  2014a).	  
	  
PHF8	  regulates	  lysosome	  activation	  KEGG	  pathway	  enrichment	  of	  the	  T-­‐class	  PHF8-­‐dependent	  secretome	  revealed	  metabolic	  pathways,	  antigen	  processing	  and	  presentation,	  and	  lysosomal	  pathways	  as	  exclusively	  T-­‐class-­‐specific	  (Figure	  57).	  Lysosome-­‐related	  secreted	  proteins	  were	  mostly	  peptidase	  family	  members,	  which	  were	  previously	  identified	  in	  LPS-­‐induced	  macrophage	  secretome	  (Eichelbaum	  et	  al,	  2012;	  Liu	  et	  al,	  2014;	  Meissner	  et	  al,	  2013),	  are	  part	  of	  the	  antigen	  processing	  and	  presentation	  pathways	  and	  are	  involved	  in	  multiple	  immunity-­‐related	  processes	  (Conus	  &	  Simon,	  2010).	  The	  T-­‐class	  PHF8-­‐dependent	  secretion	  of	  these	  lysosome-­‐related	  proteins	  indicates	  that	  PHF8	  regulates	  
lysosome	  formation	  and	  activity	  upon	  LPS	  stimulation.	  
PHF8	  regulates	  the	  MHC	  expression	  and	  shedding	  upon	  LPS	  stimulation	  GOCC	  enrichment	  revealed	  various	  LPS-­‐induced	  extracellular	  compartments	  including	  vesicle,	  lysosome,	  vacuole,	  and,	  more	  importantly	  in	  agreement	  with	  GOBP	  and	  KEGG	  enrichment,	  Major	  histocompatibility	  complex	  (MHC)	  complexes	  (Figure	  61).	  In	  line	  with	  the	  role	  of	  PHF8	  as	  a	  regulator	  of	  antigen	  presentation	  GOBP,	  according	  to	  GOCC	  enrichment,	  PHF8	  regulates	  LPS-­‐inducible	  MHC	  expression	  and	  shedding	  from	  the	  cell	  membrane	  to	  the	  extracellular	  space	  in	  macrophages.	  MHC	  complex	  is	  a	  major	  regulator	  of	  adaptive	  immunity	  as	  it	  is	  responsible	  for	  the	  pathogenic	  antigen	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presentation	  on	  the	  antigen	  presenting	  cells	  upon	  activation	  of	  inflammatory	  response,	  to	  facilitate	  recognition	  of	  these	  peptides	  by	  T	  cells	  (Figure	  62)	  (Janeway	  et	  al,	  2001);	  thus,	  as	  a	  regulator	  of	  MHC	  components,	  	  PHF8	  may	  be	  an	  important	  mediator	  of	  activation	  of	  adaptive	  immunity.	  	  
PHF8	  regulates	  the	  LPS-­‐induced	  secretion	  of	  proteins	  with	  cytokine/chemokine	  activity	  The	  GOMF	  enrichment	  of	  T-­‐class	  PHF8-­‐dependent	  secretome	  also	  revealed	  various	  inflammation	  response-­‐related	  proteins	  showing	  more	  than	  2-­‐fold	  enrichment	  (Figure	  63).	  More	  importantly,	  cytokine	  activity	  and	  chemokine	  activity	  were	  among	  the	  PHF8-­‐dependent	  T-­‐class	  GOMF	  and	  these	  were	  in	  common	  with	  previous	  LPS-­‐inducible	  secretome	  of	  BMDMs	  (Appendix	  5),	  indicating	  that	  PHF8	  is	  a	  major	  regulator	  of	  secretion	  of	  proteins	  with	  cytokine	  or	  chemokine	  activity	  in	  LPS	  response.	  	  
PHF8	  promotes	  adhesion,	  communication,	  and	  activation	  of	  the	  cells	  of	  adaptive	  immunity	  	  In	  our	  manual	  analysis,	  we	  observed	  that	  PHF8	  affected	  the	  LPS-­‐induced	  secretion	  of	  select	  adaptive	  immunity	  regulators,	  including	  Complement	  factors	  B	  (Cfb)	  and	  H	  (Cfh),	  Interleukin	  Enhancer	  Binding	  Factor	  3	  (ILF3)	  (Marcoulatos	  et	  al,	  1998),	  Ly86	  (Nagai	  et	  al,	  2002),	  amyloid	  precursor	  protein	  (APP)	  (Gitter	  et	  al,	  2000),	  integral	  membrane	  protein	  2B	  (Itmb2),	  and	  metalloproteinase	  domain-­‐containing	  proteins	  8	  (ADAM8),	  and	  17	  (ADAM17).	  Specifically,	  LPS-­‐induced	  secretion	  of	  complement	  factors	  from	  macrophages	  is	  important	  for	  both	  recognition	  of	  pathogens	  and	  activation	  of	  adaptive	  immunity	  (Carroll,	  2004),	  indicating	  the	  regulatory	  role	  of	  PHF8	  in	  these	  BPs.	  In	  agreement	  with	  previous	  LPS-­‐induced	  BMDM	  secretome	  (Meissner	  et	  al,	  2013),	  we	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identified	  ADAM17	  as	  an	  LPS-­‐induced	  macrophage	  secretome	  component;	  ADAM17	  is	  an	  adaptive	  immunity	  regulator	  responsible	  for	  shedding	  of	  membrane-­‐bound	  proteins,	  one	  such	  shed	  protein	  being	  APP	  (Gitter	  et	  al,	  2000).	  The	  presence	  of	  ADAM17	  with	  APP	  in	  the	  LPS-­‐induced	  secretome	  confirms	  APP	  shedding	  from	  the	  membrane.	  	  GOBP	  analysis	  (Figure	  58)	  also	  revealed	  some	  components	  of	  the	  PHF8-­‐dependent	  T-­‐class	  secretome	  are	  involved	  in	  cell	  adhesion	  and	  cell	  communication,	  including	  MHC	  complexes,	  serglycin	  (SRGN),	  Lectin-­‐Galactoside-­‐Binding	  Soluble	  3-­‐Binding	  Protein	  (Lgals3BP),	  intercellular	  adhesion	  molecule	  1	  (Icam1),	  Integrin	  alpha	  4	  (Itga4),	  Itgb2,	  cathepsin	  B	  (Ctsb),	  urokinase	  plasminogen-­‐activator	  surface	  receptor	  (PLAUR),	  syndecan	  4	  (Sdc4),	  and	  poliovirus	  receptor-­‐related	  1	  (Pvrl1).	  SRGN	  and	  Lgals3BP	  are	  cell-­‐cell	  communication	  regulators	  activated	  by	  TLR4	  (Kolset	  &	  Pejler,	  2011;	  Schnoor	  et	  al,	  2008).	  Icam1	  is	  a	  cell-­‐surface	  glycoprotein	  expressed	  on	  immune	  cells	  that	  binds	  to	  integrins	  (Frank	  &	  Lisanti,	  2008);	  integrins	  Itga4	  and	  Itgb2	  in	  turn	  regulate	  cell	  migration	  and	  adaptive	  immunity	  (Harburger	  &	  Calderwood,	  2009),	  and	  are	  in	  common	  with	  LPS-­‐induced	  BMDM	  secretome	  (Meissner	  et	  al,	  2013).	  Similarly,	  the	  released	  adhesion	  molecules	  Ctsb	  (Conus	  &	  Simon,	  2010),	  PLAUR	  (Malla	  et	  al,	  2011),	  SDC4	  (Götte,	  2003),	  and	  Pvrl1	  (Kim	  et	  al,	  2010)	  are	  involved	  in	  regulating	  cell	  migration	  in	  inflammation.	  	  From	  a	  system	  perspective,	  we	  next	  used	  Search	  Tool	  for	  the	  Retrieval	  of	  Interacting	  Genes/Proteins	  (STRING)	  (Jensen	  et	  al,	  2009)	  to	  explore	  the	  pathway	  links	  in	  the	  PHF8-­‐dependent,	  T-­‐class	  secretome.	  A	  protein-­‐protein	  interaction	  (PPI)	  network	  was	  mapped	  among	  the	  secreted	  proteins	  categorized	  in	  different	  GOBP,	  GOCC,	  and	  GOMF	  (Figure	  64);	  this	  network	  was	  dominated	  by	  response	  to	  signaling	  BP	  as	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highlighted	  with	  red	  nodes.	  Based	  on	  these	  protein	  ‘nodes’	  in	  the	  PPI	  network,	  we	  used	  IPA	  to	  identify	  the	  canonical	  pathways	  that	  share	  common	  nodes,	  which	  revealed	  the	  interplay	  between	  pathways	  involving	  antigen	  processing	  and	  presentation,	  complement	  regulation,	  cell	  adhesion,	  and	  endocytosis	  as	  the	  coordinator	  of	  inflammation	  response	  (Figure	  65).	  	  
PHF8	  positively	  regulates	  the	  activation	  and	  proliferation	  of	  T	  cells	  via	  secretion	  of	  
specific	  proteins	  involved	  in	  antigen	  presentation	  and	  activation	  of	  adaptive	  
immunity	  Our	  findings	  of	  the	  IPA	  analysis	  on	  secreted	  proteins	  associated	  with	  the	  activation	  of	  adaptive	  immunity	  in	  the	  PHF8-­‐dependent	  secretome	  (Figure	  65)	  implicated	  that	  PHF8	  positively	  links	  innate	  immunity	  and	  adaptive	  immunity.	  To	  elucidate	  the	  role	  of	  PHF8	  in	  this	  link,	  we	  examined	  the	  LPS-­‐induced	  mRNA	  expression	  of	  select	  genes	  from	  the	  secreted	  proteins	  in	  T-­‐class	  PHF8-­‐dependent	  secreted	  cluster	  based	  on	  their	  relevance	  to	  antigen	  processing/presentation	  and	  the	  activation	  of	  adaptive	  immunity.	  Among	  them,	  Leukemia	  inhibitory	  factor	  (Lif)	  is	  a	  known	  regulator	  of	  T-­‐cell	  maturation	  (Shen	  et	  al,	  1994).	  Similarly,	  the	  cytokine	  TNF	  Superfamily	  Member	  9	  (Tnfsf9)	  regulates	  innate	  and	  adaptive	  immunity	  through	  activation	  of	  CD4+	  T	  cells	  (Fernández	  Do	  Porto	  et	  al,	  2012).	  The	  chemokines	  Ccl2,	  Ccl7,	  Ccl9,	  Ccl22,	  and	  Cxcl16	  activate	  adaptive	  immunity	  by	  promoting	  the	  activation	  and	  migration	  of	  T	  cells	  (Luther	  &	  Cyster,	  2001).	  Cfb	  is	  a	  complement	  factor	  that	  regulates	  adaptive	  immunity	  response	  (Carroll,	  2004).	  ADAM17	  and	  beta-­‐2-­‐microglobulin	  (B2m)	  regulate	  T	  cell	  proliferation	  and	  differentiation	  (Agrawal	  &	  Kishore,	  2000;	  Li	  et	  al,	  2007)	  while	  CD74	  regulates	  cell	  survival	  in	  adaptive	  immunity	  (Leng	  et	  al,	  2003).	  Triggering	  receptor	  expressed	  on	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myeloid	  cells	  2	  (TREM2)	  is	  a	  T-­‐cell	  regulator	  (Sharif	  &	  Knapp,	  2008)	  while	  Itga4	  helps	  traffic	  leukocytes	  to	  the	  site	  of	  inflammation	  (Grégoire	  et	  al,	  2007;	  Harburger	  &	  Calderwood,	  2009).	  Moreover,	  IFNγ-­‐Inducible	  Protein	  30	  (Ifi30)	  is	  involved	  in	  CD8+	  T	  cell	  proliferation	  in	  mice	  (Singh	  et	  al,	  2011).	  As	  the	  antigen	  processing/presentation	  massagers,	  cathepsins	  regulates	  the	  formation	  of	  CD4+	  T	  lymphocytes	  (Conus	  &	  Simon,	  2010).	  As	  shown	  in	  Figure	  66,	  the	  mRNA	  expression	  of	  these	  T	  cell	  regulating	  secretion	  products	  increased	  significantly	  4	  hours	  following	  LPS	  stimulation	  in	  WT	  cells	  while	  the	  increase	  was	  disrupted	  in	  PHF8-­‐KD	  cells.	  Moreover,	  with	  the	  exception	  of	  Ccl2	  and	  Ccl7,	  mRNA	  expressions	  of	  these	  genes	  decreased	  8	  hours	  after	  the	  LPS	  stimulation,	  consistent	  with	  the	  pattern	  of	  PHF8-­‐dependent,	  T-­‐class	  protein	  secretion.	  Since	  previous	  studies	  found	  that	  Ccl2	  and	  Ccl7	  mRNA	  expression	  persisted	  even	  with	  the	  prolonged	  LPS	  stimulation	  (Eichelbaum	  et	  al,	  2012;	  Kang	  et	  al,	  2009)	  and	  the	  secretion	  pattern	  did	  not	  agree	  with	  the	  secretome	  analysis,	  we	  concluded	  that	  there	  might	  be	  other	  intermediate	  events	  affecting	  their	  phenotypic	  regulation.	  Moreover,	  this	  demonstrates	  that	  the	  quantitative	  proteomic	  studies	  are	  very	  powerful	  in	  understanding	  the	  regulation	  of	  signaling	  events	  in	  the	  extracellular	  space.	  	   After	  validation	  of	  the	  LPS-­‐induced	  mRNA	  expression	  of	  T	  cell	  activating	  extracellular	  proteins,	  we	  wanted	  to	  determine	  the	  immediate	  outcome	  of	  PHF8-­‐dependent	  secretion	  of	  these	  molecules	  on	  the	  activation	  and	  proliferation	  of	  T	  cells.	  Using	  flow-­‐cytometry	  we	  performed	  T	  cell	  activity	  and	  proliferation	  assays	  on	  T	  cells	  that	  were	  incubated	  with	  either	  WT	  or	  PHF8-­‐KD	  RAW	  cells	  that	  were	  previously	  stimulated	  with	  LPS	  for	  0,	  8,	  or	  24	  h.	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   To	  assess	  the	  T	  cell	  activation,	  we	  monitored	  the	  T	  cell	  activation	  markers	  CD25,	  CD44,	  and	  CD69	  via	  flow-­‐cytometry	  (Figure	  67).	  CD8+	  T	  cells	  that	  were	  treated	  with	  LPS-­‐stimulated	  WT	  RAW	  cells	  showed	  efficient	  activation	  while	  those	  treated	  with	  LPS-­‐stimulated	  PHF8-­‐KD	  cells	  showed	  impaired	  activation.	  To	  determine	  whether	  this	  effect	  was	  translated	  into	  the	  proliferation	  process,	  we	  assayed	  the	  T	  cell	  proliferation	  using	  flow	  cytometry.	  In	  line	  with	  the	  activation	  markers,	  proliferated	  CD8+	  T	  cells	  were	  found	  after	  6	  days	  of	  co-­‐incubation	  with	  WT	  cells	  while	  PHF8-­‐KD	  cells	  lost	  the	  ability	  to	  promote	  the	  proliferation	  of	  T	  cells	  with	  or	  without	  LPS	  stimulation	  (Figure	  68),	  all	  indicating	  the	  regulatory	  function	  of	  PHF8	  in	  the	  activation	  of	  adaptive	  immunity.	  	  
DISCUSSION	  The	  mechanism	  of	  the	  gene-­‐specific	  control	  of	  inflammation	  by	  TLR4-­‐induced	  chromatin	  modification	  was	  previously	  discovered	  by	  microarray	  analysis	  of	  LPS-­‐induced	  differential	  gene	  expression.	  Unknown	  was	  exactly	  how	  different	  classes	  of	  genes	  are	  regulated	  at	  the	  epigenetic	  level	  by	  specific	  chromatin	  modifiers.	  We	  have	  now	  identified	  the	  LPS-­‐induced,	  PHF8-­‐dependent,	  T-­‐class	  secretome	  at	  the	  more	  physiologically	  relevant	  protein	  level,	  directly	  and	  systematically	  extending	  the	  function	  of	  PHF8	  in	  a	  broad	  range	  of	  biological	  processes	  and	  pathways.	  	  	  Here,	  we	  identified	  PHF8	  as	  a	  major	  regulator	  acute	  inflammation	  that	  modulates	  the	  secretion	  of	  specific	  proteins	  from	  macrophages	  upon	  LPS	  stimulation.	  Our	  proteomic	  screening	  demonstrates	  that	  PHF8	  is	  a	  major	  macrophage	  regulator	  in	  phenotypic	  response	  that	  modulates,	  not	  only	  the	  transcription,	  but	  also	  the	  secretion	  of	  various	  components	  of	  adaptive	  immunity	  activators.	  Moreover,	  this	  report	  is	  the	  first	  to	  show	  evidence	  on	  connecting	  the	  missing	  link	  between	  innate	  and	  adaptive	  
	   161	  
immunity.	  Moreover,	  our	  analysis	  revealed	  various	  signaling	  pathways	  that	  are	  in	  interplay	  with	  LPS-­‐induced	  inflammation	  via	  extracellular	  matrix.	  Further,	  deciphering	  the	  important	  regulators	  of	  T	  cell	  activation	  and	  proliferation	  (Takeda	  &	  Akira,	  2015),	  we	  provided	  evidence	  for	  PHF8-­‐dependent	  regulation	  of	  extracellular	  pathways	  involved	  in	  activation	  of	  adaptive	  immunity	  through	  secretion	  of	  specific	  signaling	  or	  messenger	  molecules:	  selectins	  recruit	  leukocytes,	  chemokines	  activate	  leukocytes	  activating	  integrins,	  and	  the	  integrins	  regulate	  adhesion	  to	  the	  vascular	  endothelium	  (Harburger	  &	  Calderwood,	  2009).	  By	  profiling	  the	  LPS-­‐induced	  PHF8-­‐dependent	  secretome,	  we	  have	  characterized	  novel	  extracellular	  functions	  controlled	  by	  PHF8	  as	  a	  broad	  regulator	  of	  the	  innate	  immunity-­‐dependent	  activation	  of	  adaptive	  immunity.	  This	  discovery	  agrees	  with	  a	  previous	  report	  suggesting	  a	  possible	  adaptive	  immunity	  function	  of	  PHF8	  as	  a	  transcriptional	  activator	  of	  hairy	  and	  enhancer	  of	  split-­‐1	  (HES1),	  Deltex	  1	  (DTX1),	  IL7	  Receptor	  (IL7R),	  Neurogenic	  locus	  notch	  homolog	  protein	  3	  (NOTCH3)	  for	  regulating	  T	  cell	  differentiation	  (Radtke	  et	  al,	  2013).	  Specifically,	  our	  secretome	  data	  indicate	  that	  PHF8	  is	  responsible	  for	  activation	  of	  adaptive	  immunity	  by	  regulating	  the	  secretion	  of	  multiple	  chemoattractants	  as	  well	  as	  multiple	  products	  of	  MHC	  genes	  that	  play	  crucial	  roles	  in	  antigen	  presentation	  to	  T	  cell	  (Agrawal	  &	  Kishore,	  2000).	  Our	  combined	  results	  indicate	  that	  PHF8	  is	  an	  epigenetic	  regulator	  of	  a	  broad	  range	  of	  secreted	  proteins	  that	  are	  crucial	  for	  leukocyte/T	  cell	  activation	  and	  proliferation.	  	  In	  this	  study,	  we	  used	  an	  unbiased	  LFQ	  based	  proteomic	  strategy	  to	  screen	  extracellular	  components,	  the	  most	  significant	  products	  of	  the	  innate	  immunity	  promoting	  adaptive	  immunity,	  of	  LPS-­‐induced	  macrophages.	  First,	  our	  proteomic	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technique	  demonstrated	  that	  unbiased	  screening	  of	  extracellular	  proteins	  can	  help	  us	  identify	  major	  regulators	  of	  signaling	  events	  that	  are	  involved	  in	  cell-­‐cell	  communication.	  This	  technique	  is	  powerful	  in	  showing	  evidence	  for	  extracellular	  functions	  of	  well-­‐known	  signaling	  molecules	  as	  well	  as	  uncovering	  candidates	  for	  novel	  functional	  characterization.	  Moreover,	  this	  technique	  can	  overcome	  many	  issues,	  like	  the	  need	  for	  previous	  knowledge	  or	  highly	  specific	  antibodies,	  associated	  with	  the	  previously	  used	  techniques	  such	  as	  ELISA.	  In	  addition,	  this	  technique	  is	  very	  efficient	  as	  the	  number	  of	  identified	  proteins	  in	  a	  single	  proteomic	  experiment	  surpasses	  all	  the	  previously	  known	  techniques	  of	  extracellular	  screening.	  Further,	  we	  demonstrate	  that	  accurate	  bioinformatic	  analysis	  of	  LFQ	  screening	  helps	  us	  decipher	  the	  functional	  outcome	  of	  the	  signaling	  events	  in	  extracellular	  screening	  while	  it	  also	  provides	  information	  on	  the	  interplay	  of	  various	  signaling	  pathways.	  	  Our	  proteomic	  analysis	  of	  extracellular	  molecules	  of	  LPS-­‐induced	  macrophages	  revealed	  various	  mechanisms	  involved	  in	  the	  regulation	  of	  macrophage	  inflammation.	  This	  method	  can	  also	  be	  used	  in	  identification	  of	  regulators	  of	  various	  other	  signaling	  pathways	  such	  as	  immunity,	  tumor	  formation	  or	  growth,	  stress	  prevention,	  coagulation,	  adhesion,	  cell-­‐cell	  communication,	  and	  vascular	  function	  as	  these	  are	  main	  signaling	  events	  that	  are	  mainly	  regulated	  through	  extracellular	  components	  (Teti,	  1992;	  van	  der	  Pol	  et	  al,	  2012;	  Yáñez-­‐Mó	  et	  al,	  2015).	  Moreover,	  similar	  extracellular	  screening	  of	  cancer	  cells	  or	  tissues	  would	  help	  us	  discover	  deregulated	  signaling	  mechanisms	  that	  are	  significant	  in	  cancer	  formation	  or	  progression.	  This	  method	  can	  also	  be	  used	  to	  identify	  biomarkers	  related	  to	  cancer.	  In	  summary,	  proteomic	  analysis	  of	  extracellular	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proteins	  can	  reveal	  unknown	  mechanisms;	  provide	  information	  on	  disease-­‐specific	  biomarkers,	  and	  deregulated	  signaling	  pathways.	  
FUTURE	  WORK	  Here,	  we	  performed	  an	  extracellular	  proteomic	  screening	  to	  identify	  secretion	  products	  of	  LPS-­‐induced	  macrophages	  to	  reveal	  the	  role	  of	  PHF8	  in	  activation	  of	  adaptive	  immunity.	  The	  accurate	  and	  fast	  validation	  of	  the	  secretome	  data	  can	  be	  achieved	  through	  analysis	  of	  intracellular	  expression	  patterns	  using	  various	  biochemical	  methods	  such	  as	  ELISA,	  proteomics,	  and	  immunoblotting.	  However,	  the	  most	  extensive	  analysis	  of	  expression	  screening	  can	  be	  achieved	  with	  proteomics,	  in	  which	  the	  need	  for	  large	  amounts	  of	  samples	  and	  previous	  knowledge	  of	  proteins	  or	  antibodies	  is	  avoided.	  Thus,	  the	  increase	  in	  not	  only	  the	  secretion	  but	  also	  expression	  of	  the	  regulators	  of	  adaptive	  immunity	  will	  be	  possible	  via	  the	  intracellular	  global	  profiling	  of	  paired	  WT	  and	  PHF8-­‐KD	  that	  were	  either	  left	  unstimulated	  or	  stimulated	  with	  LPS.	  Such	  unbiased	  screening	  will	  help	  us	  understand	  other	  signaling	  events	  that	  are	  in	  interplay	  with	  inflammation	  response	  and	  explain	  the	  relationship	  between	  the	  expression	  and	  secretion	  of	  them.	  Moreover,	  that	  will	  also	  enable	  us	  monitor	  other	  known	  molecules	  that	  are	  involved	  in	  immunosuppression,	  providing	  link	  to	  regulation	  of	  inflammatory	  phenotype	  by	  PP2Ac.	  	  Another	  advantage	  of	  proteomic	  screening	  is	  that	  it	  enables	  us	  to	  detect	  PTMs	  in	  an	  unbiased	  and	  quantitative	  manner.	  By	  performing	  detailed	  sequence	  and	  structural	  analysis	  of	  peptide	  contents	  of	  the	  extracellular	  secretome,	  information	  on	  the	  abundance	  of	  PTMs,	  proteolytic	  shedding,	  and	  alternative	  splicing	  can	  be	  gathered.	  This	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will	  enable	  us	  identify	  signaling	  events	  in	  inflammation	  response	  as	  well	  as	  discover	  mechanisms	  for	  post-­‐translational	  regulation	  of	  important	  inflammatory	  molecules.	  	  
FIGURES	  
	  
Figure	  51	  Schematic	  of	  ELISA	  procedure.	  	  
Abbreviations:	  Ab,	  antibody;	  B,	  biotin	  label;	  C,	  cytokine-­‐secreting	  cells;	  E,	  enzyme-­‐conjugated	  
detection	  protein.	  Adopted	  from	  (Klinman	  &	  Nutman,	  2001).	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Figure	  52	  Scheme	  of	  the	  protein	  profiling	  process	  with	  antibody	  microarrays.	  	  
Proteins	  are	  isolated	  from	  the	  respective	  samples,	  labeled	  and	  applied	  to	  the	  array.	  Adopted	  from	  
(Mustafa	  et	  al,	  2011).	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Figure	  53	  Workflow	  of	  the	  LFQ	  secretome	  analysis	  	  	  	  
	  
Figure	  54	  Immunoblot	  of	  cell	  lysates	  for	  phenotype	  detection	  
Immunoblots	  show	  accurate	  inflammation	  phenotype	  and	  successful	  PHF8-­‐KD	  (Erdoğan	  et	  al,	  
2016).	  
PHF8 PHF8	  (long	  exposure) P-­‐p65	  (S536) p65 P-­‐IκBα γTubulin 
0	   2	   4	   8	   24 shCON shPHF8 0	   2	   4	   8	   24 h	  1μg/mL	  LPS 
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Figure	  55	  Scatter	  plots	  showing	  Pearson	  correlation	  of	  samples.	  	  
The	  replicates	  of	  WT	  (top)	  and	  PHF8KD	  (bottom)	  secretome	  with	  time	  points	  indicated	  0	  (left),	  8	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Figure	  56	  The	  LFQ	  secretome	  heatmap	  	  
The	  LFQ	  secretome	  heatmap	  of	  the	  differentially	  secreted	  proteins	  from	  paired	  WT	  (shCON)	  and	  
PHF8-­‐KD	  (shPHF8)	  RAW	  264.7	  macrophages	  under	  different	  inflammatory	  conditions.	  The	  color	  
key	  (right	  bottom)	  indicates	  LPS-­‐induced	  changes	  (increase	  in	  red,	  decrease	  in	  green)	  in	  secretion	  
of	  proteins	  in	  logarithmic	  scale.	  Time	  points	  are	  indicated	  for	  the	  non-­‐stimulated	  (0	  h)	  and	  
stimulated	  cells	  (8	  and	  24	  h).	  Two	  PHF8-­‐dependent	  classes	  of	  proteins	  are	  highlighted	  with	  green	  
and	  yellow	  demonstrating	  T	  class	  (Left),	  and	  NT	  class	  (Right)	  PHF8-­‐dependent	  secretome,	  
respectively,	  on	  the	  cluster	  column	  (Erdoğan	  et	  al,	  2016).	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Figure	  57	  Comparison	  of	  the	  secretome	  to	  previous	  studies	  
Top	  panel	  shows	  the	  comparison	  of	  all	  secreted	  proteins	  while	  the	  bottom	  panel	  shows	  the	  
comparison	  of	  LPS-­‐induced	  secreted	  proteins.	  The	  present	  study	  of	  the	  secretome	  is	  represented	  
by	  a	  light	  grey	  circle	  while	  the	  Liu	  et	  al.(Liu	  et	  al,	  2014)	  and	  Meissner	  et	  al.(Meissner	  et	  al,	  2013)	  
secretome	  are	  represented	  by	  red	  and	  blue	  circles,	  respectively	  (Erdoğan	  et	  al,	  2016).	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Figure	  59	  T-­‐class	  PHF8-­‐dependent	  KEGG	  pathways	  (Erdoğan	  et	  al,	  2016).	  	  
	  
Figure	  60	  Processes	  associated	  with	  activated	  PHF8.	  	  
DAVID	  analysis	  identified	  biological	  processes	  associated	  with	  activated	  PHF8	  peaks	  (Wang	  et	  al,	  
2014a).	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Figure	  62	  Detailed	  map	  of	  the	  human	  MHC	  
The	  organization	  of	  the	  class	  I,	  class	  II,	  and	  class	  III	  regions	  of	  the	  human	  MHC	  are	  shown,	  with	  
approximate	  genetic	  distances	  given	  in	  thousands	  of	  base	  pairs	  (kb).	  The	  genes	  shown	  in	  the	  class	  
III	  region	  encode	  the	  complement	  proteins	  C4	  (two	  genes,	  shown	  as	  C4A	  and	  C4B),	  C2	  and	  factor	  B	  
(shown	  as	  Bf)	  as	  well	  as	  genes	  that	  encode	  the	  cytokines	  tumor	  necrosis	  factor-­‐α	  (TNF)	  and	  
lymphotoxin	  (LTA,	  LTB).	  The	  genes	  are	  colour	  coded,	  with	  the	  MHC	  class	  I	  genes	  being	  shown	  in	  
red,	  except	  for	  the	  MIC	  genes,	  which	  are	  shown	  in	  blue;	  these	  are	  distinct	  from	  the	  other	  class	  I-­‐
like	  genes	  and	  are	  under	  different	  transcriptional	  control.	  The	  MHC	  class	  II	  genes	  are	  shown	  in	  
yellow.	  Genes	  in	  the	  MHC	  region	  which	  have	  immune	  functions	  but	  are	  not	  related	  to	  the	  MHC	  
class	  I	  and	  class	  II	  genes	  are	  shown	  in	  purple.	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Figure	  64	  The	  overall	  protein-­‐protein	  interaction	  network	  of	  the	  T-­‐class	  secretome	  	  
PPI	  covers	  proteins	  that	  belong	  to	  the	  highly	  enriched	  GOBP/GOCC/GOMF	  is	  composed	  mostly	  of	  
response	  signaling	  BP	  (red	  nodes)	  (Erdoğan	  et	  al,	  2016).	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Figure	  65	  IPA	  network	  analysis	  of	  T-­‐class	  secretome	  
IPA	  reveals	  the	  interplaying	  pathways	  regulated	  by	  T-­‐class	  PHF8-­‐dependent	  secretome	  in	  cross-­‐
talk	  with	  high	  confidence	  (p<0.05)	  (Erdoğan	  et	  al,	  2016).	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Figure	  66	  PHF8	  regulates	  the	  mRNA	  expression	  of	  T	  cell	  activating	  proteins	  
mRNA	  expression	  of	  the	  selected	  genes	  that	  are	  related	  to	  antigen	  processing	  and	  presentation,	  
and	  T	  cell	  activation	  in	  paired	  WT	  (shCON)	  and	  PHF8-­‐KD	  (shPHF8)	  RAW	  cells.	  The	  heatmap	  
showing	  the	  quantitative	  secretion	  pattern	  of	  these	  proteins	  found	  in	  the	  LFQ	  secretome	  analysis	  
is	  given	  on	  the	  right	  (Erdoğan	  et	  al,	  2016).	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Figure	  67	  T	  cell	  activation	  markers	  
The	  histograms	  obtained	  from	  the	  T-­‐cell	  activation	  assays	  demonstrates	  the	  PHF8	  dependence	  of	  
T-­‐cell	  activation.	  CD8+	  T	  cells	  isolated	  from	  P14	  transgenic	  mouse	  were	  co-­‐cultured	  with	  either	  
WT	  (grey	  histograms)	  or	  PHF8-­‐KD	  (histograms	  in	  black	  line)	  RAW	  cells	  that	  were	  LPS	  stimulated	  
with	  1μg/ml	  LPS	  for	  0,	  8,	  and	  24	  h	  respectively.	  The	  population	  distributions	  of	  multiple	  surface	  
markers	  of	  T	  cell	  activation	  CD25,	  CD44,	  and	  CD69	  were	  analyzed	  by	  flow	  cytometry	  (Erdoğan	  et	  
al,	  2016).	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Figure	  68	  T	  cell	  proliferation	  assay	  
The	  flow	  cytometric	  assay	  demonstrates	  the	  PHF8	  dependence	  of	  T-­‐cell	  proliferation.	  CD8+	  T	  cells	  
isolated	  from	  P14	  transgenic	  mouse	  were	  labeled	  with	  CFSE,	  then	  co-­‐cultured	  with	  either	  WT	  
(top)	  or	  PHF8-­‐KD	  (bottom)	  RAW	  cells	  that	  were	  LPS	  stimulated	  with	  1μg/ml	  LPS	  for	  0,	  8,	  and	  24	  h	  
respectively.	  The	  numbers	  on	  the	  proliferation	  tables	  show	  the	  percentage	  of	  every	  division	  of	  
proliferated	  cells	  among	  total	  CD8+	  T	  cells	  (Erdoğan	  et	  al,	  2016).	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CHAPTER	  5:	  PHF8	  AND	  G9A	  WORK	  ANTAGONISTICALLY	  TO	  REGULATE	  THE	  
SECRETION	  OF	  ‘TOLERIZABLE’	  PROTEINS	  IN	  A	  PHENOTYPE-­‐DEPENDENT	  MANNER	  
OVERVIEW	  The	  inflammation	  response	  is	  a	  tightly	  regulated	  process,	  whose	  phenotype	  is	  determined	  by	  the	  gene-­‐specific	  transcriptional	  regulation.	  G9a	  is	  known	  as	  one	  of	  the	  essential	  epigenetic	  modulators	  of	  transcriptional	  suppression	  in	  ET	  through	  methylation	  of	  H3K9	  (Liu	  et	  al,	  2014).	  Here,	  as	  oppose	  to	  G9a,	  we	  identified	  PHF8	  as	  the	  positive	  regulator	  of	  acute	  inflammation	  removing	  the	  methyl	  mark	  on	  the	  H3K9me1/2,	  the	  same	  site	  that	  G9a	  methylates.	  Our	  comparison	  analysis	  of	  two	  separate	  secretome	  studies	  revealed	  that	  PHF8	  and	  G9a	  antagonistically	  regulate	  the	  transcription	  and	  translation	  of	  the	  same	  set	  of	  inflammatory	  genes.	  Our	  results	  shed	  light	  on	  the	  phenotypic	  regulation	  of	  bacterial	  inflammation	  response	  downstream	  NFκB	  pathway.	  	  Mechanistically,	  we	  found	  that	  inflammatory	  phenotype	  is	  determined	  by	  the	  chromatin	  plasticity	  (active	  PHF8	  versus	  active	  G9a)	  through	  a	  transient	  switch	  turned	  off	  by	  PP2Ac	  inhibiting	  PHF8	  and	  activating	  G9a	  for	  successful	  immunosuppression	  in	  ET.	  In	  summary,	  PHF8,	  the	  eraser	  of	  H3K9me1/2,	  is	  the	  primary	  driver	  for	  establishing	  the	  transcriptionally	  active	  state	  of	  the	  gene-­‐specific	  chromatin	  in	  acutely	  inflamed	  cells	  as	  oppose	  to	  enrichment	  of	  silent	  chromatin	  with	  H3K9me1/2	  by	  G9a,	  the	  writer	  of	  H3K9me1/2.	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INTRODUCTION	  
Regulation	  of	  K9me-­‐mediated	  Macrophage	  Inflammation	  Response	  As	  the	  first	  histone	  PTM	  site	  regulating	  the	  phenotypic	  inflammation	  response,	  H3K9	  plays	  a	  central	  role	  in	  the	  epigenetic	  regulation	  through	  methylation	  or	  acetylation.	  	  H3K9	  methylation	  achieves	  successive	  repression	  of	  pro-­‐inflammatory	  genes	  by	  (1)	  influencing	  DNA	  methylation,	  (2)	  formation	  of	  heterochromatin,	  (3)	  prohibiting	  the	  activating	  H3K9	  acetylation,	  (4)	  actively	  recruiting	  transcriptional	  repressors	  of	  the	  HP1	  family,	  and	  (5)	  preventing	  the	  recruitment	  of	  RNA-­‐PII	  (Mehta	  &	  Jeffrey,	  2015).	  Hypermethylation	  of	  H3K9	  has	  been	  observed	  in	  the	  regulation	  of	  inflammatory	  processes,	  such	  as	  TNFα	  silencing	  in	  ET	  in	  THP1	  monocytes	  (El	  Gazzar	  et	  al,	  2008),	  transcriptional	  state	  of	  some	  of	  the	  LPS-­‐induced	  promoters	  in	  human	  dendritic	  cells	  (Saccani	  &	  Natoli,	  2002),	  IL-­‐1β	  promoter	  in	  the	  severe	  systemic	  inflammation	  (Chen	  et	  al,	  2009),	  and	  IFNβ-­‐inducible	  antiviral	  genes	  (Fang	  et	  al,	  2012).	  The	  methylation	  state	  of	  H3K9	  is	  dynamically	  regulated	  by	  specific	  KMTs,	  including	  G9a,	  and	  KDMs,	  including	  PHF8	  (Figure	  69).	  On	  the	  other	  hand,	  H3K9	  acetylation	  has	  been	  reported	  in	  the	  regulation	  of	  inflammation	  response.	  H3K9	  acetylation	  by	  HATs	  causes	  inhibition	  of	  HDAC	  activity	  as	  well	  as	  activation	  of	  transcription	  of	  pro-­‐inflammatory	  genes	  IL1,	  IL2,	  IL8,	  and	  IL12	  (Villagra	  et	  al,	  2010;	  Yang	  et	  al,	  2009).	  In	  addition,	  acetylation	  of	  H3K9	  along	  with	  phosphorylation	  of	  H3S10	  is	  involved	  in	  the	  positive	  regulation	  of	  pro-­‐inflammatory	  signaling	  (Saccani	  &	  Natoli,	  2002)	  and	  contributes	  to	  the	  recruitment	  of	  RNA-­‐PII	  through	  decreased	  H3K9	  methylation	  (Sánchez-­‐Pernaute	  et	  al,	  2008).	  Moreover,	  this	  phosphoacetylation	  induces	  acetylation	  of	  H3K14,	  which	  in	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turn	  enhances	  NFκB	  binding	  to	  promoters	  of	  pro-­‐inflammatory	  cytokines	  (Barnes,	  2009;	  Yamamoto	  et	  al,	  2003).	  In	  ET,	  this	  pro-­‐inflammatory	  effect	  is	  reversed	  for	  successful	  suppression	  of	  NFκB	  target	  genes	  via	  increased	  HDAC	  activity	  (Ashburner	  et	  al,	  2001;	  Aung	  et	  al,	  2006;	  Hamon	  &	  Cossart,	  2008;	  Zhong	  et	  al,	  2002).	  During	  immunosupression,	  HDACs	  are	  recruited	  by	  corepressor	  complexes	  or	  transcription	  factors	  such	  as	  NFκB,	  STATs,	  and	  Forkhead	  box	  P3	  (FOXP3)	  (Villagra	  et	  al,	  2010).	  These	  observations	  suggest	  that	  dynamic	  changes	  of	  the	  H3K9	  PTMs	  constitute	  the	  core	  of	  the	  epigenetic	  regulator	  of	  inflammation	  phenotype.	  	  
G9a	  Histone	  Methyltransferase	  G9a	  is	  a	  major	  me1	  and	  me2	  KMT	  of	  euchromatin	  (Tachibana	  et	  al,	  2002).	  G9a	  methylates	  H1,	  H3K9	  and	  H3K27	  in	  vitro	  and	  in	  vivo	  (Tachibana	  et	  al,	  2001;	  Tachibana	  et	  al,	  2005;	  Trojer	  et	  al,	  2009;	  Weiss	  et	  al,	  2010;	  Wu	  et	  al,	  2011).	  G9a	  is	  a	  member	  of	  the	  Suv39h1	  subgroup	  of	  SET	  domain	  containing	  proteins	  (Shinkai	  &	  Tachibana,	  2011)	  as	  it	  contains	  an	  evolutionary	  conserved	  SET	  domain	  involved	  in	  methyltransferase	  activity	  and	  an	  ankyrin	  repeat	  domain	  for	  protein-­‐protein	  interactions	  (Figure	  70)	  (Shankar	  et	  al,	  2013).	  The	  SET	  domain	  is	  involved	  in	  the	  transfer	  of	  methyl	  groups	  from	  SAM	  to	  ε	  amino	  group	  of	  target	  lysine.	  The	  commercially	  available	  inhibitors	  such	  of	  G9a	  act	  by	  binding	  to	  the	  substrate-­‐binding	  pocket	  to	  make	  it	  inaccessible	  (Chang	  et	  al,	  2010;	  Vedadi	  et	  al,	  2011).	  	  G9a	  recognizes	  a	  7-­‐aminoacid	  peptide	  with	  RK/ARK	  consensus	  sequence,	  such	  as	  the	  amino	  acid	  residues	  6-­‐TARKSTG-­‐12	  of	  H3	  (Chin	  et	  al,	  2007;	  Chin	  et	  al,	  2005;	  Rathert	  et	  al,	  2008).	  Within	  the	  consensus	  sequence,	  arginine	  residue	  adjacent	  to	  the	  target	  lysine	  is	  the	  requirement	  for	  G9a	  activity.	  Moreover,	  G9a	  prefers	  a	  hydrophilic	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residue	  at	  positions	  1	  and	  5,	  a	  small	  amino	  acid	  like	  Alanine	  at	  position	  2,	  and	  a	  hydrophobic	  residue	  at	  position	  6	  of	  the	  target	  peptide	  (Rathert	  et	  al,	  2008).	  In	  addition,	  phosphorylation	  of	  S10	  and	  T11	  on	  H3	  impairs	  the	  methylation	  activity	  of	  G9a.	  The	  substrate	  specificity	  of	  G9a	  makes	  it	  a	  demethylase	  for	  not	  only	  histones	  but	  also	  various	  non-­‐histone	  proteins	  such	  as	  p53,	  CEBP,	  and	  Myoblast	  determination	  protein	  (MyoD)	  (Shinkai	  &	  Tachibana,	  2011).	  Methylation	  by	  G9a	  negatively	  affects	  the	  transcription	  activity	  of	  these	  transcription	  factors.	  On	  the	  other	  hand,	  G9a	  may	  act	  as	  a	  transcriptional	  activator,	  independently	  of	  its	  methyltransferase	  activity,	  based	  on	  its	  interacting	  partners	  (Figure	  71)	  Moreover,	  G9a	  acts	  as	  both	  activator	  and	  suppressor	  of	  transcriptional	  activity	  of	  Hypoxia-­‐inducible	  factor	  1-­‐alpha	  (HIF1-­‐α)	  through	  alternative	  methylation	  of	  either	  histone	  targets	  or	  non-­‐histone	  targets	  (Figure	  72)	  (Casciello	  et	  al,	  2015).	  	  In	  addition	  to	  having	  the	  role	  to	  regulate	  transcription	  through	  H3K9	  methylation,	  G9a	  is	  specifically	  involved	  in	  gene-­‐specific	  regulation	  of	  various	  other	  biological	  processes	  such	  as	  mouse	  development	  (Tachibana	  et	  al,	  2002;	  Tachibana	  et	  al,	  2005),	  neuronal	  function	  (Kramer	  et	  al,	  2011;	  Schaefer	  et	  al,	  2009),	  ATRA	  response	  (Son	  et	  al,	  2012),	  rRNA	  transcription,	  autophagy	  (Artal-­‐Martinez	  de	  Narvajas	  et	  al,	  2013),	  cell	  migration	  (Chen	  et	  al,	  2010;	  Dong	  et	  al,	  2012),	  and	  cell	  growth	  in	  cancer	  invasion	  (Chen	  et	  al,	  2010;	  Kondo	  et	  al,	  2008);	  thus,	  it	  may	  be	  a	  potential	  target	  for	  associated	  diseases	  (Casciello	  et	  al,	  2015;	  Kelly	  et	  al,	  2010;	  Shankar	  et	  al,	  2013;	  Suzuki	  et	  al,	  2014).	  More	  importantly,	  G9a	  regulates	  immune	  responses	  (Thomas	  et	  al,	  2008),	  (Yuan	  et	  al,	  2007),	  T-­‐cell	  development	  (Lehnertz	  et	  al,	  2003),	  and	  proviral	  silencing	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(Dong	  et	  al,	  2008;	  Leung	  et	  al,	  2011),	  indicating	  its	  significance	  in	  the	  gene-­‐specific	  regulation	  of	  immunity.	  	  
G9a	  in	  regulation	  of	  immunity	  G9a	  activity	  is	  a	  major	  contributor	  of	  the	  ET	  due	  to	  silencing	  of	  the	  promoters	  of	  “T-­‐class”	  genes	  (El	  Gazzar	  et	  al,	  2008).	  During	  ET,	  G9a	  is	  involved	  in	  the	  recruitment	  of	  HP1	  to	  RelB	  for	  suppression	  of	  NFκB	  target	  genes	  (Chan	  et	  al,	  2005;	  Chen	  et	  al,	  2009;	  El	  Gazzar	  et	  al,	  2007).	  In	  addition,	  G9a-­‐HP1	  complex	  subsequently	  recruits	  DNMT3	  to	  those	  target	  promoters	  for	  CpG	  methylation	  of	  the	  “T-­‐class”	  genes	  in	  ET	  (El	  Gazzar	  et	  al,	  2008).	  Recently	  G9a	  was	  also	  discovered	  as	  a	  regulator	  of	  major	  co-­‐repressor	  complexes	  in	  ET	  of	  macrophages,	  indicating	  its	  importance	  in	  the	  gene-­‐specific	  epigenetic	  control	  of	  the	  ET	  response	  (Liu	  et	  al,	  2014).	  In	  addition	  to	  TNF	  target	  genes,	  the	  transcription	  of	  interleukin	  and	  interfeuron-­‐inducible	  genes	  are	  regulated	  by	  G9a	  activity	  (Chen	  et	  al,	  2009;	  Fang	  et	  al,	  2012;	  Gyory	  et	  al,	  2004).	  The	  role	  of	  G9a	  in	  regulation	  of	  inflammation	  response	  is	  not	  restricted	  to	  innate	  immunity,	  adaptive	  immunity	  is	  also	  regulated	  by	  G9a	  through	  regulation	  of	  lymphocyte	  development	  and	  activation	  (Thomas	  et	  al,	  2008),	  gene	  expression	  during	  CD4+	  T	  helper	  (Th)	  cell	  differentiation	  and	  function	  (Lehnertz	  et	  al,	  2010),	  and	  lymphocyte	  migration	  (Zhang	  et	  al,	  2015).	  	  As	  they	  share	  a	  common	  methylation/demethylation	  target,	  PHF8	  and	  G9a	  may	  regulate	  the	  same	  set	  of	  genes	  in	  an	  opposite	  manner.	  In	  this	  system,	  PHF8	  acts	  as	  an	  activator	  of	  transcription	  through	  demethylation	  of	  repressive	  H3K9me1/2	  while	  G9a	  acts	  as	  a	  suppressor	  through	  methylation	  of	  H3K9.	  As	  PHF8	  is	  a	  positive	  regulator	  of	  the	  LPS-­‐induced	  gene	  expression,	  here	  we	  explored	  whether	  the	  H3K9	  KMT	  G9a	  works	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antagonistically	  to	  PHF8	  to	  negatively	  regulate	  innate	  immune	  response.	  To	  assess	  functional	  relevant	  targets,	  we	  compared	  G9a-­‐dependent	  and	  PHF8-­‐dependent	  macrophage	  secretome	  products	  in	  ET	  and	  in	  acute	  inflammation,	  respectively.	  Our	  comparison	  analysis	  revealed	  that	  a	  big	  portion	  of	  inflammatory	  genes	  with	  phenotype-­‐specific	  secretion	  pattern	  was	  epigenetically	  regulated	  by	  the	  differential	  activities	  of	  PHF8	  and	  G9a	  in	  LPS-­‐induced	  macrophages.	   	  
MATERIALS	  AND	  METHODS	  
Bioinformatic	  Analysis	  Mass	  spectra	  were	  analyzed	  using	  MaxQuant	  software	  version	  1.5.0.30	  using	  the	  Andromeda	  search	  engine	  against	  the	  mouse	  Uniprot	  sequence	  database	  including	  248	  common	  contaminants	  and	  reversed	  versions	  of	  all	  sequences	  (Cox	  &	  Mann,	  2008;	  Cox	  et	  al,	  2011).	  Maximum	  allowed	  mass	  error	  was	  set	  to	  4.5	  ppm	  for	  monoisotopic	  precursor	  ions	  and	  0.5	  Da	  for	  MS/MS	  peaks.	  Enzyme	  specificity	  was	  set	  to	  trypsin	  and	  a	  maximum	  of	  two	  missed	  cleavages	  were	  allowed.	  We	  set	  carbamidomethylcysteine	  as	  a	  fixed	  modification,	  and	  N-­‐terminal	  acetylation	  and	  methionine	  oxidation	  as	  variable	  modifications.	  For	  identification	  of	  proteins,	  we	  kept	  requirements	  of	  at	  least	  one	  unique	  or	  razor	  peptide	  per	  protein	  group.	  LFQ	  was	  performed	  in	  in	  MaxQuant	  using	  the	  built	  in	  XIC-­‐based	  fast	  LFQ	  algorithm	  (Luber	  et	  al,	  2010).	  We	  set	  the	  required	  false	  positive	  rate	  as	  5%	  at	  the	  peptide	  and	  1%	  at	  the	  protein	  level,	  and	  the	  minimum	  required	  peptide	  length	  as	  7	  amino	  acids.	  Contaminants,	  reverse	  identification	  and	  proteins	  only	  identified	  by	  site	  were	  excluded	  from	  further	  data	  analysis.	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For	  each	  LPS	  treated	  sample	  of	  a	  given	  phenotype	  and	  time	  point,	  ratios	  were	  calculated	  from	  the	  individual	  protein	  LFQ	  intensities	  and	  the	  corresponding	  median	  LFQ	  intensities	  of	  the	  untreated	  sample.	  Missing	  values	  were	  imputed	  only	  for	  untreated	  samples	  by	  random	  sampling	  from	  a	  generated	  narrow	  normal	  distribution	  around	  the	  detection	  limit	  for	  proteins.	  The	  calculated	  ratios	  were	  log2	  normalized.	  In	  order	  to	  retrieve	  those	  proteins	  with	  a	  statistically	  different	  quantitative	  ratio	  among	  different	  LPS	  stimulation	  length	  we	  used	  multiple	  samples	  statistic	  analysis	  via	  ANOVA	  with	  a	  permutation-­‐based	  FDR	  controlled	  filter.	  The	  p-­‐value	  cut-­‐off	  was	  calculated	  at	  5%	  FDR.	  This	  multiple	  samples	  test	  technique	  does	  not	  capture	  proteins	  with	  no	  dynamic	  (i.e.	  stable	  over	  time)	  since	  they	  are	  of	  no	  interest.	  Further,	  to	  understand	  the	  role	  of	  antagonistic	  PHF8-­‐G9a-­‐dependent	  gene	  regulation	  of	  LPS-­‐induced	  inflammation	  and	  interacting	  signaling	  pathways,	  we	  comprehensively	  analyzed	  the	  functional	  categories	  of	  the	  components	  that	  show	  both	  increased	  secretion	  in	  G9a-­‐inhibitor	  treated	  BMDM	  cells	  after	  prolonged	  LPS	  stimulation	  and	  decreased	  secretion	  in	  PHF8-­‐KD	  cells	  after	  acute	  LPS	  stimulation	  using	  David	  bioinformatics	  database	  in	  the	  context	  of	  GOBP,	  GOCC,	  and	  GOMF	  (Huang	  et	  al,	  2009).	  In	  addition,	  using	  STRING	  database,	  we	  analyzed	  the	  constituents	  of	  the	  common	  secretome	  to	  visualize	  the	  antagonistically	  regulated	  pathways	  of	  inflammatory	  response	  (Snel	  et	  al,	  2000).	  Further,	  we	  validated	  these	  results	  with	  the	  Upstream	  Regulator	  Analysis	  (URA)	  in	  IPA.	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RESULTS	  
PHF8	  and	  G9a	  regulate	  a	  subset	  of	  inflammatory	  protein	  secretion	  in	  LPS-­‐induced	  
macrophages	  in	  a	  phenotype-­‐dependent	  manner	  PHF8	  is	  a	  G9a	  antagonist	  that	  regulates	  gene-­‐specific	  chromatin	  states	  in	  acute	  inflammation	  as	  G9a	  is	  the	  writer	  of	  H3K9me1/2	  in	  chronically	  inflamed	  macrophages	  while	  PHF8	  is	  the	  H3K9me1/2	  eraser	  in	  acutely	  inflamed	  cells.	  	  To	  understand	  differential	  regulation	  of	  inflammatory	  response	  by	  G9a	  in	  ET	  versus	  PHF8	  in	  acute	  inflammation,	  we	  compared	  the	  ET-­‐specific	  G9a-­‐dependent	  secretome	  (Liu	  et	  al,	  2014)	  with	  that	  of	  PHF8	  during	  acute	  inflammation[1].	  For	  this	  comparison	  we	  performed	  the	  MaxQuant	  database	  search	  with	  both	  sets	  of	  RAW	  data	  for	  accurate	  and	  precise	  normalization	  of	  the	  LFQ.	  Moreover,	  to	  understand	  LPS-­‐induced	  phenotype-­‐specific	  secretome	  that	  are	  antagonistically	  regulated	  by	  the	  activities	  of	  PHF8	  and	  G9a,	  in	  acute	  inflammation	  and	  ET,	  respectively,	  we	  trimmed	  the	  dataset	  to	  proteins	  showing	  increased	  secretion	  pattern	  in	  G9a-­‐inhibitor	  UNC0638	  treated	  BMDM	  cells	  compared	  to	  that	  of	  WT	  after	  prolonged	  LPS	  stimulation	  and	  decreased	  secretion	  pattern	  in	  PHF8-­‐KD	  cells	  compared	  to	  that	  of	  WT	  after	  acute	  LPS	  stimulation,	  i.e.	  identical	  proteins,	  which	  were	  secreted	  in	  an	  opposite	  manner.	  This	  filtering	  gave	  us	  373	  proteins	  whose	  secretion	  was	  antagonistically	  regulated	  by	  PHF8	  or	  G9a	  in	  a	  phenotype-­‐dependent	  manner	  and	  we	  refer	  to	  this	  set	  of	  proteins	  as	  ‘PHF8-­‐G9a	  common	  secretome’	  throughout	  this	  report	  (Appendix	  6).	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PHF8	  is	  a	  G9a-­‐antagonist	  that	  regulates	  the	  inflammatory	  phenotype	  in	  acute	  
inflammation	  
	  To	  understand	  the	  role	  of	  antagonistic	  PHF8-­‐G9a-­‐dependent	  gene	  regulation	  of	  LPS-­‐induced	  inflammation	  and	  interacting	  signaling	  pathways,	  we	  comprehensively	  analyzed	  the	  functional	  categories	  of	  the	  PHF8-­‐G9a	  common	  secretome	  using	  David	  Bioinformatics	  database	  for	  GOBP,	  GOMF,	  and	  GOCC	  enrichment.	  With	  this	  analysis,	  we	  identified	  41,	  33,	  25,	  21,	  17,	  14,	  and	  11	  secreted	  proteins,	  respectively,	  belonging	  to	  translation,	  immune	  response,	  defense	  response,	  response	  to	  wounding,	  inflammatory	  response,	  cell	  proliferation,	  and	  chemotaxis	  GOBPs	  (Figure	  73).	  Moreover,	  the	  wound	  response	  proteins	  were	  in	  common	  with	  inflammatory	  response	  GOBP.	  Some	  of	  these	  proteins	  function	  in	  cell	  proliferation	  and	  macrophage	  cell	  fate	  decision.	  Further,	  secretion	  of	  many	  proteins	  associated	  with	  cell	  adhesion,	  cell	  migration,	  and	  movement-­‐associated	  cytoskeleton	  was	  regulated	  antagonistically	  by	  the	  inflammatory-­‐phenotypic	  PHF8	  versus	  G9a	  activity.	  	  In	  agreement	  with	  the	  GOBP	  analysis,	  GOMF	  enrichment	  revealed	  31,	  17,	  16,	  and	  7	  proteins	  involved	  in	  RNA	  binding,	  structural	  constitutes	  of	  ribosome,	  cytokine	  activity,	  and	  chemokine	  acivity,	  respectively	  (Figure	  74).	  More	  importantly,	  the	  identification	  of	  secretion	  of	  many	  cytokines,	  chemokines,	  complement	  factors,	  CD14,	  and	  CD74	  antigens	  in	  PHF8-­‐G9a	  common	  secretome	  indicates	  PHF8	  and	  G9a	  are	  major	  regulators	  of	  inflammatory-­‐state	  specific	  proteins/markers	  in	  macrophages.	  Specifically,	  immune	  signaling	  molecules,	  select	  cytokines/chemokines,	  and	  antigen	  processing/presentation	  factors	  that	  were	  identified	  as	  major	  components	  of	  the	  T-­‐class	  PHF8-­‐dependent	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secretome	  were	  identified	  in	  the	  PHF8-­‐G9a	  common	  secretome,	  indicating	  that	  PHF8	  is	  a	  G9a-­‐antagonist	  in	  acute	  inflammation.	  GOCC	  enrichment	  revealed	  proteins	  involved	  in	  translational	  initiation,	  and	  ribosome	  	  (Figure	  74);	  this	  observation	  coincided	  with	  the	  fact	  that	  the	  H3K9me1/2	  eraser	  PHF8	  acts	  as	  a	  transcriptional/translational	  activator	  to	  regulate	  ribosomal	  RNA	  transcription	  (Feng	  et	  al,	  2010).	  In	  addition	  inflammatory-­‐phenotypic	  compartments	  such	  as	  the	  lysosome,	  Golgi-­‐associated	  vesicles,	  and	  MHC	  complexes	  were	  identified	  in	  the	  GOCC	  enrichment	  (Figure	  75);	  more	  importantly,	  all	  the	  PHF8-­‐dependent	  MHC	  complex	  components	  were	  commonly	  identified	  in	  the	  G9a-­‐suppressed	  secretome.	  
PHF8	  and	  G9a	  are	  antagonistic	  regulators	  of	  translation,	  immune	  response,	  and	  
cell	  adhesion/communication	  To	  uncover	  the	  pathways	  antagonistically	  regulated	  by	  acutely	  active	  PHF8	  versus	  chronically	  active	  G9a,	  we	  performed	  STRING	  PPI	  analysis	  on	  the	  dataset	  of	  the	  PHF8-­‐G9a	  common	  secretome.	  	  This	  analysis	  revealed	  multiple,	  interconnected	  sub-­‐networks	  linking	  the	  signaling	  of	  immune	  response,	  translational	  regulation,	  cell	  adhesion/communication,	  nucleotide	  binding,	  and	  lysosome/proteasome	  (Figure	  76).	  Further,	  IPA	  canonical	  pathway	  analysis	  revealed	  cell	  growth,	  cell	  movement,	  cell	  death,	  and	  cell-­‐cell	  interaction	  as	  macrophage	  response-­‐dependent	  pathways	  regulated	  by	  G9a	  and	  PHF8	  antagonistically	  (Figure	  77).	  Moreover,	  we	  identified	  interconnected	  pathways	  of	  the	  PHF8-­‐G9a	  common	  secretome,	  including	  antigen	  presentation,	  the	  communication	  between	  innate	  and	  adaptive	  immune	  cells,	  IL-­‐8	  signaling,	  differential	  regulation	  of	  cytokine	  production,	  adhesion,	  mTOR,	  and	  Eukaryotic	  initiation	  factor	  2	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(EIF2)	  signaling	  indicating	  that	  PHF8	  and	  G9a	  regulate	  immune	  response	  antagonistically	  through	  affecting	  the	  interplay	  between	  these	  pathways	  (Figure	  78).	  	  Finally,	  URA	  in	  IPA	  validated	  the	  regulation	  of	  inflammatory	  pathways	  functioning	  in	  inflammatory	  response,	  cell	  movement,	  chemotaxis,	  homing	  of	  leukocytes,	  migration	  of	  leukocytes,	  migration	  of	  phagocytes,	  and	  recruitment	  of	  neutrophils	  through	  analysis	  of	  the	  secretion	  pattern	  of	  common	  PHF8-­‐G9a	  secretome	  and	  their	  previously	  characterized	  upstream	  regulators	  (Figure	  79).	  Moreover,	  the	  URA	  demonstrated	  that	  these	  outcomes	  are	  explained	  by	  the	  TLR-­‐dependent	  signaling,	  supporting	  the	  specificity	  of	  the	  secretome	  analysis.	  	  These	  results	  indicated	  that,	  in	  an	  opposing	  manner,	  G9a	  and	  PHF8	  regulate	  the	  secretion	  of	  the	  same	  set	  of	  LPS-­‐inducible	  proteins	  through	  modulating	  the	  methylation	  level	  of	  H3K9	  in	  their	  associated	  chromatin.	  	  
DISCUSSION	  This	  study	  is	  the	  first	  to	  provide	  the	  evidence	  for	  a	  novel	  function	  of	  PHF8	  in	  chromatin-­‐associated	  inflammation	  control	  and	  the	  subsequent	  activation	  of	  adaptive	  immunity.	  In	  agreement	  with	  the	  previous	  discovery	  of	  ET-­‐specific	  G9a-­‐dependent	  modulation	  of	  silent	  chromatin	  enriched	  with	  the	  transcriptionally	  repressive	  histone	  H3K9me2	  code	  (Liu	  et	  al,	  2014),	  we	  now	  further	  reveal	  that	  PHF8,	  the	  eraser	  of	  H3K9me1/2,	  is	  the	  primary	  driver	  for	  establishing	  the	  transcriptionally	  active	  state	  of	  the	  gene-­‐specific	  chromatin	  in	  acutely	  inflamed	  cells.	  	  For	  the	  first	  time,	  our	  post-­‐
translational	  level	  data	  indicated	  that	  acutely	  active	  PHF8	  promotes	  the	  LPS-­‐induced	  secretion	  of	  proteins	  in	  common	  with	  the	  ones	  suppressed	  by	  G9a	  under	  the	  chronic	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inflammatory	  condition,	  we	  conclude	  that	  PHF8	  is	  the	  antagonist	  of	  G9a	  in	  regulating	  the	  gene-­‐specific	  chromatin	  state	  under	  the	  acute	  inflammatory	  condition.	  	  The	  chromatin	  plasticity	  that	  determines	  the	  phenotypic	  outcome	  by	  differential	  activities	  of	  PHF8	  and	  G9a	  is	  shown	  in	  Figure	  80.	  This	  plasticity	  mechanism	  regulating	  inflammatory	  phenotype-­‐specific	  chromatin	  modifications	  in	  transcriptional	  regulation	  of	  select	  classes	  of	  genes	  involved	  the	  acute	  inflammation-­‐specific	  activity	  of	  PHF8	  and	  ET-­‐specific	  activity	  of	  G9a.	  Our	  model	  shows	  that	  KDM	  activity	  of	  PHF8	  is	  modulated	  through	  reversible	  phosphorylation	  by	  differentially	  activated	  kinases	  or	  protein	  phosphatase(s)	  under	  different	  inflammatory	  conditions.	  LPS-­‐induced	  acute	  inflammation	  of	  macrophages	  leads	  to	  H3K9me1/2	  demethylation	  by	  PHF8,	  which	  subsequently	  increases	  the	  secretion	  of	  T-­‐class	  proteins.	  With	  prolonged	  LPS	  exposure,	  as	  in	  ET,	  PHF8	  KDM	  activity	  is	  suppressed,	  likely	  by	  PP2Ac-­‐mediated	  dephosphorylation.	  This	  leads	  to	  decrease	  in	  secretion	  of	  those	  T-­‐class	  proteins.	  In	  addition,	  G9a	  activity	  is	  induced	  in	  the	  ET	  macrophages,	  contributing	  to	  the	  suppressed/silent	  state	  of	  the	  chromatin	  (Liu	  et	  al,	  2014).	  Thus,	  through	  targeting	  similar	  sets	  of	  proteins	  involved	  in	  phenotype-­‐specific	  inflammatory	  response,	  both	  PHF8	  and	  G9a	  are	  the	  regulators	  of	  the	  LPS-­‐induced	  chromatin	  modifications	  but	  function	  in	  an	  opposing	  manner	  under	  either	  an	  acute-­‐	  or	  chronic-­‐inflammatory	  condition.	  Our	  studies	  of	  the	  interchangeable	  chromatin	  regulators	  under	  different	  inflammatory	  conditions	  may	  mechanistically	  derive	  biomarkers	  of	  immunopathology	  associated	  with	  the	  extremes	  of	  deregulated	  inflammation.	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FUTURE	  WORK	  Understanding	  the	  biochemical	  dynamics	  of	  chromatin	  regulation	  in	  macrophage	  LPS	  response	  is	  essential	  in	  prevention	  and	  treatment	  of	  diseases	  of	  deregulated	  inflammation.	  To	  this	  end,	  even	  though	  some	  chromatin	  regulators	  of	  inflammation	  have	  been	  studied	  individually,	  a	  comprehensive	  study	  that	  screens	  the	  pool	  of	  multiple	  complexes	  of	  chromatin	  regulators	  is	  needed.	  To	  analyze	  chromatin	  on	  a	  broad	  proteomic	  scale	  Chromatin	  enrichment	  for	  proteomics	  (ChEP)	  technique	  has	  been	  developed	  recently	  (Kustatscher	  et	  al,	  2014b).	  This	  technique	  is	  very	  advantageous	  to	  other	  previous	  methods,	  such	  as	  Tandem	  affinity	  purification	  (TAP)-­‐MS,	  in	  screening	  the	  transient	  chromatin-­‐bound	  components	  in	  the	  cell	  and	  changes	  in	  global	  chromatin	  composition.	  Moreover,	  it	  is	  quick,	  enables	  comparison	  of	  drug	  treatments,	  and	  quantitative	  analysis.	  ChEP	  was	  previously	  used	  to	  monitor	  chromatin	  plasticity	  in	  interphase	  (Kustatscher	  et	  al,	  2014a);	  thus,	  it	  will	  be	  a	  great	  method	  to	  compare	  the	  chromatin	  components	  of	  (a)	  LPS-­‐stimulated	  WT	  and	  PHF8-­‐KD	  RAW	  cells	  or	  (b)	  WT	  cells	  treated	  with/without	  the	  G9a	  inhibitor	  UNC0638	  in	  ET	  state,	  covering	  the	  transient	  changes	  in	  chromatin	  and	  chromatin	  plasticity.	  This	  will	  help	  us	  discover	  other	  complexes	  involved	  in	  PHF8-­‐dependent	  inflammation	  response.	  In	  addition	  to	  the	  global	  chromatin	  components,	  understanding	  specific	  gene	  promoters	  that	  are	  PHF8-­‐bound	  in	  acute	  and	  G9a-­‐bound	  in	  chronic	  inflammation	  will	  be	  essential	  in	  understanding	  the	  outcome	  of	  the	  chromatin	  plasticity	  in	  inflammation	  response.	  To	  analyze	  the	  genes	  that	  are	  differentially	  regulated	  by	  PHF8	  and	  G9a	  in	  different	  inflammation	  states,	  we	  will	  perform	  ChIP-­‐Seq	  analysis	  of	  PHF8-­‐bound	  and	  G9a-­‐bound	  DNA	  in	  different	  inflammation	  states.	  This	  analysis	  will	  help	  us	  discover	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specific	  genes	  that	  contribute	  to	  inflammation	  response.	  In	  addition,	  it	  will	  also	  enable	  us	  validate	  and	  enhance	  the	  secretome	  analysis.	  	  
FIGURES	  
	  
Figure	  69	  Histone	  H3K9	  methyltransferases	  (HMTs)	  and	  demethylases	  (HDMs).	  	  
Adopted	  from	  ideno	  2015	  	  	  
	  
Figure	  70	  G9a	  structure.	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G9a	  structural	  organization	  characterized	  by	  automethylationsite	  at	  its	  N-­‐terminal	  end,	  ankyrin	  
repeats	  that	  recognize	  mono-­‐	  and	  di-­‐methylated	  H3K9,	  and	  a	  catalytic	  SET	  domain	  responsible	  for	  
catalytic	  activity	  adopted	  from	  casciello	  et	  al	  2015.	  	  	  
	  
Figure	  71	  Transcriptional	  repression	  and	  activation	  by	  G9a.	  	  
G9a	  recruitment	  by	  transcription	  factors	  and	  association	  with	  distinct	  co-­‐factor	  com-­‐	  plexes	  leads	  
to	  opposing	  outcomes	  on	  gene	  expression.	  Transcriptional	  repression	  of	  genes	  such	  as	  myogenin,	  
p21,	  JAK2	  and	  embryonic	  β-­‐globin	  is	  dependent	  on	  G9a	  methyltransferase	  activity	  (SeT	  domain).	  
On	  the	  other	  hand,	  G9a	  recruitment	  by	  Gr,	  runx2	  and	  NF-­‐e2/p45	  leads	  to	  activation	  of	  target	  
genes	  in	  a	  SeT-­‐domain	  independent	  manner.	  This	  occurs	  through	  association	  of	  G9a	  with	  co-­‐
activators	  such	  as	  p300	  and	  CArM1,	  as	  well	  as	  the	  Mediator	  complex.	  Adopted	  from	  Shankar	  et	  al	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Figure	  72	  G9a	  regulates	  hypoxia	  response.	  	  
Hypoxia	  leads	  to	  increased	  G9a	  activity,	  leading	  to	  the	  repression	  of	  a	  specific	  subset	  of	  hypoxia	  
genes	  while	  it	  is	  involved	  in	  the	  activation	  of	  various	  target	  genes.	  Adopted	  from	  casciello	  et	  al.	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Figure	  73	  GOBP	  enrichment	  of	  the	  common	  secretome	  	  
GOBP	  regulated	  by	  both	  G9a	  and	  PHF8	  antagonistically	  (Erdoğan	  et	  al,	  2016).	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GOBP	  regulated	  by	  both	  G9a	  and	  PHF8	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Figure	  74	  GOMF	  enrichment	  of	  the	  common	  scretome	  	  
GOMF	  regulated	  by	  G9a	  and	  PHF8	  antagonistically	  (Erdoğan	  et	  al,	  2016).	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GOMF	  Regulated	  by	  both	  G9a	  and	  PHF8	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Figure	  75	  GOCC	  enrichment	  of	  the	  common	  secretome	  	  

























































































































































































































































GOCC	  regulated	  by	  both	  G9a	  and	  PHF8	  (>4	  fold)	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Figure	  76	  Protein-­‐protein	  interaction	  network	  of	  the	  common	  secretome	  
PPI	  of	  the	  secretome	  differentially	  regulated	  by	  G9a	  and	  PHF8	  was	  determined	  by	  STRING	  in	  high	  
confidence	  (confidence	  score	  0.7)	  (Erdoğan	  et	  al,	  2016).	  	  
	   200	  
	  
Figure	  77	  Top	  10	  canonical	  pathways	  regulated	  antagonistically	  by	  G9a	  and	  PHF8	  
IPA	  network	  analysis	  revealed	  differentially	  regulated	  canonical	  pathways	  by	  PHF8	  and	  G9a	  
depending	  on	  the	  inflammatory	  phenotype	  (Erdoğan	  et	  al,	  2016).	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Figure	  78	  Canonical	  pathways	  in	  cross	  talk	  regulated	  by	  both	  G9a	  and	  PHF8	  
The	  cross	  talk	  shows	  regulation	  of	  different	  innate	  immune	  responses	  (Erdoğan	  et	  al,	  2016).	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Figure	  79	  Upstream	  regulators	  and	  targeted	  canonical	  pathways	  	  
These	  regulators	  are	  pathways	  are	  predicted	  by	  IPA	  analysis	  as	  due	  to	  LPS-­‐inducible,	  PHF8-­‐
dependent	  secreted	  proteins.	  Using	  the	  secretome	  data	  (proteins	  in	  the	  middle),	  IPA	  predicts	  the	  
possible	  upstream	  intracellular	  proteins	  (top,	  cyan)	  and	  the	  canonical	  pathways	  that	  become	  
regulated	  through	  signaling	  (bottom,	  blue).	  Green	  shade	  shows	  proteins	  with	  decreased	  secretion,	  
and	  red	  shade	  shows	  proteins	  with	  increased	  secretion	  in	  LPS-­‐stimulated	  PHF8-­‐KD	  RAW	  cells	  
compared	  with	  LPS-­‐stimulated	  WT	  RAW	  cells.	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Figure	  80	  The	  mechanism	  of	  the	  G9a-­‐	  vs	  PHF8-­‐	  dependent	  chromatin	  plasticity	  
The	  mechanism	  underlies	  gene-­‐specific	  chromatin	  plasticity	  corresponding	  to	  the	  changes	  of	  
immune	  cellular	  responses	  to	  LPS	  stimulation(s).	  	  Under	  the	  acute	  inflammatory	  conditions	  the	  
gene-­‐specific-­‐repressive	  function	  of	  the	  Kme	  writer	  G9a	  is	  antagonized	  by	  the	  Kme	  eraser	  PHF8.	  
‘HAT’	  refers	  to	  histone	  acetylase,	  and	  ‘HDAC’	  refers	  to	  histone	  deacetylase	  (Erdoğan	  et	  al,	  2016).	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APPENDIX	  1:	  T-­‐CLASS	  SECRETOME	  
Uniprot	  ID	   Gene	  name	  
	  
Uniprot	  ID	   Gene	  name	  
	  
Uniprot	  ID	   Gene	  name	  
Q921H8	   Acaa1a	  
	  
F8VQG4	   H2-­‐T24	  
	  
Q8CIH9	   Ppat	  
Q8CAY6	   Acat2	  
	  
Q3THW5	   H2afv	  
	  
Q9CR16	   Ppid	  
Q91V92	   Acly	  
	  
P70288	   Hdac2	  
	  
Q9D0W5	   Ppil1	  
Q99KI0	   Aco2	  
	  
P20060	   Hexb	  
	  
Q61074	   Ppm1g	  
Q9Z0F8-­‐2	   Adam17	  
	  
P43276	   Hist1h1b	  
	  
O88531	   Ppt1	  
E9Q359	   Adam8	  
	  
P15864	   Hist1h1c	  
	  
F6SPQ1	   Ppt2	  
P28474	   Adh5	  
	  
P43277	   Hist1h1d	  
	  
Q7TMR0	   Prcp	  
P28650	   Adssl1	  
	  
P43274	   Hist1h1e	  
	  
Q9JIF0-­‐2	   Prmt1	  
E9Q616	   Ahnak	  
	  
Q8CGP6	   Hist1h2ah	  
	  
Q99KP6	   Prpf19	  
P31230	   Aimp1	  
	  
F8WIX8	   Hist1h2al	  
	  
G3UXL2	   Prps1l3	  
Q9JII6	   Akr1a1	  
	  
Q6ZWY9	   Hist1h2bc	  
	  
E9PZ00	   Psap	  
P45376	   Akr1b1	  
	  
P84228	   Hist1h3b	  
	  
O55234	   Psmb5	  
Q9EST5	   Anp32b	  
	  
P62806	   Hist1h4a	  
	  
O88685	   Psmc3	  
E9Q5H2	   Anp32e	  
	  
Q9CX86	   Hnrnpa0	  
	  
Q3TXS7	   Psmd1	  
Q60709	   Aplp2	  
	  
O88569	   Hnrnpa2b1	  
	  
Q9D8W5	   Psmd12	  
P12023	   App	  
	  
Q9Z204-­‐2	   Hnrnpc	  
	  
O35226	   Psmd4	  
Q5XJY5	   Arcn1	  
	  
O35737	   Hnrnph1	  
	  
P26516	   Psmd7	  
Q9CWJ9	   Atic	  
	  
Q8R081	   Hnrnpl	  
	  
P29351	   Ptpn6	  
Q3TKX1	   Atp6ap1	  
	  
G3XA10	   Hnrnpu	  
	  
Q9JKF6	   Pvrl1	  
Q9CYN9	   Atp6ap2	  
	  
P07901	   Hsp90aa1	  
	  
Q8BND5-­‐2	   Qsox1	  
P62814	   Atp6v1b2	  
	  
Q8BM72	   Hspa13	  
	  
Q5SW88	   Rab1	  
P01887	   B2m	  
	  
P38647	   Hspa9	  
	  
P46061	   Rangap1	  
E9QAI5	   Cad	  
	  
P63038	   Hspd1	  
	  
O89086	   Rbm3	  
P10148	   Ccl2	  
	  
Q64433	   Hspe1	  
	  
Q91VM5	   Rbmxl1	  
Q03366	   Ccl7	  
	  
Q8BU30	   Iars	  
	  
Q8BK67	   Rcc2	  
P51670	   Ccl9	  
	  
P13597-­‐2	   Icam1	  
	  
Q9JJH1	   Rnase4	  
P15379-­‐2	   Cd44	  
	  
Q9ESY9	   Ifi30	  
	  
Q8VEE4	   Rpa1	  
P04441	   Cd74	  
	  
O35664-­‐3	   Ifnar2	  
	  
P62983	   Rps27a	  
P04186	   Cfb	  
	  
P47879	   Igfbp4	  
	  
P60122	   Ruvbl1	  
P06909	   Cfh	  
	  
Q8K3I6	   Il27	  
	  
Q9WTM5	   Ruvbl2	  
B1AWE0	   Clta	  
	  
Q45VK5	   Ilf3	  
	  
P14069	   S100a6	  
Q68FD5	   Cltc	  
	  
P24547	   Impdh2	  
	  
D3YXK2	   Safb	  
Q8K4Q8	   Colec12	  
	  
Q792F9	   Itga4	  
	  
P32020-­‐2	   Scp2	  
P61924	   Copz1	  
	  
Q542I8	   Itgb2	  
	  
O35988	   Sdc4	  
Q9WUM4	   Coro1c	  
	  
O89051	   Itm2b	  
	  
Q61112	   Sdf4	  
Q61147	   Cp	  
	  
P52293	   Kpna2	  
	  
P17563	   Selenbp1	  
O88668	   Creg1	  
	  
P70168	   Kpnb1	  
	  
Q62178	   Sema4a	  
P09581	   Csf1r	  
	  
Q61792	   Lasp1	  
	  
Q62179	   Sema4b	  
P21460	   Cst3	  
	  
P35951	   Ldlr	  
	  
O09126	   Sema4d	  
Q8R242-­‐2	   Ctbs	  
	  
Q07797	   Lgals3bp	  
	  
E9Q4Q2	   Sf1	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Q9CWL8	   Ctnnbl1	  
	  
P48678	   Lmna	  
	  
Q8K4Z5	   Sf3a1	  
P10605	   Ctsb	  
	  
P14733	   Lmnb1	  
	  
G3UVU2	   Sf3a2	  
Q9R013	   Ctsf	  
	  
P11152	   Lpl	  
	  
Q9D554	   Sf3a3	  
P06797	   Ctsl1	  
	  
O88188	   Ly86	  
	  
G5E866	   Sf3b1	  
O70370	   Ctss	  
	  
P08905	   Lyz2	  
	  
Q3UJB0	   Sf3b2	  
Q9WUU7	   Ctsz	  
	  
O09159	   Man2b1	  
	  
Q921M3	   Sf3b3	  
D3YW23	   Cxcl10	  
	  
Q3THS6	   Mat2a	  
	  
Q923D4	   Sf3b5	  
I7HIQ2	   Cxcl16	  
	  
Q8K310	   Matr3	  
	  
Q8VIJ6	   Sfpq	  
P10889	   Cxcl2	  
	  
P97310	   Mcm2	  
	  





P49717	   Mcm4	  
	  
Q9D7I0	   Shisa5	  
Q62165	   Dag1	  
	  
P97311	   Mcm6	  
	  
Q9CZN7	   Shmt2	  
Q922B2	   Dars	  
	  
Q61881	   Mcm7	  
	  
Q6P6I8	   Sirpa	  
Q62418-­‐3	   Dbnl	  
	  
P08249	   Mdh2	  
	  
Q6P5F6	   Slc39a10	  
A2ADY9	   Ddi2	  
	  
Q8VE43	   Metrnl	  
	  
E9Q748	   Slpi	  
Q9JIK5	   Ddx21	  
	  
Q7TPV4	   Mybbp1a	  
	  
Q62189	   Snrpa	  
Q9Z1N5	   Ddx39b	  
	  
Q3V4D5	   Naa10	  
	  
Q78ZM0	   Snx3	  
Q61656	   Ddx5	  
	  
Q6PGB6-­‐2	   Naa50	  
	  
P13609	   Srgn	  
P00375	   Dhfr	  
	  
Q9QWR8	   Naga	  
	  
Q99MR6-­‐3	   Srrt	  
O35286	   Dhx15	  
	  
Q78ZA7	   Nap1l4	  
	  
Q6PDM2	   Srsf1	  
O70133	   Dhx9	  
	  
P09405	   Ncl	  
	  
P84104-­‐2	   Srsf3	  
P63037	   Dnaja1	  
	  
Q62433	   Ndrg1	  
	  
Q8BL97-­‐3	   Srsf7	  
Q91YW3	   Dnajc3	  
	  
Q9D0T1	   Nhp2l1	  
	  
Q8BH40	   Stx7	  
Q6NZB0	   Dnajc8	  
	  
E9Q5C9	   Nolc1	  
	  
G3X956	   Supt16	  
Q8C255	   Dpep2	  
	  
Q99K48	   Nono	  
	  
O08784	   Tcof1	  
Q91WV0	   Dr1	  
	  
Q9Z0J0	   Npc2	  
	  
P40142	   Tkt	  
Q9CQ43	   Dut	  
	  
Q61937	   Npm1	  
	  
Q61029	   Tmpo	  
O35228	   Ebi3	  
	  
Q02819	   Nucb1	  
	  
P41274	   Tnfsf9	  
Q61508	   Ecm1	  
	  
P29758	   Oat	  
	  
Q8BFY9-­‐2	   Tnpo1	  
Q9QZD9	   Eif3i	  
	  
Q9CZ30	   Ola1	  
	  
Q9ER38	   Tor3a	  
Q91VC3	   Eif4a3	  
	  
Q8R357	   Olfm1	  
	  
O89023	   Tpp1	  
P19096	   Fasn	  
	  
Q62422	   Ostf1	  
	  
Q7M739	   Tpr	  
Q920E5	   Fdps	  
	  
Q921K2	   Parp1	  
	  
Q99NH8	   Trem2	  
Q9R059	   Fhl3	  
	  
P31240	   Pdgfb	  
	  
Q9Z0P5	   Twf2	  
Q04646-­‐2	   Fxyd2	  
	  
P12382	   Pfkl	  
	  
Q8CDN6	   Txnl1	  
Q9R0N0	   Galk1	  
	  
Q8C605	   Pfkp	  
	  
P26369	   U2af2	  
P16858	   Gapdh	  
	  
Q8CHP8	   Pgp	  
	  
Q9Z1F9	   Uba2	  
Q64737	   Gart	  
	  
Q61753	   Phgdh	  
	  
Q80X50-­‐2	   Ubap2l	  
E9Q7H5	   Gm8991	  
	  
P27612	   Plaa	  
	  
Q9JKB1	   Uchl3	  
P05202	   Got2	  
	  
P35456	   Plaur	  
	  
Q9JMA1	   Usp14	  
P28798	   Grn	  
	  
E9QPE8	   Plec	  
	  
D3YYD5	   Vps29	  
O09131	   Gsto1	  
	  
Q9R0E2	   Plod1	  
	  
Q9EQH3	   Vps35	  
P01900	   H2-­‐D1	  
	  
Q9R0B9	   Plod2	  
	  
P61965	   Wdr5	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P01902	   H2-­‐K1	  
	  
Q9R0E1	   Plod3	  
	  
Q9CQV8	   Ywhab	  
P01897	   H2-­‐L	  
	  
P55065	   Pltp	  
	  
P10404	   	  	  
Q8HWB2	   H2-­‐Q4	  
	  
Q923G2	   Polr2h	  
	   	   	  	  
APPENDIX	  2	  :	  NT-­‐CLASS	  SECRETOME	  
Uniprot	  ID	   Gene	  name	  
	  
Uniprot	  ID	   Gene	  name	  
Q8BGQ7	   Aars	  
	  
Q9QUR7	   Pin1	  
P63260	   Actg1	  
	  
P58389	   Ppp2r4	  
Q8BK64	   Ahsa1	  
	  
P62192	   Psmc1	  
Q61024	   Asns	  
	  
P46471	   Psmc2	  
P50516	   Atp6v1a	  
	  
P54775	   Psmc4	  
P62204	   Calm1	  
	  
P62196	   Psmc5	  
Q04447	   Ckb	  
	  
P62334	   Psmc6	  
Q9Z1Q5	   Clic1	  
	  
Q8BG32	   Psmd11	  
Q8CIE6	   Copa	  
	  
Q9WVJ2	   Psmd13	  
Q9JIF7	   Copb1	  
	  
Q8VDM4	   Psmd2	  
O55029	   Copb2	  
	  
P14685	   Psmd3	  
O89079	   Cope	  
	  
Q99JI4	   Psmd6	  
Q9QZE5	   Copg1	  
	  
Q8BGJ5	   Ptbp1	  
O89053	   Coro1a	  
	  
D3Z7C6	   Ptges3	  
Q9ERK4	   Cse1l	  
	  
Q60972	   Rbbp4	  
P97821	   Ctsc	  
	  
Q60973	   Rbbp7	  
Q9JHU4	   Dync1h1	  
	  
Q91VI7	   Rnh1	  
Q8CGC7	   Eprs	  
	  
P07091	   S100a4	  
P97855	   G3bp1	  
	  
Q920A5	   Scpep1	  
Q9CQM9	   Glrx3	  
	  
Q3TMX0	   Sdcbp	  
P70349	   Hint1	  
	  
Q9EPK6	   Sil1	  
Q8JZK9	   Hmgcs1	  
	  
Q78PY7	   Snd1	  
Q9Z2X1	   Hnrnpf	  
	  
Q08943	   Ssrp1	  
P11499	   Hsp90ab1	  
	  
Q80YX1-­‐2	   Tnc	  
G5E8F1	   Itgam	  
	  
P06804	   Tnf	  
P09056	   Lif	  
	  
Q62318	   Trim28	  
P17897	   Lyz1	  
	  
E9PXX7	   Txndc5	  
P31938	   Map2k1	  
	  
Q02053	   Uba1	  
Q9CQT1	   Mri1	  
	  
Q9WUP7-­‐2	   Uchl5	  
Q922D8	   Mthfd1	  
	  
Q9Z1Z0	   Uso1	  
Q99J77	   Nans	  
	  
Q3U4W8	   Usp5	  
Q7TQI3	   Otub1	  
	  
P20152	   Vim	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APPENDIX	  3:	  COMMON	  PROTEINS	  WITH	  SECRETOME	  FROM	  MEISSNER	  ET	  AL.	  
Uniprot	  ID	   Gene	  name	  
	  
Uniprot	  ID	   Gene	  name	  
Q99KI0	   Aco2	  
	  
P01575	   Ifnb1	  
O35598	   Adam10	  
	  
Q3TBV5	   Il1rn	  
Q9Z0F8	   Adam17	  
	  
Q8K3I6	   Il27	  
P54923	   Adprh	  
	  
P34902	   Il2rg	  
P10518	   Alad	  
	  
O09046	   Il4i1	  
E9Q4G8	   Alcam	  
	  
P08505	   Il6	  
P05064	   Aldoa	  
	  
Q64339	   Isg15	  
Q60709	   Aplp2	  
	  
Q792F9	   Itga4	  
P12023	   App	  
	  
G5E8F1	   Itgam	  
Q9WV54	   Asah1	  
	  
Q542I8	   Itgb2	  
Q9CYN9	   Atp6ap2	  
	  
O89051	   Itm2b	  
P01887	   B2m	  
	  
P11672	   Lcn2	  
Q09200	   B4galnt1	  
	  
P35951	   Ldlr	  
Q9JMK0	   B4galt5	  
	  
Q07797	   Lgals3bp	  
Q91XV3	   Basp1	  
	  
O89017	   Lgmn	  
P01027	   C3	  
	  
Q64281	   Lilrb4	  
E9QAI5	   Cad	  
	  
Q9WVG5	   Lipg	  
P14211	   Calr	  
	  
Q9DBH5	   Lman2	  
P10148	   Ccl2	  
	  
P11152	   Lpl	  
O88430	   Ccl22	  
	  
Q91ZX7	   Lrp1	  
P10855	   Ccl3	  
	  
P19973	   Lsp1	  
P14097	   Ccl4	  
	  
O88188	   Ly86	  
P30882	   Ccl5	  
	  
O09159	   Man2b1	  
Q03366	   Ccl7	  
	  
O54782	   Man2b2	  
P51670	   Ccl9	  
	  
Q8K2I4	   Manba	  
P10810	   Cd14	  
	  
P08249	   Mdh2	  
P15379	   Cd44	  
	  
Q8VE43	   Metrnl	  
P04441	   Cd74	  
	  
Q9Z2L6	   Minpp1	  
P06909	   Cfh	  
	  
P26041	   Msn	  
P11680	   Cfp	  
	  
Q3V4D5	   Naa10	  
Q9D8B3	   Chmp4b	  
	  
Q9QWR8	   Naga	  
Q8WTY4	   Ciapin1	  
	  
O88325	   Naglu	  
Q68FD5	   Cltc	  
	  
O09043	   Napsa	  
O89001	   Cpd	  
	  
Q8VEJ4	   Nle1	  
O88668	   Creg1	  
	  
Q11011	   Npepps	  
P07141	   Csf1	  
	  
O35375	   Nrp2	  
P09920	   Csf3	  
	  
Q02819	   Nucb1	  
P21460	   Cst3	  
	  
P29758	   Oat	  
Q8R242	   Ctbs	  
	  
P09103	   P4hb	  
P16675	   Ctsa	  
	  
P29341	   Pabpc1	  
P10605	   Ctsb	  
	  
Q9WU78	   Pdcd6ip	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P97821	   Ctsc	  
	  
P31240	   Pdgfb	  
P18242	   Ctsd	  
	  
P08003	   Pdia4	  
O70370	   Ctss	  
	  
Q922R8	   Pdia6	  
Q9WUU7	   Ctsz	  
	  
P35456	   Plaur	  
D3YW23	   Cxcl10	  
	  
Q3TCN2	   Plbd2	  
I7HIQ2	   Cxcl16	  
	  
Q8BG07	   Pld4	  
P10889	   Cxcl2	  
	  
Q9R0B9	   Plod2	  
Q91UZ6	   D17H6S56E-­‐5	  
	  
Q9R0E1	   Plod3	  
Q9CPT4	   D17Wsu104e	  
	  
B2RXS4	   Plxnb2	  
Q91YW3	   Dnajc3	  
	  
P24369	   Ppib	  
O35228	   Ebi3	  
	  
O88531	   Ppt1	  
Q61508	   Ecm1	  
	  
F6SPQ1	   Ppt2	  
E9QN08	   Eef1d	  
	  
Q7TMR0	   Prcp	  
P63242	   Eif5a	  
	  
O08795	   Prkcsh	  
Q8K482	   Emilin2	  
	  
Q64695	   Procr	  
Q9EQH2	   Erap1	  
	  
Q08761	   Pros1	  
P57759	   Erp29	  
	  
E9PZ00	   Psap	  
Q9D1Q6	   Erp44	  
	  
B0V2N1	   Ptprs	  
P09528	   Fth1	  
	  
Q9JKF6	   Pvrl1	  
Q9CPX4	   Ftl1	  
	  
O89086	   Rbm3	  
P23188	   Furin	  
	  
Q9CQ01	   Rnaset2	  
P70699	   Gaa	  
	  
Q5XJF6	   Rpl10a	  
Q8BHN3	   Ganab	  
	  
P07091	   S100a4	  
P17439	   Gba	  
	  
P04918	   Saa3	  
Q60648	   Gm2a	  
	  
Q920A5	   Scpep1	  
Q8BFR4	   Gns	  
	  
O35988	   Sdc4	  
Q99P91	   Gpnmb	  
	  
Q3TMX0	   Sdcbp	  
P28798	   Grn	  
	  
Q62179	   Sema4b	  
P01900	   H2-­‐D1	  
	  
P22777	   Serpine1	  
P01902	   H2-­‐K1	  
	  
P10923	   Spp1	  
Q8HWB2	   H2-­‐Q4	  
	  
P13609	   Srgn	  
P06339	   H2-­‐T23	  
	  
P54227	   Stmn1	  
F8VQG4	   H2-­‐T24	  
	  
Q8R0B4	   Tardbp	  
P29416	   Hexa	  
	  
O88968	   Tcn2	  
P20060	   Hexb	  
	  
Q62351	   Tfrc	  
P97825	   Hn1	  
	  
Q8C1A5	   Thop1	  
Q6PGH2	   Hn1l	  
	  
P12032	   Timp1	  
P08113	   Hsp90b1	  
	  
P06804	   Tnf	  
Q8BM72	   Hspa13	  
	  
P41274	   Tnfsf9	  
P20029	   Hspa5	  
	  
Q62393	   Tpd52	  
P63038	   Hspd1	  
	  
O89023	   Tpp1	  
Q64433	   Hspe1	  
	  
Q99NH8	   Trem2	  
Q9JKR6	   Hyou1	  
	  
E9PXX7	   Txndc5	  
P13597	   Icam1	  
	  
Q6P5E4	   Uggt1	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Q9JHJ8	   Icoslg	  
	  
P20152	   Vim	  
Q9ESY9	   Ifi30	  
	  
P10404	   	  	  
O35664	   Ifnar2	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APPENDIX	  4:	  COMMON	  PROTEINS	  WITH	  SECRETOME	  FROM	  LIU	  ET	  AL.	  
Uniprot	  ID	   Gene	  name	  
	  
Uniprot	  ID	   Gene	  name	  
	  
Uniprot	  ID	   Gene	  name	  
P42208	   1-­‐Sep	  
	  
Q9CPX4	   Ftl1	  
	  
P46471	   Psmc2	  
O55131	   6-­‐Sep	  
	  
P97855	   G3bp1	  
	  
P54775	   Psmc4	  
Q80UG5	   8-­‐Sep	  
	  
Q00612	   G6pdx	  
	  
P62196	   Psmc5	  
Q8C1B7	   10-­‐Sep	  
	  
P70699	   Gaa	  
	  
P62334	   Psmc6	  
Q8BGQ7	   Aars	  
	  
Q9R0N0	   Galk1	  
	  
Q3TXS7	   Psmd1	  
Q921H8	   Acaa1a	  
	  
Q8BHN3	   Ganab	  
	  
Q8BG32	   Psmd11	  
Q8CAY6	   Acat2	  
	  
P16858	   Gapdh	  
	  
Q9D8W5	   Psmd12	  
Q91V92	   Acly	  
	  
Q9CZD3	   Gars	  
	  
Q9WVJ2	   Psmd13	  
P28271	   Aco1	  
	  
P17439	   Gba	  
	  
O35593	   Psmd14	  
Q99KI0	   Aco2	  
	  
Q61598	   Gdi2	  
	  
Q8VDM4	   Psmd2	  
Q91V12	   Acot7	  
	  
Q9CPV4	   Glod4	  
	  
P14685	   Psmd3	  
P63260	   Actg1	  
	  
Q9QUH0	   Glrx	  
	  
O35226	   Psmd4	  
P57780	   Actn4	  
	  
Q9CQM9	   Glrx3	  
	  
Q99JI4	   Psmd6	  
P61164	   Actr1a	  
	  
E9PZF0	   Gm20390	  
	  
P26516	   Psmd7	  
P61161	   Actr2	  
	  
Q60648	   Gm2a	  
	  
G3UXZ5	   Psme1	  
Q99JY9	   Actr3	  
	  
J3QP68	   Gm4204	  
	  
G3X9V0	   Psme2	  
P28474	   Adh5	  
	  
Q9CQI3	   Gmfb	  
	  
Q8BGJ5	   Ptbp1	  
P54923	   Adprh	  
	  
P62880	   Gnb2	  
	  
P29351	   Ptpn6	  
P46664	   Adss	  
	  
P68040	   Gnb2l1	  
	  
Q3UEB3	   Puf60	  
P28650	   Adssl1	  
	  
O88958	   Gnpda1	  
	  
D3YWR7	   Qdpr	  
P50247	   Ahcy	  
	  
Q8BFR4	   Gns	  
	  
P35278	   Rab5c	  
E9Q616	   Ahnak	  
	  
P06745	   Gpi	  
	  
P51150	   Rab7a	  
Q8BK64	   Ahsa1	  
	  
Q99P91	   Gpnmb	  
	  
P63001	   Rac1	  
P31230	   Aimp1	  
	  
Q60631	   Grb2	  
	  
Q05144	   Rac2	  
Q9WTP6	   Ak2	  
	  
P28798	   Grn	  
	  
P54728	   Rad23b	  
Q9JII6	   Akr1a1	  
	  
P13020	   Gsn	  
	  
P62827	   Ran	  
P45376	   Akr1b1	  
	  
Q8R050	   Gspt1	  
	  
P34022	   Ranbp1	  
P47738	   Aldh2	  
	  
O09131	   Gsto1	  
	  
Q9D0I9	   Rars	  
Q9JLJ2	   Aldh9a1	  
	  
Q8HWB2	   H2-­‐Q4	  
	  
Q60972	   Rbbp4	  
P05064	   Aldoa	  
	  
Q3THW5	   H2afv	  
	  
O89086	   Rbm3	  
P05063	   Aldoc	  
	  
Q61035	   Hars	  
	  
Q9CWZ3	   Rbm8a	  
O08583	   Alyref	  
	  
P49710	   Hcls1	  
	  
Q91VM5	   Rbmxl1	  
O35381	   Anp32a	  
	  
P51859	   Hdgf	  
	  
Q8BK67	   Rcc2	  
Q9EST5	   Anp32b	  
	  
P29416	   Hexa	  
	  
P26043	   Rdx	  
E9Q5H2	   Anp32e	  
	  
P20060	   Hexb	  
	  
P82343	   Renbp	  
P07356	   Anxa2	  
	  
P70349	   Hint1	  
	  
Q9QUI0	   Rhoa	  
Q5SVG5	   Ap1b1	  
	  
P43276	   Hist1h1b	  
	  
Q9CQ01	   Rnaset2	  
P17426	   Ap2a1	  
	  
P43277	   Hist1h1d	  
	  
Q91VI7	   Rnh1	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Q9DBG3	   Ap2b1	  
	  
P43274	   Hist1h1e	  
	  
Q8VCT3	   Rnpep	  
Q8R5A3	   Apbb1ip	  
	  
Q8CGP6	   Hist1h2ah	  
	  
I7HLV2	   Rpl10	  
O35841	   Api5	  
	  
P84228	   Hist1h3b	  
	  
Q5XJF6	   Rpl10a	  
P12023	   App	  
	  
P62806	   Hist1h4a	  
	  
P35979	   Rpl12	  
P08030	   Aprt	  
	  
G3UVV4	   Hk1	  
	  
P47963	   Rpl13	  
Q5XJY5	   Arcn1	  
	  
P63158	   Hmgb1	  
	  
P19253	   Rpl13a	  
P84078	   Arf1	  
	  
P30681	   Hmgb2	  
	  
Q9CR57	   Rpl14	  
Q99PT1	   Arhgdia	  
	  
P14901	   Hmox1	  
	  
P62717	   Rpl18a	  
Q61599	   Arhgdib	  
	  
P97825	   Hn1	  
	  
A2A547	   Rpl19	  
Q9WV32	   Arpc1b	  
	  
Q6PGH2	   Hn1l	  
	  
Q9CQM8	   Rpl21	  
Q9CVB6	   Arpc2	  
	  
Q9CX86	   Hnrnpa0	  
	  
P67984	   Rpl22	  
Q9JM76	   Arpc3	  
	  
P49312	   Hnrnpa1	  
	  
P62830	   Rpl23	  
P59999	   Arpc4	  
	  
O88569	   Hnrnpa2b1	  
	  
E9Q132	   Rpl24	  
Q9CPW4	   Arpc5	  
	  
Q99020	   Hnrnpab	  
	  
P61358	   Rpl27	  
P50429	   Arsb	  
	  
Q9Z204	   Hnrnpc	  
	  
P14115	   Rpl27a	  
Q9WV54	   Asah1	  
	  
Q9Z2X1	   Hnrnpf	  
	  
P27659	   Rpl3	  
Q9CWJ9	   Atic	  
	  
G3XA10	   Hnrnpu	  
	  
P62889	   Rpl30	  
O08997	   Atox1	  
	  
P00493	   Hprt1	  
	  
P62900	   Rpl31	  
Q3TKX1	   Atp6ap1	  
	  
P07901	   Hsp90aa1	  
	  
P62911	   Rpl32	  
Q9CYN9	   Atp6ap2	  
	  
P11499	   Hsp90ab1	  
	  
Q9D1R9	   Rpl34	  
P50516	   Atp6v1a	  
	  
P08113	   Hsp90b1	  
	  
Q6ZWV7	   Rpl35	  
P62814	   Atp6v1b2	  
	  
Q3U2G2	   Hspa4	  
	  
Q9JJI8	   Rpl38	  
P01887	   B2m	  
	  
P20029	   Hspa5	  
	  
Q9D8E6	   Rpl4	  
Q91XV3	   Basp1	  
	  
P63017	   Hspa8	  
	  
P47962	   Rpl5	  
Q07813	   Bax	  
	  
P38647	   Hspa9	  
	  
P47911	   Rpl6	  
Q8R016	   Blmh	  
	  
P63038	   Hspd1	  
	  
P14148	   Rpl7	  
Q9CY64	   Blvra	  
	  
Q64433	   Hspe1	  
	  
P47955	   Rplp1	  
Q923D2	   Blvrb	  
	  
Q9JKR6	   Hyou1	  
	  
P99027	   Rplp2	  
Q64152	   Btf3	  
	  
Q8BU30	   Iars	  
	  
P63325	   Rps10	  
P01027	   C3	  
	  
O88844	   Idh1	  
	  
P62281	   Rps11	  
Q9CXW3	   Cacybp	  
	  
Q9ESY9	   Ifi30	  
	  
Q6ZWZ6	   Rps12	  
P62204	   Calm1	  
	  
P08505	   Il6	  
	  
P62301	   Rps13	  
P14211	   Calr	  
	  
Q924B0	   Impa1	  
	  
P62264	   Rps14	  
Q6ZQ38	   Cand1	  
	  
Q8BKC5	   Ipo5	  
	  
P62843	   Rps15	  
P40124	   Cap1	  
	  
E9QKZ2	   Ipo9	  
	  
P62245	   Rps15a	  
Q99LB4	   Capg	  
	  
Q9JKF1	   Iqgap1	  
	  
P14131	   Rps16	  
Q60865	   Caprin1	  
	  
Q64339	   Isg15	  
	  
P63276	   Rps17	  
Q5RKN9	   Capza1	  
	  
Q91V64	   Isoc1	  
	  
Q9CZX8	   Rps19	  
P47754	   Capza2	  
	  
Q9JHU9	   Isyna1	  
	  
P25444	   Rps2	  
P47757	   Capzb	  
	  
G5E8F1	   Itgam	  
	  
P60867	   Rps20	  
Q9DCC5	   Cbx3	  
	  
Q542I8	   Itgb2	  
	  
Q9CQR2	   Rps21	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P10148	   Ccl2	  
	  
O89051	   Itm2b	  
	  
P62267	   Rps23	  
P10855	   Ccl3	  
	  
Q99MN1	   Kars	  
	  
P62849	   Rps24	  
P14097	   Ccl4	  
	  
Q3U0V1	   Khsrp	  
	  
P62852	   Rps25	  
P30882	   Ccl5	  
	  
P70168	   Kpnb1	  
	  
P62855	   Rps26	  
P51670	   Ccl9	  
	  
Q9CPY7	   Lap3	  
	  
P62983	   Rps27a	  
P80314	   Cct2	  
	  
Q61792	   Lasp1	  
	  
P62908	   Rps3	  
P80318	   Cct3	  
	  
P11672	   Lcn2	  
	  
P62702	   Rps4x	  
P80315	   Cct4	  
	  
Q61233	   Lcp1	  
	  
P62754	   Rps6	  
P80316	   Cct5	  
	  
P06151	   Ldha	  
	  
P62242	   Rps8	  
P80317	   Cct6a	  
	  
P16045	   Lgals1	  
	  
Q6ZWN5	   Rps9	  
P80313	   Cct7	  
	  
Q8C253	   Lgals3	  
	  
P14206	   Rpsa	  
P42932	   Cct8	  
	  
Q07797	   Lgals3bp	  
	  
A2AVJ7	   Rrbp1	  
P10810	   Cd14	  
	  
O89017	   Lgmn	  
	  
P60122	   Ruvbl1	  
P04441	   Cd74	  
	  
P48678	   Lmna	  
	  
P50543	   S100a11	  
Q61081	   Cdc37	  
	  
P14733	   Lmnb1	  
	  
P07091	   S100a4	  
P60766	   Cdc42	  
	  
P11152	   Lpl	  
	  
P14069	   S100a6	  
P04186	   Cfb	  
	  
Q91ZX7	   Lrp1	  
	  
P04918	   Saa3	  
P18760	   Cfl1	  
	  
Q505F5	   Lrrc47	  
	  
Q9R1T2	   Sae1	  
P11680	   Cfp	  
	  
P19973	   Lsp1	  
	  
Q60710	   Samhd1	  
Q9D8B3	   Chmp4b	  
	  
P24527	   Lta4h	  
	  
Q9D1J3	   Sarnp	  
Q9D1P4	   Chordc1	  
	  
O88188	   Ly86	  
	  
P26638	   Sars	  
Q04447	   Ckb	  
	  
Q9WTL7	   Lypla2	  
	  
P32020	   Scp2	  
Q9Z1Q5	   Clic1	  
	  
P08905	   Lyz2	  
	  
Q920A5	   Scpep1	  
Q9QYB1	   Clic4	  
	  
O09159	   Man2b1	  
	  
O35988	   Sdc4	  
B1AWE0	   Clta	  
	  
O54782	   Man2b2	  
	  
Q3TMX0	   Sdcbp	  
Q68FD5	   Cltc	  
	  
Q80ZP8	   Manf	  
	  
Q61112	   Sdf4	  
Q9DBP5	   Cmpk1	  
	  
P31938	   Map2k1	  
	  
Q9D662	   Sec23b	  
Q3U5Q7	   Cmpk2	  
	  
P63085	   Mapk1	  
	  
G3X972	   Sec24c	  
Q9D1A2	   Cndp2	  
	  
Q61166	   Mapre1	  
	  
P17563	   Selenbp1	  
Q8CIE6	   Copa	  
	  
Q3THS6	   Mat2a	  
	  
Q8BH69	   Sephs1	  
Q9JIF7	   Copb1	  
	  
Q8K310	   Matr3	  
	  
Q60854	   Serpinb6	  
O55029	   Copb2	  
	  
P14152	   Mdh1	  
	  
A2BE93	   Set	  
O89079	   Cope	  
	  
P08249	   Mdh2	  
	  
Q8K4Z5	   Sf3a1	  
Q9QZE5	   Copg1	  
	  
P34884	   Mif	  
	  
G5E866	   Sf3b1	  
P61202	   Cops2	  
	  
P26041	   Msn	  
	  
Q921M3	   Sf3b3	  
O88543	   Cops3	  
	  
Q9CQ65	   Mtap	  
	  
Q8VIJ6	   Sfpq	  
O88544	   Cops4	  
	  
Q922D8	   Mthfd1	  
	  
Q8BJU0	   Sgta	  
P61924	   Copz1	  
	  
P62774	   Mtpn	  
	  
Q9JJU8	   Sh3bgrl	  
O89053	   Coro1a	  
	  
Q9JK81	   Myg1	  
	  
Q91VW3	   Sh3bgrl3	  
Q9WUM3	   Coro1b	  
	  
Q8VDD5	   Myh9	  
	  
Q78PY7	   Snd1	  
Q9WUM4	   Coro1c	  
	  
Q60605	   Myl6	  
	  
P62305	   Snrpe	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Q9CQI6	   Cotl1	  
	  
Q60817	   Naca	  
	  
Q6NZD2	   Snx1	  
Q6NVF9	   Cpsf6	  
	  
Q9QWR8	   Naga	  
	  
Q9CWK8	   Snx2	  
O88668	   Creg1	  
	  
O88325	   Naglu	  
	  
Q78ZM0	   Snx3	  
P63254	   Crip1	  
	  
Q99KQ4	   Nampt	  
	  
Q9D8U8	   Snx5	  
P09581	   Csf1r	  
	  
Q99J77	   Nans	  
	  
Q6P8X1	   Snx6	  
P21460	   Cst3	  
	  
Q78ZA7	   Nap1l4	  
	  
Q91VH2	   Snx9	  
Q62426	   Cstb	  
	  
Q8BP47	   Nars	  
	  
P08228	   Sod1	  
P16675	   Ctsa	  
	  
B1AU76	   Nasp	  
	  
P10923	   Spp1	  
P10605	   Ctsb	  
	  
P09405	   Ncl	  
	  
P13609	   Srgn	  
P97821	   Ctsc	  
	  
P29595	   Nedd8	  
	  
Q6PDM2	   Srsf1	  
P18242	   Ctsd	  
	  
Q9D0T1	   Nhp2l1	  
	  
Q62093	   Srsf2	  
P06797	   Ctsl1	  
	  
Q9JHW2	   Nit2	  
	  
P84104	   Srsf3	  
O70370	   Ctss	  
	  
P15532	   Nme1	  
	  
P32067	   Ssb	  
Q9WUU7	   Ctsz	  
	  
Q99K48	   Nono	  
	  
F8WJK8	   St13	  
D3YW23	   Cxcl10	  
	  
Q9Z0J0	   Npc2	  
	  
Q60864	   Stip1	  
P10889	   Cxcl2	  
	  
Q11011	   Npepps	  
	  
Q9Z1Z2	   Strap	  
Q99LF4	   D10Wsu52e	  
	  
A6PWC3	   Nrd1	  
	  
Q8BH40	   Stx7	  
Q922B2	   Dars	  
	  
Q9CZ44	   Nsfl1c	  
	  
Q64324	   Stxbp2	  
P31786	   Dbi	  
	  
Q02819	   Nucb1	  
	  
P11031	   Sub1	  
Q62418	   Dbnl	  
	  
Q3UKN6	   Nucb2	  
	  
Q9CX34	   Sugt1	  
D3YX34	   Dctn1	  
	  
O35685	   Nudc	  
	  
Q6A028	   Swap70	  
A2ADY9	   Ddi2	  
	  
P61971	   Nutf2	  
	  
Q7TMK9	   Syncrip	  
Q501J6	   Ddx17	  
	  
Q9CZ30	   Ola1	  
	  
Q9WVA4	   Tagln2	  
Q9Z1N5	   Ddx39b	  
	  
Q62422	   Ostf1	  
	  
Q93092	   Taldo1	  
Q61656	   Ddx5	  
	  
Q7TQI3	   Otub1	  
	  
P48428	   Tbca	  
Q6Q899	   Ddx58	  
	  
P09103	   P4hb	  
	  
P10711	   Tcea1	  
P54823	   Ddx6	  
	  
P50580	   Pa2g4	  
	  
P83940	   Tceb1	  
P00375	   Dhfr	  
	  
P29341	   Pabpc1	  
	  
P62869	   Tceb2	  
O35286	   Dhx15	  
	  
P63005	   Pafah1b1	  
	  
P11983	   Tcp1	  
O70133	   Dhx9	  
	  
Q61206	   Pafah1b2	  
	  
Q9Z1A1	   Tfg	  
Q8K1M6	   Dnm1l	  
	  
Q9DCL9	   Paics	  
	  
Q9WVA2	   Timm8a1	  
Q9Z2W0	   Dnpep	  
	  
Q8CIN4	   Pak2	  
	  
P40142	   Tkt	  
Q8C255	   Dpep2	  
	  
Q99LX0	   Park7	  
	  
P26039	   Tln1	  
Q99KK7	   Dpp3	  
	  
Q921K2	   Parp1	  
	  
P06804	   Tnf	  
O08553	   Dpysl2	  
	  
P60335	   Pcbp1	  
	  
P25119	   Tnfrsf1b	  
Q9R0P5	   Dstn	  
	  
Q61990	   Pcbp2	  
	  
Q62393	   Tpd52	  
Q9JHU4	   Dync1h1	  
	  
P23506	   Pcmt1	  
	  
Q3TUJ9	   Tpd52l2	  
Q61508	   Ecm1	  
	  
P17918	   Pcna	  
	  
P17751	   Tpi1	  
P10126	   Eef1a1	  
	  
P56812	   Pdcd5	  
	  
P21107	   Tpm3	  
O70251	   Eef1b	  
	  
Q9WU78	   Pdcd6ip	  
	  
Q6IRU2	   Tpm4	  
Q9D8N0	   Eef1g	  
	  
P27773	   Pdia3	  
	  
O89023	   Tpp1	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P58252	   Eef2	  
	  
P08003	   Pdia4	  
	  
Q64514	   Tpp2	  
Q8C845	   Efhd2	  
	  
Q8K183	   Pdxk	  
	  
P63028	   Tpt1	  
Q9WVK4	   Ehd1	  
	  
P70296	   Pebp1	  
	  
Q99NH8	   Trem2	  
Q9EQP2	   Ehd4	  
	  
O70591	   Pfdn2	  
	  
Q62318	   Trim28	  
P48024	   Eif1	  
	  
Q9WU28	   Pfdn5	  
	  
Q9DCG9	   Trmt112	  
Q8BJW6	   Eif2a	  
	  
P12382	   Pfkl	  
	  
P68373	   Tuba1c	  
Q6ZWX6	   Eif2s1	  
	  
Q9DBJ1	   Pgam1	  
	  
P68372	   Tubb4b	  
Q99L45	   Eif2s2	  
	  
Q9DCD0	   Pgd	  
	  
P99024	   Tubb5	  
Q9Z0N1	   Eif2s3x	  
	  
P09411	   Pgk1	  
	  
Q922F4	   Tubb6	  
P23116	   Eif3a	  
	  
Q9CQ60	   Pgls	  
	  
Q9Z0P5	   Twf2	  
Q8JZQ9	   Eif3b	  
	  
Q9D0F9	   Pgm1	  
	  
P10639	   Txn	  
Q8R1B4	   Eif3c	  
	  
Q61753	   Phgdh	  
	  
Q9CQM5	   Txndc17	  
O70194	   Eif3d	  
	  
Q9DAK9	   Phpt1	  
	  
E9PXX7	   Txndc5	  
P60229	   Eif3e	  
	  
Q7M6Y3	   Picalm	  
	  
Q8CDN6	   Txnl1	  
Q9DCH4	   Eif3f	  
	  
P53810	   Pitpna	  
	  
Q9JMH6	   Txnrd1	  
Q9Z1D1	   Eif3g	  
	  
P52480	   Pkm	  
	  
Q3TW96	   Uap1l1	  
Q91WK2	   Eif3h	  
	  
P52480	   Pkm	  
	  
Q02053	   Uba1	  
Q9QZD9	   Eif3i	  
	  
Q3TCN2	   Plbd2	  
	  
Q9Z1F9	   Uba2	  
Q3UGC7	   Eif3j1	  
	  
Q8CIH5	   Plcg2	  
	  
P68037	   Ube2l3	  
Q8QZY1	   Eif3l	  
	  
Q8BG07	   Pld4	  
	  
P61089	   Ube2n	  
P60843	   Eif4a1	  
	  
E9QPE8	   Plec	  
	  
Q9CZY3	   Ube2v1	  
Q8BGD9	   Eif4b	  
	  
Q9R0E2	   Plod1	  
	  
Q9D2M8	   Ube2v2	  
P63073	   Eif4e	  
	  
P55065	   Pltp	  
	  
Q9JKB1	   Uchl3	  
Q9WUK2	   Eif4h	  
	  
Q543K9	   Pnp	  
	  
P61961	   Ufm1	  
P59325	   Eif5	  
	  
Q9D819	   Ppa1	  
	  
Q6P5E4	   Uggt1	  
P63242	   Eif5a	  
	  
P17742	   Ppia	  
	  
Q91ZJ5	   Ugp2	  
O55135	   Eif6	  
	  
P24369	   Ppib	  
	  
Q9Z1Z0	   Uso1	  
P70372	   Elavl1	  
	  
Q9CR16	   Ppid	  
	  
Q9JMA1	   Usp14	  
P17182	   Eno1	  
	  
Q61074	   Ppm1g	  
	  
Q3U4W8	   Usp5	  
Q8CGC7	   Eprs	  
	  
P62137	   Ppp1ca	  
	  
Q9Z1Q9	   Vars	  
P84089	   Erh	  
	  
Q3UM45	   Ppp1r7	  
	  
P70460	   Vasp	  
P57759	   Erp29	  
	  
P63330	   Ppp2ca	  
	  
Q62465	   Vat1	  
Q9D1Q6	   Erp44	  
	  
Q76MZ3	   Ppp2r1a	  
	  
P61759	   Vbp1	  
Q9R0P3	   Esd	  
	  
Q6P1F6	   Ppp2r2a	  
	  
Q64727	   Vcl	  
Q8BWY3	   Etf1	  
	  
P58389	   Ppp2r4	  
	  
Q01853	   Vcp	  
Q5SUT0	   Ewsr1	  
	  
O88531	   Ppt1	  
	  
P20152	   Vim	  
P26040	   Ezr	  
	  
P35700	   Prdx1	  
	  
Q9EQH3	   Vps35	  
Q05816	   Fabp5	  
	  
Q61171	   Prdx2	  
	  
Q99KC8	   Vwa5a	  
Q8R1F1	   Fam129b	  
	  
P99029	   Prdx5	  
	  
P32921	   Wars	  
Q921M7	   Fam49b	  
	  
Q9QUR6	   Prep	  
	  
P70315	   Was	  
E9PWY9	   Farsa	  
	  
Q9DBC7	   Prkar1a	  
	  
O88342	   Wdr1	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Q9WUA2	   Farsb	  
	  
O08795	   Prkcsh	  
	  
Q6P1B1	   Xpnpep1	  
P19096	   Fasn	  
	  
Q9Z2Y8	   Prosc	  
	  
Q6P5F9	   Xpo1	  
Q920E5	   Fdps	  
	  
Q99KP6	   Prpf19	  
	  
P62960	   Ybx1	  
Q91Z50	   Fen1	  
	  
E9PZ00	   Psap	  
	  
P62259	   Ywhae	  
Q8K1B8	   Fermt3	  
	  
Q99K85	   Psat1	  
	  
P61982	   Ywhag	  
P97807	   Fh	  
	  
Q9Z2U1	   Psma5	  
	  
P68510	   Ywhah	  
P26883	   Fkbp1a	  
	  
Q9QUM9	   Psma6	  
	  
P68254	   Ywhaq	  
Q62446	   Fkbp3	  
	  
Q9Z2U0	   Psma7	  
	  
P63101	   Ywhaz	  
B7FAU9	   Flna	  
	  
P62192	   Psmc1	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APPENDIX	  5:	  COMMON	  PROTEINS	  WITH	  LPS-­‐INDUCIBLE	  SECRETOME	  FROM	  LIU	  
ET	  AL.	  
Uniprot	  ID	   Gene	  name	  
	  
Uniprot	  ID	   Gene	  name	  
	  
Uniprot	  ID	   Gene	  name	  
Q8BGQ7	   Aars	  
	  
Q920E5	   Fdps	  
	  
Q61074	   Ppm1g	  
Q921H8	   Acaa1a	  
	  
P97855	   G3bp1	  
	  
P58389	   Ppp2r4	  
Q8CAY6	   Acat2	  
	  
Q9R0N0	   Galk1	  
	  
O88531	   Ppt1	  
Q91V92	   Acly	  
	  
P16858	   Gapdh	  
	  
Q99KP6	   Prpf19	  
Q99KI0	   Aco2	  
	  
Q9CQM9	   Glrx3	  
	  
E9PZ00	   Psap	  
P63260	   Actg1	  
	  
P28798	   Grn	  
	  
P62192	   Psmc1	  
P28474	   Adh5	  
	  
O09131	   Gsto1	  
	  
P46471	   Psmc2	  
P28650	   Adssl1	  
	  
Q8HWB2	   H2-­‐Q4	  
	  
P54775	   Psmc4	  
E9Q616	   Ahnak	  
	  
Q3THW5	   H2afv	  
	  
P62196	   Psmc5	  
Q8BK64	   Ahsa1	  
	  
P20060	   Hexb	  
	  
P62334	   Psmc6	  
P31230	   Aimp1	  
	  
P70349	   Hint1	  
	  
Q3TXS7	   Psmd1	  
Q9JII6	   Akr1a1	  
	  
P43276	   Hist1h1b	  
	  
Q8BG32	   Psmd11	  
P45376	   Akr1b1	  
	  
P43277	   Hist1h1d	  
	  
Q9D8W5	   Psmd12	  
Q9EST5	   Anp32b	  
	  
P43274	   Hist1h1e	  
	  
Q9WVJ2	   Psmd13	  
E9Q5H2	   Anp32e	  
	  
Q8CGP6	   Hist1h2ah	  
	  
Q8VDM4	   Psmd2	  
P12023	   App	  
	  
P84228	   Hist1h3b	  
	  
P14685	   Psmd3	  
Q5XJY5	   Arcn1	  
	  
P62806	   Hist1h4a	  
	  
O35226	   Psmd4	  
Q9CWJ9	   Atic	  
	  
Q9CX86	   Hnrnpa0	  
	  
Q99JI4	   Psmd6	  
Q3TKX1	   Atp6ap1	  
	  
O88569	   Hnrnpa2b1	  
	  
P26516	   Psmd7	  
Q9CYN9	   Atp6ap2	  
	  
Q9Z204	   Hnrnpc	  
	  
Q8BGJ5	   Ptbp1	  
P50516	   Atp6v1a	  
	  
Q9Z2X1	   Hnrnpf	  
	  
P29351	   Ptpn6	  
P62814	   Atp6v1b2	  
	  
G3XA10	   Hnrnpu	  
	  
Q60972	   Rbbp4	  
P01887	   B2m	  
	  
P07901	   Hsp90aa1	  
	  
O89086	   Rbm3	  
P62204	   Calm1	  
	  
P11499	   Hsp90ab1	  
	  
Q91VM5	   Rbmxl1	  
P10148	   Ccl2	  
	  
P38647	   Hspa9	  
	  
Q8BK67	   Rcc2	  
P51670	   Ccl9	  
	  
P63038	   Hspd1	  
	  
Q91VI7	   Rnh1	  
P04441	   Cd74	  
	  
Q64433	   Hspe1	  
	  
P62983	   Rps27a	  
P04186	   Cfb	  
	  
Q8BU30	   Iars	  
	  
P60122	   Ruvbl1	  
Q04447	   Ckb	  
	  
Q9ESY9	   Ifi30	  
	  
P07091	   S100a4	  
Q9Z1Q5	   Clic1	  
	  
G5E8F1	   Itgam	  
	  
P14069	   S100a6	  
B1AWE0	   Clta	  
	  
Q542I8	   Itgb2	  
	  
P32020	   Scp2	  
Q68FD5	   Cltc	  
	  
O89051	   Itm2b	  
	  
Q920A5	   Scpep1	  
Q8CIE6	   Copa	  
	  
P70168	   Kpnb1	  
	  
O35988	   Sdc4	  
Q9JIF7	   Copb1	  
	  
Q61792	   Lasp1	  
	  
Q3TMX0	   Sdcbp	  
O55029	   Copb2	  
	  
Q07797	   Lgals3bp	  
	  
Q61112	   Sdf4	  
O89079	   Cope	  
	  
P48678	   Lmna	  
	  
P17563	   Selenbp1	  
Q9QZE5	   Copg1	  
	  
P14733	   Lmnb1	  
	  
Q8K4Z5	   Sf3a1	  
P61924	   Copz1	  
	  
P11152	   Lpl	  
	  
G5E866	   Sf3b1	  
O89053	   Coro1a	  
	  
O88188	   Ly86	  
	  
Q921M3	   Sf3b3	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Q9WUM4	   Coro1c	  
	  
P08905	   Lyz2	  
	  
Q8VIJ6	   Sfpq	  
O88668	   Creg1	  
	  
O09159	   Man2b1	  
	  
Q8BJU0	   Sgta	  
P09581	   Csf1r	  
	  
P31938	   Map2k1	  
	  
Q78PY7	   Snd1	  
P21460	   Cst3	  
	  
Q3THS6	   Mat2a	  
	  
Q78ZM0	   Snx3	  
P10605	   Ctsb	  
	  
Q8K310	   Matr3	  
	  
P13609	   Srgn	  
P97821	   Ctsc	  
	  
P08249	   Mdh2	  
	  
Q6PDM2	   Srsf1	  
P06797	   Ctsl1	  
	  
Q922D8	   Mthfd1	  
	  
P84104	   Srsf3	  
O70370	   Ctss	  
	  
Q9QWR8	   Naga	  
	  
Q8BH40	   Stx7	  
Q9WUU7	   Ctsz	  
	  
Q99J77	   Nans	  
	  
P40142	   Tkt	  
D3YW23	   Cxcl10	  
	  
Q78ZA7	   Nap1l4	  
	  
P06804	   Tnf	  
P10889	   Cxcl2	  
	  
P09405	   Ncl	  
	  
O89023	   Tpp1	  
Q922B2	   Dars	  
	  
Q9D0T1	   Nhp2l1	  
	  
Q99NH8	   Trem2	  
Q62418	   Dbnl	  
	  
Q99K48	   Nono	  
	  
Q62318	   Trim28	  
A2ADY9	   Ddi2	  
	  
Q9Z0J0	   Npc2	  
	  
Q9Z0P5	   Twf2	  
Q9Z1N5	   Ddx39b	  
	  
Q02819	   Nucb1	  
	  
E9PXX7	   Txndc5	  
Q61656	   Ddx5	  
	  
Q9CZ30	   Ola1	  
	  
Q8CDN6	   Txnl1	  
P00375	   Dhfr	  
	  
Q62422	   Ostf1	  
	  
Q02053	   Uba1	  
O35286	   Dhx15	  
	  
Q7TQI3	   Otub1	  
	  
Q9Z1F9	   Uba2	  
O70133	   Dhx9	  
	  
Q921K2	   Parp1	  
	  
Q9JKB1	   Uchl3	  
Q8C255	   Dpep2	  
	  
P12382	   Pfkl	  
	  
Q9Z1Z0	   Uso1	  
Q9JHU4	   Dync1h1	  
	  
Q61753	   Phgdh	  
	  
Q9JMA1	   Usp14	  
Q61508	   Ecm1	  
	  
E9QPE8	   Plec	  
	  
Q3U4W8	   Usp5	  
Q9QZD9	   Eif3i	  
	  
Q9R0E2	   Plod1	  
	  
P20152	   Vim	  
Q8CGC7	   Eprs	  
	  
P55065	   Pltp	  
	  
Q9EQH3	   Vps35	  
P19096	   Fasn	  
	  
Q9CR16	   Ppid	  
	   	   	  	  
APPENDIX	  6:	  PHF8-­‐G9a	  COMMON	  SECRETOME	  
Uniprot	  ID	  
Protein	  




Name	   Gene	  Name	  
P10404	   ENV1	   2	  
	  
Q9DBH5	   LMAN2	   Lman2	  
Q80UG5-­‐2	   SEPT9	   42256	  
	  
P48678	   LMNA	   Lmna	  
Q8C1B7-­‐3	   SEP11	   42258	  
	  
P11152	   LIPL	   Lpl	  
Q91V92	   ACLY	   Acly	  
	  
Q91ZX7	   LRP1	   Lrp1	  
P28271	   ACOC	   Aco1	  
	  
E9PX73	   E9PX73	   Ly9	  
Q99KI0	   ACON	   Aco2	  
	  
P17897	   LYZ1	   Lyz1	  
Q91V12-­‐2	   BACH	   Acot7	  
	  
O09159	   MA2B1	   Man2b1	  
P60710	   ACTB	   Actb	  
	  
Q3THS6	   METK2	   Mat2a	  
J3QNB3	   J3QNB3	   Adam17	  
	  
P97310	   MCM2	   Mcm2	  
Q64191	   ASPG	   Aga	  
	  
P08249	   MDHM	   Mdh2	  
P50247	   SAHH	   Ahcy	  
	  
Q8VE43	   METRL	   Metrnl	  
E9Q616	   E9Q616	   Ahnak	  
	  
E9PVX6	   E9PVX6	   Mki67	  
Q8BK64	   AHSA1	   Ahsa1	  
	  
Q922D8	   C1TC	   Mthfd1	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Q9JII6	   AK1A1	   Akr1a1	  
	  
Q9JK81	   MYG1	   Myg1	  
P45376	   ALDR	   Akr1b1	  
	  
Q60817	   NACA	   Naca	  
E9Q4G8	   E9Q4G8	   Alcam	  
	  
Q9QWR8	   NAGAB	   Naga	  
Q9JLJ2	   AL9A1	   Aldh9a1	  
	  
Q8VEJ4	   NLE1	   Nle1	  
P97822-­‐2	   AN32E	   Anp32e	  
	  
Q99K48	   NONO	   Nono	  
P07356	   ANXA2	   Anxa2	  
	  
Q9Z0J0	   NPC2	   Npc2	  
Q60709	   Q60709	   Aplp2	  
	  
E9Q039	   E9Q039	   Npepps	  
P12023	   A4	   App	  
	  
A6PWC3	   A6PWC3	   Nrd1	  
Q99PT1	   GDIR1	   Arhgdia	  
	  
O35375-­‐5	   NRP2	   Nrp2	  
P59999	   ARPC4	   Arpc4	  
	  
Q02819	   NUCB1	   Nucb1	  
Q61024	   ASNS	   Asns	  
	  
O35685	   NUDC	   Nudc	  
O08997	   ATOX1	   Atox1	  
	  
Q9JKX6	   NUDT5	   Nudt5	  
Q9CYN9	   RENR	   Atp6ap2	  
	  
E9Q7G0	   E9Q7G0	   Numa1	  
P50516	   VATA	   Atp6v1a	  
	  
Q7TQI3	   OTUB1	   Otub1	  
P01887	   B2MG	   B2m	  
	  
Q8CIN4	   PAK2	   Pak2	  
Q09200	   B4GN1	   B4galnt1	  
	  
P60335	   PCBP1	   Pcbp1	  
Q9JMK0	   B4GT5	   B4galt5	  
	  
P23506	   PIMT	   Pcmt1	  
O54962	   BAF	   Banf1	  
	  
Q9WU78	   PDC6I	   Pdcd6ip	  
Q07813	   BAX	   Bax	  
	  
Q8C605	   Q8C605	   Pfkp	  
Q9CY64	   BIEA	   Blvra	  
	  
Q8BG07-­‐2	   PLD4	   Pld4	  
Q8BGS2-­‐2	   BOLA2	   Bola2	  
	  
E9QPE8	   E9QPE8	   Plec	  
Q9Z0S1	   BPNT1	   Bpnt1	  
	  
Q9R0E2	   PLOD1	   Plod1	  
P01027	   CO3	   C3	  
	  
Q9R0B9	   PLOD2	   Plod2	  
Q9CXW3	   CYBP	   Cacybp	  
	  
Q9R0E1	   PLOD3	   Plod3	  
Q6ZQ38	   CAND1	   Cand1	  
	  
Q99K51	   PLST	   Pls3	  
Q60865	   CAPR1	   Caprin1	  
	  
P55065	   PLTP	   Pltp	  
P47757-­‐2	   CAPZB	   Capzb	  
	  
B2RXS4	   PLXB2	   Plxnb2	  
Q9ER72	   SYCC	   Cars	  
	  
Q9D819	   IPYR	   Ppa1	  
Q9DCC5	   Q9DCC5	   Cbx3	  
	  
P30412	   PPIC	   Ppic	  
P10148	   CCL2	   Ccl2	  
	  
Q9CR16	   PPID	   Ppid	  
O88430	   CCL22	   Ccl22	  
	  
Q61074	   PPM1G	   Ppm1g	  
P10855	   CCL3	   Ccl3	  
	  
P97470	   PP4C	   Ppp4c	  
P14097	   CCL4	   Ccl4	  
	  
P35700	   PRDX1	   Prdx1	  
P30882	   CCL5	   Ccl5	  
	  
Q61171	   PRDX2	   Prdx2	  
P51670	   CCL9	   Ccl9	  
	  
O08807	   PRDX4	   Prdx4	  
P42932	   TCPQ	   Cct8	  
	  
O08795	   GLU2B	   Prkcsh	  
P10810	   CD14	   Cd14	  
	  
Q9JIF0-­‐2	   ANM1	   Prmt1	  
P15379-­‐2	   CD44	   Cd44	  
	  
Q64695	   EPCR	   Procr	  
P04441	   HG2A	   Cd74	  
	  
Q08761	   PROS	   Pros1	  
P40240	   CD9	   Cd9	  
	  
G3UXL2	   G3UXL2	   Prps1l3	  
Q4VAA2	   CDV3	   Cdv3	  
	  
Q99K85	   SERC	   Psat1	  
P04186	   CFAB	   Cfb	  
	  
Q9QUM9	   PSA6	   Psma6	  
P06909	   CFAH	   Cfh	  
	  
O55234	   PSB5	   Psmb5	  
P11680	   PROP	   Cfp	  
	  
Q60692	   PSB6	   Psmb6	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Q9Z1Q5	   CLIC1	   Clic1	  
	  
P62334	   PRS10	   Psmc6	  
Q3UMW8	   CLN5	   Cln5	  
	  
Q3TXS7	   PSMD1	   Psmd1	  
B1AWE0	   B1AWE0	   Clta	  
	  
Q8BG32	   PSD11	   Psmd11	  
Q68FD5	   CLH1	   Cltc	  
	  
Q9D8W5	   PSD12	   Psmd12	  
P53996-­‐2	   CNBP	   Cnbp	  
	  
Q9WVJ2	   PSD13	   Psmd13	  
Q8CIE6	   COPA	   Copa	  
	  
Q8VDM4	   PSMD2	   Psmd2	  
O35864	   CSN5	   Cops5	  
	  
O35226	   PSMD4	   Psmd4	  
O89053	   COR1A	   Coro1a	  
	  
Q99LS3	   SERB	   Psph	  
Q9WUM4	   COR1C	   Coro1c	  
	  
Q9R0Q7	   TEBP	   Ptges3	  
G3X9T8	   G3X9T8	   Cp	  
	  
B0V2N1-­‐6	   PTPRS	   Ptprs	  
Q9ERK4	   XPO2	   Cse1l	  
	  
Q9JKF6	   PVRL1	   Pvrl1	  
P07141	   CSF1	   Csf1	  
	  
P63001	   RAC1	   Rac1	  
P09920	   CSF3	   Csf3	  
	  
Q05144	   RAC2	   Rac2	  
P21460	   CYTC	   Cst3	  
	  
P62827	   RAN	   Ran	  
Q62426	   CYTB	   Cstb	  
	  
P34022	   RANG	   Ranbp1	  
Q8R242-­‐2	   DIAC	   Ctbs	  
	  
P46061	   RAGP1	   Rangap1	  
Q9CWL8	   CTBL1	   Ctnnbl1	  
	  
Q9D0I9	   SYRC	   Rars	  
P70698	   PYRG1	   Ctps1	  
	  
Q60972	   RBBP4	   Rbbp4	  
P10605	   CATB	   Ctsb	  
	  
A2AFJ1	   A2AFJ1	   Rbbp7	  
P97821	   CATC	   Ctsc	  
	  
O89086	   RBM3	   Rbm3	  
P18242	   CATD	   Ctsd	  
	  
E9Q7W0	   E9Q7W0	   Rbpj	  
Q9R013	   CATF	   Ctsf	  
	  
Q8VE37	   RCC1	   Rcc1	  
P06797	   CATL1	   Ctsl	  
	  
Q8BK67	   RCC2	   Rcc2	  
Q9WUU7	   CATZ	   Ctsz	  
	  
Q9CQ01	   RNT2	   Rnaset2	  
D3YW23	   D3YW23	   Cxcl10	  
	  
Q91VI7	   RINI	   Rnh1	  
I7HIQ2	   I7HIQ2	   Cxcl16	  
	  
P47968	   RPIA	   Rpia	  
P10889	   CXCL2	   Cxcl2	  
	  
P47963	   RL13	   Rpl13	  
Q7TMB8	   CYFP1	   Cyfip1	  
	  
P62717	   RL18A	   Rpl18a	  
Q922B2	   SYDC	   Dars	  
	  
P67984	   RL22	   Rpl22	  
D3YX34	   D3YX34	   Dctn1	  
	  
P62830	   RL23	   Rpl23	  
Q8VDW0	   DX39A	   Ddx39a	  
	  
E9Q132	   E9Q132	   Rpl24	  
Q9Z1N5	   DX39B	   Ddx39b	  
	  
P61255	   RL26	   Rpl26	  
Q61656	   DDX5	   Ddx5	  
	  
P61358	   RL27	   Rpl27	  
O35286	   DHX15	   Dhx15	  
	  
P41105	   RL28	   Rpl28	  
Q91YW3	   DNJC3	   Dnajc3	  
	  
P62900	   RL31	   Rpl31	  
Q6NZB0	   DNJC8	   Dnajc8	  
	  
Q9D1R9	   RL34	   Rpl34	  
Q8C255	   DPEP2	   Dpep2	  
	  
Q9JJI8	   RL38	   Rpl38	  
Q91WV0	   NC2B	   Dr1	  
	  
P14148	   RL7	   Rpl7	  
P62627	   DLRB1	   Dynlrb1	  
	  
P62918	   RL8	   Rpl8	  
Q61508	   ECM1	   Ecm1	  
	  
G3UW34	   G3UW34	   Rpl9-­‐ps6	  
P10126	   EF1A1	   Eef1a1	  
	  
P62281	   RS11	   Rps11	  
E9QN08	   E9QN08	   Eef1d	  
	  
P62245	   RS15A	   Rps15a	  
Q9D8N0	   EF1G	   Eef1g	  
	  
P14131	   RS16	   Rps16	  
Q8C845	   Q8C845	   Efhd2	  
	  
P62267	   RS23	   Rps23	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Q9EQP2	   EHD4	   Ehd4	  
	  
P62852	   RS25	   Rps25	  
Q8BMJ3	   IF1AX	   Eif1ax	  
	  
P62855	   RS26	   Rps26	  
Q8R1B4	   EIF3C	   Eif3c	  
	  
Q9WTM5	   RUVB2	   Ruvbl2	  
O70194	   EIF3D	   Eif3d	  
	  
P50543	   S10AB	   S100a11	  
Q9DCH4	   EIF3F	   Eif3f	  
	  
P07091	   S10A4	   S100a4	  
Q9Z1D1	   EIF3G	   Eif3g	  
	  
P14069	   S10A6	   S100a6	  
Q9QZD9	   EIF3I	   Eif3i	  
	  
O35988	   SDC4	   Sdc4	  
Q9DBZ5	   EIF3K	   Eif3k	  
	  
Q9D1M0	   SEC13	   Sec13	  
Q8QZY1	   EIF3L	   Eif3l	  
	  
P17563	   SBP1	   Selenbp1	  
Q99JX4	   EIF3M	   Eif3m	  
	  
Q62178	   SEM4A	   Sema4a	  
P60843	   IF4A1	   Eif4a1	  
	  
O09126	   SEM4D	   Sema4d	  
A2AFK7	   A2AFK7	   Eif4a3	  
	  
Q9CY58	   PAIRB	   Serbp1	  
Q8BGD9	   IF4B	   Eif4b	  
	  
Q60854	   SPB6	   Serpinb6	  
P63073	   IF4E	   Eif4e	  
	  
P22777	   PAI1	   Serpine1	  
P70445	   4EBP2	   Eif4ebp2	  
	  
E9Q4Q2	   E9Q4Q2	   Sf1	  
Q9WUK2-­‐2	   IF4H	   Eif4h	  
	  
D3YW09	   D3YW09	   Sf3a2	  
P70372	   ELAV1	   Elavl1	  
	  
Q9D554	   SF3A3	   Sf3a3	  
P17182	   ENOA	   Eno1	  
	  
G5E866	   G5E866	   Sf3b1	  
Q8CGC7	   SYEP	   Eprs	  
	  
Q8VIJ6	   SFPQ	   Sfpq	  
Q9EQH2	   ERAP1	   Erap1	  
	  
Q91VW3	   SH3L3	   Sh3bgrl3	  
H3BLJ9	   H3BLJ9	   Esd	  
	  
Q9D7I0	   SHSA5	   Shisa5	  
Q8R1F1	   NIBL1	   Fam129b	  
	  
Q9CZN7	   Q9CZN7	   Shmt2	  
Q9WUA2	   SYFB	   Farsb	  
	  
Q9EPK6	   SIL1	   Sil1	  
Q920E5	   FPPS	   Fdps	  
	  
Q6P6I8	   Q6P6I8	   Sirpa	  
Q9R059	   FHL3	   Fhl3	  
	  
E9Q748	   E9Q748	   Slpi	  
Q62446	   FKBP3	   Fkbp3	  
	  
Q3UKJ7	   SMU1	   Smu1	  
B7FAU9	   B7FAU9	   Flna	  
	  
Q62189	   SNRPA	   Snrpa	  
Q80X90	   FLNB	   Flnb	  
	  
P62305	   RUXE	   Snrpe	  
Q3TUE1	   Q3TUE1	   Fubp1	  
	  
O88307	   SORL	   Sorl1	  
P23188	   FURIN	   Furin	  
	  
Q148R4	   Q148R4	   Spink5	  
Q8BHN3	   GANAB	   Ganab	  
	  
P10923	   OSTP	   Spp1	  
P16858	   G3P	   Gapdh	  
	  
Q64337	   SQSTM	   Sqstm1	  
B1ATI9	   B1ATI9	   Gas7	  
	  
P13609	   SRGN	   Srgn	  
P17439	   GLCM	   Gba	  
	  
Q64674	   SPEE	   Srm	  
Q9CPV4	   GLOD4	   Glod4	  
	  
Q99MR6-­‐3	   SRRT	   Srrt	  
D3Z1D6	   D3Z1D6	   Gm10335	  
	  
Q6PDM2	   SRSF1	   Srsf1	  
L7N202	   L7N202	   Gm16477	  
	  
Q62093	   SRSF2	   Srsf2	  
Q3THK7	   GUAA	   Gmps	  
	  
Q60864	   STIP1	   Stip1	  
P05202	   AATM	   Got2	  
	  
P11031	   TCP4	   Sub1	  
P28798	   GRN	   Grn	  
	  
Q9CX34	   SUGT1	   Sugt1	  
Q8R050-­‐2	   ERF3A	   Gspt1	  
	  
H7BWX9	   H7BWX9	   Sumo2	  
P10922	   H10	   H1f0	  
	  
G3X956	   G3X956	   Supt16	  
P01899	   HA11	   H2-­‐D1	  
	  
Q93092	   TALDO	   Taldo1	  
P01900	   HA12	   H2-­‐D1	  
	  
P48428	   TBCA	   Tbca	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P01902	   HA1D	   H2-­‐K1	  
	  
P10711	   TCEA1	   Tcea1	  
P01897	   HA1L	   H2-­‐L	  
	  
Q62351	   TFR1	   Tfrc	  
Q8HWB2	   Q8HWB2	   H2-­‐Q4	  
	  
P04202	   TGFB1	   Tgfb1	  
P06339	   HA15	   H2-­‐T23	  
	  
P62075	   TIM13	   Timm13	  
Q9QZQ8-­‐2	   H2AY	   H2afy	  
	  
P26039	   TLN1	   Tln1	  
P70349	   HINT1	   Hint1	  
	  
Q80YX1-­‐2	   TENA	   Tnc	  
P15864	   H12	   Hist1h1c	  
	  
P06804	   TNFA	   Tnf	  
P43274	   H14	   Hist1h1e	  
	  
P25119	   TNR1B	   Tnfrsf1b	  
P84228	   H32	   Hist1h3b	  
	  
P41274	   TNFL9	   Tnfsf9	  
P30681	   HMGB2	   Hmgb2	  
	  
Q8BFY9-­‐2	   TNPO1	   Tnpo1	  
P97825	   HN1	   Hn1	  
	  
Q9ER38	   TOR3A	   Tor3a	  
P11499	   HS90B	   Hsp90ab1	  
	  
Q64514-­‐2	   TPP2	   Tpp2	  
Q8BM72	   HSP13	   Hspa13	  
	  
Q7M739	   Q7M739	   Tpr	  
P63017	   HSP7C	   Hspa8	  
	  
P63028	   TCTP	   Tpt1	  
Q64433	   CH10	   Hspe1	  
	  
Q99NH8	   TREM2	   Trem2	  
Q61699-­‐2	   HS105	   Hsph1	  
	  
Q62318	   TIF1B	   Trim28	  
Q8BU30	   SYIC	   Iars	  
	  
Q9DCG9	   TR112	   Trmt112	  
P13597-­‐2	   ICAM1	   Icam1	  
	  
Q62348	   TSN	   Tsn	  
Q9JHJ8	   ICOSL	   Icoslg	  
	  
P05213	   TBA1B	   Tuba1b	  
F6RPJ9	   F6RPJ9	   Ide	  
	  
P68373	   TBA1C	   Tuba1c	  
P58044	   IDI1	   Idi1	  
	  
P99024	   TBB5	   Tubb5	  
P01575	   IFNB	   Ifnb1	  
	  
Q922F4	   TBB6	   Tubb6	  
Q3TBV5	   Q3TBV5	   Il1rn	  
	  
Q80X50-­‐2	   UBP2L	   Ubap2l	  
B0QZX1	   B0QZX1	   Il2rg	  
	  
P61087	   UBE2K	   Ube2k	  
O09046	   OXLA	   Il4i1	  
	  
F7CDT0	   F7CDT0	   Ube2m	  
P08505	   IL6	   Il6	  
	  
Q8R317	   UBQL1	   Ubqln1	  
P24547	   IMDH2	   Impdh2	  
	  
Q9Z1Z0-­‐4	   USO1	   Uso1	  
Q9JKF1	   IQGA1	   Iqgap1	  
	  
Q9JMA1	   UBP14	   Usp14	  
Q542I8	   Q542I8	   Itgb2	  
	  
P20152	   VIME	   Vim	  
O89051	   ITM2B	   Itm2b	  
	  
D3YYD5	   D3YYD5	   Vps29	  
Q99MN1	   SYK	   Kars	  
	  
Q9EQH3	   VPS35	   Vps35	  
Q6WVG3	   KCD12	   Kctd12	  
	  
P61965	   WDR5	   Wdr5	  
G3UZG5	   G3UZG5	   Klhdc4	  
	  
Q91WQ3	   SYYC	   Yars	  
F8VQJ3	   F8VQJ3	   Lamc1	  
	  
Q9JKB3-­‐2	   YBOX3	   Ybx3	  
Q61792	   LASP1	   Lasp1	  
	  
P61982	   1433G	   Ywhag	  
P11672	   NGAL	   Lcn2	  
	  
P68510	   1433F	   Ywhah	  
P35951	   LDLR	   Ldlr	  
	  
P63101	   1433Z	   Ywhaz	  
P16045	   LEG1	   Lgals1	  
	  
G5E8F1	   G5E8F1	   	  	  
Q8C253	   Q8C253	   Lgals3	  
	  
Q3TMX0	   Q3TMX0	   	  	  
P09056	   LIF	   Lif	  
	  
Q3TUJ9	   Q3TUJ9	   	  	  
Q64281-­‐2	   LIRB4	   Lilrb4	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